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Abstract 
Receptor activity modifying proteins (RAMPs 1, 2 and 3) a family of single transmembrane 
accessory proteins, which were discovered for predominantly regulating ligand selectivity and 
trafficking of G-protein coupled receptors (GPCRs) for the Calcitonin (CT) family of peptides. 
Calcitonin family of peptides mainly include: Calcitonin (CT), Calcitonin gene related peptide 
(CGRP), Adrenomedullin (AM) and Amylin (AMY). Functional receptors to these peptides 
comprise RAMP heterodimers with either Calcitonin receptor (CTR) or Calcitonin like receptor 
(CLR). Over the last few years, these three isoforms of human RAMPs have been identified to 
form heterodimers with several other GPCRs.  
Given the expanding number RAMP-GPCR interactions being identified every year, it is important 
to understand the role of individual RAMP isoform in both normal and pathological conditions. 
Since the CT family of peptides are recognized hypocalcaemic peptides that have been studied 
extensively for developing therapies for low bone mass skeletal disorders, we intended to 
investigate the role of RAMPs in regulating bone mass. Our pilot study suggested that not RAMP1 
but RAMP2 and RAMP3 play an important role in regulating skeletal development. The current 
work aims to investigate the phenotypic consequence of globally silencing RAMP3 expression in 
129/SvEv mice on the skeletal development.  
Using microCT, dynamic histomorphometry and histology we have demonstrated that RAMP3 KO 
129/SvEv mice have anabolic acceleration in skeletal development at an early age that provides 
protection against age-dependent bone loss. Furthermore, using qPCR and western blotting we 
have shown that the expression of individual RAMP regulates osteoblasts differentiation and that 
the in response to the stimulation of PTH, AM and AMY, the expression of RAMPs in RAMP3 KO 
primary osteoblasts is significantly different to that in WT primary osteoblasts. We have also 
determined a variant of CTR that responds to AMY stimulation in primary osteoblasts. Additionally 
our study provides novel insights into role of RAMP3 in regulating the Wnt/β-catenin pathway in 
primary osteoblasts. 
This study provides evidence of RAMP3 being an anabolic regulator of skeletal development. 
Whether this is due to its roles in regulating functions of the CT family of peptides; AM and AMY, 
or through exerting its effects on other osteotropic hormone receptors that interact with RAMP3 is 
not yet elucidated. Nevertheless the modulation of RAMP3 function may offer opportunities for 
anabolic therapies for treating low mass skeletal disorders. 
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Low bone mass skeletal disorders like Osteoporosis are amongst the major health concerns 
worldwide. It is estimated that about 3 million people suffer from osteoporosis in the U.K that 
account for about 0.3 million fractures every year with a mortality rate as high as 10-20% due to 
frequent fractures (Lewiecki 2004) (National Health Service (NHS)). Majority of the skeletal 
disorders arise from an imbalance in bone remodeling resulting in an increased bone resorption 
and reduced bone formation. Therapeutic approaches for treating skeletal disorders, therefore, are 
aimed towards restoring this balance in bone remodeling. Most of the current therapies such as 
bisphosphonates are anti-catabolic. However given that the patients affected by skeletal disorders 
are over the age of 60 and have reduced bone formation, it is important to develop anabolic 
therapeutic targets for treating these disorders.  
Calcitonin (CT) family of peptides are known hypocalcaemic hormones hence receptors for these 
peptides are amongst the potential therapeutic targets for treating skeletal disorders. Receptors for 
calcitonin family of peptides comprise G-protein couple receptors (GPCRs) - Calcitonin Receptor 
(CTR) and Calcitonin-like Receptor (CLR). For most of the CT peptides, a functional receptor 
arises from the hetero-dimerization of either of these GPCRs with an accessory protein called the 
Receptor Activity Modifying Protein (RAMP). To date three isoforms of RAMPs; 1, 2 and 3, have 
been identified in human. Murine knock-out (KO) studies for the GPCRs – CTR and CLR, aimed 
at ablating the hypocalcaemic effect of the CT peptides unexpectedly revealed high bone-mass 
skeletal phenotypes.  
In our pilot study we determined the skeletal phenotype of individual RAMP knockout model. We 
observed that alteration in RAMP2 and RAMP3 but not RAMP1 influenced the skeletal phenotype. 
RAMP2 heterozygous mice at 8 weeks of age had increased cortical porosity, reduced cortical 
thickness and increased marrow cavity along with increased inter vertebral distance in the spine 
(Kadmiel et al 2011). RAMP3 knockout mice had increased cortical thickness and bone volume 
compared to the wild types, at the age of 8 weeks. However this data was obtained from very few 
numbers (n=3 each genotype).  
This dissertation presents an investigation of the potential role of Receptor Activity Modifying 
Protein3 (RAMP3) in treating skeletal disorders. We focus on characterizing the skeletal 
phenotype and the primary osteoblast cultures derived from RAMP3 KO mice. We further 
investigate the effects of hypocalcaemic peptide stimulation on the primary osteoblasts in order to 
determine whether RAMP3 is a potential anabolic therapeutic target for treating skeletal disorders.   
Chapter 1: Introduction 1 
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1.1 Bone  
Bone is a dynamic tissue that undergoes constant remodelling. In humans, 206 bones form the 
“skeleton” which predominantly provides the bipedal structure, support and movement to the 
human body. This mechanical structure of the bone provides grace, flexibility and posture that 
make human-beings superior to other organisms. The skeleton also protects vital organs such as 
heart, brain and lungs, acts as a reservoir for essential minerals including calcium and phosphate, 
growth factors and fat, and also acts as a site for generating the cellular components of blood – 
haematopoiesis. Solid bone is composed of predominantly an inorganic component, 
‘hydroxylapatite’ a hydrated calcium phosphate Ca10(PO4)6(OH)2, which accounts for 70% of dry 
weight of the composite bone, linked to the organic component predominantly the protein 
‘collagen’, although there are many smaller non-collagenous organic molecules in bone matrix 
including glycoseaminoglycans, proteoglycans, and growth factors (Iozzo 1998, Mohan & Baylink 
1991, Vejlens 1971, Wendel et al 1998). Depending on the orientation of the collagen fibres, bone 
can be either compact or spongy/cancellous. 
1.1.1 Structure of bone: In 1678, Leeuwenhoek first observed the microscopic canal system and 
cells in the bone. It was then realised that bone is not a homogenous solid structure. 
Leeuwenhoek’s observations were later extensively studied and characterised by Havers in his 
monogram “Osteologia Nova,” in 1691, cited by Enlow in 1962 (Enlow 1962). The canal system 
was later termed as the ‘Haversian system’ and the cells were named osteocytes.  
The compact bone is called cortical and spongy bone is called trabecular bone. The cortical bone 
surrounds the trabecular bone at in the metaphyseal and epiphyseal regions and has a lamellar 
structure that is made up of inter-connected vascular and neuronal canals. The proportion of 
cortical to trabecular bone varies between each type of bone. Bone is arranged in concentric 
circles around the canals with embedded bone cells – osteocytes which communicate with each 
other through the canaliculi. Each canal and the concentric bone containing embedded osteocytes 
forms an ‘osteon’ (Enlow 1962).  
Three main cell types – the osteoblasts, osteocytes and osteoclasts, regulate bone formation and 
maintenance. Osteoblasts and osteocytes are mono-nucleated cells that arise from differentiation 
of the progenitor mesenchymal stem cells, whereas osteoclasts are multinucleated differentiated 
haematopoietic stem cells.  
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1.1.2 Bone formation: The process of bone formation is called ossification. There are two types 
of ossification: intramembranous and endochondral. In flat bones such as the mandible and the 
calvaria, the mesenchymal stem cells undergo differentiation and form mature osteoblasts (Ducy 
et al 2000). In other bones, bone formation takes place through endochondral ossification. It is 
the process in which the cartilage undergoes vascular invasion and mineralisation. The dead 
chondrocytes in the cartilage are then replaced by the osteoblasts (Horton & Machado 1988) (Fig 
1.1 below). 
 
 
 Fig 1.1: Schematic representation of endochondral ossification where the cartilage is vascularised and then 
mineralised to form bone. Image adapted from the image of endochondral ossification published by Benjamin 
Cummings, Pearson Education, Inc.  
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1.1.3 Bone cells:  
1.1.3.i Osteoblasts  
 
 
Osteoblasts are the ‘bone forming’ cells that differentiate from mesenchymal stem cells. A high 
concentration of alkaline phosphatase in the cell membrane is a characteristic feature of 
osteoblasts. A number of transcription factors are involved in osteoblast differentiation. First, 
Runx2 commits the mesenchymal stem cells to differentiate into pre-osteoblasts instead of 
chondrocytes or adipocytes. Then Runx2, β-catenin, and Osterix direct the differentiation of the 
pre-osteoblasts to form mature osteoblasts (Day et al 2005, Ducy et al 1997, Komori 2006). 
Growth factors including fibroblast growth factor (FGF), bone morphometric proteins (BMPs) and 
Wnt regulate osteoblast differentiation (Chen et al 1997a, Levasseur 2001, Mayahara et al 1993). 
Differentiation of osteoblasts from progenitor mesenchymal stem cells is summarised in Figure 1.5 
(Bonewald 2011). Osteoblasts also produce Osteoprotegerin (OPG) that inhibits osteoclasts 
formation and cytokines like colony stimulating factor1 (CSF-1) and RANK ligand which when 
cleaved activates osteoclastogenesis (Taichman & Emerson 1994, Udagawa et al 1990, Yasuda 
et al 1998). 
Mature and progenitor osteoblasts express several integrins, adhesion molecules and receptors 
for oestrogen, parathyroid hormone, prostaglandins, vitamin D and various cytokines (Calvi et al 
2001, Eriksen et al 1988, Hakeda et al 1985, Sooy et al 2005). Despite being a bone cell, the 
differentiation, proliferation and regulation of osteoblasts is dictated by growth factors and 
hormones released by various organs. It is hence important to review the regulation of osteoblasts 
by organs other than bones; although, a complete comprehension of regulation of all the 
50µm 
Fig 1.2: Osteoblasts lining the cortical bone surface (black arrows) seen in tibia. 
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hormones that regulate osteoblasts is beyond the scope of this project. In this section we shall 
briefly review the complexity of osteoblast endocrinology. 
Insulin like growth factor (IGF) and fibroblast growth factor (FGF) both regulate the proliferation of 
progenitor osteoblast cells and osteoblast differentiation through the IGF receptor (IGFR) and 
FGF receptor (FGFR) (Chen et al 2012, Marie 2003). Wnt, Transforming Growth Factor-beta 
(TGFβ) and Bone Morphogenetic Proteins (BMPs) activate Lrp5/6 and fizzled receptor complex, 
TGF receptor and BMP receptors (BMPR) respectively to regulate the differentiation of 
mesenchymal stem cells to mature osteoblasts (Redlich & Smolen 2012). The Wnt - Fizzled 
pathway regulates osteoblast differentiation through the activation of cytoplasmic β-catenin 
whereas TGF and BMPs stimulation results in transcriptional activation of runt-related transcription 
factor 2 (RUNX2) through SMAD proteins (Redlich & Smolen 2012).  
One of the most important hormonal osteoblast regulation is through the ‘calcium homeostasis’ 
pathway. Increased serum calcium levels, results in secretion of calcitonin by the ‘C- cells’ of the 
thyroid gland. Increased serum calcitonin results increases the incorporation serum calcium into 
mineralised bone by activating osteoblasts. Calcitonin also inhibits osteoclast activity of 
mobilization of bone and calcium. When the serum calcium levels drop, parathyroid glands secrete 
the parathyroid hormone (PTH) which increases the osteoclast mediated bone resorption that 
releases calcium in the blood, hence regulating serum calcium levels (Copp & Cheney 1962).  
Osteoblasts express PTH receptor 1 (PTHR1) on their cell surface and intermittent PTH 
stimulation induces bone formation. Sex hormones, oestrogen and testosterone blocks PTH 
mediated osteoclast differentiation by affecting the hematopoietic blasts cells and by affecting 
osteoblasts. Oestrogen and testosterone stimulate osteoblasts by activating the Oestrogen 
receptors α and β (ERα/β) and androgen receptor (AR) respectively. The activation of ER and 
AR blocks the cAMP signalling of PTHR1 receptor that is in turn responsible for the activation of 
osteoclast differentiation (Kaji et al 1996). Activation of ER and AR also induces osteoblast 
differentiation in progenitor osteoblasts and downstream Src/Shc/ERK signally in mature 
osteoblasts that has an anti-apoptotic effect on the cells (Kung 2003). Oestrogen stimulation also 
reduces the secretion of interleukin 6 (IL-6) that promotes osteoclast activity. 
Another hormone that plays an important role in regulating osteoblast function is Insulin. Insulin 
secreted by the Beta-cells of the pancreas activates the insulin receptor (IR) expressed by 
osteoblasts and induces the production of osteocalcin which in turn increases the production of 
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insulin. Insulin also down regulates the production of osteoprotegerin (OPG), a decoy RANKL 
receptor (Karsenty & Ferron 2012).Insulin also promotes the production of Leptin in fat cells in 
the adipose tissue. Leptin activates the leptin receptor (LepR) present on the serotonin producing 
neurons of the raphe nuclei in the brainstem which results in activation of the sympathetic tonus 
(Paz-Filho et al 2012). This in turn activates the beta2 androgenic receptor on the osteoblasts 
(ADRB2) which increases the expression of Enterococcal surface protein (Esp) which down 
regulates osteocalcin mediated insulin production (Paz-Filho et al 2012). Several other hormones 
and cytokines not mentioned in this review regulate osteoblast activity. 
Figure 1.3 overleaf, summarises the complexity of osteoblast endocrinology and different receptors 
through which various organs regulate osteoblasts. 
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1.1.3.ii Osteocytes:  
 
 
Osteocytes are the most abundant cell type in the bone. These mono-nucleated cells with 
extended cytoplasmic processes are decedents of the mesenchymal stem cells resulting from 
osteoblast differentiation (Manolagas 2000, Marotti et al 1976) (see Fig 1.5(Bonewald 2011)). 
Osteocytes are generated from a subpopulation of osteoblasts that get trapped in the matrix in 
pockets called the osteocytic lacunae (Baud 1968), (Fig 1.4) (Franz-Odendaal et al 2006). Once 
the osteocytes are embedded in the matrix, they rapidly develop long dendritic extensions (Baud 
1968). The location of the osteocytes allows them to regulate bone remodelling in response to 
mechanical forces and thus act as mechanoreceptors of the bone (Ajubi et al 1999). Osteocytes 
also maintain the bone matrix by regulating calcium concentrations. There is evidence that the 
osteocyte cytoplasmic calcium concentration is about 1.5mM whereas the calcium concentration in 
the extra cellular matrix is a much lower of about 0.5mM (Baud 1968, Knothe Tate et al 2004). 
This suggests a continuous flow of calcium ions out of the cells and into the bone matrix (Knothe 
Tate et al 2004). 
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Fig 1.4: Osteocytes embedded in the bone matrix (black arrows) seen in tibia cortical bone. 
 
Fig 1.5: Osteoblast and osteocyte differentiation from mesenchymal stem cells and the various 
transcription factors involved in the process. Image adapted from (Bonewald 2011) 
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1.1.3.iii Osteoclasts: 
 
 
 
Osteoclasts are the bone resorbing multinucleated cells that descend from haematopoietic stem 
cells (Fig 1.6). Osteoclasts are generated from asynchronous fusion of precursor mono-nucleated 
cells and may have 4 -20 nuclei. Osteoclasts differentiation depends on RANK receptor activation 
from the RANKL produced by osteoblasts. Macrophage colony stimulation factor (M-CSF) which 
is essential for proliferation of monocytes is also essential for RANK formation (Yasuda et al 
1998).  Hence the key regulators of osteoclast differentiation include the cytokines: RANKL and 
M-CSF (Teti et al 1989, Udagawa et al 1990). The transcription factors that regulate osteoclast 
differentiation include NF-κB, c-Fos, MiTf and PU-1 (Franzoso et al 1997, Grigoriadis et al 1994, 
Hertwig 1942, Tondravi et al 1997). Osteoclast differentiation is summarised in Figure 1.7 below.  
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Fig 1.7: Schematic representation of osteoclast differentiation from hematopoietic stem cells and the various 
transcription factors involved. Image adapted from (Boyle et al 2003, Wendel et al 1998) 
 
Fig 1.6: Tartrate resistant acid phosphatase positive, multinucleated osteoclasts stained red (black arrows) 
seen on trabecular bone surface of tibia section. 
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Osteoclasts have abundant Golgi complex and mitochondria. The cytoplasm of an osteoclast has 
a foamy appearance due to the presence of large vacuoles. The transport vesicles within 
osteoclasts are filled with cathepsin K and tartrate resistant acid phosphatase (TRAcP) that are 
characteristic to these cells. The basolateral cell membrane expresses Na+ and K+ ATPase, 
Na+/H+ and HCo3-/Cl- exchangers and receptors such as RANK, OPG receptor, M-CSF receptor 
and Calcitonin receptor (CTR) (Nakagawa et al 1998, Teti et al 1989, Udagawa et al 1990). The 
bicarbonate exchangers expressed on the basolateral membrane remove excess bicarbonate from 
the cytoplasm to maintain intracellular pH (Hall and Chambers1989). 
Osteoclasts form Howship’s lacunae by resorbing the underlying bone matrix. The bone resorbing 
activity of osteoclasts depends on the stretch of plasma membrane that forms the zone of contact 
with the bone which is called the “ruffled border”. Around this zone of contact, actin in the cell 
cytoskeleton generates a sealing zone (Gothlin & Ericsson 1976). The ruffled border is rich in 
integrins, and Calcium channels (C1C7) that regulate adhesion and mobility of the cell, and 
produces ATPase that helps in resorbing the underlying bone (Blair et al 1989). The ruffled 
border also releases acids, metalloproteinases and cathepsins that degrade the bone matrix 
(Nesbitt & Horton 1997). The degradation products are removed via transcytosis (Väänänen et al 
2000). 
1.1.4 Bone remodelling: 
An adult skeleton is constantly broken down by osteoclasts and replaced by new bone formed by 
osteoblasts. This tightly regulated lifelong process is called bone remodelling. In humans, a bone 
remodelling cycle lasts for about 120 days (20 days resorption, 100 days bone formation) 
(Vignery & Baron 1980). Bone remodelling can either occur at the growth plate during skeletal 
development of occur as a part of the bone turnover process, where mature bone is replaced by 
new bone as a part of skeletal maintenance. 
The remodelling process is always initiated by recruitment and activation of osteoclasts. The 
recruitment and differentiation of osteoclasts is mediated by osteoblasts by releasing M-CSF and 
RANKL cytokines. Osteoclasts release enzymes to breakdown the underlying bone matrix. The 
resorption pits generated by the osteoclasts release local factors such as osteocalcin, calcium, 
hydroxylproline which then recruit osteoblasts and inhibit osteoclast-mediated resorption. 
Osteoclasts also release insulin like growth factors (IGFs) that inhibit their own activity and 
enhance osteoblast activity (Mackie 2003). This is known as the early resorptive phase. On 
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completion of resorption of the bone, the osteoclasts leave the resorption site and osteoblasts 
migrate into the resorption site (reversal phase) and produce new bone (formative phase). A sub 
population of the osteoblasts get mineralised and embedded in the new bone matrix forming  
osteocytes, and others form the bone lining of the completely mineralised (Franz-Odendaal et al 
2006, Manolagas 2000). It is important that the initiation and termination of both resorption and 
formation of bone occurs properly. This mechanism is called coupling (Parfitt et al 1987). Once 
the formation of the new osteon is completed, the bone goes into the quiescent phase. Bone 
remodelling occurs in small regions called the bone multicellular units (BMUs), and each BMU is 
different from the other (Frost 1991, Hill 1998, Parfitt et al 1987). It is therefore evident that the 
bone microenvironment regulates the cell activation sequence. The interaction between osteoblast 
and osteoclast at the resorption site is summarised in Figure 1.8 below (Stein 1999). 
 
 
 
 
 
 
 
 
 
 
 
Many hormones including insulin, oestrogen, testosterone, parathyroid hormone (PTH), growth 
hormone (GH), calcitonin family of peptides, 1,25-dihyhroxy vitamin D3, glucocorticoids and 
thyroid hormones are known to regulate bone remodelling (Canalis 1983, Mackie 2003). Bone 
remodelling is also regulated by the mechanical use of skeleton and  growth factors such as 
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Fig 1.8: Schematic representation of the interactions between osteoclast (red) and osteoblasts (blue) at the 
bone resorption site whilst bone remodelling. The zone under osteoclasts (marked with dotted line) is the 
resorption pit generated by the osteoclast. Image adapted from (Stein 1999) 
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insulin like growth factor (IGF) I and II, platelet derived growth factor (PDGF), interleukins (IL1 
and 6), transforming growth factor-b (TGF-b) and tumor necrosis factor (TNF) (Canalis 1983, 
Mackie 2003). An imbalance in the levels of any of these growth factors or hormones results in 
an imbalance in bone remodelling which in turn results in a compromised bone quality. 
Additionally, since many of these hormones also regulate differentiation of osteoblasts and 
osteoclasts, an altered hormone level can also result in alteration in cell population of either cell 
types eventually contributing to compromised bone quality. 
Compromised skeletal quality increases bone fragility that leads to skeletal disorders characterised 
with frequent fractures, inflammation and pain. Skeletal disorders are amongst major health 
concerns worldwide. Apart from pathological disorders like osteoporosis, Paget’s disease, 
osteonecrosis, osteogenesis imperfect, osteoarthritis and osteomyelitis, skeletal disorders can also 
result from metastatic cancer and prolonged cancer treatments like glucocorticoids, aromatase 
inhibitors and androgen deprivation (Confavreux et al 2007, Love et al 1992, Lukert 1992, Lukert 
et al 1992).    
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1.2 Osteoporosis 
Amongst the various skeletal disorders, the most common disorder is Osteoporosis. Osteoporosis 
is defined as “a skeletal disease characterized by compromised bone strength predisposing a 
person to an increased risk of fracture. Bone strength primarily reflects the integration of bone 
density and quality.”(Klibanskie 2001). Figure 1.9 below is a representative scanning electron 
micrograph image comparing healthy and osteoporotic bone. 
 
 
 
According to National Health Service (NHS), about 3 million people are estimated to suffer from 
osteoporosis in the U.K that accounts for about 0.3 million fractures every year. The mortality rate 
of patients has been estimated to be as high as 10-20% due to frequent fractures (Lewiecki 
2004). Death usually occurs due to hospital acquired infections due to frequent admissions to 
hospital. Patients who recover suffer loss of independence and shortened lifespan subsequently. 
Although most commonly osteoporosis is associated with post-menopausal women, men and 
young adults can also be affected. Hormonal disorders such as reduction in oestrogen or 
testosterone, hyperthyroidism, pituitary gland disorders, hyperparathyroidism, Cushing’s syndrome 
(adrenal gland) are commonly associated with osteoporosis. In men, osteoporosis can be caused 
by low testosterone levels, hypogonadism or use of glucocorticoids. In women the predominant 
reason for osteoporosis is menopause although, hysterectomy before the age of 45 or loss of 
Fig 1.9: Scanning electron micrograph of normal (left) and osteoporotic bone (right). By kind permission of  
Prof . Tim Arnett (Bone Research Society). Osteoporotic bone shows compromised bone integrity.  
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menstrual periods due to over dieting is also associated with osteoporosis. It is observed that 
women (80%) are more prone to develop osteoporosis than men (20%) (Lewiecki 2004). 
1.2.1 Diagnosis and current therapies:  
Osteoporosis is diagnosed by measuring bone mineral density (BMD) using dual energy X-ray 
absorptiometry scan (DEXA). The standard deviation of the difference in patient’s BMD and that 
of a health young adult is calculated as the “T-score”. A T-score above -1 is normal, between -1 
and -2.5 is classified as osteopenia and below -2.5 is classified as osteoporosis. 
According to the National Institute for health and Clinical Excellence (NICE) guidelines, treatment 
for osteoporotic patients depends on sex, whether patient is post-menopausal and if he/she has 
a previous history of fractures. All patients diagnosed of osteoporosis are prescribed calcium and 
vitamin D supplements. Exercise and change in lifestyle may be recommended to patients. Most 
common therapeutics used in the U.K, according to NICE guidelines, are summarised and 
detailed overleaf (Figure 1.10) 
 
 Fig 1.10: Schematic representation of major therapeutic approaches used to treat osteoporosis patients in 
the UK according to NICE guidelines.  
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A complete comprehension of the therapies for osteoporosis is beyond the scope of this project. 
However, the mode of action for a few main therapies is described below: 
1.2.1.i Bisphosphonates: Bisphosphonates are a class of inorganic pyrophosphate analogues that 
have a high affinity to bone mineral during bone resorption (Rogers et al 1994). Nitrogen 
containing bisphosphonates such as Alendronate and Risedronate, act on the mevalonate 
pathway by hindering the prenylation of GTP-binding proteins, such as Rho, Ras and Rab by the 
enzyme farnesyl pyrophosphate synthetase (FPP) (Luckman et al 1998, Rogers et al 1999, van 
Beek et al 2003). This induces apoptosis in osteoclasts. Non-nitrogen containing bisphosphonate 
like Etidronate, Clodronate cripples osteoclast activity hence reducing bone resorption (Auriola et 
al 1997, Russell & Rogers 1999). 
1.2.1.ii Strontium renelate: Strontium ranelate, a strontium salt of ranelic acid, is a substitute for 
calcium. The nucleus size of Strontium is similar to Calcium and is hence absorbed by the body 
and incorporated in bone and teeth enamel. It increases bone formation by increasing osteoblast 
precursor proliferation and reduces bone resorption by hindering osteoclasts differentiation (Marie 
et al 1993, Meunier 2004, Meunier et al 2004). 
1.2.1.iii Selective oestrogen receptor modulator (SERM): SERM - Raloxifene is a synthetic 
compound that selectively act as antagonist or agonist in different tissues (Jones et al 1984). 
Raloxifene is used to prevent fractures in post-menopausal breast cancer patients, as it acts as 
an antagonist in uterus and breasts. However, it acts as an agonist in bone hence protecting bone 
loss resulting from oestrogen deprivation (Jones et al 1984).  
1.2.1.iv Recombinant PTH and anti-RANKL therapy - Teriparatide and Denosumab: 
Teriparatide is a recombinant human parathyroid hormone (1-34) of the whole 84 amino acid 
peptide which on regular administration of smaller doses results in anabolic skeletal effect (Deal & 
Gideon 2003, Dempster et al 1993, Hori et al 1988). Teriparatide can be prescribed in 
combination with Denosumab, a monoclonal antibody against RANKL to RANK which is important 
for osteoclast formation as a more efficient treatment than either agent alone (Lacey et al 1998, 
Tsai et al 2013).  
In spite of their effectiveness to reduce fracture risk, these therapies have several side effects. 
Bisphosphonates are not prescribed to patients with stomach and kidney related pathological 
symptoms. There are reports of patients not taking bisphosphonates due to nausea, dyspepsia, 
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and diarrhoea (Ettinger et al 1998). There is compelling evidence to support that both 
bisphosphonates and Denosumab cause osteonecrosis of jaw resulting from reduced bone 
remodelling rate (Compston 2011, Odvina et al 2005). However this is only true when 
concentrations of drugs are administered as in oncology levels. Strontium ranelate is reported to 
increase risk of venous vein thromboembolism and is not suitable for patients suffering from 
phenylketonuria as it contains a phenyl group (NICE guidelines). In the NICE survey on ‘The 
clinical effectiveness and cost effectiveness of prevention and treatment of osteoporosis’ (2004), 
it was reported  that despite reducing the risk of breast cancer related skeletal destruction SERMs 
result in deep vein thrombosis and is hence not prescribed to patients with thromboembolism. 
Another drug that is recently been discontinued by the European Medicines Agency 2012, is the 
nasal spray of synthetic salmon Calcitonin (sCT) due to increased risk of developing cancer. 
However the sCT injections are still administered but are restricted to Paget’s disease patients 
and to vertebral fracture patients (European-Medicines-Agency 20 July 2012). 
Since all the current major therapies except for Teriparatide, are anti-resorptive they lead to a low 
bone turnover state where bone formation also decreases with the decrease in bone-remodeling 
activity (Baron & Hesse 2012). The need for discovering bone anabolic therapies hence, 
demands itself. Ideally, the anabolic therapy should induce bone formation by the quiescent bone 
surface that is not simultaneously undergoing bone remodelling (Lane & Kelman 2003). Many 
promising anabolic therapies include parathyroid hormone related peptide analogues (PTHrP), 
Calcium sensing receptor and the members of the Calcitonin family of peptides. 
Calcitonin family of peptides mainly comprise Calcitonin (CT), Calcitonin gene related peptide 
(CGRP), Amylin (AMY) and Adrenomedullin (AM). Each of these peptides influences skeletal 
regulation. However, with recent evidence of the accessory proteins that subtly modulate the 
receptor pharmacology of the CT family of peptides, new targets for skeletal therapies have been 
identified. In this study we focussed on the effects of accessory proteins called the Receptor 
Activity Modifying Proteins (RAMPs) on skeletal regulation through CT family peptide.  
It is therefore important to understand the endocrinology of the CT family of peptides and to 
review the effects of these peptides and their receptors on the skeleton.  
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1.3 Calcitonin family of peptides 
As mentioned earlier the calcitonin (CT) family of peptide comprise CT, CGRP, AMY and AM 
principally. Recently Intermedin is included in the group (Amara et al 1982, Cooper et al 1987, 
Copp & Cheney 1962, Kitamura et al 1993a). These peptides have a characteristic secondary 
structure. They all have a 6-7 amino acid (aa) ring formed by disulphide bonds between two Cys 
residues towards the N-terminus and amidation at the C-terminus of the peptide (Albrandt et al 
1995). The structure, expression and function of each of these peptides are reviewed in the 
following sections.   
1.3.1 Calcitonin (CT): 
 
 
 
 
Calcitonin (CT) the founder member of the CT family of peptide, is a 32 amino acid peptide with 
an amidated C-terminus and a disulphide bridge at the N–terminus forming a 7 amino acid ring 
(Fig 1.11). In humans mature CT results from a 141 amino acid precursor peptide known as the 
prepro-calcitonin (PreProCT) which originates from the calcitonin-1 gene (CALC-I) on 
chromosome 11 (Becker KL 1996, Becker L 1995, Copp & Cheney 1962). Alternate splicing of 
CT gene at exon 4 results in a 37 amino acid peptide, Calcitonin gene related peptide (CGRP) 
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Fig 1.11:  Calcitonin, 32 amino acid peptide with amidated C-terminus and a 6 ring structure at N-terminus formed 
due to disulphide bride between C1 and C7. Adapted from MSc thesis: RAMPs potential role in regulation of bone 
mass and skeletal disorders, 2008, University of Sheffield. 
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(Amara et al 1982). CGRP is a neuropeptide and a potent vasodilator, which was first reported in 
rat and then in human (Evans et al 1983, Tippins et al 1984).   
CT is primarily secreted by C cells in thyroid gland in response to increase in serum calcium 
levels (Copp & Cheney 1962, Neher et al 1968). CT is known to play an important role in 
calcium homeostasis as it regulates production of 1α,25 (OH)2D3 and tubular reabsorption of 
calcium in the kidney (Sexton et al 1999, Shinki et al 1999). But most importantly CT inhibits 
extracellular Ca2+ sensing, thereby activating a potent anti-resorptive signal resulting in decrease 
in skeletal resorption (Zaidi et al 1996).  
A single large dose of CT decreases serum levels of Luteinizing hormone (LH), testosterone and 
Follicle-stimulating hormone (FSH) in humans (Mulder 1993). On the other hand upon chronic 
administration of CT, increase in serum β-endhorphin, cortisol and Adrenocorticotropic hormone 
(ACTH) levels are reported in migraine patients (Becker L 1995). 
CT interacts via a 7 transmembrane G – protein coupled receptor known as the Calcitonin 
receptor (CTR) which is highly expressed in renal cells, neural cells, breast cancer cell lines and 
most importantly in osteoclasts but not in osteoblasts (Findlay & Sexton 2004, Wang et al 
2004). Activation of CTR results in intracellular adenylate cyclase and phospholipase C (PLC) 
enzyme activation mediated signalling (Findlay & Sexton 2004). 
Osteoclasts are sensitized to parathyroid hormone induced (PTH–induced) stimulation, on CT 
withdrawal, resulting in increased serum Ca2+ levels and urinary deoxypyridinoline (DPD) cross 
links, which is a bone resorption marker (Zaidi et al 2002). CT also down regulates osteoclast 
mediated bone resorption (Wallach et al 1999). This phenomenon is supported by in vitro 
evidence of rapid cessation in mobility and size reduction of osteoclast upon CT administration 
(Chambers & Magnus 1982, Nicholson et al 1986). CT is also known to interfere with 
osteoclastogenesis, by hindering mononucleated cell fusion to form multinucleated osteoclasts 
(Takahashi et al 1988). It is one of the most potent antiresorptive hormones and is cleverly 
exploited during physiological calcium stress. 
Despite convincing evidence, physiological importance of CT in skeletal maintenance is 
challenged by experiments in transgenic animals and unanswered phenomena like, why 
thyroidectomy or increased Ca2+ levels in case of medullary thyroid carcinoma fails to induce 
osteoporosis (Zaidi et al 2002) remain unknown. Global CT/CGRP knockout (KO) animals 
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interestingly exhibit osteosclerotic phenotype with increased trabecular bone volume due to 
elevated bone formation (Hoff et al 2002). Basal calcium metabolism parameters such as levels 
of serum Ca2+, PTH, phosphorous and 1α,25 (OH)2D3 were the same in both KO and wild type 
(WT) animals (Hoff et al 2002). Interestingly there was an increase in serum Ca2+ and urinary 
DPD levels, 2 to 4 hr post exogenous human PTH (hPTH) treatment in KO but not WT. This 
suggested that hPTH induced bone resorption in KO animals. The resorptive effect of exogenous 
PTH was neutralised by the increased serum CT levels in WT animals suggesting that the bone 
resorption in KO animals was due to the lack of functional CT (Hoff et al 2002). Following this 
study Gagel et. al. in 2007 reported that osteosclerotic phenotype of the global CT/CGRP KO 
mice is lost after backcrossing to a C57BL/6 homogenous background; however there is instead 
an age related skeletal phenotype observed with increased cortical porosity (Davey et al 2008, 
Gagel RF et al 2007). Certainly, effect of CGRP on bone metabolism, confounds the phenotype 
resulting from CT/CGRP global KO (Davey et al 2008). It is not only important to carry out 
individual KO studies for each of these peptides, but also to understand the individual 
mechanisms through which they conserve skeletal tissues.  
1.3.2 Calcitonin gene related peptide (CGRP): 
 
 
 
As mentioned earlier the CALC 1 gene transcribes two distinct mRNAs that translate into a 32 
amino acid CT and 37 amino acid long Calcitonin gene related peptide (CGRP) (Fig 1.12 and 
1.13) (Amara et al 1982, Nagasaki et al 2004). It was reported that these two different mRNA 
 Fig 1.12:  CGRP, 37 amino acid peptide with amidated C-terminus and a 6 ring structure  at  N-
terminus formed due to disulphide bride between C2 and C7. Adapted from MSc thesis: RAMPs 
potential role in regulation of bone mass and skeletal disorders, 2008, University of Sheffield. 
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variants had a tissue specific expression (Amara et al 1984). CT is expressed primarily in C cells 
of thyroid, whereas CGRP is expressed mainly in brain, spinal cord and cranial nerve ganglia 
(Rosenfeld et al 1983). CGRP resulting from the CALC 1 gene is known as CGRP α. An isoform 
of CGRP α, CGRP β, is produced from a different gene which shares sequence homology with 
the CALC1 gene. In human, both these isoforms differ by a single amino acid (O'Connell et al 
1993, Steenbergh et al 1985). 
 
 
 
 
 
 
Apart from the brain (Mulderry et al 1985, Rodrigo et al 1985) and spinal cord, CGRP is also 
highly expressed in pituitary (Tschopp et al 1985), nerve fibres throughout cardiovascular system 
(Brain et al 1985), lungs, thyroid, pancreatic islets, gastrointestinal tract (Kraenzlin et al 1985), 
Fig 1.13: Schematic representation of alternate splicing of CALC 1 gene resulting in Calcitonin and 
Calcitonin gene related peptide (CGRP). Adapted from Nagasaki et. al. 2004. Image previously 
represented in MSc thesis: RAMPs potential role in regulation of bone mass and skeletal disorders, 2008, 
University of Sheffield. 
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urogenital tract (Ghatei et al 1985) and blood vessels. CGRP is a known neurotransmitter and a 
highly potent vasodilator. In skeletal muscles, CGRP increases cAMP accumulation and inhibits 
incorporation of glucose into glycogen thus reducing glucose uptake (Beaumont, Pittner et al. 
1995). 
Like CT, CGRP influences skeletal regulation. CGRP increases mineralisation in osteoblast 
cultures by inhibiting tumor necrosis factor α (TNFα) and activating interleukin 6 (IL6) and insulin 
like growth factor -1 (IGF-1) (Michelangeli et al 1989, Millet & Vignery 1997, Sakagami et al 
1993, Shih & Bernard 1997). CGRP also induces subtle anti-resorptive effects by hindering 
osteoclast development (Shih & Bernard 1997). Systemic administration of CGRP induces 
increase in bone mineral density which is osteoblast mediated (Ballica et al 1999). Furthermore a 
similar effect on osteoblasts is observed in vitro.   
1.3.3 Amylin (AMY): 
 
 
 
 
Amylin (AMY) or islet amyloid polypeptide (IAPP) was purified and sequenced from amyloid rich 
pancreas of type 2 diabetes patients, under the name diabetes-associated peptide (DAP). AMY 
gene, which is the gene for prepro-IAPP, is localized to the locus 12p12.3-p12.1 and shares 
             Fig 1.14:  Amylin: a) 37 amino acid peptide with amidated C-terminus and a 6 ring structure at N-terminus 
formed due to disulphide bride between C2 and C7. b) Micelle bound human AMY structure (Hauschka 
1986, Patil et al 2009). Adapted from MSc thesis: RAMPs potential role in regulation of bone mass and 
skeletal disorders, 2008, University of Sheffield. 
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regulators with the insulin gene (Bronsky et al 2006, German et al 1992). It is a 37 amino acid 
peptide and has 46% and 43% sequence similarity with CGRP α and β respectively (Cooper et al 
1987) (Fig 1.14). 
AMY is principally stored in β cell secretary granules of pancreatic islets and co-secreted with 
insulin in response to glucose levels (Kanatsuka et al 1989, Lukinius et al 1989, Pieber et al 
1993). Amylin, like CGRP, helps insulin in reducing glucose uptake by inhibiting the incorporation 
of glucose into glycogen in skeletal muscles (Beaumont et al 1995, Leighton & Foot 1990, Pittner 
et al 1994).  
AMY is thought to increase glycogenolysis by cAMP mediated mechanism (Pittner, Beaumont et 
al. 1995). But a cAMP independent mechanism is also hypothesised, where there is an increase 
in intracellular glucose 6 – phosphate (G-6-P) which results in reduction of glucose 
phosphorylation by hexokinase, and retention of transported glucose (Castle et al 1998, Deems et 
al 1991, Pittner et al 1995). This function requires an intact disulphide bond between Cys2 and 
Cys7 and the amide at C-terminus (Pittner et al 1994). Both insulin and AMY expression and 
secretion rise with insulin resistant states, although in hyperglycaemic conditions, AMY secretion 
exceeds insulin levels (Pieber et al 1993). AMY also reduces food intake, gastric empting and 
intestinal transit thereby regulating the rate of appearance of glucose in blood stream after meals 
(Clementi et al 1996, Lutz et al 1994). It is also expressed in intestine, stomach, lungs and brain 
(Asai et al 1990, Ferrier et al 1989).  
Human AMY, forms stable aggregates called amyloid deposits, which underlines the disease 
pathogenesis of type 2 diabetes. The fibrillar structures in the deposits have a cytotoxic effect on 
the insulin producing β cells, causing cell death and eventually islet destruction (de Koning et al 
1994). Interestingly rat AMY which differs from human AMY by 6 amino acids, in the 18–29 
region; 3 of which are Proline substitutions at positions 25, 28 and 29, does not form fibrils 
(Green et al 2003, Leffert et al 1989). Owing to this pathogenic effect, human AMY is not used 
in research.  
Another functional similarity between CGRP and AMY is that AMY increases intracellular cAMP 
levels and stimulates Na+-K+ pumps in skeletal muscle (Clausen 2000, Pittner et al 1994). This 
Na+-K+ pump stimulation results in Na+ efflux and K+ influx in skeletal muscles. Intravenous 
infusion of AMY in rats resulted in a 16% drop in plasma K+, which is inferred to be a result of K+ 
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uptake by skeletal muscle (Clausen 2000, Vine et al 1998). Results from this study implicate that 
AMY can be a potential therapeutic target to treat hyperkalemia (Clausen 2000). 
The receptor for AMY is a heterodimer of CTR and RAMP1/2/3 (Christopoulos et al 1999, Muff 
et al 1999, Parameswaran & Spielman 2006). As mentioned earlier, in skeletal system, CTR is 
expressed in osteoclasts but not in osteoblasts (Findlay & Sexton 2004, Wang et al 2004). This 
indicates that osteoblasts lack the AMY receptor. AMY administration resulted in hypocalcaemia 
(Une et al 1993). AMY also reduces basal PTH mediated resorption in calvarial bone of neonatal 
mice, which is thought to be due to effect of AMY on osteoclasts (Pietschmann et al 1993). 
Interestingly Jill Cornish in 1995, reported, that along with increase in intracellular cAMP, AMY 
also stimulated osteoblast proliferation in both in vivo and in vitro models (Cornish et al 1995). 
This implicates the presence of a AMY receptor on osteoblasts (Cornish et al 1998b). Since AMY 
does both, decrease the rate of bone resorption and increase osteoblast proliferation, it becomes 
a potential candidate for treating local skeletal defects (Ellegaard et al 2010). Another interesting 
aspect of this combined function is that N-terminal fragment AMY(1-8), retains the osteoblast 
proliferative function but loses the antiresorptive regulation (Cornish et al 1998b). AMY 
administration partially reverses osteopenia in overiectomized (OVX) rats (Horcajada-Molteni et al 
2000). Systemic administration of both full length and AMY (1-8) in mice, for 4 weeks, resulted 
in increased bone volume at nanomolar concentrations (Cornish et al 2000, Cornish et al 
1998a). Local administration of AMY (1-8) resulted in increase in bone volume, tibial length, and 
cortical and trabecular thickness in male mice (Cornish et al 2000). However this report is 
questioned by a recent research which demonstrated that AMY (1-8) lacks skeletal anabolic 
activity in bone in vivo and in vitro (Ellegaard et al 2010) 
AMY or IAPP KO mice were generated by Gebre-Medhin’s group in 1998 who studied insulin 
secretion and glucose tolerance in these models (Gebre-Medhin et al 1998). Their study 
suggested that AMY KO males but not females, had increased body mass, increased insulin 
response and reduced plasma glucose levels (Gebre-Medhin et al 1998). A similar sex 
dependent phenotype was observed by Rachel Davey’s group in 2006. This group studied the 
same model for skeletal phenotype and it was observed that AMY KO males had increased 
femoral length and growth plate height (Davey et al 2006). The KO males also had increased 
trabecular thickness (TbTh) in the distal femora with no change in net trabecular bone volume 
(BV) (Davey et al 2006). Although in both the sexes, adult AMY KOs had a net decrease in 
trabecular BV and increased trabecular number (N) (Davey et al 2006). 
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1.3.4 Adrenomedullin (AM): 
   
 
 
Adrenomedullin (AM) was discovered as a hypotensive peptide by monitoring elevated rat platelet 
cAMP activity and was found abundantly in normal adrenal medulla and in pheochromocytoma 
tissues arising from adrenal medulla (Kitamura et al 1993a). Two transcripts arise from the AM 
gene AM1 and AM2 (recently termed as Intermedin) (Bell & McDermott 2008). AM shares a 
slight sequence homology to both CGRP and AMY, although the 14 amino acid elongations at the 
amino terminal is not observed in any other member of CT family of peptides (Kitamura et al 
2002, Kitamura et al 1993a). In humans, AM is a 52 amino acid peptide with an intramolecular 
disulphide bond between C16 and C21 and has an amidated Tyrosine at the carboxy terminus 
(Kitamura et al 1993a) (Fig 1.15). 
Mature AM peptide arises from a precursor peptide called the preproadrenomedullin (preproAM) 
which contains 185 amino acid residues (Kitamura et al 1993b). This preproAM is thought to 
synthesise both proadrenomedullin (proAM) and a 20 amino acid hypotensive peptide called the 
“Proadrenomedullin N-terminal 20 peptide (PAMP)” (Kitamura et al 1994, Kitamura et al 1993b). 
AM gene consists of 4 exons, where the mature AM is encoded in exon 4 and PAMP in encoded 
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Fig 1.15:  Adrenomedullin: a) 52 amino acid peptide with amidated C-terminus and a 6 ring structure 
due to disulphide bride between C16 and C21 (Kitamura et al 2002, Mohan & Baylink 1991). Adapted 
from MSc thesis: RAMPs potential role in regulation of bone mass and skeletal disorders, 2008, 
University of Sheffield. 
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in exon 2 (Okazaki et al 1996). There are 2 activator protein 1 (AP1) binding sites and 8 
activator protein 2 (AP2) binding sites upstream of 5’ region of exon1. Additionally exon 1 also 
has consensus sequences for cAMP-regulated enhancer (CRE) (Fink et al 1988, Okazaki et al 
1996). It is believed that AP2 mediates transcription activation on protein kinase C and cAMP 
induction and so AM expression is thought to be regulated by these two signal transduction 
pathways (Kitamura 2002, Imagawa 1987). Since AM is known to stimulate platelet cAMP, 
presence of AP2 binding site and presence of CRE sequence suggest a feedback mechanism 
(Kitamura 2002). Apart from this, AM gene promoter has a nuclear factor kB (Nf-kB) site and the 
5’ flanking region has TATA, CAAT and CC boxes which are important in the transcriptional 
regulation of AM gene (Kitamura et al 2002). 
AM receptors are heterodimers of CLR and RAMP2/3 (Christopoulos et al 1999, Muff et al 1999, 
Parameswaran & Spielman 2006). At cellular level, AM induces various signal transduction 
pathways. Dose dependent increase in intracellular cAMP on AM administration is a well-
established phenomenon (Kitamura et al 1993a). Increase in intracellular ionic calcium Ca2+ is 
reported in bovine aortic endothelial cells (Shimekake et al 1995). Apart from cAMP and protein 
kinase C, AM is also thought to induce nitric oxide (NO) pathway. It has been reported that most 
of the vasodilator activity of AM results from NO generation in the vasculature (Yang et al 1996). 
This was confirmed by the counter action of the nitric oxide synthase (NOS) inhibitor and de-
endothelialisation (Yang et al 1996). Increase in intracellular Ca2+ on AM administration, is 
hypothesised to activate phospholipase C, which in turn produces NOS and NO (Kitamura et al 
2002). 
Normal human plasma AM concentration is 1- 10 pmol/l suggesting AM expression in peripheral 
tissues (Hinson et al 2000). AM is expressed in lung and kidney apart from the adrenal medulla 
(Kitamura et al 1993a). In the cardiovascular system, AM is synthesised by heart and blood 
vessels (Kitamura et al 1993b). AM is also expressed in the reproductive organs- uterus, ovary, 
oviduct, testis, prostrate and the epididymis (Cameron & Fleming 1998, Chan et al 2008a, Chan 
et al 2008b, Li et al 2010, Li et al 2008, Upton et al 1997, Yang et al 1996). In the adrenal 
medulla, AM is stored in granules and is released by regulatory pathways, whereas in other 
tissues it is hypothesised to be rapidly synthesized and secreted in blood or act as an autocrine-
paracrine regulator (Bean et al 1994, Kitamura et al 2002). In most of the tissues mentioned 
above, co-expression of AM and its receptors is reported, this emphasises the autocrine–
paracrine regulation (Kitamura et al 2002). 
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AM is considered to be one of the most potent endogenous vasodilators (Cockcroft et al 1997). 
The importance of AM in normal development of vascular smooth muscles was recently elucidated 
by Kathleen Caron’s group (Caron & Smithies 2001). Extreme hydrops felatis was observed in 
E12.5 mice embryos of AM global KO (Fig 1.16). The yolk sac of KO animals was distended with 
fluids resulting from the massive oedema (Fig 1.16).  
 
 
 
 
 
 
Abnormality in the lymphatic vessel development was suggested to be a plausible explanation in 
the observed phenotype, as lymphatic vessels sprout from veins at E12.5 in mice, which coincides 
with the onset of hydrops in these animals (Caron & Smithies 2001).  
In rat models, intra-cerebroventricular administration of AM induces hypertension, tachycardia and 
consequent increase and decrease in renal synaptic nerve activity (Kitamura et al 2002, Saita et 
al 1998). In kidney, AM dilates both afferent and efferent arterioles, reflecting a renal vasodilator 
and diuretic activity of the peptide (Hirata et al 1995, Kitamura et al 2002).  
Effect of AM peptide (full length or AM-(27–52) fragment) stimulation, varies in different tissue 
preparations. AM inhibits proliferation of vascular smooth muscle cells and induces significant 
proliferation in primary canine chondrocytes from articular cartilage, and in both primary 
osteoblasts and in osteoblastic cell lines (Cornish et al 1997, Cornish et al 2003, Kano et al 
1996). This mitogenic effect of AM was similar to the effect resulting from insulin like growth 
factor – 1 (IGF-1) and transforming growth factor-β, which might be of significance (Cornish et al 
1997). Two different secondary messengers involved with GPCR activation - cAMP and 
diacylglycerol. Both these secondary messengers are hypothesised to be responsible for the two 
contradictory proliferative effects in different tissues (Cornish et al 1997). The effect on 
osteoblasts, is hypothesised to involve mitogen-activated protein kinase (MAPK) signal 
transduction in contrast to cAMP activation (Cornish et al 2003). IGF -1, AMY and AM are 
        
Fig 1.16: Fig 3 from Caron et. al. showing a) the distended yolk sack and c) extreme hydrops fetalis in AM 
KO(-/-) E12.5 mice embryos. With kind permission from Prof Caron (University of North Carolina) (Caron 
& Smithies 2001). 
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thought to share the same molecular mechanism to result the mitogenic effect on osteoblasts 
(Cornish et al 2004). Local administration of AM resulted in a 2-4 fold increase in bone formation 
indices and a dose dependent increase of bone area (Cornish et al 1997). Interestingly, unlike 
AMY, AM does not influence osteoclast mediated bone resorption drawing our attention to the 
difference in receptor expression in osteoclasts and osteoblasts (Cornish & Reid 2001). 
1.4 Receptors of the CT family of peptides 
Functional receptors for the CT family of peptide arise from heterodimers formed between family-
B (Secretin-like) GPCRs - Calcitonin receptor (CTR) or Calcitonin like receptor (CLR) and 
accessory proteins called the Receptor activity modifying proteins – RAMPs. The structural and 
functional aspects of individual proteins are discussed briefly in the following sections. 
1.4.1 Calcitonin receptor (CTR) and Calcitonin like receptor (CLR): 
Calcitonin receptor was cloned in 1993 by Sexton et. al. and was identified to be a 474 aa 
peptide which acted as a receptor for CT (Sexton et al 1993). The gene for CTR – CALCR is 
localised to 7q21.3 on the chromosome (Sexton et al 1993). Soon another functional receptor - 
CLR (461 aa) was discovered which was identified to be a receptor for CGRP, and the gene - 
CALCRL was found to be localised to 2q32.1 (Fluhmann et al 1995, Gorn et al 1992). Both CTR 
and CLR have a typical GPCR structure of seven transmembrane domains (TM1 – TM7) which are 
connected by three intracellular loops (IC1, IC2 and IC3) and three extracellular loops (EC1, EC2 
and EC3) and have a intracellular carboxy terminus and extracellular amino terminus (Fig 1.17 
overleaf) (Harmar 2001). The intracellular C-terminus interacts with GTPase/G protein, a hetero-
trimer complex formed by α (associated with GTP), β and γ subunits (Harmar 2001). An in-depth 
GPCR activation discussion is beyond the scope of this review, but briefly - a typical GPCR 
activation results from a conformational change in GPCR following ligand interaction that 
dissociates the Gα subunit from the Gβ and Gγ subunit, which further activates downstream 
intracellular signalling pathways like cAMP or phosphatidylinositol signalling (Harmar 2001). 
These downstream signal transductions depends on the type of α subunit Gαs, Gαi/o, Gαq/11  and  
Gα12/13 (Harmar 2001).  
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Since CTR and CLR were identified to be receptors for CT, which was a known to be a 
hypocalcaemic peptide, there was an impetus in skeletal research with respect to CTR and CLR. 
CTR is expressed in osteoclasts but not in osteoblast, whereas CLR is expressed in both 
osteoclasts and osteoblasts (Findlay & Sexton 2004, Nicholson et al 1986, Wang et al 2004). 
Homozygous deletion of exon 6 and 7 of CTR results in embryonic lethality whereas haplo-
insufficient CTR animals had increased bone formation with no influence on bone resorption 
(Dacquin et al 2004). To study the effects of CTR deficiency, Davey et al generated a viable 
global CTR KO mice line which had >94% but <100% deletion of CTR, using the Cre-lox system 
that excised exon 13, 14 and 3’UTR (Davey et al 2008). These KO animals showed protection 
against induced hypercalcaemia (Davey et al 2008). Global CLR deficiency resulted in embryonic 
lethality – midgestation death due to extreme hydrops fetalis (Dackor et al 2006). 
 
 
 
Fig 1.17: Predicted CLR structure showing 7 transmembrane domains and a large extracellular amino 
terminus that takes part in forming the receptor. Courtesy of Prof. Tim Skerry, Prof Artymiuk, and Dr Richards 
(University of Sheffield). Previously reported in MSc thesis: RAMPs potential role in regulation of bone mass 
and skeletal disorders, 2008, University of Sheffield. 
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1.4.2 Receptor Activity Modifying Proteins (RAMPs): 
The known receptor pharmacology of CT family of peptides changed dramatically on the discovery 
of accessory proteins called the receptor-activity-modifying-proteins (RAMPs), by Linda 
McLatchie and her group in 1998 (McLatchie et al 1998). Until then, functional receptors for 
CGRP, AM and AMY remained unidentified. Rhodopsin-like receptors (RDC1), CLR and G10D 
(GPCR 182) were amongst the hypothesised receptors for CGRP and AM (Fluhmann et al 1995, 
Kapas et al 1995, McLatchie et al 1998). McLatchie cloned the first RAMP protein by expression-
cloning strategy using SK-N-MC cell complementary DNA library. Xenopus oocytes were injected 
with pools of RNA, complementary to the cDNA libraries, and were then screened for cAMP 
response on CGRP stimulation. Following repeated screening and subdivision, a cDNA encoding 
148 amino acids peptide was isolated, which was called RAMP1. Interestingly RAMP1 like CLR, 
on its own did not result in a cAMP response to CGRP. It was later determined that both RAMP1 
and CLR form a heterodimer which forms a functional receptor for CGRP and that RAMP1 was 
also obligatory for CLR trafficking to the cell surface (McLatchie et al 1998). RAMP1 protein 
sequence has a single transmembrane domain towards the carboxy terminal and a long amino 
terminal signal sequence (Fig 1.18). 
 
 
Fig 1.18:  Proposed RAMP1 structure by Prof. Artymuk, Prof Skerry and Dr Richards (University of Sheffield). 
This proposed structure exhibits a large extracellular domain, followed by a single transmembrane domain and 
a short intracellular carboxy terminus. Previously published in MSc thesis: RAMPs potential role in regulation 
of bone mass and skeletal disorders, 2008, University of Sheffield. 
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The long N-terminal sequence determines the ligand specificity of CLR by actively forming a part 
of the receptor or by altering CLR structure in such a way that it forms a functional receptor 
(Fraser et al 1999). The transmembrane domain is thought to stabilize the heterodimer complex, 
and C-terminus interacts with intracellular proteins like G proteins (Fraser et al 1999). RAMP1 
also altered terminal glycosylation of CLR and this mature form of CLR had a higher molecular 
weight, and was responsible for its CGRP receptor phenotype (McLatchie et al 1998). 
Subsequently, two isoforms- RAMP2 (175 amino acid peptide) and RAMP3 (148 amino acid 
peptide) which were 31% identical to RAMP1 were cloned and isolated (McLatchie et al 1998). It 
was observed that all the RAMP isoforms have evolutionarily conserved 4 Cys residues (Cys40, 
Cys57,Cys72 and Cys104), but RAMP1 and RAMP3 have an extra pair of Cys residues which 
result in disulphide bonds at 1-5, 2-4 and 3-6 (McLatchie et al 1998, Steiner et al 2003). These 
disulphide bonds not only determine the protein structures, but are also indispensable in RAMP–
GPCR heterodimer processing (Steiner et al 2003). There are N-glycosylation sites in RAMP2 
and RAMP3 which are not present in RAMP1 (Flahaut et al 2003, McLatchie et al 1998). 
RAMP3 has a PDZ binding motif at its C terminus which is absent in RAMP1 and RAMP2 
(Bomberger et al 2005, Pietschmann et al 1993). This PDZ motif plays an important role in 
receptor trafficking as it interacts with the  Na+/H+ exchanger regulatory factor-1 (NHERF-1), 
which inhibits internalisation of receptor complex post ligand stimulation by tethering it to the actin 
cytoskeleton (Bomberger et al 2005). Both RAMP1 and RAMP3 form stable homodimers. 
Although not necessary for RAMP-GPCR interaction, these homodimers may dynamically regulate 
the availability of RAMP isoforms for receptor interaction (Sexton et al 2001).  
RAMP2 and RAMP3 effectively transport CLR to the cell surface similar to RAMP1 (McLatchie et 
al 1998). Both RAMP2 and RAMP3 when co-transfected, one at a time with CLR, showed 
response to AM but not to CGRP, and again this response was not noticed when RAMP2, 
RAMP3 or CLR were expressed on their own (McLatchie et al 1998). RAMP2 and RAMP3 do not 
glycosylate their partner CLR when presented at cell surface which might be the reason why CLR 
loses its CGRP receptor phenotype (McLatchie et al 1998). Interestingly, it was observed that the 
CLR/RAMP complex are formed in the Golgi which are then processed, transported to cell 
membrane, recycled and degraded in their heterodimer form (McLatchie et al 1998). 
Internalisation of the CLR-RAMP complex is implicated to be β-arrestin and dymin dependent and 
degradation is thought to be due to arrestin interaction (Hilairet et al 2001a, Hilairet et al 2001b). 
Most certainly it was correctly hypothesised that CLR/RAMP3 complex escapes this degradation 
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and is recycled due to the PDZ domain present in RAMP3 mentioned earlier (Bomberger et al 
2005).     
It was discovered that RAMPs not only form heterodimer with CLR but also with CTR, although 
CTR does not require RAMPs for its cell surface transport. In 1999, Christopoulos et. al. reported 
3 functional receptors for AMY arising from interaction between CTR and RAMPs (Christopoulos 
et al 1999, Muff et al 1999). Using radio-ligand binding and cAMP assays, it was discovered 
three functional receptors for AMY are formed due to dimerization of CTR with each of the RAMP 
isoforms. Hence it was discovered that RAMPs not only chaperone partner GPCRs to cell surface 
but also give ligand specificity to the receptors. Receptor interactions of RAMPs with CTR and 
CLR are summarised below in Fig 1.19. 
 
 
 
 
 
Fig 1.19:  A schematic representation of RAMP interactions with CLR (left) and CTR (right) which result in 
different functional receptors for the CT family peptides. Adapted from Parameswaran et. al. 2006. Image 
created using proposed protein structures of RAMP1 and CLR by Prof Artymiuk, Prof Skerry and Dr Richards 
for University of Sheffield. 
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A number of RAMP-GPCR interactions have been identified to date. So far, it has been reported 
that RAMPs interact with GPCR class II receptors: PTH receptor 1 and 2 (RAMP2 and 3), 
glucagon receptor (RAMP3) and vasointestinal peptide/pituitary adenylate cyclase-activating 
peptide 1 (VIP/VPAC1) receptor (RAMP1 and 3) (Christopoulos et al 2003), and with a GPCR 
class III receptor - calcium sensing receptor (CaSR) (RAMP1 and 3) (Bouschet et al 2005, 
Christopoulos et al 2003, Foord et al 2005). This wide range of RAMP – GPCR interaction is no 
surprise considering the tissue expression profile of RAMPs. A schematic representation mRNA 
expression of RAMP isoforms in a few different tissues is shown below in Fig 1.20 (McLatchie et 
al 1998, Parameswaran & Spielman 2006). 
 
 
 
Transgenic mice models revealed the functional characteristics of RAMP isoforms. In an attempt 
to study vasodilatory regulation of CGRP through CLR/RAMP1 receptor, global RAMP1 KO mice 
were generated. These RAMP1 deficient mice exhibited hypertension without having an effect on 
heart rate (HR) and had increased serum pro-inflammatory cytokines (TNF-α, IFN-γ, IL-12, and 
IL-6) levels and increased serum CGRP levels post lipopolysaccharide (LPS) administration. This 
suggested a potential regulation of blood pressure and inflammatory response by CGRP through 
CLR/RAMP1 receptor (Tsujikawa et al 2007). 
 
Fig 1.20:  A schematic representation of mRNA expression in different tissues. (+) indicate the level of 
expression and (-) indicates very low or undetected expression. Fig adapted from Parameswaran et. al. 
2006 and is based on the information published by McLatchie in 1998. 
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RAMP2 transgenic animals show an altogether different phenotype. Global RAMP2 KO animals 
are embryonically lethal and die mid-gestation due to Hydrops fetalis, a phenotype similar to one 
observed in AM and CLR deficient mice (Caron & Smithies 2001, Dackor et al 2006, Ichikawa-
Shindo et al 2008) (Fig 1.21). This suggests that a severe phenotype results from the loss of AM 
signalling. 
 
 
 
 
 
 
RAMP2 heterozygous mice are viable but have reduced litter size and increased serum calcium 
and prolactin levels (Dackor et al 2007). On the other hand, overexpression of RAMP2 in smooth 
muscles of mice showed increase in AM sensitivity. These transgenic mice had enhanced 
reduction of blood pressure on AM administration (Tam et al 2006). 
RAMP3 KO animals are born healthy with no known abnormalities up to 6 months. After 6 
months, RAMP3 KO animals did not show normal physiological age related gain in weight when 
compared wild-type RAMP3 animals (Dackor et al 2007). Loss of RAMP3 neither affects blood 
pressure nor fertility of the animal (Dackor et al 2007).   
Embryonic lethality exhibited by RAMP2 KOs, severally affected blood pressure in RAMP1 KO 
animals and unaffected physiology of RAMP3 KO animals demonstrates that RAMP isoforms have 
significantly different functions and that they play an important role in pathological and 
physiological regulation.  
 
 
 
 
Fig 1.21:  Images of RAMP2 KO neonatal mice displaying increased fluids in the body due to hydrops 
fetalis (first two panels) and pericardial effusion (last two panels) similar to AM KO mice. With kind 
permission from Prof Shindo Takayuki (Ichikawa-Shindo et al 2008). 
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1.5 Importance of investigating receptors for CT family of peptides 
To date, there is compelling evidence that all the members of the CT family of peptide either have 
an anti-resorptive or an anabolic effect on the skeleton. CT and AMY inhibit osteoclast mediated 
resorption by either affecting the cell adhesion to bone surface or by inhibiting maturation and 
AMY, AM and CGRP induce osteoblast proliferation (Fig 1.22). 
 
 
 
 
Since all the CT family peptides have such profound effect on the skeleton by inducing bone 
formation, silencing these peptides or their receptors, was thought to result in reduction in bone 
density. However, knockout experiments show opposite phenotypes. CT/ CGRP deficient models 
have increased bone density (Hoff et al 2002) (Fig 1.23 overleaf). 
 
 
Fig 1.22:  Overall anabolic effect of CT family of peptides on skeleton. CT and AMY inhibit the activity of the 
bone resorbing cells – osteoclasts (blue) and AM, AMY and CGRP induce proliferation of bone forming cells 
– osteoblasts (red). Diagram created using images kindly provided by Tim Arnett (Osteoclast) and Karin 
LaPudala (bone matrix created for Eveo). 
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This unexpected phenotype encouraged similar research in the receptors for these peptides. We 
studied the transgenic RAMP2 +/- and RAMP3 -/- animals created by Dr Caron for 
Adrenomedullin research. Our pilot research showed interesting data that suggested that both 
these isoforms had skeletal regulation (Fig 1.24). Further investigation confirmed the hypothesis 
that RAMPs 2 and 3 but not RAMP1 play an important role in regulating skeletal phenotype 
(Pacharne 2008). 
 
 
 
 
Fig 1.23:  Results published by Hoff et. al. showing a) Increase in bone volume to tissue volume ratio 
(BV/TV) in 1 and 3 month old male and female CT/CGRP KO mice,  b) Increased bone density in 
vertebrae of CT/CGRP KO animals and  c) Increased  growth in CT/CGRP KO animals (Hoff et al 
2002).Figures reproduced with permission. 
 
Fig 1.24: MicroCT analysis of femurs from WT, RAMP2 +/- and RAMP3 KO animals. RAMP2 animals had 
increase lumen & cortical. RAMP3 on the other hand and a two fold increase in bone density and increased 
trabecular and cortical thickness. Previously reported in MSc thesis: RAMPs potential role in regulation of bone 
mass and skeletal disorders, 2008, University of Sheffield. 
 
WT RAMP2 +/- RAMP3 -/- 
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Although it is certain that RAMP2 and RAMP3 influence skeletal regulation, the exact mechanism 
through which this occurs remains unknown. Furthermore, molecular mechanisms pertaining to 
RAMP and their ligands (CT family of peptides) are also not yet clearly understood. For, e.g., – 
the mechanisms by which AMY influences osteoblast proliferation, in spite of absence of AMY 
receptors on these cells, and whether is there a compensatory mechanism between RAMP 
isoforms, definitely require further investigation. Considering the complicated receptor 
pharmacology of RAMPs it is very important to clearly identify the specific receptor combination 
and the resulting downstream mechanisms that regulate the skeletal phenotype.  
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1.6 Hypothesis, aim and objectives  
In light of evidence from our pilot study that RAMP2 and RAMP3 but not RAMP1 regulate skeletal 
development in mice, and that alteration in the RAMP2 gene result in a decrease in the bone 
volume, whereas silencing the RAMP3 gene completely, resulted in increase in the bone volume, 
we hypothesized that silencing the gene for receptor activity modifying protein 3 -RAMP3 in 
129/SvEv mice, results in an advanced skeletal phenotype. 
With an aim to test whether RAMP3 is a potential therapeutic for treating skeletal disorders, we 
tested our hypothesis by determining:  
 The skeletal phenotype of WT and RAMP3 KO 129/SvEv mice at different ages by microCT, 
dynamic histomorphometry and histology. 
 The skeletal response to ovariectomy in both WT and RAMP3 KO 129/SvEv mice by 
microCT analysis. 
 The primary calvarial osteoblast differentiation profile of WT and RAMP3 KO by mineralizing 
fibroblast-colony-forming assay. 
 The expression of RAMPs 1/2 and 3 mRNA and protein expression during primary osteoblast 
differentiation in WT and RAMP3 KO osteoblasts. 
 The effect of RAMP expression in primary WT and RAMP3 KO osteoblasts on Amylin, 
Adrenomedullin, PTH and Wnt and DKK stimulation. 
 
Further, given the evidence that osteoblasts do not express the traditional calcitonin receptor 
(CTR) that forms a functional receptor for Amylin, but still respond to Amylin stimulation, we 
hypothesized that osteoblasts either express a novel Amylin receptor, or have a transcription 
variant of the CTR. 
To test this hypothesis, we determined:  
 The complete sequence of the CTR transcript variant expressed in WT 129/SvEv 
differentiated primary osteoblast by PCR technique using over lapping primers.  
 The expression of CTR protein in both WT and RAMP3 KO differentiating primary osteoblast. 
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Chapter 2: Accelerated skeletal development in RAMP3 KO mice. 
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2.1 Introduction 
Literature evidence to date supports the notion that RAMP1 plays an important role in the 
regulating blood pressure and inflammatory responses induced by Calcitonin gene related peptide 
(CGRP) through the CLR/RAMP1 receptor and that RAMP2 plays a key role in regulating 
vascularization induced by Adrenomedullin (AM) through the CLR/RAMP2 receptor (Caron & 
Smithies 2001, Tsujikawa et al 2007). The involvement of RAMPs in skeletal regulation was not 
elucidated until 2011 where our pilot study showed that RAMP2 heterozygous 129/SvEv mice 
had increased bone volume, reduced bone mineral density and under developed vertebra with 
increased inter-vertebral spaces (Kadmiel et al 2011). Furthermore, even with very few number of 
animals (n=3 each genotype), this pilot study also gave us encouraging evidence of RAMP3 KO 
mice having increased bone cortical thickness and bone mineral density.  
As discussed earlier, RAMP3 forms one of the obligatory functional receptors for Amylin (AMY) 
and Adrenomedullin (AM) with GPCRs CTR and CLR respectively, and is associated with PTH 
receptor 2 and Calcium sensing receptor (CaSR) (Bouschet et al 2005, Christopoulos et al 
2003, Christopoulos et al 1999, McLatchie et al 1998). RAMP3 chaperons the partner GPCRs to 
the cell membrane and most importantly, determines the ligand specificity of the partner GPCR 
(Bouschet et al 2005, McLatchie et al 1998). All the four ligands; AMY, AM, PTH and Calcium 
are potent skeletal regulators, and have both anabolic and anti-resorptive effect on the skeleton 
(discussed previously in Introduction, Section 1.3). With the need to develop anabolic therapeutic 
targets, it is important to determine whether RAMP3 regulates the anabolic effect of these ligands 
on the skeleton.  
The skeletal phenotypes resulting from alteration of the ligands AMY and AM are discussed in 
detail earlier. Global deletions of GPCRs CTR, CLR, PTHR, CaSR are embryonically lethal. CTR 
KO-Cre skeletal model mentioned earlier show protection against induced hypercalcaemia (Davey 
et al 2008). Parathyroid cell specific CaSR KO mice show severe impediment of skeletal 
development, and heterozygous mice show reduced cortical and trabecular bone volume and 
thickness (Chang et al 2008). PTHR2 KO mice have not yet been studied with respect to 
skeletal phenotype.  
The WT and RAMP3 KO 129/SvEv mice used in our work were generated from the animals 
obtained from Dr Kathleen Caron’s research group in North Carolina USA, who have successfully 
established stable 129/SvEv transgenic embryonic stem (ES) cell models for CT peptides and 
2 Chapter 2: Accelerated skeletal development in RAMP3 KO mice. 
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RAMPs (Dackor et al 2007). The 129/SvEv mouse strain is one of the most stable strains used 
for gene targeting and gene trap approaches to manipulate embryonic stem (ES) cells (Auerbach 
et al 2000). A study of establishment and chimera analysis of ES cells, suggests that C56BL/6-
derived ES cell lines have a greater tendency to lose their ability to colonize the germ-line than 
129-derived ES cell lines making 129/SvEv ES cells more suitable for generating transgenic 
models (Auerbach et al 2000). 
The wild type skeletal phenotype of the 129/SvEv strain is not yet well characterised. However to 
date, this strain has been used to study various skeletal phenotype with respect to G protein α-
subunit gene Gnai3, Wnt1-inducible signalling protein 3, undifferentiated mesenchymal stem cell 
(MSC) specific Sox 5/6/9 etc. (Akiyama et al 2002, Kutz et al 2005, Plummer et al 2012). A 
comparative study of homeobox genes Hox a1/b1/b2 on pure 129SvEv background and 
129SvEv-C57BL/6J hybrid background showed no difference in the skeletal phenotype on 
account of the difference in strains (Buckley 2002) 
This chapter focuses on the characterisation of the skeletal phenotype of WT and RAMP3 KO 
129/SvEv mice to test the hypothesis, that silencing the gene for receptor activity modifying 
protein 3 -RAMP3 in 129/SvEv mice, results in an advanced skeletal phenotype. 
This was done by determining, 
 Bone morphometric parameters of WT and RAMP3 KO 129/SvEv mice at post natal day 
5, 4 weeks and 8 weeks of age by microCT analysis.  
 The bone apposition rate of young adult mice at the age of 8 weeks, by dynamic 
histomorphometry. 
 The differences in growth plate and number of osteoblasts and osteoclasts in the long 
bones of young adult mice at the age of 8 weeks, by histology. 
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2.2 Methods and materials 
2.2.1 Animals: 
RAMP2 heterozygous (Het) and RAMP3 knockout (KO) mouse on 129/SvEv strain were 
obtained from Dr Kathleen Caron (Department of Cell and Molecular Physiology, University of 
North Carolina). 
RAMP3 KO mice were generated by Dr Caron’s group on the 129/SvEv background mouse 
strain. Briefly, 129S6/SvEv-TC-1 embryonic stem cells were electroporated with linearized 
targeting vectors that excised exon 2 and 3 along with the stop codon and 3’ untranslated region 
of RAMP3 gene, and inserted a Neomycin cassette by homologous recombination (Dackor et al 
2007). Similarly, RAMP2 Het animals were also generated by Dr Caron’s group on 129/SvEv 
mouse strain by targeting RAMP2 promoter, 5′-untranslated region translation start site, and 
exons 1 and 2 (Dackor et al 2007). 
Wild-type (WT) 129/SVEV mice were generated and colonies were established in the University 
of Sheffield (Department of Animal and Plant science) from the founder RAMP2 heterozygous 
(Het) and RAMP3 knockout (KO) mice obtained from Dr Kathleen Caron. First generation  (F1) 
of mice obtained from RAMP3 KO and RAMP2 Het crossing resulted in the progeny that 
comprised half R3 +/- R2 +/+  genotype progeny and half  R3 +/- R2 +/-  genotype progeny. 
The R3 +/- R2 +/+ male and females were then crossed to obtain the second generation (F2) 
that comprised half RAMP3 +/- RAMP2 +/+, one quarter RAMP3 -/-RAMP2+/+ and one 
quarter RAMP3 +/+ RAMP2 +/+ populations. The RAMP3 +/+ RAMP2 +/+ animals were the 
WT 129/SVEV animals that were used to generate the colony. Figure 2.1 illustrates this breeding 
plan.  
Both the WT and RAMP3 KO breeding colonies in Sheffield were then backcrossed for nine 
generations to obtain congenic colonies (Simpson et al 1997). Animals from the 11th generation 
were used to breed animals for the experiments. 
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 Fig 2.1: A schematic representation on WT 129/SvEv mice generation from RAMP3 KO and RAMP2 Het mice. 
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2.2.2 Genotyping:  
2.2.2.i Genomic DNA extraction:  Genomic DNA was extracted from the mouse ear-clips using 
the DNeasy Blood & Tissue Kit (Qiagen ®). Bench protocol, provided by the manufacturer, for the 
kit was used for DNA extraction. Briefly, the tissues sample was lysed with Proteinase K at 56oC. 
The genomic DNA was then separated in the DNeasy™ Mini spin columns. It was then washed 
and eluted in elution buffer. 
Buffer solutions used (in order) per ear-clip are as follows: 
ATL buffer:      180µl 
Proteinase K:      20µl 
AL buffer + Absolute ethanol (1:1):   400µl each 
AW1 and 2 (wash) buffer:   500µl each 
AE (elution) buffer:    200µl each 
2.2.2.ii PCR for genotyping:  Identical PCR reaction mix and PCR conditions were used to 
genotype RAMP3 KO and RAMP2 Het mice. GoTaq® DNA Polymerase kit (Promega® 
Cooperation, Madison, USA) was used to determine WT/RAMP3 genotype. Each 25μl reaction 
mix contained 5μl of 5X Green GoTaq® reaction buffer (final conc. 1x), dNTP at a final 
concentration of 0.2mM (10mM each dNTP stock), MgCl2 at a final concentration of 1.5mM 
(25mM each stock) and 2.5 units GoTaq® DNA Polymerase. Proportions for PCR mix are 
mentioned below along with the respective PCR conditions. PCR primer sequences are 
summarised in table 3.1 overleaf. PCR amplicons were visualized by electrophoresis in 1.5% 
Agarose gel (Sigma®) prepared in Tris-base-EDTA buffer containing 0.5ug/ml ethidium bromide. 
 
PCR reaction mix: 
5X Green GoTaq® reaction buffer:       5μl 
MgCl2:      0.75μl 
dNTP mix :     0.5μl 
Forward Primer:    1.25μl 
Reverse primer:    1.25μl 
GoTaq® DNA Polymerase:   0.5μl 
Genomic DNA:    1-2μg 
          Nuclease free water:             upto 25μl 
Thermocycler conditions: 
1) Hold 950C Enter 
2) 950C – 1.30min 
3) 950C – 30sec 
4) 580C - 30 sec (BOTH RAMP2/3) 
5) 720C – 1.30min 
 (Repeated 3-5, 30 cycles) 
6) 720C - 3min 
7) Hold at 40C 
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Genotype Primer ID Primer Sequence Tm Amplicon 
 
RAMP3 KO 
Mr3.1 5’ GTGCTCAAGGGTTCTGTCTG 3’ 59.4
0
C 
650bps (WT) 
800bps(R3) 
Mr3.10 5’ GACCTGGTTCATCTCTGGCTCC 3’ 64.0
0
C 
Neo60 5’ GCTTCCTCTTGCAAAACCACA 3’ 57.9
0
C 
 
RAMP2 Het 
Mr2.45F 5′ TCTGTCTGGATGCTGCCTTGC 3’ 61.8
o
C 
900bps (WT) 
675bps (R2) 
Mr2.46R 5’ GAAGTCAGGCAGTCAGGGTTG 3’ 61.8
o
C 
NeoOligo 5′ GACGAGTTCTTCTGAGGGGA 3’ 59.4
0
C 
 
 
2.2.3 Animal housing and humane culling: 
Animals were culled humanely in accordance to home office regulations Schedule 1, Animals 
(Scientific Procedures) Act 1986 at required ages.  Neonatal mice were culled by anaesthetic 
overdose of Pentobarbital (solution for euthanasia - JM Loveridge Ltd, UK) (dosage 0.1ml per 
100grms). Adult mice were culled by cervical dislocation following anaesthesia. 
2.2.4 Age groups: 
Sex-matched WT and RAMP3 KO mice were used to study skeletal phenotype at three different 
ages: Post natal day 5 (PND5), 4 weeks and 8 weeks.  
Intervention (Chapter3): Skeletal phenotype in response to ovariectomy (OVX) was studied in 
female WT and RAMP3 KO mice at the age of 12 weeks (baseline group/OVX conducted) and 
16 weeks (sham and OVX group) 
2.2.5 Treatments:  
2.2.5.i Dual Calcein labelling treatment: 
Eight week old WT and RAMP3 mice were injected with Calcein (100mg/kg) twice, one week 
apart before culling. The first label was administered in the 7th week and the second in the 8th 
week. Animals were culled the day after the second labelling while monitoring the animal’s health 
during the course of the entire treatment.  
 
 
 
 
Table 2.1: RAMP3 and WT genotyping primer sequences 
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2.2.6 Specimen preparation:  
Culled animals were dissected immediately after death in clean conditions with sterile instruments 
following weight and tail length measurements. First the skin was removed, then viscera and soft 
tissues. Organs of interest (brain and uterus) were either snap-frozen in liquid nitrogen or fixed in 
10% buffered formalin. Intact skeleton was stripped off soft tissue before separating long bones 
and vertebrae. 
Skeletons of post natal day 5 animals were treated with Alcian blue and Alizarin red stains. 
(Procedure detailed below in Section 3.2.7). 
Femora and tibiae of adult mice were dissected and fixed appropriately depending on whether 
they were being processed for histology, dynamic histomorphometry or microcomputer 
tomography. Third and fourth caudal vertebrae were then dissected, separated and fixed for 
microCT analysis. 
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2.2.7 Alcian Blue / Alzarin Red staining: 
Skeletal staining was performed to study the extent of ossification in neonatal skeleton. Post natal 
day 5 skeletons were stained with Alcian Blue / Alzarin Red. The right hind limb was separated 
before staining and fixed in 70% ethanol for MicroCT analysis. The rest of the skeleton was used 
for staining. Briefly, the staining procedure consists of the following steps. 
Dehydration: First the pups were fixed and dehydrated in 90% ethanol for 7 days, with changes 
of ethanol on the 3rd and the 5th day. 
Alcian Blue staining: After dehydration, pups were immersed in freshly prepared Alcian blue 
solution (appendix) for 3 days at room temperature to stain the collagen present in the skeleton. 
Rehydration: Following the Alcian staining, pups were rehydrated sequentially with: 
i) 70% ethanol for 4-6 hrs with ethanol change at 2-3 hours, 
ii) Followed by 40 % ethanol rehydration for 4-6 hrs with ethanol change at 2-3 hours. 
iii) Followed by 15 % ethanol rehydration for 4-6 hrs with ethanol change at 2-3 hours. 
iv) Finally - water for 3 days (or until the pups sank). 
KOH treatment: After rehydration, pups were treated with freshly prepared 1% KOH for 1-2 days 
at room temperature until the soft tissue holding the skeleton together, became transparent. 
Samples were carefully monitored as there is a risk of skeleton falling apart if this treatment 
continues for a long period. 
Alzarin Red staining: Skeletons were then immersed in freshly prepared Alzarin Red S solution 
(appendix), until the bone was stained purple (2-3 days). Care was taken to change the Alzarin 
Red S solution every day to enhance the staining. 
KOH treatment: Skeletons were again treated with freshly prepared 1% KOH solution for 2-3 
hours at room temperature. Subsequently the KOH solution was replaced and the 2-3 hour 
incubation was repeated. At least 3 repetitions of this step was carried out to obtain adequate 
transparency. Skeletons were photographed and stored in 100% glycerol. 
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2.2.8 Weights and Tail lengths: 
Whole body weight: All animals were weighed, on portable digital weighing scales immediately 
post-culling. 
Uterus weight:  The uteri of female mice of each group (baseline, sham and ovariectomy) were 
weighed immediately post-culling on a digital weighing scale. 
Tail lengths were measured from the base of the tail to the apex (Fig. 2.2) using GuoGen MC 
01120028 digital callipers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             Fig 2.2i: A schematic representation of measured region of the mouse tail. 
Measured tail length 
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Femur and tibial lengths in post natal day 5 pups were measured from the photographs of 
Alizarin red and Alcian blue stained skeletons using the software ImageJ™. Briefly, every skeleton 
was photographed with a scale alongside it. Known distance on the photographed scale, was 
used to incorporate a digital scale in the software, which then gave measurement of each bone 
when a line was drawn over the bone in each image (Fig2.2ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.1 mm 
Fig 2.2ii: Representation of method used to measure tibia length in postnatal day 5 mice. 
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2.2.9 Micro Computed Tomography (MicroCT) Analysis: 
Computed tomography is amongst the most useful techniques used to explore details of 3D 
structures in a non-destructive way. This cutting edge technology generates cross sections of 3D 
structures, using an X-ray source. These cross sections can then be interpolated in different 
planes to study different internal structures. Micro Computed Tomography (MicroCT) is the same 
system but has resolution in the order of few micrometres. 
MicroCT analysis was carried out in the SkyScan 1172 Desktop X-ray microCT system (SkyScan 
N.V. Belgium) featuring a high performance resolution of 10 Megapixel (Mp). It has an X-ray 
source which is 20-100 kV for less than 5μm spot size and 20- 80 kV for less than 8 μm spot 
size which is accompanied with a 12 bit cooled X-ray camera. Spatial resolutions of either 4.5 or 
17μm were used depending on specimen and area to be scanned. 
2.2.9.i Specimen processing:  
For each animal, both left and right femur, tibiae and caudal were fixed in 70% ethanol 
immediately after dissection. Bone specimens of animals that were labelled with Calcein green 
were stored in dark at room temperature.  
2.2.9.ii MicroCT scanning: 
Each bone was wrapped in cellophane wrap and then mounted in plastic container which was 
placed in the microCT scanner. The position of the bone in the machine was adjusted and 
confirmed so that the required region of the bone is scanned appropriately. A 0.5mm aluminium 
filter and medium-pixel camera was specifically used for adult mouse bones. Care was taken to 
remove the Aluminium filter for neonatal bones.  
Whole long bones were scanned at lower resolution: 17.5μm with an averaging 2 frame rotation to 
reduce the size of the scanned file without affecting the analysis, whereas trabecular and cortical 
regions were scanned at a higher resolution: 4.5μm with 360o rotation to ensure detailed imaging 
and analysis.  
2.2.9.iii Reconstruction: 
Scanned image datasets were then reconstructed in NRecon® (Version 1.4.1.0) in order to 
convert raw microCT images into greyscale cross-section images. The greyscale image datasets 
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generated for individual bone was then analysed by interpolating region of interests (ROIs) in CT 
Analyser Version 1.7.0.5 software. The threshold levels for reconstruction and for analysis for 
different bones are summarized in the following table (Table 2.2). 
 
 
Age and Bone Resolution 
(μm) 
Reconstruction threshold 
(Arbitrary value) 
3D analysis threshold 
(Arbitrary value) 
PND 5 whole Femur /Tibia 10 μm 0.16 100 - 255 
Adult Whole Femur / Tibia / 
vertebra 
17.5 μm 0.16 100 - 255 
Adult Femur/ Tibia trabecular 4.5 μm 0.16 80 - 255 
Adult Femur/Tibia cortical 4.5 μm 0.16 90 - 255 
 
2.2.9.iv Regions of Interest (ROIs) for analysis: 
For whole bone analysis, ROIs were drawn around the whole bone in each cross section 
throughout the dataset, whereas for cortical and trabecular analysis, only a defined section of the 
whole bone was selected. This was done by setting an offset and height (1.0mm) for the region of 
the bone to be analysed. The offset was from a particular reference point, which is usually a 
physical marker of the bone. Reference point- physical markers used for tibia and femur 
trabecular and cortical analysis are represented overleaf in Fig 2.3 and Table 2.3 summarises the 
offset and height values used specific bone. 
 
 
 
 
 
 
 
Table 2.2: Summary of the resolutions and threshold levels used for reconstruction and 3D analysis for different 
areas of different bones 
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Bone Analysis Reference point Offset value ROI height 
Femur trabecular 20 slices above growth plate (distal end) 46 (0.2mm) 229 (1.00mm) 
Tibia trabecular 
and cortical 
10 slices below growth plate (proximal end) -275 229 (1.00mm) 
Femur cortical Slice - third Trocanter reduces rapidly -687(3.0mm) 229 (1.00mm) 
Proximal Tibia: trabecular & 
cortical analysis  
Distal femur: 
Trabecular analysis 
Femoral shaft: 
cortical analysis 
10 slices below growth plate  20 slices above growth plate Slice from which third 
trochanter reduces rapidly 
Fig 2.3: Summary of the physical markers used to determine regions of interest for cortical and trabecular 
analysis. Each top panel (x-ray image generated by microCT) is the area of bone scanned at 4.5 µm resolution 
with a 0.5mm aluminium filter and medium camera. Bottom panels (black) represent the bone cross section 
generated on reconstruction of microCT scans, at the marked levels (red lines) in top panels.  
Table 2.3: Summary of the physical markers and ROI settings used to measure high resolution bone area by 
MicroCT. 
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Once the specific area of the bone was defined using the reference point, trabecular and cortical 
area in the cross-sections was marked. Figures 2.4 (A) and (B) represent the ROIs drawn in the 
first and last slices of the dataset to analyse tibia trabecular and cortical ROI selection. Analysis 
was carried out by interpolating the ROIs of the entire dataset. 
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Fig. 2.4: Representative image depicting the microCT region of interests used to analyse tibia trabecular (A) and 
cortical (B) bone morphometric parameters. On the left, the green –grey panel show the part of bone scanned at 
4.5µm resolution with a medium camera. The Red lines at the proximal end of the tibia show the physical marker 
used to decide the 1.0mm ROIs for analysis.  Black and grey panels (both A and B): the first and the last cross 
section of each analysed area of the bone (left), the ROI marked in red for each section (middle) and the final 
analysis grey-scale image(right). 
A 
B 
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Similarly, Fig 2.5 (A) and (B) represent the ROIs drawn in the first and last slices of the dataset 
to analyse femur trabecular and cortical ROI selection. Analyses were then carried out by 
interpolating the ROIs of the entire dataset. 
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Fig 2.5: Representative image depicting the microCT region of interests used to analyse femur trabecular (A) 
and cortical (B) bone morphometric parameters. On the left, the green –grey panel show the part of bone 
scanned at 4.5µm resolution with a medium camera. The Red lines at the proximal end of the tibia show the 
physical marker used to decide the 1.0mm ROIs for analysis. Black and grey panels (both A and B): the first and 
the last cross section of each analysed area of the bone (left),the ROI marked in red for each section (middle) 
and the final analysis grey-scale image (right). 
A 
B 
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2.2.9.v Morphometric measures: 
Quantification of bone morphometric parameters was automatically calculated for individual bone 
scan by the algorithms in the analysis software: CT Analyser (Version 1.7.0.5). The marked ROIs 
were uploaded in the batch analyser called the BATMAN, an allied tool of microCT Analyser. A 
predefined greyscale threshold was used for whole bone, trabecular and cortical bone. 
(summarised previously – Table 2.3). The BATMAN also corrects artificial speckles in the scans.  
The typical order of tests run on every batch was as follows: 
i) Thresholding (defines grey scale of the scans), 
ii) Despeckle (set to remove white speckles/ artefacts within the 3D space with volume “less 
than” 10 voxels in the ROI) and, 
iii) 3D analysis (calculates the morphometric parameters) 
 
2.2.10 Results:   
2.2.10.i Quantitative results:  
MicroCT analysis results were quantified to determine bone morphometric parameters such as 
whole, cortical and trabecular bone volume (BV), tissue volume (TV), bone volume to tissue 
volume ratio (BV/TV), cortical and trabecular thickness (Th), trabecular separation (Sp), 
trabecular number (N) and bone pattern factor (Pf). These parameters were generated through 
the BATMAN. 
2.2.10.ii Qualitative results: 3D rendering: 
Qualitative analysis of the bone structure was carried out by rendering realistic 3D models of the 
scanned bone datasets in Golden software’s Voxler 1.1. Models were also generated on the CTVol 
the generic rendering software of the microCT machine Skyscan1172. Since the Volxer software 
had enhanced algorithms to create clip-planes and reduced opacity densitometric models, this 
software was preferred over the CTVol. Models were generated for whole bones, trabecular 
regions of femur and tibia and cortical regions of femur and tibia. Briefly, the ROI dataset was 
uploaded in the Voxler software. The 3D model was generated by using graphical output 
‘VolRender’. Models were represented in either grayscale or in rainbow colour gradient 
(densitometric model) with different opacities. For adult bones, densitometric models were 
generated at ‘0.1408450704’ opacity. Transverse and longitudinal sections of a whole bone 
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model were obtained using an additional algorithm called ‘ClipPlane’. Figure 2.6 is a screenshot of 
the software whilst rendering a femur model with the ‘VolRender’ and ‘ClipPlane’ tools. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   ClipPlane 
Fig 2.6: A screen shot of the software Voxler ™ whilst rendering a femur model. The ‘VolRender’ generates the 
3D model as seen on left. The additional graphical tool ‘ClipPlane’ allows the user to cut through the model and 
view the inner structure of the model as seen in on the right. 
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2.2.11 Dynamic histomorphometry: Dual Calcein labelling: 
Eight week old WT (n=5) and RAMP3 KO (n=6) mice were studied to determine bone apposition 
rate by dynamic histomorphometry. Quantification of the bone apposition rate was done using the 
OsteoMeasure™ system (OsteoMatrics®) on a upright microscope with fluorescence (Leitz DMRB 
from Leica with Sony DCX-950P 3CCD digital camera). 
Specimen processing: Post microCT, left tibiae (fixed in 70% ethanol), were embedded in resin. 
Resin embedding and sectioning of bone was carried out by the staff members of bone analysis 
laboratory, core facility (University of Sheffield). Six longitudinal mid sections, 3µm apart, were 
analysed per specimen for each experiment. 
Endocortical dual calcein labels were measures on both lateral and medial sides of the tibia. An 
off-set of 250µm is left immediately after the growth plate on the lateral side. Six areas of 
interests 250µm x 250µm totalling 3mm, were then measured on each side of the bone. (Fig. 
2.7).  
Calculations: Bone apposition rate was calculated using the following formula: 
Bone apposition rate= Inter label thickness (In.L.Th) / time between labels (day). 
 
 
 
 
250µm 
Fig 2.7: Representative image depicting the method used to measure the endocortical dual Calcein labels in 
Tibia. An offset of 250µm (red double headed arrow) is left after the growth plate. The first 500µm field of 
interest starts after the offset. In total, 6 x 500µm areas (3mm) were measured on each, lateral and medial 
side. Arrows mark the direct of measurement (successive field of interests). WT n=5 and RAMP3 KO n=6. 
Image generated from protocol provided by Darren Laith (Bone analysis laboratory, core facility, University of 
Sheffield, 2013). 
Medial side Lateral side 
500µm 
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2.2.12 Histology: Haematoxylin and Eosin (H&E) staining and Tartrate-resistant acid 
phosphatase (TRAP) stained sections: 
Eight week old WT and RAMP3 KO (n=6 each genotype) mice were used to carry out 
histological analysis. 
2.2.12.i Specimen processing: Right tibiae were fixed in ice cold 4%paraformaldehyde. Bones 
were then decalcified and embedded in paraffin wax blocks before sectioning and staining (bone 
analysis laboratory, core facility - University of Sheffield). Briefly bones were decalcified in EDTA 
at room temperature for 4 weeks using 10-20 times volume of EDTA to volume of bone. The 
EDTA solution was changed each week. On completion of decalcification process, bones were 
embedded in paraffin wax and sectioned. Out of the six longitudinal mid sections 3µm apart, three 
alternate sections were used for haematoxylin & eosin staining and the other three sections were 
used for TRAP staining (bone analysis laboratory, core facility - University of Sheffield).  
2.2.12.ii Haematoxylin and Eosin (H&E) stained sections were used to study the bone versus 
cartilage differences. These sections were also used to determine the differences between the 
ratio of proliferative to hypertrophic zones in WT and RAMP3 KO samples. Tartrate-resistant 
acid phosphatase (TRAP) stained sections were used to determine the number of osteoblast and 
osteoclasts and the osteoblast-osteoclast coverage. These measurements were performed on 
both the endocortical and the trabecular surface of tibia. Virtual sections: H&E and TRAP 
sections were scanned in the ScanScope® (Aperio®) scanner. All histological analyses were then 
carried out manually on virtual sections in ImageScope™ (Aperio®), the e-slide viewing software. 
2.2.12.iii Virtual analysis:  
Trabecular area: Scanned images of the H&E and TRAP sections were uploaded in the 
ImageScope™ software. Trabecular area in the section was measured by marking a ~2.0mm 
distance in the marrow cavity from the midpoint of the growth-plate. The trabecular region in the 
section of the bone was manually marked in an overlapping virtual layer. The software then 
simultaneously calculates the number of trabecular area manually drawn and the area of each 
trabecular unit (see Fig. 2.8). The average thickness of the trabecular units was calculated by the 
formula:   
 
Trabecular thickness: Total area of all the trabecular units / Number of trabecular units. 
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A 
B 
C D 
Fig 2.8: Representative image depicting the method used to quantify the trabecular area in e-slide using 
ImageScope®. The top panel is a screen-capture showing the marking of 2.0mm distance from the growth 
(A). Middle panel (B) shows the region of interests drawn around the trabecular units. Panel C, is a zoomed 
image showing the accuracy of trabecular marking. The measurements of manually marked regions generated 
by the software is shown in panel D. n=6 each group. 
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2.2.12.iv Osteoblast and osteoclast numbers: Number of Osteoclasts (N.Ob.), osteoblast 
covered bone surface (Ob.S.), number of osteoclasts (N.Oc.) and osteoclast covered bone 
surface (Oc.S.) were determined on both the endocortical surface of the bone and the trabecular 
bone. Cells were manually marked on the viewing software. Active osteoblasts were quantified. 
They were differentiated from the bone lining cells by their cuboidal shape. Osteoclasts with 3 or 
more nuclei were quantified. Similar to the dual calcein labels, the endocortical measurements 
were done in 12, 300µm x 300µm regions: 6 on the medial and 6 on the lateral side. Trabecular 
measurements were done in a 750µm x 750µm area. An offset of 300µm from the growth-plate 
was maintained in both endocortical and trabecular measurement (Fig. 2.9). 
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Fig 2.9: Panels A and B representative images depicting the method used to measure the endocortical (A) and 
trabecular (B) bone cell measurements in tibia. An offset of 300µm (red double headed arrow) is left after the 
growth plate. Panels C and D (zoomed ROI of C) show TRAP positive osteoclast in red (Red arrows) and 
osteoblasts lined on the bone surface (black arrows). n=6 each group. Image A, generated from protocol 
provided by Darren Laith (Bone analysis laboratory, core facility, University of Sheffield, 2013). 
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2.2.12.v Growth plate analysis: The proliferative and hypertrophic zones of the growth plate were 
studied in order to characterise the growth plate of WT and RAMP3 KO mice. Using virtual slides, 
number of proliferative cells (N.PC), number of hypertrophic cells (N. HC) and the ratio of 
proliferative zone to hypertrophic zone (PC:HC) were determined by manually marking the cells. 
Three H&E stained tibial longitudinal mid sections (6µm apart) were analysed per sample. An 
area of 1mm x 0.6mm mid growth plate region was analysed in each section. First, individual 
chondrocyte columns were manually marked as each column represents a clonal expansion of 
stem cells (Farnum & Wilsman 1993). Then proliferative and hypertrophic chondrocytes were 
marked manually with different colours in overlapping layers. Finally the extent of proliferative 
zone and hypertrophic zone within each column was marked. The software then simultaneously 
calculated the number of cells and PC/HC zone. Figure 2.10 below, details this process. 
   
 
 
 
 
 
 
 
 
 
 
 
 
Statistical analysis: GraphPad Prism 
 
700µm 100µm 
Fig 2.10: Representative image depicting the method used to analyse growth plate. The left panel is a tibial 
section with the manually marked analysis region (black box). The right panel is the zoomed region of analysis 
with the different markings. The yellow manual drawing marks individual chondrocyte column, pink dots mark 
proliferative cells, light blue dots mark the hypertrophic cells. Proliferative zone length is marked by black line 
with pink label, whereas the hypertrophic zone length is marked with black line with green label.  
78 
 
Using the GraphPad Prism Version 5.01, data was statistically analysed using either unpaired two 
tailed Student’s T- test with 95% confidence interval or paired two-way ANOVA test followed by 
Bonferroni’s post multiple comparison correction test depending on the experimental dataset. P 
value < 0.05 was considered significant. The level of significance was indicated by number of ‘*’ 
signs presented on the plots. 
Unpaired data sets were represented as box and whisker plots with upper and lower quartiles of 
the dataset. Paired datasets were represented as bar graphs. Specific statistical test and its 
representation are detailed in respective results section. 
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2.3 Results 
2.3.1 Five day old pups:  
Skeletal phenotype of postnatal day 5 WT and RAMP3 KO males and females were determined 
using Alcian Blue / Alzarin Red skeletal staining and microCT. Since skeletal staining interfered 
with the microCT analysis, right femur and tibia of the pups were dissected for microCT prior to 
staining the rest of the intact skeleton. The phenotype of WT and RAMP3 KO mice at post natal 
day 5 is detailed below. Unpaired two tailed Student’s T- test with 95% confidence interval and P 
value < 0.05 considered significant was used to analyse the data statistically. 
2.3.1.i Whole body weights, tail lengths and whole bone lengths  
RAMP3 KO male and female mice had significantly (*) higher whole body weight compared to 
WT mice. Figure 2.11 below represents the differences in whole body weights in both male and 
female WT and RAMP3 KO mice. 
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Tail length:  
Fig 2.11: Box and whisker plot showing whole body weights in post natal day 5 old WT and RAMP3 KO male 
(left) and female (right) mice. Unpaired Student’s T- test showed a significant increase in both RAMP3 KO 
male (p value=0.043) and female (p value=0.025) body weights compared to WT male and females. In 
males WT n=11 and RAMP3 KO n=7. In females, WT n=5 and RAMP3 KO n=12. 
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Although there was no significant difference in female tail lengths, it was observed that RAMP3 
KO male mice had significantly (*) longer tails compared to WT male mice (Fig. 2.12i). 
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Fig 2.12i: Box and whisker plot showing differences in tail lengths in post natal day 5 old WT and RAMP3 KO 
male (left) and female (right) mice. Unpaired Student’s T- test demonstrated a significant increase in RAMP3 
KO male (p value=0.041) tail length. There was no significant difference in female tail lengths. In males, WT 
n=5 and RAMP3 KO n=4. In females, WT n=5 and RAMP3 KO n=7. 
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The femoral and tibial lengths of RAMP3 KO male and female mice were compared to that of WT 
mice.  There were no significant differences in the whole bone lengths in either male or females 
(Figure 2.12ii). 
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Fig 2.12ii: Box and whisker plot showing femoral and tibial lengths of male (A,C) and female (B,D) RAMP3 
KO and WT mice. Unpaired Student’s T- test demonstrated no significant differences between RAMP3 KOs 
and WTs.  
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2.3.1.ii MicroCT analysis whole femur and tibia:  
Whole femur and tibia of post natal day 5 mice were scanned at a 10.00 µm resolution. Since the 
samples were stained with Alcian blue and Alzarin red prior to the microCT analysis, bone mineral 
density was not analysed. Also since the femurs and tibia-fibula complexes in the females were 
broken, they were excluded from the comparisons and this resulted in reduced numbers (WT 
n=4). RAMP3 KO male and female mice had significantly increased femoral bone volume (BV) 
compared to male and female WT mice (Fig. 2.13 (A) and (B) overleaf). However, neither male 
nor females had significant differences in tibial BV (Fig 2.13 (C) and (D) overleaf).  Mean ± SEM 
(standard error of mean) values for each group and the statistical significance is tabulated below 
(Table 2.4).   
 
 
Bone morphometric 
parameter 
Units 
WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
PND5 male femur BV 
mm
3
 0.33 ± 0.029 n=9 
 
0.47 ± 0.047 n=5 
 
0.0189 
 
* 
PND5 female femur BV 
mm
3
 0.31 ± 0.02 n=4 
 
0.56 ± 0.70 n=9 
 
0.0435 * 
PND5 male tibia-fibula BV 
mm
3
 0.38 ± 0.031 n=10 
 
0.39 ± 0.047 n=6 
 
0.7843 NS 
PND5 female tibia-fibula BV 
mm
3
 0.42 ± 0.054 n=4 
 
0.57 ± 0.071 n=7 
 
0.1909 NS 
Table 2.4: Statistical analysis of 5 day old whole femur and tibia bone volume 
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Fig 2.13: Box and whisker plots showing the differences in whole femur (A,B) and tibia(C,D) bone volume 
(BV) in males (A,C) and females (B,D). Both male and female RAMP3 KO whole femur BV is significantly 
more than WT whole femur BV. In males, WT n=9 (femur) and n=10 (tibia-fibula), RAMP 3 KO n=5 (femur) 
and n=6 (tibia-fibula). In females, WT n=4 (femur and tibia-fibula) and RAMP 3 KO n=9 (femur) and n=7 
(tibia- fibula). 
A B 
C D 
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2.3.1.iii Three dimension model rendering: 
Femoral microCT scans were used to render 3D bone models to study the structural differences 
between WT and RAMP3 KO bones. Densitometric femur models translate microCT analysis into 
visual differences. As seen in Fig. 2.14, RAMP3 KO representative model has increased opacity 
when compared to WT femur.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.14: Representative 3D femur models of post natal day 5 mice. Densitometric model represents the 
density of the structure by gradient colours: purple being least dense and red being most dense (legend: right 
bottom). Blue scale (left) represents voxels and the scale to the right represents the millimetres and the 
densitometric gradient. WT femur (left) models appears more transparent compared to RAMP3 KO femur 
(right) suggesting increased density in the RAMP3 KO femur. 
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2.3.1.iv Skeletal staining: 
Fourteen WT and fifteen RAMP3 KO sex-matched 5 day old mice were stained with Alcian Blue 
/ Alizarin Red to reveal gross skeletal differences. The RAMP3 KO mice had bigger, more 
mineralised and more developed skeleton compared to WT of the same age. Advanced 
development of the skeleton was most evident in the RAMP3 KO vertebrae which had larger 
vertebral body and more developed and more mineralised spinous and transverse processes than 
the WT vertebrae (Fig. 2.15). The advanced development in RAMP3 KO skeleton was seen 
irrespective of the gender of the mice and was robust to differences in inter-litter pup sizes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
1 
cm 
WT RAMP3 KO 
Fig 2.15: Representative Alcian blue / Alizarin red stained skeletons of WT (left) and RAMP3 KO (right) post 
natal day 5 mice. Alcian blue stains the cartilage blue and Alizarin red stains the mineralised tissue purple. 
RAMP3 KO skeleton is larger and shows advanced development evidently seen in the zoomed spine panel. 
RAMP3 KO vertebral body is larger; more mineralised and has more developed transverse process compared 
to WT vertebrae. WT n= 14 (10 males, 4 females) and RAMP3 KO n=15 (6 males, 9 females). 
86 
 
2.3.2 Four week old mice: 
The skeletal phenotype of 4 week old WT and RAMP3 KO male and female mice was determined 
using microCT. The phenotype of WT and RAMP3 KO mice at this age is detailed below. 
Unpaired two tailed Student’s T- test with 95% confidence interval and P value < 0.05 
considered significant was used to analyse the data statistically. 
2.3.2.i Whole body weight  
Unlike post natal day 5, 4 week old RAMP3 KO male and female mice had significantly (*) lower 
whole body weight compared to WT mice. Figure 2.16 below represents the differences in whole 
body weights in both male and female WT and RAMP3 KO mice. 
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Fig 2.16: Box and whisker plot showing whole body weights in 4 week old WT and RAMP3 KO male (left) and 
female (right) mice. Unpaired Student’s T- test showed a significant increase in both RAMP3 KO male (p 
value=0.025) and female (p value=0.01) body weights compared to WT male and females. In males WT 
n=15 and RAMP3 KO n=7. In females, WT n=8 and RAMP3 KO n=11. 
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2.3.2.ii MicroCT analysis and three dimensional skeletal models:  
As mentioned before, whole bones were scanned at 17.5µm and cortical and trabecular sections 
were scanned at 4.5µm. The analysed dataset was checked for outliers using GraphPad prism. 
Following this, the cleaned up data was subjected to unpaired two tailed Student’s T- test with 
95% confidence interval and P value < 0.05 was considered significant.  
Data obtained from microCT analysis was used to aid visual understanding of the skeletal 
phenotype. These 3D models where rendered in Voxler® as solid models and gradient models 
(densitometric models).  
2.3.2.ii.a Whole femur: 
Four-week old WT and RAMP3 KO mice displayed a gender dependent difference in whole femur 
bone volume. No significant difference was observed between male WT and RAMP3 KO femur 
bone volume (BV). Although, in females, RAMP3 KO femur BV was significantly higher than WT 
femur BV. Table 2.5 details mean ± standard error of mean (SEM) for WT and RAMP3 KO 
samples along with the statistical significance (red). Figure 2.17 (overleaf) are box and whisker 
plots representing the femur bone volume in males (A) and females (B). 
 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
4 week male whole 
femur BV 
mm
3
 3.14 ± 0.18 n=8 3.20 ± 0.23 n=7 0.8387 NS 
4 week female whole 
femur BV 
mm
3
 2.90 ± 0.11 n=8 3.33 ± 0.12 n=9 0.0201 * 
Table 2.5:  Statistical analysis: 4 week old male whole femur bone volume 
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Fig 2.17: Box and whisker plot showing whole femur bone volume in 4 week old WT and RAMP3 KO male 
(left) and female (right) mice. Unpaired Student’s T- test suggests a significant increase in female RAMP3 KO 
whole femur bone volume (p value=0.020) when compared to WT (right). No significant differences observed 
in male femur comparisons (left).In males, WT n=8 and RAMP3 KO n=7 and in females, WT n=8 and 
RAMP3 KO n=9. 
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2.3.2.ii.b Whole tibia-fibula: 
Similar to whole femur BV, whole tibia-fibula BV showed sex dependent skeletal phenotype. No 
significant difference was observed between male WT and RAMP3 KO tibia-fibula BV (Fig. 2.18 
left). However, RAMP3 KO females had significantly higher tibia-fibula whole BV than WTs (Fig. 
2.18 right). Table 2.6 details mean ± standard error of mean (SEM) for WT and RAMP3 KO 
samples along with the statistical significance (red). 
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Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
4 week male whole 
tibia-fibula BV 
mm
3
 4.27 ± 0.29 n=7 4.39 ± 0.22 n=8 0.7411 NS 
4 week female whole 
tibia-fibula BV 
mm
3
 3.95 ± 0.16 n=8 4.64 ± 0.11 n=9 0.0022 ** 
Table 2.6:  Statistical analysis: 4 week old male whole tibia-fibula bone volume 
Fig 2.18: Box and whisker plot showing tibia-fibula whole bone volume in 4 week old WT and RAMP3 KO 
male (left) and female (right) mice. Unpaired Student’s T- test demonstrated a significant increase in female 
RAMP3 KO whole femur bone volume (p value=0.002) when compared to WT (right). No significant 
differences observed in male femur comparisons (left).In males, WT n=7 and RAMP3 KO n=8 and females, 
WT n=8 and RAMP3 KO n=9. 
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2.3.2.ii.c Femur cortical bone:  
Cortical microCT analysis was performed at a higher resolution to enable detailed micro-
architectural analysis. Neither male nor female RAMP3 KO mice had statistically significant 
differences from WT in their femoral cortices (Fig. 2.19 overleaf). Table 2.7 below, details mean 
± standard error of mean (SEM) for WT and RAMP3 KO samples along with the statistical 
significance. 
 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
4 week male femur 
cortical BV mm
3
 0.46 ± 0.00 n=8 0.49 ± 0.02 n=6 0.1702 NS 
4 week male femur 
cortical Th mm 0.10 ± 0.00 n=8 0.08 ± 0.00 n=6 0.2668 NS 
4 week female femur 
cortical BV mm
3
 0.45 ± 0.00 n=10 0.45 ± 0.00 n=9 0.7526 NS 
4 week female femur 
cortical Th mm 0.10 ± 0.00 n=10 0.10 ± 0.00 n=11 0.9901 NS 
Table 2.7: Statistical analysis of 4 week old male femur cortical bone. 
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Fig 2.19: Box and whisker plot showing femur cortical bone volume (left) and thickness (right) in 4 week old 
WT and RAMP3 KO male (top) and female (bottom) mice. Unpaired Student’s T- test showed neither male 
nor female WT and RAMP3 KO have significant differences in cortical bone volume and thickness. In males 
WT n=8 and RAMP3 KO n=6 (BV and Th) and in females, WT n=10 (BV and Th) and RAMP3 KO n=9 (BV) 
and n=11 (Th) 
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2.3.2.ii.d Tibia cortical bone:  
Similar to femur cortical analysis, neither male nor female WT and RAMP3 KO mice had any 
statistically significant differences observed in their tibial cortices (Fig. 2.20 overleaf). Table 2.8 
below, details mean ± standard error of mean (SEM) for WT and RAMP3 KO samples along with 
the statistical significance. 
 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
4 week male tibia 
cortical BV 
mm
3
 
0.53 ± 0.01 n=7 0.54 ± 0.37 n=5 0.4569 NS 
4 week male tibia 
cortical Th 
mm 
0.09 ± 0.00 n=6 0.09 ± 0.01 n=7 0.9794 
NS 
4 week female tibia 
cortical BV 
mm 
0.51 ± 0.00 n=9 0.51 ± 0.01 n=10 0.7961 
NS 
4 week female tibia 
cortical Th 
mm 
0.08 ± 0.00 n=9 0.09 ± 0.00 n=11 0.8290 
NS 
Table 2.8:  Statistical analysis of 4 week old male tibia cortical bone. 
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Fig 2.20: Box and whisker plot showing tibia cortical bone volume(BV) –left, and thickness (Th) –right,  in 4 
week old WT and RAMP3 KO male (top) and female (bottom) mice. Unpaired Student’s T- test showed 
neither male nor female WT and RAMP3 KO have significant differences in cortical bone volume and 
thickness. In males WT n=7(BV) and 6 (Th) and RAMP3 KO n=5 (BV) and 7 (Th). In females, WT n=9 (BV 
and Th) and RAMP3 KO n=10 (BV) and n=11 (Th) 
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2.3.2.ii.e Femur trabecular bone:  
Trabecular microCT analysis measured bone morphometric parameters that included total bone 
volume (BV), bone volume to tissue volume ratio (BV/TV), Thickness (Th), separation between 
individual trabecular units (Sp), number of trabecular units (N) and pattern factor that 
quantitatively describes the ratio of inter-trabecular connectivity (Pf).  
In WT and RAMP3 KO male 4 week old mice, there was no significant difference between femur 
trabecular bone morphometric parameters. However, in females, RAMP3 KO mice had highly 
significant increase in trabecular thickness, increase in pattern factor and reduction in trabecular 
number compared to WT female mice. This suggested that RAMP3 KO female mice have an 
overall thicker and well-connected trabecular meshwork at this age. Table 2.9 below, details 
mean ± standard error of mean (SEM) for WT and RAMP3 KO samples along with the statistical 
significance (red). Figures 2.21 and 2.22 represent the trabecular differences.  
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
4 week male femur 
trabecular BV 
mm
3
 
0.18 ± 0.01 n=8 0.20 ± 0.01 n=5 0.5697 NS 
4 week male femur 
trabecular BV/TV 
% 
5.18 ± 0.37 n=8 5.36 ± 0.42 n=5 0.7667 NS 
4 week male femur 
trabecular Th 
mm 
0.03 ± 0.00 n=8 0.04 ± 0.00 n=6 0.2320 NS 
4 week male femur 
trabecular Sp 
mm 
0.30 ± 0.01 n=8 0.30 ± 0.01 n=6 0.8160 NS 
4 week male femur 
trabecular N 
1/mm 
1.57 ± 0.11 n=8 1.54 ± 0.10 n=6 0.8773 NS 
4 week male femur 
trabecular Pf 
1/mm 
31.63 ± 2.87 n=8 30.77 ± 1.83 n=6 0.8200 NS 
4 week female femur 
trabecular BV 
mm
3
 
0.18 ± 0.01 n=9 0.17 ± 0.011 n=9 0.7137 NS 
4 week female femur 
trabecular BV/TV 
% 
5.22 ± 0.17 n=9 5.00 ± 0.20 n=11 0.4169 NS 
4 week female femur 
trabecular Th 
mm 
0.03 ± 0.00 n=9 0.035 ± 0.00 n=9 0.002 *** 
4 week female femur 
trabecular Sp 
mm 
0.29 ± 0.01 n=9 0.32 ± 0.01 n=11 0.1298 NS 
4 week female femur 
trabecular N 
1/mm 
1.65 ± 0.06 n=9 1.47 ± 0.06 n=11 0.0477 * 
4 week female femur 
trabecular Pf 
1/mm 
27.87 ± 1.77 n=9 32.22 ± 0.97 n=9 0.0471 * 
 
Table 2.9:  Statistical analysis of 4 week old male and female femur trabecular bone. 
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Fig 2.21: Box and whisker plot showing femur trabecular analysis in 4 week old WT and RAMP3 KO males. 
Unpaired Student’s T- test showed that male WT and RAMP3 KO do not have any significant differences in 
trabecular BV (A), BV/TV (B), Th(C), Sp (D), N (E) and Pf(F). In males WT n=8 and RAMP3 KO n=5 (BV 
and BV/TV) and 6 (Th,Sp,N and Pf).  
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Fig 2.22: Box and whisker plot showing femur trabecular analysis in 4 week old WT and RAMP3 KO females. 
Unpaired Student’s T- test showed that female RAMP3 KO trabecular bone has significant increase in trabecular Th, 
p=0.0002 (C) and Pf, p=0.047 (F). Trabecular N on the other hand is significantly lower (p=0.048) in RAMP3 KO 
when compared to WT (E). No significant differences were observed in trabecular BV (A), BV/TV (B) and Sp (D).In 
females WT n=9 and RAMP3 KO n=9 (BV,Th,Pf) and 11 (BV/TV,Sp and N). 
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2.3.2.ii.f Tibia trabecular bone: 
Like the femur trabecular analysis, tibia trabecular bone showed a sex dependent skeletal 
phenotype. Male WT and RAMP3 KO mice did not have differences in trabecular bone. However, 
in females, RAMP3 KO mice had significant increase in trabecular thickness compared to WT 
female mice. Table 2.10 below, details mean ± standard error of mean (SEM) for WT and 
RAMP3 KO samples along with the statistical significance (red). Figures 2.23 and 2.24 represent 
the trabecular differences observed. 
 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
4 week male tibia 
trabecular BV 
mm
3
 
0.03 ± 0.00 n=8 0.04 ± 0.00 n=7 0.8417                 NS 
4 week male tibia 
trabecular BV/TV 
% 
3.08 ± 0.17 n=8 3.00 ± 0.21 n=7 0.7853                 NS 
4 week male tibia 
trabecular Th 
mm 
0.03 ± 0.00 n=8 0.04 ± 0.00 n=7 0.2488                     NS 
4 week male tibia 
trabecular Sp 
mm 
0.42 ± 0.01 n=8 0.41 ± 0.02 n=7 0.7138                 NS 
4 week male tibia 
trabecular N 
1/mm 
0.91 ± 0.05 n=8 0.87 ± 0.06 n=7 0.5954                 NS 
4 week male tibia 
trabecular Pf 
1/mm 
39.36 ± 1.67 n=8 41.42 ± 1.92 N=7 0.4313                     NS 
4 week female tibia 
trabecular BV 
mm
3
 
0.10 ± 0.01 n=8 0.10 ± 0.01 n=10 0.7631                 NS 
4 week female tibia 
trabecular BV/TV 
% 
3.19 ± 0.14 n=8 3.19 ± 0.19 n=10 0.9916                 NS 
4 week female tibia 
trabecular Th 
mm 
0.03 ± 0.00 n=7 0.04 ± 0.00 n=10 0.0024                 ** 
4 week female tibia 
trabecular Sp 
mm 
0.43 ± 0.02 n=8 0.44 ± 0.03 n=10 0.6506                 NS 
4 week female tibia 
trabecular N 
1/mm 
0.94 ± 0.05 n=8 0.92 ± 0.05 n=10 0.7370                 NS 
4 week female tibia 
trabecular Pf 
1/mm 
36.80 ± 0.76 n=7 38.15 ± 0.89 n=10 0.2970                 NS 
Table 2.10:  Statistical analysis of 4 week old male and female tibia trabecular bone. 
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 Fig 2.23: Box and whisker plot showing tibia trabecular analysis in 4 week old WT and RAMP3 KO males. 
Unpaired Student’s T- test demonstrated that male WT and RAMP3 KO do not have any significant differences 
in trabecular BV (A), BV/TV (B), Th(C), Sp (D), N (E) and Pf(F). In males WT n=8 and RAMP3 KO n=7. 
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Fig 2.24: Box and whisker plot showing tibia trabecular analysis in 4 week old WT and RAMP3 KO females. 
Unpaired Student’s T- test showed that female RAMP3 KO trabecular bone has significant increase in 
trabecular Th, p=0.002 (C) compared to WT. No significant differences observed in trabecular BV (A), 
BV/TV (B), Sp (D), N (E) and Pf(F).  WT n=8 (BV, BV/TV,Sp,N) and n=7 (Th, Pf). RAMP3 KO n=10. 
A B 
C D 
E
D 
F
D 
100 
 
2.3.2.ii.g Caudal vertebra: 
Whole 4th caudal vertebrae of WT and RAMP3 KO 4 week old male and females were scanned 
for microCT analysis at 17.5µm resolution and the whole vertebral bone volume (BV) and 
thickness (Th) were determined. Cortical and trabecular analysis was not performed separately 
and the physical marker references could not be identified. Hence consistent scanning areas 
could not be determined. Protocol is yet to be optimised. Both male and female caudal vertebrae 
had significantly increased vertebral BV in RAMP3 KO mice compared to WTs (Fig. 2.25 (left 
column)). In males RAMP3 KO vertebrae also had a significant increase in bone thickness (Fig 
2.25 (top right)). Table 2.11 below details the mean ± standard error of mean (SEM) for WT and 
RAMP3 KO samples along with the statistical significance (red). 
 
 
 
 
 
 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
4 week male caudal 
vertebra BV 
mm
3
 
1.23 ± 0.12 n=5 1.58 ± 0.07 n=4 0.0445 * 
4 week male caudal 
vertebra Th 
mm 
0.06 ± 0.00 n=5 0.07 ± 0.00 n=4 0.0367 * 
4 week female caudal 
vertebra BV 
mm
3
 
1.24 ± 0.08 n=8 1.48 ± 0.07 n=8 0.0324 * 
4 week female caudal 
vertebra Th 
mm 
0.06 ± 0.00 n=8 0.07 ± 0.00 n=8 0.0806 NS 
Table 2.11: Statistical analysis of 4 week old male and female caudal vertebra. 
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Fig 2.25: Box and whisker plot showing caudal vertebral bone analysis in 4 week old WT and RAMP3 KO 
females. Unpaired Student’s T- test demonstrated that both male and female RAMP3 KO caudal vertebrae had 
significantly increased vertebral BV when compared to WT: male p=0.045 and female p=0.032 (A,B). 
Vertebral thickness was significantly higher in RAMP3 KO male vertebra, p=0.037 (C).  In males WT n=5 and 
RAMP3 KO n=4 and in females, WT and RAMP3 KO n=8. 
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2.3.2.ii.h Three dimension skeletal models of 4 week old mice: 
Both solid and gradient 3D models were generated to study the structural differences between 
RAMP3 KOs and WTs. Gradient densitometric whole femur models revealed that RAMP3 KOs 
have denser femurs, although, statistical significance was only achieved in female femurs. Figure 
2.26 below, is a representative image of whole femur gradient models where purple is least 
density of the structure and red is highest density of the structure.  
The Figure 2.27 overleaf summarises representative images of femur cortical, tibia trabecular and 
whole vertebral models. Solid grey-scale models of femur cortical, tibia trabecular and whole 
vertebrae overleaf, reflect the microCT analysis. No obvious structural differences were observed 
in femur cortical models. Tibia trabecular models showed thicker trabecular units in RAMP3 KO 
models compared to WTs. Female RAMP3 KO tibia trabecular model depicts the significant 
increase in trabecular thickness determined in microCT analysis. Lastly, whole vertebra solid 
models suggest genotype-dependent structural differences in vertebrae. RAMP3 KO vertebral 
models appear to have slender but well defined vertebral body with denser transverse process 
compared to WTs.  
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Fig 2.26: Representative 3D skeletal gradient models of 4 week old, WT and RAMP3 KO male (left panels) 
and female (right panels) mice. Gradient models of whole femur suggest that RAMP3 KO femurs in general 
are denser to WT femur however microCT data suggests statistical significance in difference of BV in female 
RAMP3 KO whole femur and WTs only. 
mm 
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Fig 2.27: Representative 3D skeletal models of 4 week old, WT and RAMP3 KO male (left panels) and female 
(right panels) mice. Within each image, left model is of WT and right of RAMP3 KO. Top-most panel is of 
femur cortical solid grey-scale models that do not show any structural differences in RAMP3 KOs and WTs. 
Middle panel of tibia trabecular solid model show thicker trabecular units in RAMP3 KO females (right most). 
The last panel of caudal vertebra show structural differences between WT and in the RAMP3 KO.It is evident 
that RAMP3 KO vertebrae are slender with denser vertebral bodies and transverse process.  
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2.3.3 Eight week old mice: 
Skeletal phenotypes of 8 week old WT and RAMP3 KO male and female mice were determined 
by microCT. Histology and dynamic histomorphometry was performed on male tibiae. The 
phenotype of WT and RAMP3 KO mice at this age is detailed below. Unpaired two tailed 
Student’s T- test with 95% confidence interval and P value < 0.05 considered significant was 
used to analyse the data statistically. 
2.3.3.i Whole body weight  
Eight week-old RAMP3 KO male had significantly (***) higher whole body weight compared to 
WT mice. There was no significant difference in the body weights of female mice. Figure 2.28 
below represents the differences in whole body weights in both male and female WT and RAMP3 
KO mice. 
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Fig 2.28: Box and whisker plot showing whole body weights in 8 week old WT and RAMP3 KO male (left) and 
female (right) mice. Unpaired Student’s T- test showed a significant increase in RAMP3 KO male (p 
value=0.0008) compared to WT males. n=4 each genotype. 
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2.3.3.ii MicroCT analysis: 
2.3.3.ii.a Whole femur and tibia:  
MicroCT analysis suggested that at 8 weeks of age, RAMP3 KO male mice had significantly lower 
tibia-fibula bone volume compared to WTs. There was no statistically significant difference 
between femurs of WT and RAMP3 KO male mice. Table 2.12 below details the arithmetic means 
± standard error of means (SEM) along with statistical significance (red). Figure 2.29 is a 
graphical representation of the same.   
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Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
8 week male whole 
femur BV 
mm
3
 10.06 ± 0.412 n=6 9.64 ± 0.37 n=7 0.4630 NS 
8 week male whole 
tibia-fibula BV 
mm
3
 11.18 ± 0.19 n=5 10.31 ± 0.21 n=6 0.0136 * 
Table 2.12: Statistical analysis of 8 week old male whole femur and tibia. 
Fig 2.29: Box and whisker plot showing whole femur (left) and tibia (right) bone volume of 8 week old WT and 
RAMP3 KO male mice. Unpaired Student’s T- test showed a significant decrease in RAMP3 KO tibia-fibula 
bone volume (p value=0.0136) compared to WT males but not in the femur bone volume. For femur analysis 
n=6 (WT) and 7(RAMP3KO) and for tibia-fibula analysis n= 5 (WT) and 6 (RAMP3 KO). 
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MicroCT analysis suggested that at 8 weeks of age, there are no statistically significant difference 
between femora and tibia-fibula complexes of WT and RAMP3 KO female mice. Table 2.13 below 
details the arithmetic means ± standard error of means (SEM) along with statistical significance 
(red). Figure 2.30 is a graphical representation of the same.   
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Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
8 week female whole 
femur BV 
mm
3
 10.28 ± 0.45 n=4 10.69 ± 0.24 n=4 0.4594 NS 
8 week female whole 
tibia-fibula BV 
mm
3
 11.03 ± 0.28 n=4 11.17 ± 0.18 n=4 0.6704 NS 
Table 2.13: Statistical analysis of 8 week old male whole femur and tibia. 
Fig 2.30: Box and whisker plot showing whole femur (left) and tibia (right) bone volume of 8 week old WT and 
RAMP3 KO female mice. Unpaired Student’s T- test showed no significant differences in whole bone volume of 
WT and RAMP3 KO femora and tibia-fibula complexes. 
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2.3.3ii.b Femur cortical bone:  
No significant differences were observed in 8 week old WT and RAMP3 KO male and female 
femur cortices. Table 2.14 below details the means ± standard error of means (SEM) along with 
statistical significance. Figure 2.31 overleaf is a graphical representation of the same.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
8 week male femur 
cortical BV 
mm
3
 0.83 ± 0.02 n=7 0.77 ± 0.04 n=6 0.4630 NS 
8 week male femur 
cortical Th 
mm 0.23 ± 0.01 n=7 0.23 ± 0.01 n=6 0.5480 NS 
8 week female femur 
cortical BV 
mm
3
 0.71 ± 0.02 n=4 0.70 ± 0.02 n=4 0.8408 NS 
8 week female femur 
cortical Th 
mm 0.21 ± 0 n=4 0.2 ± 0.01 n=4 0.4263 NS 
Table 2.14:  Statistical analysis of 8 week old male whole femur cortical bone. 
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Fig 2.31: Box and whisker plot showing femur cortical bone volume (left) and thickness (right) of 8 week old 
WT and RAMP3 KO male (A,B) and female (C,D) mice. Unpaired Student’s T- test demonstrated no 
significant differences in the bone volume and thickness between WT and RAMP3 KO male and female, femur 
cortices. Males: n=7 (WT) and 6 (RAMP3 KO). Females: n=4 each genotype. 
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2.3.3.ii.c Tibia cortical bone:  
No significant differences were observed in 8 week old WT and RAMP3 KO male and female tibia 
cortical bone volume and female tibia cortical thickness. However, in RAMP3 KO male mice, tibia 
cortical thickness was significantly reduced. Table 2.15 below details the means ± standard error 
of means (SEM) along with statistical significance (red). Figure 2.32 is a graphical representation 
of the same.   
 
 
 
 
 
 
 
 
 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
8 week male tibia 
cortical BV 
mm
3
 0.87 ± 0.03 n=7 0.82 ± 0.02 n=7 0.2139 NS 
8 week male tibia  
cortical Th 
mm 0.18 ± 0.00 n=7 0.16 ± 0.00 n=7 0.0203 * 
8 week female tibia 
cortical BV 
mm
3
 0.74 ± 0.02 n=4 0.84 ± 0.07 n=4 0.2588 NS 
8 week female tibia  
cortical Th 
mm 0.18 ± 0.06 n=4 0.18 ± 0 n=4 0.6396 NS 
Table 2.15: Statistical analysis of 8 week old male whole tibia cortical bone. 
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Fig 2.32: Box and whisker plot showing whole tibia cortical bone volume (left) and thickness (right) of 8 week 
old WT and RAMP3 KO male (A,B) and female (C,D) mice. Unpaired Student’s T- test demonstrated a 
significant decrease in RAMP3 KO tibia thickness (p value=0.0203) compared to WT male mice (B). No 
significant difference was detected in the tibial bone volume in both males and females and cortical thickness 
in females. Males: n=7 each group, females: n=4 each group. 
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2.3.3.ii.d Femur trabecular bone:  
Eight week old male WT and RAMP KO mice did not show any significant difference in femur 
trabecular architecture, except for pattern factor. RAMP3 KO mice had significantly higher femur 
trabecular pattern factor (Pf) compared to WT. In females, RAMP3 KO mice had a significant 
increase in femur trabecular thickness compared to WTs. Table 2.16 below, details the mean ± 
standard error of mean (SEM) for WT and RAMP3 KO samples along with the statistical 
significance (red). Figures 2.33 and 2.34 are graphical representation of the statistical analysis in 
males and females. 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
8 week male femur 
trabecular BV 
mm
3
 0.27 ± 0.01 n=6 0.27 ± 0.01 n=6 0.8491 NS 
8 week male femur 
trabecular BV/TV 
% 6.99 ± 0.49 n=4 6.24 ± 0.44 n=4 0.2960 NS 
8 week male femur 
trabecular Th 
mm 0.04 ± 0.00 n=6 0.04 ± 0.00 n=6 0.9635 NS 
8 week male femur 
trabecular Sp 
mm 0.34 ± 0.01 n=6 0.36 ± 0.01 n=6 0.2121 NS 
8 week male femur 
trabecular N 
1/mm 0.83 ± 0.05 n=5 0.94 ± 0.11 n=6 0.4182 NS 
8 week male femur 
trabecular Pf 
1/mm 22.84 ± 1.00 n=7 25.80 ± 0.76 n=7 0.0368 * 
8 week female femur 
trabecular BV 
mm
3
 0.3 ± 0.01 n=4 0.31 ± 0.01 n=4 0.6110 NS 
8 week female femur 
trabecular BV/TV 
% 8.0 ± 0.3 n=4 8.6 ± 0.3 n=4 0.1899 NS 
8 week female femur 
trabecular Th 
mm 0.04 ± 0.001 n=4 0.05 ± 0.0012 n=4 0.0299 * 
8 week female femur 
trabecular Sp 
mm 0.32 ± 0.011 n=4 0.32 ± 0.003 n=4 0.9321 NS 
8 week female femur 
trabecular N 
1/mm 1.89 ± 0.05 n=4 1.91 ± 0.08 n=4 0.8665 NS 
8 week female femur 
trabecular Pf 
1/mm 20.6 ± 1.0 n=4 19.3 ± 0.5 n=4 0.2913 NS 
 
 
 
 
 
Table 2.16: Statistical analysis of 8 week old male whole tibia cortical bone. 
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Fig 2.33: Box and whisker plot showing femur trabecular analysis in 8 week old WT and RAMP3 KO males. 
Unpaired Student’s T- test showed that male WT and RAMP3 KO do not have any significant differences in 
trabecular BV (A), BV/TV (B), Th(C), Sp (D), N (E). However femur trabecular Pf (F) in RAMP3 KO mice is 
higher than WT mice. WT n=6 (BV, Th and Sp), n=4 (BV/TV), n=5 (N) and n=7 (Pf). RAMP3 KO n=6 (BV, 
Th, Sp and N), n=4 (BV/TV) and n=7 (Pf). 
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Fig 2.34: Box and whisker plot showing femur trabecular analysis in 8 week old WT and RAMP3 KO females. 
Unpaired Student’s T- test showed that female WT and RAMP3 KO do not have any significant differences in 
trabecular BV (A), BV/TV (B), Sp (D), N (E) and Pf (F). However femur trabecular Th(C) in RAMP3 KO 
mice is significantly higher than WT mice (p=0.029). n=4 each group. 
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2.3.3.ii.e Tibia trabecular bone:  
MicroCT analysis of tibia trabecular bone of 8 week old WT and RAMP3 KO males suggested a 
significant increase in trabecular thickness of RAMP3 KO mice compared to WTs. There were no 
other trabecular differences determined. In females, the RAMP3 KO mice had a significant 
increase in tibia trabecular bone volume/tissue volume ratio (BV/TV), trabecular thickness (Th), 
and trabecular number (N). There was a significant reduction in trabecular separation (Sp). 
Table 2.17 below, details mean ± standard error of mean (SEM) for WT and RAMP3 KO samples 
along with the statistical significance (red). Figures 2.35 and 2.36 are graphical representation of 
the statistical analysis of male and female tibia trabecular bone. 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± SEM. P Value Significance 
8 week male tibia 
trabecular BV 
mm
3
 0.18 ± 0.019 n=5 0.18 ± 0.01 n=6 0.8465 NS 
8 week male tibia 
trabecular BV/TV 
% 3.34 ± 0.19 n=5 3.94 ± 0.40 n=6 0.2437 NS 
8 week male tibia 
trabecular Th 
mm 0.04 ± 0.00 n=5 0.04 ± 0.00 n=6 0.0155 * 
8 week male tibia 
trabecular Sp 
mm 0.61 ± 0.02 n=5 0.55 ± 0.05 n=6 0.2741 NS 
8 week male tibia 
trabecular N 
1/mm 0.83 ± 0.05 n=5 0.94 ± 0.11 n=6 0.4182 NS 
8 week male tibia 
trabecular Pf 
1/mm 52.10 ± 10.29 n=5 50.02 ± 8.36 n=6 0.8769 NS 
8 week female tibia 
trabecular BV 
mm
3
 0.13 ± 0.01 n=4 0.13 ± 0.01 n=4 0.7735 NS 
8 week female tibia 
trabecular BV/TV 
% 4. ± 0.2 n=4 5.25 ± 0.22 n=4 0.0058 ** 
8 week female tibia 
trabecular Th 
mm 0.04 ± 0.001 n=4 0.05 ± 0.001 n=4 0.0436 * 
8 week female tibia 
trabecular Sp 
mm 0.53 ± 0.01 n=4 0.42 ± 0.03 n=4 0.0150 * 
8 week female tibia 
trabecular N 
1/mm 0.93 ± 0.04 n=4 1.17 ± 0.04 n=4 0.0047 ** 
8 week female tibia 
trabecular Pf 
1/mm 29.23 ± 2.5 n=4 28.43 ± 0.74 n=4 0.7696 NS 
 
 
Table 2.17: Statistical analysis of 8 week old male whole tibia trabecular bone. 
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 Fig 2.35: Box and whisker plot showing tibia trabecular analysis in 8 week old WT and RAMP3 KO males. 
Unpaired Student’s T- test showed that male RAMP3 KO trabecular bone has significant increase in trabecular 
Th, p=0.035 (C) compared to WT. No significant differences observed in trabecular BV (A), BV/TV (B), Sp 
(D), N (E) and Pf(F).  WT n=5 and RAMP3 KO n=6. 
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Fig 2.36: Box and whisker plot showing tibia trabecular analysis in 8 week old WT and RAMP3 KO females. 
Unpaired Student’s T- test showed that male RAMP3 KO trabecular bone has significant increase in trabecular 
BV/TV (p=0.015), Th (p=0.043), N (p=0.004) and a significant decrease in trabecular separation (Sp) 
(p=0.015) compared to WT. n=4 each group. 
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2.3.3.ii.f Three dimension skeletal models: Three-dimensional models were generated from 
microCT scans of bones using Voxler rendering software (Fig. 2.37 below). Individual models 
reflected the data observed in microCT analyses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.37: Representative 3D skeletal models of femur cortical, tibia cortical and tibia trabecular bone (from top to 
bottom). WTs are to the left and RAMP3 KO are to the right. RAMP3 KO tibia show longer and thinner tibial crest (red 
arrows) responsible for reduction in total tibia cortical thickness of RAMP3 KOs in microCT. The last bottom panel 
shows thicker trabecular structure in RAMP3 KO models compared to WT, again reflecting the increase in trabecular 
thickness in RAMP3 KOs seen in the microCT analysis earlier. 
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2.3.3.iii Dynamic histomorphometry: 
The distance between double calcein labels was determined on lateral and medial endocortical 
surface by fluorescent microscopy. The inter-label width determined was then used to calculate 
the bone apposition rate on the endocortical surface. Figure 2.38 shows representative images of 
whole tibia longitudinal section and an enlarged view of an analysed region on the lateral 
endocortical surface. The following Fig. 2.39 overleaf shows representative fields of view of lateral 
and medial endocortical surface of WT (n=4) and RAMP3 KO (n=4). Table 2.18 (overleaf) 
summaries the mean ± SEM values of inter-label width and bone apposition rate and respective 
statistical significance (red). Lastly, Fig. 2.40 is a graphical representation of the inter-label width 
and bone apposition rate analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100um 
  
 100um 
 
Fig 2.38: Representative images of plastic embedded whole tibia longitudinal section of WT (left, top) and 
RAMP3 KO (right, top) 8 week old male mice. Bottom panels are zoomed images of an analysed region of the 
lateral endocortical surface showing increased inter-label width in the RAMP3 KO (right, bottom) compared to 
WT (left, bottom). WT n=5 and RAMP3 KO n=6. 
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RAMP3 KO 
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Fig 2.39: Representative ‘fields of view’ of medial and lateral endocortical surface of four WT (left) and four 
RAMP3 KO (right) plastic embedded tibia longitudinal sections. Increased inter-label width is evident in all 
eight RAMP3 KO panels compared to the WTs. n = 4. 
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Bone morphometric 
parameter 
Units WT Mean ± SEM.       RAMP3 KO Mean ± 
SEM. 
P Value Significance 
8 week male inter 
Calcein label width 
µm 10.66 ± 0.85 n=5 14.88 ± 1.19 n=6 0.0218 * 
8 week male bone 
apposition rate 
µm/day 1.52 ± 0.12 n=5 2.12 ± 0.17 n=6 0.0223 * 
Table 2.18:  Statistical analysis – dynamic histomorphometry of 8 week old males 
Fig 2.40: Box and whisker plots for inter label width (left) and bone apposition rate (right) of 8 week old male 
tibia-endocortical surfaces. RAMP3 KO mice have significant increase in both, the inter-label width 
(p=0.0218) and the bone apposition rate (p=0.0223). WT n=5 and RAMP3 KO n=6. 
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2.3.3.iv Histology:  
Both Haematoxylin and Eosin (H&E) stained and Tartrate-resistant acid phosphatase (TRAP) 
stained tibia sections revealed differences in trabecular area, number of osteoblasts and 
osteoclasts and growth plate of WT and RAMP3 KO mice in histological analyses.  
Noticeable structural differences observed in tibia sections: RAMP3 KO tibia where narrower, had 
differences in the arrangement of chondrocytes in the growth plate and increase in the area and 
surface of trabecular unit compared to WTs (Fig. 2.41).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.41: Representative H&E stained longitudinal tibia section of WT (top) and RAMP3 KO (bottom) 8 week 
old males. The tibiae in RAMP3 KO mice were observed to be narrower than WTs. RAMP3 KO and WT mice 
had differences in the arrangement of chondrocyte in the growth plate (black arrows). Trabecular area and 
surface was higher in RAMP3 KO mice (red arrows).  
500µm 
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2.3.3.iv.a Trabecular analysis 
H&E stained sections showed significant increase in total trabecular area and trabecular thickness 
(average trabecular area per trabecular unit) in RAMP3 KO males compared to WT males. 
Unpaired Student’s t-test was used to determine the statistical significance. Table 2.19 
summarises mean ± SEM values and respective statistical significance. Figure 2.42 is a graphical 
representation of the same.  
 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± 
SEM. 
P Value Significance 
8 week male tibia total 
trabecular area 
µm
2
 
187746 ± 14532 
n=5 
265877 ± 20627 
n=5 
0.0147 * 
8 week male tibia total 
trabecular  surface 
µm 
13422 ± 959.4 
n=5 
16074 ± 1327 
n=5 
0.1440 NS 
8 week male tibia average 
trabecular area per 
trabecular unit 
( trabecular thickness) 
µm
2
 
5566 ± 525.5 
n=5 
8365 ± 1077 
n=5 
0.0477 * 
8 week male tibia total 
number of trabecular units 
Arbitrary 
number 
34.00 ± 1.30 
n=5 
33.20 ± 3.43 
n=5 
0.8327 NS 
 
 
 
 
 
 
Table 2.19:  Statistical analysis – Histology: trabecular analysis 8 week old males. 
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Fig 2.42: Box and whisker plots representing statistical analysis of trabecular measurements in tibia sections of 
8 week old RAMP3 KO and WT male mice. Unpaired t-test suggests, RAMP3 KO mice have significantly 
increased total trabecular area (A) and average trabecular area per unit (trabecular thickness) (C). No 
significant difference was determined in trabecular surface (B) and number of trabecular unites (D) between 
RAMP3 KO and WT mice. Three sections where measured per sample. n=5 each group. 
C 
A B 
D 
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2.3.3.v Osteoblasts and osteoclasts quantification:  
Number of osteoblasts and osteoclasts were determined on the endocortical and trabecular 
surfaces of tibia in RAMP3 KO and WT males. Considering difference in cell population on the 
medial and lateral endocortical surface, the number of osteoblasts and osteoclasts were counted 
and analysed separately for each side. Unpaired Student’s t-test was used to determine the 
statistical significance of the differences between WT and RAMP3 KO mice. 
2.3.3.v.a Medial endocortical osteoblast and osteoclast quantification: 
No significant differences were observed in medial endocortical bone surface (En.S), number of 
osteoblast (Ob.N), number of osteoclast (Oc.N), osteoblast covered bone surface (Ob.S) or 
osteoclast covered bone surface (Oc.S) between WT and RAMP3 KO 8 week male mice. Table 
2.20 below summarises the mean ± SEM values and statistical significance if any (red). Figure 
2.43 overleaf is a graphical representation of the same.  
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± 
SEM. 
P Value Significance 
Tibia, medial endocortical 
bone surface 
µm 1830 ± 42.87 n=6 1841 ± 67.22 n=6 0.8916 NS 
Tibia, medial endocortical 
osteoblast number 
Arbitrary 
number 
90 ± 7 n=6 96 ± 13 n=6 0.7300 NS 
Tibia, medial endocortical 
osteoclast number 
Arbitrary 
number 
1 ± 0 n=6 3 ± 2  n=6 0.2518 NS 
Tibia, medial endocortical 
osteoblast covered bone 
surface 
µm 1282 ± 85.15 n=6 1290 ± 157.1 n=6 0.9663 NS 
Tibia, medial endocortical 
osteoclast covered bone 
surface 
µm 102.3 ± 64.96 n=6 96.16 ± 53.85 n=6 0.9437 NS 
 
 
 
Table 2.20:  Statistical analysis –medial endocortical osteoblast and osteoclast quantification. 
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Fig 2.43: Box and whisker plots showing statistical analysis of medial endocortical osteoblast & osteoclast 
quantification in 8 week old male WT and RAMP3 KO mice. There was no significant difference in endocortical bone 
surface (En.S) (A), osteoblast number (Ob. N) (B), osteoclast number (Oc. N.) (C), osteoblast covered bone surface 
(Ob.S) and osteoclast covered bone surface (Oc.S) between the groups. n=6 each group. 
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2.3.3.v.b Lateral endocortical osteoblast and osteoclast quantification: 
No significant differences were observed in lateral endocortical bone surface (En.S), number of 
osteoblast (Ob.N), number of osteoclast (Oc.N), osteoclast covered bone surface (Oc.S) 
between WT and RAMP3 KO 8 week male mice. However, RAMP3 KO mice had a significant 
reduction in osteoblast covered bone surface (Ob.S) indicating smaller osteoblasts in RAMP3 KO 
mice. Unpaired Student’s t-test was used to determine the statistical significance between the WT 
and RAMP3 KO mice. Table 2.21 below summarises the mean ± SEM values and statistical 
significance (red). Figure 2.44 overleaf is a graphical representation of the same.  
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± 
SEM. 
P Value Significance 
Tibia, lateral endocortical 
bone surface 
µm 2110 ± 150.2 n=6 1864 ± 72.76 n=6 0.1718 NS 
Tibia, lateral endocortical 
osteoblast number 
Arbitrary 
number 
141 ± 9 n=6 140 ± 10 n=5 0.9282 NS 
Tibia, lateral endocortical 
osteoclast number 
Arbitrary 
number 
1 ± 1 n=6 1 ± 1 n=6 0.8892 NS 
Tibia, lateral endocortical 
osteoblast covered bone 
surface 
µm 1990 ± 84.28 n=6 1679 ± 56.40 n=6 0.0118 * 
Tibia, lateral endocortical 
osteoclast covered bone 
surface 
µm 46.17 ± 43.72 n=6 22.56 ± 15.11 n=6 0.6208 NS 
 
 
 
Table 2.21:  Statistical analysis - lateral endocortical osteoblast and osteoclast quantification. 
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Fig 2.44: Box and whisker plots representing statistical analysis of lateral endocortical osteoblast and 
osteoclast quantification in 8 week old male WT and RAMP3 KO mice. There was no significant difference in 
endocortical bone surface (En.S) (A), osteoblast number (Ob. N) (B), osteoclast number (Oc. N.) (C) and 
osteoclast covered bone surface(Oc.S). There was a significant reduction in osteoblast covered bone surface 
(Ob.S) (p = 0.0118). WT n= 5 (Ob N) and n= 6 (En.S, Oc. N, Ob.S, Oc.S). 
A 
B C 
D E 
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2.3.3.v.c Trabecular osteoblast and osteoclast quantification: 
In trabecular osteoblast and osteoclast quantification, RAMP3 KOs had significantly higher 
trabecular bone surface, higher osteoblast number and a higher osteoblast covered bone surface 
compared to WTs. There was no significant difference in osteoclast number and osteoclast 
covered bone surface. Table 2.22 below summarises the mean ± SEM values and statistical 
significance (red). Figure 2.45 overleaf is a graphical representation of the same. 
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± 
SEM. 
P Value Significance 
Tibia, trabecular bone 
surface 
µm 2925 ± 257.0 n=5 4189 ± 339.3 n=5 0.0178 * 
Tibia, trabecular osteoblast 
number 
Arbitrary 
number 
94 ± 11 n=5 137 ± 12 n=5 0.0336 * 
Tibia, trabecular osteoclast 
number 
Arbitrary 
number 
18 ± 2 n=5 27 ± 5 n=5 0.1414 NS 
Tibia, trabecular osteoblast 
covered bone surface 
µm 1433 ± 155.6 n=5 1992 ± 174.3 n=5 0.0437 * 
Tibia, trabecular osteoclast 
covered bone surface 
µm 530.0 ± 111.6 n=5 721.6 ± 84.06 n=5 0.2075 NS 
 
 
 
 
 
 
 
Table 2.22:  Statistical analysis - lateral endocortical osteoblast and osteoclast quantification. 
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Fig 2.45: Box and whisker plots demonstrating statistical analysis of trabecular osteoblast and 
osteoclast quantification in 8 week old male WT and RAMP3 KO mice. There was a significant 
increase in trabecular bone surface (p=0.0178) (T.S) (A), osteoblast number (p=0.0338) (Ob. N) 
(B) and osteoblast covered bone surface (p=0.0437)(Ob.S). There was no significant difference in 
osteoclast number (Oc. N.)(C) and osteoclast covered bone surface(Oc.S). n=5 in both groups. 
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2.3.3.vi Growth plate analysis 
H&E tibial sections were analysed to determine differences in growth plates of WTs and RAMP3 
KO mice. It was observed that RAMP3 KO mice had larger chondrocyte columns in the growth 
plate with larger proliferative chondrocyte zone. On the other hand, the hypertrophic zone was 
variable in both WT and RAMP3 KO mice. Figure 2.46 below shows three representative growth 
plates each genotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100µm 100µm 
100µm 100µm 100µm 
100µm 
WT WT WT 
RAMP3 KO RAMP3 KO RAMP3 KO 
Fig 2.46: Representative images of tibial growth plates. Top three panels are WT and bottom three panels are 
of RAMP3 KO mice. RAMP3 KO growth plates appear to have larger chondrocyte columns (black box bracket) 
compared to WTs. Additionally, RAMP3 KOs had larger proliferative zone indicated by red brace bracket. 
Hypertrophic chondrocyte number appears to be variable in both the RAMP3 KO and WTs (blue brace 
bracket). Three H&E sections per bone were studies for growth plate analysis (n=6 each group). 
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2.3.3.vi.a Growth plate measurements: Total chondrocyte column length of 15 columns (per 
section of bone) was measured along with individual measurements of the proliferative and 
hypertrophic zones. Additionally, the average numbers of proliferative and hypertrophic cells per 
chondrocyte column were determined. In total 3 sections were analysed per sample where, n=6 
WT and RAMP3 KO. Unpaired Student’s t-test was used to determine the statistical significance 
in the differences between WT and RAMP3 KO mice. Table 2.23 summarizes mean ± SEM 
values of these quantifications with significant differences (red). Figure 2.47 overleaf is a 
graphical representation of the same.   
 
Bone morphometric 
parameter 
Units WT Mean ± SEM. RAMP3 KO Mean ± 
SEM. 
P Value Significance 
Total chondrocyte column 
length 
µm 162.0 ± 6.51 n=6 189.7 ± 7.47 n=6 0.0188 * 
Proliferative zone length µm 60.00 ± 3.22 n=6 88.89 ± 7.83 n=6 0.0066 * 
Hypertrophic zone length µm 102.0 ± 4.84 n=6 100.8 ± 4.07 n=6 0.8604 NS 
Number of proliferative 
chondrocytes 
Arbitrary 
number 
6 ± 1 n=6 7 ± 1 n=6 0.3077 NS 
Number of hypertrophic 
chondrocytes 
Arbitrary 
number 
6 ± 0 n=6 5 ± 1 n=6 0.7060 NS 
 
Table 2.23:  Statistical analysis tibial growth plate of 8 week old male mice 
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Fig 2.47: Box and whisker plots representing statistical analysis of growth plates of 8 week old male WT and 
RAMP3 KO mice. RAMP3 KO had significantly larger chondrocyte columns (A). RAMP3 KOs had significantly 
larger proliferative zones (p = 0.006) (B) but there was no difference in hypertrophic zones (C) There was no 
significant difference in the number of proliferative and hypertrophic cells (D and E). n=6 in both groups. 
A 
B C 
D E 
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2.4 Discussion 
2.4.1 Technical limitations: 
2.4.1.i Animals: The WT 129/SvEv mice used in this study were generated from RAMP2 +/- 
cross RAMP3 -/- mice that were back crossed for 9 generations to obtain a founder breeding 
pairs on a congenic background. However, these animals were not monitored for behavioural 
changes. There were no physiological abnormalities reported in the breeding animals for up to 2 
years of age in both WT and RAMP3 KO breeding lines. Since it has been reported that the 
RAMP3 KO adult mice had reduced body weights compared to WTs, we monitored the body 
weights of WT and RAMP3 KO mice up to 16 weeks of age (Dackor et. al. 2007). In contrast to 
Dackor et al, we observed that RAMP3 KO mice had reduced body weight at 4 weeks of age, 
although at time point other that 4 weeks (Fig. 2.16): post natal day 5 (PND5), 8 weeks, 12 
weeks and 16 weeks, RAMP3 KO mice either had increased body weights or that there was no 
difference (Figs. 2.11, 2.28, 3.2). We also observed that the differences in body weights were not 
sex-dependent. It can be suggested that our observations, with respect to body weights, are 
different from what has been reported because of the difference in generating and breeding WT 
129/SvEv mice. Since our WT 129/SvEv mice were generated from RAMP2 +/- and RAMP3-
/-, there could be a phenotypic trait passed on to the future generation by the RAMP3 KO parent.  
2.4.1.ii MicroCT analysis: Major skeletal analyses in our study is carried out using microCT. The 
maximum resolution that can be achieved by the microCT scanner Skyscan 1172 in University of 
Sheffield is of 4.5µm and at this resolution the camera is limited to a region of the long bone and 
does not scan the whole bole. For whole bone, the maximum resolution that can be used at a 
medium camera is 17.5 µm. A larger camera or an oversize scan can be used to scan the whole 
long bone at 4.5µm, but the raw dataset generated goes beyond 4GB in size. The reconstruction 
and analysis of the huge datasets need computer equipped with extra hard drives to cope with the 
huge data processing for each sample. The use of medium camera and above mentioned 
resolutions, were the most efficient and economical settings that have been standardised for 
Skyscan 1172 microCT scanner. Another technical limitation of microCT analysis is that, the 
measurements of bone morphometric parameters are done as the quantifications of the greyscale 
pixels in the cross section data set of the reconstructed scan. Site specific differences, for 
example: lateral v/s medial cortical thickness, cannot be measured as the measurements made 
are average quantifications. This abolishes the significance of the site specific differences in the 
134 
 
skeleton. The structural differences can only be addressed through the 3D models generated from 
the scans; however the details of the rendering are limited by the resolution of the scan.  
2.4.1.iii Histology: Eight week old male tibiae were used to conduct histological analysis. The 
most challenging technical limitation confronted during histological measurements was inconsistent 
bone sections. This limited the histological measurements to smaller areas to avoid inconsistency 
and contributed to larger error bars that affected the statistical analysis. Another difficulty faced 
with initial histology samples was improper sample fixing and delay in initiation of decalcification 
process as samples were first scanned for microCT prior to histology. These problems were later 
rectified by promptly decalcifying right side bones and scanning the left side bones which were 
later processed for dynamic histomorphometry which did not need decalcification.    
2.4.2 Silencing RAMP3 gene results in an accelerated skeletal development.  
It was observed that RAMP3 KO mice had and accelerated skeletal development at birth. As 
observed in figures 2.13 and 2.15 at PND5 of age, RAMP3 KO mice have more developed 
vertebral bodies which are larger and have developed transverse process compared to WTs. The 
microCT analysis suggests that, compared to WTs, RAMP3 KOs also have increased femoral 
bone volume and increased bone density which is evident from the increased opacity in RAMP3 
KO 3D femur model (Fig 2.14) These differences were independent of the sex of the animals. 
At 4 weeks of age, RAMP3 KO males and females still maintain the sex independent accelerated 
development in the caudal vertebra which have slender and denser bone structure (Fig. 2.27). 
This increase in bone volume is supported by the microCT analysis data (Fig 2.25). There is an 
increase in femur and tibia-fibula bone volume of RAMP3 KO mice (Figs. 2.17 and 2.18); 
however, this difference is only in female which is accounted by an increase in tibia trabecular 
thickness and trabecular pattern factor which is evident from the 3D trabecular models (Figs. 2.26 
and 2.27). The increase in the bone morphometric parameters is observed in 4 week old RAMP3 
KO animals despite the reduced body weights in RAMP3 KOs at this age. 
At 8 weeks of age, the RAMP3 KO males have increased whole tibia BV and females have 
increased whole femur BV (Fig. 2.29). Both male and female RAMP3 KOs have increased tibia 
trabecular thickness (microCT) and trabecular area (histology) (Figs. 2.35 and 2.41 
respectively). The enhanced trabecular structure of RAMP3 KOs is obvious in the 3D models and 
H&E stained tibia sections (Figs. 2.36 and Fig. 2.41). The increase in trabecular area was 
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resulted from a significant increase in the number of osteoblasts and osteoblast covered 
trabecular bone surface (Fig. 2.45). Hence there was a significant increase in osteoblast activity 
on the trabecular surface of the RAMP3 KO tibiae. There was no significant increase in the 
number of osteoclasts and osteoclast covered region (Fig.2.45). It was also observed that the 8 
week old male tibiae had a decrease in tibia cortical bone thickness. Interestingly this reduction in 
the tibia cortical bone thickness in RAMP3 KOs was due to the thinner, longer and enhanced 
curvature of the tibial crest seen in 3D cortical model (Fig. 2.36). There is evidence that RAMP3 
KO male tibiae have decreased response to bone loading (Livesey et al 2013, University of 
Sheffield, yet to be published data). The change in the structure of the tibia cortical bone that is 
observed in this study could be due to one of the reasons why RAMP3 KO male tibiae have 
resistance to bone loading as observed by Livesey et al. Despite the reduction in tibia cortical 
thickness in RAMP3 KO mice determined by the microCT techniques, dynamic histomorphometry 
suggested an increase in bone apposition rate in both medial and lateral periosteal regions of the 
RAMP3 KO tibiae (Figs. 2.38 and 2.39). This suggested that the differences in the cortical bone 
were not identified by the microCT analysis even at 4.5µm resolution. There could be other 
differences in the bone morphometric parameters at other time points that were not identified by 
microCT. Interestingly the number of osteoblasts and osteoclasts on the lateral endocortical 
surface of RAMP3 KO mice were not significantly different from that of WT mice (Fig. 2.43). 
However, the lateral endocortical bone surface covered with osteoblasts in RAMP3 KOs was 
significantly less compared to the WTs (Fig. 2.44). This suggested that the osteoblasts on the 
lateral endocortical surface of RAMP3 KO mice were smaller in size compared to the osteoblasts 
in WTs (Fig. 2.48 below). One of the reasons for smaller osteoblasts in RAMP3 KOs could be 
that they were proliferating, which could imply that the RAMP3 KO osteoblasts had increased 
proliferation compared to WT on the lateral endocortical surface. Moreover, active osteoblasts are 
smaller but more cuboidal in shape compared the flattened bone lining cells. It can hence be 
postulated that the RAMP3 KOs have more active osteoblasts compared to the WTs. 
 
 
 
 
60µm 40µm 
Bone surface area covered by 6 
osteoblasts in WTs 
Bone surface area covered by 6 
osteoblasts in RAMP3KOs 
Fig 2.48: Schematic representation of lateral endocortical bone surface in WT and RAMP3 KO mice 
hypothesising that the reduction in the osteoblasts covered surface in RAMP3 KOs could result from smaller 
osteoblasts and there were no differences in the number of osteoblasts in WTs and RAMP3 KOs. 
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The advanced skeletal phenotype observed in postnatal day 5 animals followed by a suggestively 
anabolic skeletal phenotype, encouraged us to study the growth plate of RAMP3KO animals. 
Growth plate analysis of 8 week old males revealed a significant increase in the length of the 
chondrocyte columns in RAMP3 KO mice compared to WTs (Fig. 2.47). Interestingly the increase 
in the length was due to the expanded proliferative zone, although the number of proliferative cells 
in the columns of RAMP3 KO was not significantly different from that of the WTs (Fig. 2.47). The 
increase in the proliferative zone could be because of the increase in size of the proliferative cells 
which is when the proliferative cells become pre-hypertrophic. So the differentiation of proliferative 
cells to pre-hypertrophic could be enhanced in the RAMP3 KO mice. By having more pre-
hypertrophic cells in the proliferative zone, it can be suggested that in RAMP3 KOs the 
differentiation of proliferative chondrocyte to hypertrophic chondrocytes in accelerated which is 
followed by acceleration in the mineralization of the growth plate. This could in turn explain the 
acceleration in endochondral ossification in utero that results in the advanced development of the 
skeleton seen in the postnatal day 5 old RAMP3 KO mice. These findings give novel evidence to 
involvement of RAMP3 in chondrocyte differentiation and endochondral ossification. To date there 
is evidence of Indian hedgehog (Ihh) regulated differentiation of pre-hypertrophic chondrocytes 
into hypertrophic chondrocytes with a negative feedback loop on PTHrP expression, although 
these are no studies on RAMP3 involved Ihh-PTHrP chondrocyte differentiation (Kornenberg 
2005, Scheijen et al 2003, St-Jacques et al 1999). There is also evidence that RAMP3 
expression profoundly increase in the uterus in an oestrogen dependent manner (Hewitt et al 
2005, Watanabe et al 2006). Therefore, RAMP3 can play a regulatory, although not obligatory 
role like RAMP2, in embryogenesis, implying that RAMP3 and RAMP2 play distinct and non-
redundant roles in animal development (Dackor et al 2007). In future, it will be helpful to study 
the chondrocyte differentiation in neonatal RAMP3 KO mice, and to determine RAMP1/2/3 
expression in the growth plates of WT and RAMP3 KO mice. 
The significant differences observed in histological analysis are diminished in the microCT 
analysis. The technical limitations discussed earlier could account for the reduction of the 
significance of the differences observed by microCT analysis. Judging from the histological 
differences observed at 8 weeks of age, there would certainly be interesting differences 
supporting enhanced skeletal development in RAMP3 KOs at PND5 and 4 weeks of age at 
cellular level. Regardless of the technical limitations, it can be stated that RAMP3 KO mice have 
advanced skeletal development at early age, which could provide protection to age related bone 
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loss phenomena like osteoporosis. Increased number of osteoblasts in the RAMP3 KO trabecular 
bone is suggestive of an anabolic skeletal phenotype in the RAMP3 KOs. It is also evident from 4 
and 8 week old animals (see Figs. 2.17, 2.23, 2.24, 2.35 and 2.36) that the suggestively 
anabolic skeletal phenotype is statistically significant in female RAMP3 KOs compared to male 
RAMP3 KOs, hence it can be implied that oestrogen enhances the RAMP3 KO skeletal 
phenotype. In the next chapter we investigate the skeletal response to ovariectomy in an attempt 
to understand the role of RAMP3 in skeletal regulation in postmenopausal conditions. The 
molecular mechanisms responsible for the skeletal phenotype of RAMP3 KO mice are discussed 
in chapter 8. 
In conclusion, RAMP3 KO mice have, accelerated skeletal development at birth and in adult tibiae 
there is: 
 Significant increase in trabecular thickness without increase in total bone volume. 
 Difference in the shape of the tibial crest, 
 Significant increase in the bone apposition rate, 
 Significant increase in the number of osteoblasts in the trabecular bone, 
 Significant increase in the osteoblast covered trabecular surface and  
 Significant increase in the thickness of the growth plate. 
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Chapter 3: Skeletal response of RAMP3 KO mice to ovariectomy. 
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3.1 Introduction  
It has been suggested that a women can expect to lose about 35% of her cortical bone and 50% 
of her trabecular bone as she ages, whereas a man can expect to lose only about two-thirds of 
these amounts (Riggs et al 1982). About half of this bone loss in women is in the first decade 
after menopause (Riggs & Melton 1992). Postmenopausal osteoporosis is characterised by loss 
of bone that results in frequent fractures, mostly of vertebrae, hip, distil forearm and proximal 
femur following minimal trauma. This progression in bone loss is due to an increase in bone 
resorption and decrease in bone formation which occurs from increase in the rate of activation of 
the Bone Mineralizing Units (BMU) (Storm et al 1990). The onset of trabecular bone loss 
precedes the loss of cortical bone with aging. In postmenopausal women this loss of trabecular 
bone is aggravated. There is strong evidence to propose, that the bone loss in postmenopausal 
women mainly affects the trabecular bone in the vertebra, hip and the proximal ends of femur 
(Melton et al 1986, Riggs & Melton 1986). This loss of trabecular bone, is not due to generalised 
thinning of the trabeculae but instead it is due to complete perforation and fragmentation of 
trabecular bone (Kleerekoper et al 1985, Parfitt et al 1983). 
The details of current therapeutic approaches for treating osteoporosis are discussed in the main 
dissertation introduction (Section 1.2). In this section we shall focus on the role of oestrogen and 
oestrogen dependent CT family of peptides’ role in skeletal regulation. In older women with 
established osteoporosis, there is evidence that hormone replacement therapy arrests the drastic 
loss of bone mineral density and reduces fracture rates (Christiansen 1990, Dequeker & Geusens 
1989, Lufkin 1992, Lufkin et al 1992). Postmenopausal women treated with oestrogen for 5 years 
showed prevention of the bone loss that was observed within the placebo group. It was also 
observed that if the onset of the therapy is delayed by 5 years, bone formation increases in the 
first 3 years. In the later 2 years there was no increase in bone formation however the 1% bone 
loss seen in placebo group was not seen in the treatment group (Lindsay et al 1976).  
The influence of oestrogen on differentiation and activity of osteoblasts is discussed earlier in 
section 1.1.3.i. Briefly, oestrogen regulates osteoblast differentiation and osteoblast induced 
osteoclast differentiation and activation. Oestrogen down regulates osteoclasts by inducing 
apoptosis through TFG-β (Khosla et al 1999). Oestrogen also inhibits the PTH induced osteoclast 
resorption by blocking the cAMP pathway in osteoblasts and also by decreasing interlukin-6 (IL-
6), release from osteoblasts as IL-6 is a potent osteoclasts activator. Furthermore oestrogen also 
3 Chapter 3: Skeletal response of RAMP3 KO mice to ovariectomy. 
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induces OPG production that hinders RANKL–RANK association (Kaji et al 1996). The loss of 
oestrogen in postmenopausal women results in the loss these key regulatory pathways. Therefore 
hormone replacement therapy aims to restore this balance to protect the loss of bone mineral 
density.  
Ovariectomy is the surgical procedure used to generate an experimental murine model for 
studying postmenopausal osteoporosis. Bone loss is induced by surgically removing the ovaries. 
Ovariectomy is performed when the animals attains sexual maturity as the bone loss can be 
studies after the animals attains the peak bone formation (8 weeks to 16 weeks). Amongst the 
Calcitonin (CT) family of peptides, Adrenomedullin (AM) is associated with vasodilation in OVX 
models (Ross et al 2006). Calcitonin (CT), Calcitonin gene related peptide (CGRP) and Amylin 
(AMY) have been shown to regulate the bone morphology and induce skeletal protection to bone 
loss following ovariectomy (OVX).  
The role of Calcitonin in bone loss protection is very well understood. There is also evidence that 
prophylactic administration of CT results in protection against oestrogen induced –bone loss 
(Mazzuoli et al 1990a, Mazzuoli et al 1990b). As mentioned earlier in section 1.2, intranasal 
calcitonin spray is used as an osteoporosis treatment. However recent reports suggest that 
Novartis has withdrawn CT intranasal spray as a treatment for osteoporosis. CGPR inhibits bone 
resorption but not bone formation, however it is not as efficient as CT in preventing bone loss It 
was observed that CGRP-treated rats had a loss of 46% trabecular bone, whereas CT-treated 
rats had a loss of 21% (Valentijn et al 1997). In comparison to just OVX rats, OVX rat subjected 
to 3 µg/100 g BW/day injection of AMY, showed increase in both distal metaphyseal 
(representative of trabecular bone) and total femoral bone densities. However, this skeletal 
response was not seen in the diaphyseal femoral density (representative of cortical bone). Hence 
AMY induced a specific bone formation response in the trabecular bone and not in the cortical 
bone (Horcajada-Molteni et al 2000). 
We now have robust evidence that the RAMP3 KO mice have an advanced skeletal phenotype 
with higher significance in female RAMP3 KO mice (Chapter 2). In a study to determine AM 
induced uterine relaxation, it was observed that both pregnancy and estradiol treatment to OVX 
rats amplified RAMP3 expression in uterine arteries while progesterone had no effect (Ross et al 
2010). There is also evidence that RAMP3 expression profoundly increase in the uterus in an 
oestrogen dependent manner (Hewitt et al 2005, Watanabe et al 2006). Therefore we can 
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propose that, the absence of RAMP3 expression in RAMP3 KO female mice will influence the 
skeletal bone phenotype following ovariectomy. 
As discussed earlier, the RAMP3 KO mice and WT mice used in our study are generated on 
129/SvEv background. The skeletal response to ovariectomy (OVX) in 129/SvEv mice is not 
completely known. Hybrid 129/SvEv cross C57BL/6 mice have been used to study the response 
to OVX in AMP-activated protein kinase gene Ampkα1 KO mice, where WT hybrid 129/SvEv 
cross C57BL/6 mice show reduction in trabecular and cortical bone volume (Jeyabalan et al 
2012). The WT and RAMP3 KO models used in our study shall provide novel data on the skeletal 
response to OVX on a pure 129/SvEv background  
In this chapter we focus on determining whether the accelerated skeletal development in RAMP3 
KO mice at early ages, provided protection to oestrogen dependent bone loss and if the oestrogen 
dependent skeletal regulation is influenced by the alteration in RAMP3 expression in the RAMP3 
KO female mice. We hypothesized, the skeletal response to ovariectomy, would be different in 
RAMP3 KO 129/SvEv female mice, in comparison to the WT 129/SvEv female mice. 
To test our hypothesis, we perform microCT skeletal analysis of: 
 10 baseline 12 week old female mice (5 WT and 5 RAMP3 KO), 
 10 sham operated 16 week old female mice (5 WT and 5 RAMP3 KO) and 
 10 OVX, 16 week old female mice (5 WT and 5 RAMP3 KO). 
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3.2 Methods and materials  
The skeletal phenotype in response to ovariectomy (OVX) was studied in female WT and RAMP3 
KO mice at the age of 12 weeks (baseline group/OVX conducted) and 16 weeks (sham and 
OVX group) by microCT. Protocols used for sample processing and microCT analysis are 
previous discussed in chapter 2, section 2.2.9. This section details the surgical intervention-
ovariectomy used to mimic postmenopausal physiology in WT and RAMP3 KO mice. 
3.2.1 Ovariectomy: 
Skeletal response to ovariectomy (OVX) was studied in 12 week old WT and RAMP3 KO female 
mice. OVX (n=5/genotype) and sham operations (n=5/genotype) were conducted at 12 weeks 
of age and the animals were culled at 16 weeks of age. Baseline animals were culled at 12 
weeks. (Bagi et al 1993, Bouxsein et al 2005). 
Anaesthesia: Animals were anaesthetised using Isoflurane (IsoFlo™, Abbot®) at 2.5 – 3% in 
100% oxygen. The anaesthesia was induced (4.5l/min during the first three minutes) and 
maintained (~2.5 l/min) through a face mask linked to an active-scavenge system to reduce 
environmental contamination. Loss of righting reflex was used to determine the state of 
consciousness. 
Surgery: Ensuring the spine was straight; the animal was placed in ventral recumbency position, 
with the tail towards the surgeon. Limbs were taped to the surgery mat to maintain the animal in 
position. The dorsal mid-lumbar region was shaved and scrubbed with alcohol. A dorsal midline 
skin incision approximately 1.5 cm was over the lumbar spine. Fascia was separated by blunt 
dissection. On either sides lateral to the skin incision (3-5 mm away), a 0.5-1 cm incision was 
made in the muscle wall. Ovaries and oviducts were located and exteriorised through the muscle 
wall incisions on either sides (one at a time). To remove the ovary, the uterine horn was first 
clamped with a haemostat and ovary was cut above the clamp. The clamp was then removed and 
the tissue was replaced back into the abdomen. Similarly the other ovary was excised. The 
muscle wall was not sutured. The skin incision was sutured with Polyglactin 910 synthetic 
absorbable suture (Johnson and Johnson® W9443). Sham animals were operated with the same 
procedure except that their ovaries were exteriorised and replaced but not excised. The surgeries 
were performed by Dr Ning Wang (University of Sheffield). 
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Post operation recovery: Animals recovered from anaesthesia in recovery chambers that were 
temperature regulated at 220C.  Animals were then housed in their cages and monitored for the 
next 72 hours for suture breakage and general recovery. Sham and OVX groups were housed for 
4 weeks post operation and were culled at 16 weeks of age. 
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3.3 Results 
The response of the skeleton to ovariectomy was determined through microCT analysis. There 
were 10 baseline mice (5 WT and 5 RAMP3 KO) which were 12 weeks of age (age at which 
ovariectomy conducted), 10 sham mice of 16 weeks old (5 WT and 5 RAMP3 KO) and 10 
ovariectomized mice of 16 week old (OVX) (5 WT and 5 RAMP3 KO).  
3.3.1 Weight of Uterus  
Whole uteri were weighed in sham and ovariectomized (OVX) mice immediately post sacrifice. 
Both WT and RAMP3 KO females showed a significant reduction in whole uterus weight, due to 
excision of ovaries, in OVX group compared to their respective sham group confirming that the 
surgical intervention was executed effectively (Fig 3.1). 
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Fig 3.1: Box and whisker plot showing significant reduction of whole uterus weight in WT (p=0.0215) and 
RAMP3 KO (p = 0.0001) OVX mice compared to their respective sham group.  
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3.3.2 Whole body weights:  
There was a pattern of increase in whole body weight post OVX in both WT and RAMP3 KO 
mice. However according to 2-way ANOVA and post multiple comparison Bonferroni’s test, 
differences in the weights were not statistically significant (Fig. 3.2). 
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Fig 3.2: Box and whisker plot showing whole body weights of baseline, sham and OVX WT and RAMP3 KO 
mice. Two-way ANOVA test followed by Bonferroni’s post multiple comparisons test was used to determine 
statistical significance of differences between the treatment and genotype. Neither the genotype nor the 
treatment resulted in significant difference in body weights. n = 5 in each group. 
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3.3.3 MicroCT analysis: 
MicroCT analysis was used to determine the bone morphometric parameters for whole, cortical 
and trabecular, femur and tibia bone. Dataset was analysed using 2-way ANOVA statistical test. 
Additionally, Bonferroni’s post-multiple analysis was used to determine whether the difference 
observed was between genotypes or between treatments. 
3.3.3.i Whole femur and tibia bone volume: 
There was no significant difference resulting from intervention in the total femur and tibia bone 
volume in either WT or RAMP3 KO mice. Figure 3.3 below is a graphical representation of the 
statistical analysis. Bone morphometric values and statistical significance is summarised in table 
9.1 in the appendix.   
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Fig 3.3: Box and whisker plot showing whole femur (left) and tibia (right) bone volume of baseline, sham and 
OVX in WT and RAMP3 KO mice. Two-way ANOVA test followed by Bonferroni’s post multiple comparisons 
test was used to determine statistical significance of differences between the treatment and genotype. Neither 
the genotype nor the treatment resulted in significant difference in whole bone volumes of femurs and tibiae.  
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3.3.3.ii Femur cortical bone: 
There was no significant difference resulting from intervention in the femur cortical bone volume 
and thickness in either WT or RAMP3 KO mice. Figure 3.4 below is the graphical representation 
of the statistical analysis. Bone morphometric values and statistical significance is summarised in 
table 9.1 in the appendix   
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Fig 3.4: Box and whisker plot demonstrating femur cortical bone volume (left) and thickness (right) of 
baseline, sham and OVX groups within WT and RAMP3 KO mice. Two-way ANOVA test followed by 
Bonferroni’s post-multiple comparisons test was used to determine statistical significance of differences 
between the treatment and genotype. Neither the genotype nor the treatment resulted in significant difference 
in femur cortical parameters.  
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3.3.3.iii Tibia cortical bone: 
The tibia cortical bone volume was observed to be significantly higher in WT OVX treated mice 
compared to WT sham treated mice (p = 0.0227) while there was no significant difference in 
cortical bone volume within RAMP3 KO mice groups.  
On the other hand, the tibia cortical thickness was significantly different in all RAMP3 KO 
treatment groups. Compared to the baseline mice, cortical thickness was significantly reduced in 
the sham treated mice (p = 0.0001) while the cortical thickness was significantly increased in 
OVX treated group compared to sham treated (p = 0.0011). Figure 3.5 below is a graphical 
representation of the statistical analysis. Bone morphometric values and statistical significance is 
summarised in table 9.1 in the appendix   
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Trabecular analysis: 
Fig 3.5: Box and whisker plot showing tibia cortical bone volume (left) and thickness (right) of baseline, sham 
and OVX WT and RAMP3 KO mice. Two-way ANOVA test followed by Bonferroni’s post-multiple comparisons 
test was used to determine statistical significance of differences between the treatment and genotype. There 
was a significant increase in tibia cortical bone volume of WT OVX treated mice compared to WT sham treated 
mice (p=0.0227). Cortical thickness of RAMP3 KO sham treated mice was very significantly reduced than 
RAMP3 KO baseline mice (p=0.0001). However, cortical thickness of RAMP3 KO OVX treated mice was 
significantly increased than RAMP3 KO sham treated mice (p=0.0011). 
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3.3.3.iv Femur trabecular bone: 
Unlike the femur cortical bone, femur trabecular bone showed difference in the bone parameters 
in response to the intervention. A pattern of reduction in trabecular BV, BV/TV, Th and N and 
increase in Sp in both WT and RAMP3 KO OVX treated mice when compared to respective 
baseline and sham treated groups was observed. However, according to the two-way ANOVA test 
followed by Bonferroni’s post multiple comparisons test, these differences were not significant. 
Figure 3.6 overleaf is a graphical represents of the statistical analysis. Bone morphometric values 
and statistical significance is summarised in table 9.1 in the appendix   
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Fig 3.6: Box and whisker plot showing femur trabecular bone volume (A), BV/TV (B), thickness (Th) (C), 
separation (Sp) (D), Number (N) (E) and pattern factor (Pf) (F). No significant differences were observed in 
any of the trabecular parameters in any treatment groups of either genotype.  
D C 
A B 
E F 
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3.3.3.v Tibia trabecular bone: 
Tibia trabecular bone showed the maximum response to intervention in both WT and RAMP3 
KOs. Similar to femur trabecular bone, a pattern of reduction in trabecular BV, BV/TV, Th and N 
in both WT and RAMP3 KO OVX treated mice when compared to respective baseline and sham 
treated groups was observed. Two-way ANOVA test followed by Bonferroni’s post multiple 
comparisons test was used to determine statistical significance of differences between the 
treatment and genotype. Bone morphometric values and statistical significance is summarised in 
table 9.1 in the appendix. Individual statistical differences in tibia trabecular bone parameters in 
graphically represented and in Figures 3.7, 3.8 and 3.9.  
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Fig 3.7: Box and whisker plot showing tibia trabecular bone volume (left) and bone volume to tissue volume 
ratio BV/TV (right) in WT and RAMP3 KO baseline, sham and OVX treated mice.. RAMP3 KO OVX treated 
mice had significant reduction in trabecular bone volume compared to sham treated mice (p=0.0018).There 
was significant reduction in RAMP3 KO OVX treated tibia trabecular BV/TV compared to  both, sham treated 
(p = 0.0024) and baseline (p =  0.0038) mice. Although there was reduction in both BV and BV/TV in WT 
treatment groups, these differences were not significant. 
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Fig 3.8: Box and whisker plot showing tibia trabecular thickness (left) and separation (right) in WT and 
RAMP3 KO baseline, sham and OVX treated mice. There is a significant decrease in WT OVX treated 
trabecular thickness compared to baseline mice (p = 0.0108). On the other hand, RAMP3 KO sham treated 
mice showed a significantly higher trabecular thickness compared to WT sham treated animals (p=0.0041). 
However, there were no statistically significant differences in trabecular separation. 
Fig 3.9: Box and whisker plot showing tibia trabecular number (left) and pattern factor (right) in WT and RAMP3 
KO baseline, sham and OVX treated mice. A significant decrease was observed in RAMP3 KO OVX treated 
trabecular number compared to both baseline (p = 0.0051) and sham (p = 0.0064) treated mice. Both WT and 
RAMP KO baseline mice had significantly reduced trabecular pattern factor compared to sham (p = < 0.0001) 
and OVX treated (p = < 0.0001) mice. RAMP3KO OVX treated mice had higher trabecular pattern factor 
compared to sham treated mice (p =0.0170). 
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3.3.4 Three dimension skeletal models:  
Sham and OVX treated 3D trabecular models were generated and compared as these groups 
were both age and sex matched. There was a noticeable reduction in the trabecular bone volume 
in both WT and RAMP3 KOs in response to OVX treatment. It was observed that, WTs had 
reduction in trabecular thickness whereas RAMP3 KOs had a reduction in trabecular number 
when compared to sham treated animals. This data was observed to be consistent with the 
previous microCT analysis (Fig.3.10).  
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Fig 3.10: Representative solid grey-scale 3D tibia trabecular models reflecting the microCT analysis. Top panel 
shows WT models and bottom panels show RAMP3 KO models. Both WT and RAMP3 KO OVX treated 
trabecular models show reduction in bone volume compared to sham treated mice (left). WT OVX trabecular 
bone shows reduction in the thickness on individual trabecular unit. However, RAMP3 KOs demonstrated a 
reduction in the number of trabecular units and not the thickness of the trabecular bone.  
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3.4 Discussion  
The 129/SvEv female mice did not show a classical ovariectomy associated bone loss response. 
Although there was a non-significant decrease femur cortical bone volume of OVX RAMP3 KO 
compared to sham RAMP3 KOs, it was puzzling to see an increase in the femur cortical bone 
volume in OVX WT compared to sham WT (see Figure 3.4). Furthermore, there was a significant 
increase in the tibia cortical BV of OVX WT mice compared to sham and baseline WT mice and a 
highly significant increase in the OVX RAMP3 KO tibia cortical thickness compared to the sham 
RAMP3 KO mice (see Figure 3.5). 
An ovariectomy associated bone loss was observed in the femur trabecular bone of the OVX 
129/SvEv mice compared to sham and baseline 129/SvEv mice in both the genotypes, although 
these differences were not significantly different (see Figure 3.6). Interestingly, the tibia trabecular 
thickness was significantly reduced in OVX WT compared to the baseline WTs, but it was not 
significantly different to the sham WT mice (see Figure 3.8). The OVX RAMP3 KO mice showed 
reduction in tibia trabecular thickness compared to the sham RAMP3 KO mice, but this difference 
was not significant. The reduction in the trabecular thickness in both the OVX WT and OVX 
RAMP3 KO in comparison to the respective sham groups is more evident in the 3D models (see 
Figure 3.10). As discussed earlier in Section 2.4, microCT analysis is limited to the resolution of 
4.5µm. This resolution is evidently insufficient in detecting the site specific differences and is 
responsible for the reduced significance of the differences seen in this experiment. Given the 
evidence that regardless of the treatment, the differences in RAMP3 KO and WT mice skeleton 
have only been detected at 4.5µm and not at 17.5µm, we can conclude that quantification of the 
skeletal difference should not be limited to microCT technique.  
The RAMP3 KO mice maintained a higher trabecular thickness in the tibia in both sham and OVX 
groups compared to the sham and OVX WT mice (see Figure 3.8 and 3.10). This could suggest 
that the RAMP3 KO mice retained more trabecular bone after the oestrogen induced bone loss 
due to the accelerated skeletal development at an early age (see Figure 3.8). However, since the 
WT 129/SvEv 129 mice do not exhibit a classical oestrogen response to the ovariectomy, it is not 
possible to compare the skeletal response of the RAMP3 KOs to the WTs. One of the possible 
explanations for the WT skeletal phenotype could be that the WT 129/SvEv mice generated for 
this project are decedents of RAMP2 +/- cross RAMP3-/- pair. Despite the nine generation 
back crossing to achieve congenicity, there could to be a skeletal trait that has been passed on to 
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the WT 129/SvEv used in this project by the RAMP3 KO founder parent. The RAMP3 KOs are 
bred from RAMP3KO male and female transgenic mice generated by Dr Caron, USA, hence the 
RAMP3 KOs do not have any other phenotypic influence. Since there is no literature evidence on 
the skeletal response of pure 129/SvEv WT mice, we cannot conclude that the skeletal response 
observed in the OVX WT 129/SvEvs is due to the background strain. It is first important to 
establish a protocol to depict postmenopausal physiology in the 129/SvEv mice. Ovariectomy can 
be performed at different ages and different post-ovariectomy period can be tried to determine the 
optimum conditions.  
MicroCT analyses and 3D models (see Figure 3.9 and 3.10), of the trabecular bone give the 
impression that RAMP3 KO female mice to respond to ovariectomy, however they retain thicker 
trabecular units despite the bone loss, which could be due to the accelerated development of the 
skeleton in these animals at earlier an age (Chapter 2). Since the microCT analyses have their 
limitations, the skeletal analysis should not be limited to this technique. Histology and dynamic 
histomorphometry shall further help in understanding the skeletal response of the 129/SvEvs to 
ovariectomy.  
In conclusion, the 129/SvEv mice respond to ovariectomy differently than other strains with: 
 Increase in cortical bone volume and thickness, 
 Insignificant decrease in trabecular thickness and  
 No change in the total bone volume. 
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Chapter 4: Characteristics of primary osteoblasts from RAMP3 KO mice. 
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4.1 Introduction  
Calcitonin (CT) family of peptides, have both anabolic and anti-resorptive effects on the bone. 
There are several studies that suggest the increase of bone formation markers on CT 
administration (Wallach et al 1999). CT also has an osteoblastic effect, as it has been shown 
previously that 100nm CT induces alkaline phosphatase activity in UMR- 106-06 rat osteoblastic 
cells (Iida-Klein et al 1992, Naot & Cornish 2008). Although it is suggested that AMY essentially 
has an anabolic effect on the skeleton compared to the activity of Calcitonin, there is evidence 
that AMY regulates bone resorption and not bone formation (Dacquin et al 2004, Naot & Cornish 
2008). AMY deficient mice have an osteoporotic skeletal phenotype without having an effect in 
the rate of bone formation or the number of osteoblasts. Increased osteoclast number and activity 
is responsible for the skeletal phenotype of these animals. There were no differences in the 
alkaline phosphatase activity, type I collagen and mineralisation nodules of osteoblasts of the 
AMY deficient mice compared to WT mice (Figure S2 (Dacquin et al 2004)). Nevertheless, there 
is strong evidence that Calcitonin gene related peptide (CGRP), Adrenomedullin and Amylin all in 
vitro, induce osteoblast proliferation, suggesting an anabolic skeletal regulation by each of these 
peptides ((Cornish et al 1997, Cornish et al 1999, Naot & Cornish 2008, Villa et al 1997).  
Differentiation of osteoblasts from mesenchymal stem cells (MSCs) is discussed in the main 
dissertation introduction section 1.1.3.i. This section focuses on characterising the primary calvarial 
osteoblasts of RAMP3 KO 129/SvEv mice with respect to the expression of phenotypic markers 
of osteoblast differentiation. Primary calvarial osteoblast cultures are advantageous in studying 
osteoblasts and their progenitors at various stages of differentiation with reduced complexity 
compared with organ cultures. However, these primary osteoblast cultures are not 100% pure as 
there are sub populations of non-osteoblastic cells (Klein-Nulens 2003). Osteoblast progenitor 
cells in the culture are pushed toward osteoblast differentiation with osteogenic medium that 
favours the proliferation and differentiation of osteoblastic cells populations.  
Osteoblast growth and differentiation can be briefly divided into four stages: proliferation, 
extracellular matrix maturation, extracellular matrix mineralisation and apoptosis (Stein et al 2004, 
van Wijnen et al 2004). Figure 4.1 overleaf, is a schematic representation of the osteoblast 
differentiation stages and the expression pattern of a few principal differentiation markers. 
4 Chapter 4: Characteristics of primary osteoblasts from RAMP3 KO mice 
mice. 
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First, the progenitor osteoblasts proliferate and differentiate into pre-osteoblasts. This is followed 
by differentiation of the pre-osteoblasts into mature osteoblasts. Some of the early differentiation 
markers of osteoblasts include alkaline phosphatase (ALP) and collagen (Fletcher et al 1997, 
Stein et al 2004). ALP is a member of tissue non-specific alkaline phosphatases (TNAP), a 
hydrolase enzyme that removes phosphate group from many molecules. In bone, ALP converts 
inorganic pyrophosphate (PPi) to inorganic phosphate (Pi) which combines with calcium to forms 
hydroxylapatite which is incorporated into the bone matrix (Balcerzak et al 2003). Hence by 
regulating the amount of PPi in the extracellular matrix, ALP enhances and regulates bone 
mineralisation. The extracellular matrix maturation stage is followed by its mineralisation. The 
mineralisation of the matrix requires up-regulation of a late osteoblast differentiation marker 
Osteocalcin (Oc) (Delmas et al 1986, Stein et al 2004). Some osteoblasts get embedded in the 
mineralised matrix and eventually the cells undergo apoptosis (Stein et al 2004). 
Fig 4.1, Schematic representation of various differentiation markers and events expressed during 
osteoblast differentiation. Image adapted from (Stein et al 2004) 
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In the previous chapters, we have assessed the skeletal phenotype of the RAMP3 KO mice by 
measuring the bone morphometric parameters. We have established that RAMP3 KO mice have 
enhanced skeletal development at young age that results in an adult skeleton with increased 
trabecular bone thickness, which is beneficial against bone loss induced due to aging. 
Furthermore, at 8 weeks of age, the RAMP3 KO 129/SvEv male mice had increased trabecular 
thickness with increase in the osteoblast number and osteoblast covered bone surface compared 
to the WT mice. On the lateral endochondral surface, the osteoblasts were smaller in the RAMP3 
KO mice compared to the WTs which could be due to more dividing osteoblasts in RAMP3 KOs. 
These finding suggest that the skeletal phenotype observed in the RAMP3 KO 129/SvEv mice is 
an anabolic effect. To investigate whether this advanced skeletal phenotype is an anabolic 
phenomenon, we aimed to determine the osteoblast differentiation pattern of RAMP3 KO 
129/SvEv mice.  
ALP activity, mineralisation, collagen formation and number of colony forming units were 
determined for both WT and RAMP3 KO differentiating primary calvarial cultures which were 
differentiated in osteogenic media supplemented with ascorbic acid, dexamethasone and β-
glycerophosphate (Jonsson et al 1999).  
 
 
 
 
 
 
 
 
 
 
160 
 
4.2 Methods and materials 
4.2.1 Primary osteoblast cultures:  
Each of the primary osteoblast cultures were established from three neonatal (male, post natal 
day 3) mouse calvariae by sequential enzymatic digestion of the bone matrix. Pups were culled 
with anaesthetic over-dose following which the calvariae were excised immediately using aseptic 
techniques 
Following this cells were harvested from calvariae of WT/RAMP3 KO mice through a series of 
sequential digestions as described below: 
First digestion: Excised calvariae were washed in Hank’s balanced salt solution containing 
calcium and magnesium without phenol red (Lonza ®) followed by a 15 min digestion in 5ml 
Collagenase 1A (Sigma®) (1mg/ml prepared in Hank’s balanced salt solution). The supernatant 
was discarded from this first digestion.  
Second digestion: The calvariae were again digested at 370C on a shaker at 200rpm in 
Collagenase 1A for 30 min and the supernatant was centrifuged at 200 x g for 5 minutes. 
Pelleted cells formed the first fraction of cells which were re-suspended in non-differentiation 
media: alpha Minimum Essential Media (MEM) (Sigma®) with 10% heat inactivated fetal calf 
serum (FCS) (Sigma®) and 0.5% penicillin-streptomycin solution and stored in ice. 
Third digestion: The calvariae were washed twice with phosphate buffered saline (PBS) 
(Sigma®) and incubated at for 15 min at 370C on a shaker at 200rpm in 5ml of 4mM tetrasodium 
EDTA pH7.0 (prepared in PBS). Supernatant was centrifuged at 200 x g for 5 minutes. Pelleted 
cells formed the second fraction of cells which were re-suspended in non-differentiation media 
and stored in ice. 
Fourth digestion: The calvariae were washed twice with Hank’s balanced salt solution and again 
digested in Collagenase 1A for 30 min at 370C on a shaker at 200rpm. Supernatant was 
centrifuged at 200 x g for 5 minutes. Pelleted cells formed the third fraction of cells which were 
re-suspended in non-differentiation media and stored in ice. 
All the three fractions of cells were then pooled together and plated in two sterile T75 culture 
flasks (Nunc™) in non-differentiation media and at 370C with 5% CO2. Once the flasks reached 
80% confluency, cells were trypsinized (Trypsin-EDTA solution Gibco®) and re-seeded in either 
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in 6 well culture plates (Nunc™) or T25 culture  flasks (Nunc™) alpha MEM according to the 
experimental setup. On the third day the culture medium was switched on to the differentiation 
medium containing 5mM/l β-Glycerophosphate, 10nM dexamethasone and 100µg/ml Ascorbic 
acid (day 0) and cells were differentiated up to 20 days. Protein and RNA extractions and fixation 
of cells for staining was done at day 0, 5, 10, 15 and 20. All buffers and solutions used for 
primary culture are detailed in the appendix 9.1.3.i. 
4.2.2 Mineralizing fibroblast-colony-forming assays: 
Mineralizing fibroblast colony forming assays are sequential staining protocols that allows the 
assessment of alkaline phosphatase (ALP), mineralization, collagen and colony forming units 
(CFU) (in the same order) all from one fixed set of cell (Scutt A. 2003). Differentiating primary 
calvarial osteoblasts were fixed with cold 100% ethanol after decanting the media and a PBS 
wash was given at day 0, 5 10, 15 and 20 of differentiation with/without stimulation. After each 
assay the stained cell cultures were photographed for analysis using ImageJ™ image editing 
software. Cells were first stained for ALP and then de-stained for mineralization assay. Following 
this the cells were de-stained and stained for Collagen staining. Lastly the cells were de-stained 
and stained for CFU. Brief staining and de-staining protocol used are as follows:  
4.2.2.i Alkaline phosphatase staining: 
Staining solution (prepared fresh before use): 20mM Tris pH7.5 with 0.5mg/ml of naphthol 
phosphate AS-BI and 1mg/ml fast red B.  
Staining protocol: Fixed cells were allowed to dry and stained with ALP staining solution: 2ml per 
well of a 6 well plate, for 30 min at room temperature. Staining solution was then decanted. 
Plates were washed and dried for photographs.  
De-staining protocol: Plates were de-stained with 100% ethanol overnight on shaker at 30 rpm. 
Plates were dried and before staining for mineralization assay. 
4.2.2.ii Mineralisation assay: 
Staining solution (prepared fresh): Alizarin red solution prepared by adding 1mg/ml alizarin red 
in distilled water and pH adjusted to 5.5 with ammonium hydroxide.  
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Staining protocol: Plates were stained with Alizarin red solution: 2ml per well of a 6 well plate, 
for 30 min at room temperature. Staining solution was then decanted. Plates were washed and 
dried for photographs.  
De-staining protocol: Plates were de-stained with 5% perchloric acid prepared in distilled water 
for 5 min. Plates were then washed and dried before Collagen staining. 
4.2.2.iii Collagen staining: 
Staining solution (prepared fresh): 1mg/ml of sirius red in saturated picric acid.  
Staining protocol: Plates were stained with Alizarin red solution: 2ml per well of a 6 well plate, 
for 18hrs at room temperature. Staining solution was then decanted. Plates were washed and 
dried for photographs. 
De-staining protocol: Plates were de-stained with 0.1N NaOH mixed with methanol (50:50) until 
the collagen stain was completely removed.  Plates were washed and dried before methylene blue 
staining. 
4.2.2.iv CFU staining: 
Staining solution (prepared fresh): 1mg/ml methylene blue in 10mM borate pH 8.8 adjusted with 
NaOH. 
Staining protocol: Plates were first washed with borate buffer and then stained with 1% 
methylene blue solution for 30min staining solution was then decanted. Plates were then washed 
and dried for photographs. Number of colonies each well was quantified manually in ImageJ™ 
software. 
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4.2.2.v Image analysis:  
Each stained plate was photographed and the image was opened in the Image J software. The 
circular region of each well was marked and saved as an 8-bit (grey scale image) image. 
Threshold was set for each stain and the 8-bit image was analysed for area and intensity of the 
stain. Figure 4.2 below summarizes the image analysis steps with collagen staining image as an 
example.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.2: Summary of image analysis protocol used to quantify differentiating primary osteoblast culture staining. 
Top panels show the marking (left) and conversion of each stained well as an 8-bit image (right). Bottom 
panels show the adjustment of the threshold for collagen stain (in this example) (left) and the result output as 
the area and mean intensity of the stain (right). 
 
STEP1: Original photographed plate 
with marked well for analysis 
STEP2: Marked well saved as a new 8-bit 
image 
STEP3: Setting the threshold values STEP4: Result with calculated area 
and mean intensity  
35.43mm 
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4.3 Results  
Differentiating primary osteoblasts were fixed at day 0, 5, 10, 15 and 20 from 4 WT and 4 
RAMP3 KO primary osteoblast cultures. At each time point, each culture had 6 repeats for each 
assay. Mean intensity of each stain at each time point was statistically analysed using Two-way 
ANOVA test followed by Bonferroni’s post multiple analysis test. 
4.3.1 Alkaline phosphatase (ALP) activity:  
ALP activity in WT osteoblast cultures dropped at day 10 and peaked to maximum at day 15 of 
differentiation. This peak in ALP at day 15 was not seen in RAMP3 KO cultures. Instead the 
maximum ALP activity was at day 5 in the RAMP3 KO cultures, after which the ALP activity 
reduced gradually until day 20 of differentiation. At day 10, the RAMP3 KO cultures had 
significantly higher ALP compared to WTs, whereas at day 15 the WT cultures had significantly 
higher ALP compared to RAMP3 KOs. Table 4.1 below summarises the statistical analysis dataset 
and Figure 4.3 overleaf shows representative ALP staining images of WT and RAMP3 KO 
cultures at each differentiation time point along with a graphical representation of the statistical 
analysis. 
 
Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
WT Vs RAMP3 KO 
Day 0 0.70 -0.61 to 2.01 No NS 0.8349 
Day 5 0.57 -0.79 to 1.92 No NS > 0.9999 
Day 10 2.41 1.07 to 3.75 Yes **** < 0.0001 
Day 15 -3.27 -4.58 to -1.96 Yes **** < 0.0001 
Day 20 -0.91 -2.32 to 0.51 No NS 0.4911 
 
 
 
 
 
 
 
 
Table 4.1: Statistical analysis: Primary differentiating osteoblast – ALP assay  
165 
 
 
 
A lk a lin e  P h o s p h a ta s e  a s s a y
O s te o b a s t d iffe re n tia t io n  in  d a y s  ( t im e  p o in ts )
 S
ta
in
 i
n
te
n
s
it
y
d
a
y
 0
d
a
y
 5
d
a
y
 1
0
d
a
y
1
5
d
a
y
2
0
0
5
1 0
1 5
W T n = 2 4  e a c h  tim e  p o in t
R A M P 3  K O n = 2 4  e a c h  tim e  p o in t
****
****
 
 
 
 
 
Fig 4.3: Representative ALP staining images of WT and RAMP3 KO primary osteoblast cultures at day 0, 5, 
10, 15 and 20 of differentiation (top) along with statistical analysis to determine significant differences 
(bottom). RAMP3 KO cultures show maximum ALP activity at day 5 whereas WT have maximum ALP activity 
at day 15. ALP activity is significantly different between WT and RAMP3 KOs at day 10 and day 15 of 
differentiation (p = ‹ 0.0001). 
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4.3.2 Mineralisation assay:  
It was observed that the number of mineralising colonies was fewer in the RAMP3 KO cultures at 
each differentiation time point, compared to WT cultures. The total alizarin stain intensity was 
significantly higher in WT cultures at day 15, although, by day 20 the difference between WT and 
RAMP3 KO staining was not significant.Table 4.2 below summarises the statistical analysis 
dataset and Figure 4.4 overleaf shows representative mineralisation staining images of WT and 
RAMP3 KO cultures at each differentiation time point along with a graphical representation of the 
statistical analysis. 
 
Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
WT Vs RAMP3 KO 
Day 0 0.92 -2.94 to 4.78 No NS > 0.9999 
Day 5 -3.04 -6.86 to 0.78 No NS 0.2003 
Day 10 -3.59 -7.54 to 0.37 No NS 0.0975 
Day 15 -5.34 -9.20 to -1.47 Yes ** 0.0020 
Day 20 -3.90 -8.52 to 0.73 No NS 0.1489 
 
 
 
 
 
Table 4.2:  Statistical analysis: Primary differentiating osteoblast – mineralisation assay  
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Fig 4.4: Representative mineralisation assay staining images of WT and RAMP3 KO primary osteoblast 
cultures at day 0, 5, 10, 15 and 20 of differentiation (top) along with statistical analysis to determine significant 
differences (bottom). RAMP3 KO cultures have less mineralising colonies compared to WT cultures at each 
time point. The intensity of alizarin staining in WTs at day 15 is significantly higher than RAMP3 KOs 
(p=0.002). At day 20 there is no significant difference between WT and RAMP3 KO mineralisation. 
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4.3.3 Collagen assay: 
WT and RAMP3 KO primary osteoblast culture have similar collagen activity until day 10 of 
differentiation. After day 10 there is a significant drop in the collagen activity in RAMP3 KO 
osteoblast cultures compared to WT. Table 4.3 below summarises the statistical analysis dataset 
and Figure 4.5 overleaf shows representative collagen staining images of WT and RAMP3 KO 
cultures at each differentiation time point along with a graphical representation of the statistical 
analysis. 
 
Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
WT Vs RAMP3 KO 
Day 0 -0.53 -3.94 to 2.89 No NS > 0.9999 
Day 5 -0.21 -3.63 to 3.20 No NS > 0.9999 
Day 10 0.74 -2.68 to 4.15 No NS > 0.9999 
Day 15 -5.08 -8.80 to -1.36 Yes ** 0.0024 
Day 20 -7.60 -11.70 to -3.49 Yes **** < 0.0001 
 
 
 
 
 
Table 4.3:  Statistical analysis: Primary differentiating osteoblast - collagen assay  
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Fig 4.5: Representative collagen staining images of WT and RAMP3 KO primary osteoblast cultures at day 0, 
5, 10, 15 and 20 of differentiation (top) along with statistical analysis to determine significant differences 
(bottom). There is no difference in WT and RAMP3 KO collagen activity at day 0, 5 and 10 of differentiation. 
After day 10, RAMP 3 KOs have a significant descent in collagen activity, p=0.0024 at day 15 and ‹ 0.0001 
at day 20. 
170 
 
 
4.3.4 Colony forming units assay: 
Methylene blue staining of colony forming units suggested no statistically significant difference in 
the number of colony forming units in RAMP3 KO and WT osteoblast cultures, although RAMP3 
KO osteoblasts appeared to have bigger individual colonies compared to WTs. Table 4.4 below 
summarises the statistical analysis dataset and figure 4.6 overleaf shows representative collagen 
staining images of WT and RAMP3 KO cultures at each differentiation time point along with  a 
graphical representation of the statistical analysis. 
 
Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
                                                                       WT Vs RAMP3 KO 
Day 5 4.0 -25.53 to 33.53 No NS > 0.9999 
Day 10 2.0 -27.53 to 31.53 No NS > 0.9999 
Day 15 13.0 -16.53 to 42.53 No NS 0.3928 
Day 20 1.0 -28.53 to 30.53 No NS > 0.9999 
 
 
 
 
 
 
 
 
 
Table 4.4:  Statistical analysis: Primary differentiating osteoblast - collagen assay  
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Fig 4.6: Representative methylene blue staining image of WT and RAMP3 KO primary osteoblast cultures at 
day 0, 5, 10, 15 and 20 of differentiation (top) along with statistical analysis to determine significant 
differences (bottom). There is no difference in the number of WT and RAMP3 KO colony forming units at any 
time point, however, RAMP3 KO cultures appear to have larger individual colonies compared to WTs. 
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4.4 Discussion 
With an aim to characterise primary osteoblasts of RAMP3 KO mice, we differentiated four 
independent primary calvarial cultures of each WT and RAMP3 KO genotype and differentiated 
the cultures for 20 days. There are a few limitations of this study. Firstly, the cultures were not 
measured for proliferation at every time-point; hence cultures are not efficiently validated. Also 
since the study lacks a positive control of osteoblasts differentiation (Eg: Leptin stimulated 
cultures), the interpretation of the differentiation assays of these primary 129/SvEv cultures is 
hindered. Moreover, since the suture regions of the calvaria were included in the culture protocol 
there is a higher population of mixed fibroblasts population that do not represent the true 
osteoblast cultures.  
The osteoblast phenotypic markers were assessed at day 0, 5, 10, 15, 20 of differentiation by 
‘mineralizing fibroblast-colony-forming assays’ as described by (Scutt A. 2003). This technique is 
advantageous as all the markers: ALP, collagen, mineralisation and CFUs can be quantified from 
the same fixed cultures sequentially. Hence each assay can be correlated to the other assay for a 
set of cells. Moreover, since the quantifications were made from four independent cultures (each 
genotype) with 6 repeats each culture, each differentiation time point, these results can be 
considered robust. 
RAMP3 KO primary calvarial osteoblast cultures showed significant difference in the expression of 
ALP activity. In WT 129/SvEv mice, the ALP activity showed an initial increase in ALP activity at 
day 5 followed by a drop in the ALP activity (day 10) which was in-turn followed by maximum 
ALP activity at day 15 (Fig.4.3). In RAMP3 KOs the ALP activity was similar to WT cultures until 
day 5 of differentiation, although, unlike the WT cultures, the ALP activity did not drop drastically 
at day 10 of differentiation in the RAMP3 KOs (Fig.4.3). The ALP activity in RAMP3 KOs steadily 
increased until day 5 and then gradually declined until day 20 of differentiation. The peak in ALP 
activity, as observed in the WT cultures at day 10, was absent in the RAMP3 KOs (Fig.4.3). This 
suggests that the differentiation of the osteoblast precursor into mature osteoblasts, is different in 
the RAMP3 KO mice. As discussed earlier in Section 1.1.3.i, Runx2, β-catenin, and osterix direct 
the differentiation of the pre-osteoblasts to form mature osteoblasts, we can imply that 
expression/regulation of these transcription factors is different in the RAMP3 KO mice compared 
to the WT 129/SvEv mice  (Day et al 2005, Ducy et al 1997, Komori 2006). There is evidence 
that RAMP3 is one of the early genes response genes regulated by Wnt (Rohrs et al 2009). 
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Increase in phosphorylated β-catenin levels up-on Wnt3A stimulation, down regulate RAMP3. We 
can therefore hypothesize that there could be an up-regulation of Wnt/β-catenin pathway in the 
RAMP3 KO primary osteoblast cultures (Kenny et al 2005, Ziegler et al 2005). This could result 
in an alteration in the ALP activity. From our results, it can be suggested that RAMP3 KO mice 
have a prolonged ALP activation phase which later on gradually declines. This would eventually 
result in a prolonged extracellular matrix maturation phase which can alter the skeletal phenotype. 
Fig 4.7 is a schematic representation of the difference of ALP activity in WT and RAMP3 KO 
osteoblasts, which would have alterations in the matrix maturation phase. 
 
 
 
The number of CFUs in RAMP3 KO osteoblasts is fewer than the number of CFUs in WT 
osteoblasts, although the colonies in RAMP3 KOs are larger than the WT CFUs (Fig 4.6). In both 
the WT and RAMP3 KO, the number of CFUs reduced by day 20 of differentiation. This could 
however be a result of a technical error. Since the colonies grow bigger they overlap and merge 
into larger colonies, the software used to measure the colonies would just count the merged 
colonies as one an individual colony. Since there was heterogeneity between colonies irrespective 
of the genotype, it was not possible to calibrate / standardize the software.  
Fig 4.7: Schematic representation of the difference in the ALP activity in WT and RAMP3 KO osteoblasts, 
which will alter the matrix maturation phase of osteoblasts differentiation. 
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The fewer, but bigger colonies of RAMP3 KO had reduced mineralisation compared to WT 
osteoblasts, throughout differentiation (Fig. 4.4). However, the difference in mineralisation is only 
significant at day 15 of differentiation and most interestingly, the RAMP3 KO osteoblasts are able 
to catch up with the WTs with respect to mineralisation by day 20 of differentiation (Fig. 4.4). 
This is not observed in collagen formation. RAMP3 KO osteoblasts have similar amounts of 
collagen compared to WTs until day10 of differentiation, although, there is a significant reduction 
in collagen formation at day 15 and day 20 of differentiation (Fig. 4.5).  
From these in vitro primary osteoblast experiments we can conclude that RAMP3 KO mice have 
fewer osteoblasts that have reduced collagen formation ability, but form larger mineralisation 
nodules and are capable to mineralising the same amount of bone as the WTs. Our in vitro 
findings do not correspond to the ex vivo osteoblast analysis of histological section. This can be 
due to two reasons. Firstly, despite the use of osteogenic stimulators to differentiate the 
osteoblasts in vitro, it is not possible to mimic the in vivo microenvironment which dictates the 
osteoblast differentiation in bone. Secondly, the primary osteoblast cultures used for the in vitro 
experiments were established from neonatal mice. Hence they do not reflect the differentiation of 
osteoblasts in adult mice. Furthermore, since RAMP3 KO mice have an age dependent skeletal 
phenotype, it would be helpful to study the same differentiation patterns in primary osteoblast 
cultures derived from adult marrow cultures of RAMP3 KO and WT 129/SvEv mice in the future. 
In conclusion, RAMP3 KO primary osteoblasts have: 
 Decreased but prolonged ALP activity. 
 Decreased collagen formation and, 
 Fewer but larger colony forming units. 
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Chapter 5: Expression of RAMP1,2 and 3 mRNA in differentiating primary 
osteoblasts. 
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5.1 Introduction  
Receptor activity modifying proteins (RAMPs) are expressed in many tissues including the 
skeleton (Parameswaran & Spielman 2006). In humans, all the RAMP isoforms are highly 
expressed in the skeletal muscle, whereas in mouse RAMP1 and RAMP2 are highly expressed 
and expression of RAMP3 is yet to be fully determined (Parameswaran & Spielman 2006). 
RAMPs 1-3 are all ubiquitously expressed in rat and mouse primary osteoblasts and in cell lines 
including MC3T3-E1 and UMR106-006 osteoblast-like cell lines(Naot & Cornish 2008, Uzan et 
al 2004). RAMPs are also expressed in osteoclast cultures and the expression of individual 
RAMP isoform varies during the osteoclast differentiation (Granholm et al 2008). Nakamura et. 
al. in 2003 reported the presence of RAMP2 but not RAMP1 or 3 in mature osteoclast cultures 
and Granholm et. al. reported presence of RAMP1, 2 and 3 in osteoclast cultures (Granholm et al 
2008, Nakamura et al 2005). Additionally, it was also observed that expression of RAMP1 and 
RAMP3 decreases when the cells become multinucleated (Granholm et al 2008). It can therefore 
be suggested that, RAMPs play an important role in regulating osteoclastogenesis.   
The skeletal phenotype observed in the RAMP3 KO mice appears to be an anabolic skeletal 
effect rather than an anti-resorptive regulation. Given the evidence that the number of osteoclasts 
is neither different in the cortical bone nor in the trabecular bone and conversely with evidence 
that the number of osteoblasts is more in the trabecular bone of RAMP3 KOs we have 
demonstrated that the osteoblasts but not osteoclasts are affected in RAMP3 KO mice (Chapter 
3). Furthermore we have also demonstrated that the primary osteoblast have a different 
osteoblast differentiation pattern compared to WTs (Chapter 4). This chapter focuses on 
determining whether the expression of RAMPs plays an important role in osteoblast differentiation 
and whether the RAMP3 KO mice have an altered RAMP expression profile in comparison to the 
WTs that could potentially result in an altered signal transduction in these KO animals. 
Kadmiel et al have reported that RAMP 1 and 3 do not compensate for the absence of RAMP2 in 
RAMP2 KO mice which are embryonically lethal. However, RAMP1 and RAMP3 KO mice are 
viable which could perhaps be because other RAMPs compensates for these RAMP isoforms 
(Kadmiel et al 2012). Given that there is evidence that RAMP 1 and 3 forms intracellular 
homodimers and, although this is not yet proved experimentally, RAMP2 is also expected to form 
homodimers (Sexton et al 2001). We can therefore hypothesize that these reserves of RAMPs in 
5 Chapter 5: Expression of RAMP 1,2 and 3 mRNA in differentiation primary osteoblasts  
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the cytoplasm can compensate for the loss of other RAMPs and form functional receptors that are 
presented on the cell surface. 
 To test our investigate whether there is a differences in RAMP 1,2 and 3 mRNA expression 
between RAMP3 KO and WT primary osteoblasts, we performed quantitative PCR (qPCR) in 
differentiating primary osteoblasts of RAMP3 KO and WT 129/SvEv mice.  
Three independent primary osteoblasts cultures were established from WT and RAMP3 KO each. 
Total RNA was collected at day0, 5, 10, 15, and 20 of differentiation.  
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5.2 Methods and materials 
5.2.1 Sample preparation: 
5.2.1.i Total RNA from differentiating primary osteoblasts:  
Detailed calvarial primary culture protocol is described in Section 5.2.1. Total RNA was collected 
from differentiating calvarial primary osteoblasts of WT (SVEV/129) and RAMP3 KO genotype on 
day 0, 5, 10, 15 and 20 of differentiation. One T25 flask-worth of each culture was harvested at 
each time point. The medium was removed and 500μl of TRIZOL® reagent was added to the 
cells. The cells were collected in 1.5 ml tubes by scraping. Total RNA was then extracted using 
the protocol provided by the manufacturer (Invitrogen™). RNA in each sample was quantified in 
NanoDrop® (Thermo Scientific, Wilmington, USA), a micro-volume UV-vis spectrophotometer, at 
A260 and the purity of preparation checked by determining the 260/280 ratio. Samples were 
then stored at -200C. 
 
5.2.1.ii Controls:  
Mouse brain cDNA was used as a positive control in end point PCR. Total RNA was extracted 
from previously snap frozen WT (SVEV/129) mouse. The mouse brain (snap frozen tissue stored 
at -80˚C) was weighed and allowed to thaw at -20oC for an hour prior being chopped into small 
pieces. The 100mg chopped tissue was placed in a 7 ml tissue grinder tube and 1ml of ice-cold 
TRIZOL® reagent was added. The tissue was first homogenized by 15 passes of the loose pestle 
and then by 15 passes of the tight pestle. This homogenate was used to extract total RNA 
according to manufacturer’s guidelines (Invitrogen™). RNA was quantified and stored similar to 
total RNA from cell cultures. 
 
5.2.1.iii DNase treatment:  
Total RNA generated was subjected to DNase treatment to prevent genomic DNA contamination. 
Precision™ DNase kit (Primerdesign®) was used to treat the RNA samples. Briefly, the following 
reaction mix was incubated at 30oC for 10 min to degrade the DNA from the RNA sample:  
 
RNA sample:      50.0µl 
10X Precision™ DNase reaction buffer:   5.0µl 
Precision™ DNase:      1.0µl (for upto 100µl of RNA sample)   
DNase was inactivated by incubating the mixture at 55oC for 5 min. Samples were stored at -
20oC. 
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5.2.1.iv Reverse transcription to generate cDNA 
cDNA was generated from total RNA samples using Precision nanoScript™  Reverse transcription 
kit (Primerdesign®). Briefly, the cDNA was generated in two steps: 
 
Step 1: Annealing  
For every 1μg of RNA, a 10μl annealing reaction mix was prepared as below. The mix was then 
heated to 65oC for 5 min and the samples were then directly transferred from 65 oC to ice. 
Annealing reaction mix: 
RNA template:            1µg  
RT oligoDT:          1μl 
RNAse/DNAse free water: upto    10 μl  
Final volume:         10.0μl 
 
Step 2: Extension  
To each of the 10μl annealing reaction mix (step 1) the following 10μl RT mix was added.  
RT mix:  
nanoScript 10X Buffer:     2.0μl 
dNTP mix 10mM of each:  1.0μl 
DTT 100mM:    2.0μl 
RNAse/DNAse free water:  4.0μl (5.0μl for RT- samples) 
nanoScript enzyme:   1.0μl  (not added for RT- samples) 
 
Annealing reaction mix:   10.0μl 
Final volume:     20.0µl  
 
This reaction mix was then placed in a PCR machine with the following conditions: 
1) 55oC - 20 min  
2) 75 oC - 15min 
3) Hold at 4 oC 
Samples were then stored at -20 oC.  
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5.2.2 End point PCR:  
GoTaq® DNA Polymerase kit (Promega® Cooperation, Madison, USA) was used to detect 
RAMP1/2/3 expression in cDNA of WT and RAMP3 KO primary osteoblast differentiated for 
0,5,10,15 and 20 days. Each 25μl reaction mix contained 5μl of 5X Green GoTaq® reaction 
buffer, dNTP at a final concentration of 0.2mM (10mM each dNTP stock), MgCl2 at a  final 
concentration of 1.5mM (25mM each stock) and GoTaq® DNA Polymerase 2.5units. Proportions 
for PCR mix are mentioned below along with the respective PCR conditions. PCR amplicons were 
visualized by electrophoresis in 1.5% Agarose gel (Sigma®) prepared in Tris-base-EDTA buffer 
and containing 0.5ug/ml ethidium bromide. Primer sequences used are detailed in table 5.1 
below. 
 
PCR reaction mix: 
5X Green GoTaq® reaction buffer: 5μl 
MgCl2: 0.75μl 
dNTP mix : 0.5μl 
Forward Primer: 1.25μl 
Reverse primer: 1.25μl 
GoTaq® DNA Polymerase: 0.5μl 
cDNA: 2μg 
         Nuclease free water: upto 25μl 
 
 
 
 
Primer ID 
 
Primer Sequence Tm Position - mouse 
RAMP1/2/3 mRNA 
Amplicon 
RAMP1f 5’ CACCATCTCTTCATGGTCACTG 3’ 60.3
0
C 322 
186bps RAMP1r 3’ CAATCGTGTGCGCCACGTGC 5’ 63.5
0
C 489 
RAMP2f 5’ CATCCCACTGAGGACAGCCT 3’ 61.4
0
C 299 
302bps RAMP2r 3’ GATCATGGCCAGGAGCACAT 5’ 59.4
0
C 591 
RAMP3f 5’ AAAGCCTTCGCTGACATGAT 3’ 55.3
0
C 161 
100bps RAMP3r 3’ CCATCTCGGTGCAGTTAGTG 5’ 59.4
0
C 244 
 
 
 
Thermocycler conditions: 
1) Hold 950C Enter 
2) 950C – 1.30min 
3) 950C – 30sec 
4) 590C - 30 sec (for RAMP1) or 
4) 600C - 30 sec (for RAMP2) or 
4) 500C - 30 sec (for RAMP3) 
5) 720C - 45 sec (repeated 3-5, 35 cycles) 
6) 720C - 3min 
7) Hold at 40C 
 
Table 5.1: RAMP1/2 and 3 primer sequences for end point PCR: 
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5.2.3 Real time PCR: 
Real-time or quantitative PCR, is a technique use to simultaneously amplify and quantify the DNA 
sequence of a gene of interest. Traditionally quantification of the amplifying DNA sequence is 
carried out by two methods. 
 
Non-specific quantification: This technique measures the incorporation of a double stranded DNA 
intercalating fluorogenic dye, like SYBR green that binds to newly amplified DNA.  
 
Specific quantification: This technique measures the number of annealed DNA primers that are 
fluorescently probed. This quantification is sequence specific where primer sequences are probed 
with double dye probes like 6-carboxyfluorescein (FAM) and the probe is detected only when the 
primer sequence is hybridized with the newly synthesised complimentary DNA strand. This qPCR 
technique is commonly known as double dye probe qPCR or Taqman style qPCR. The double 
dye probe qPCR technique was used in our study. 
5.2.3.i Gene of Interest:  
Custom real-time PCR/ quantitative PCR (qPCR) assays with double dye probes – FAM labelled 
(Taqman style) were designed by Primerdesign® for each of the human and mouse RAMPs (1, 2 
and3) (Table 5.2). Primers were validated and a validated copy number positive control was 
provided for each qPCR assay. Each sample was run in triplicate per gene of interest, per 
reference gene per plate. The expression of each gene of interest was normalised to the 
expression of reference genes / house-keeping gene. The optimal number of reference genes 
needed and the most suitable reference genes were identified using the mouse geNorm™ kit by 
Primerdesign®.Primer sequences designed to detect individual RAMP expression are detailed 
below.  
 
Primer ID 
 
Primer Sequence Tm Position  Amplicon 
RAMP1f 5’ ACCTGGGATTTATAAGCCTGTTTA 3’ 56.6
0
C 1,727 
85 bps RAMP1r 3’ CATTTTTCCTCTGTCTCTTCTTCAT 5’ 56.4
0
C 1,811 
RAMP2f 5’ CCAACTGCTCCCTGGTGC 3’ 58.1
0
C 454 
93 bps RAMP2r 3’ GGAAGGGGATGAGGCAGATG 5’ 57.9
0
C 546 
RAMP3f 5’ CCAACTGCACCGAGATGGAG 3’ 58.8
0
C 270 
98 bps RAMP3r 3’ GGAGAAGAACTGCCTGTGGAT 5’ 58.0
0
C
 
367 
 
 
Table 5.2: Custom double dye probe primer sequences from Primerdesign® 
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5.2.3.ii Reference gene:  
Accurate relative quantification, of the gene of interest expression depends on the normalisation 
value obtained from the expression of a robust house-keeping gene. There is increasing evidence 
that many traditionally used house-keeping genes are not as constant as suggested previously 
(Reddy et al 2013, Stephens et al 2011). This may be due to different tissue or disease origin or 
experimental parameters (Vandesompele et al 2002). Hence it is necessary to screen a range of 
standard house-keeping genes to identify the most robust reference gene that is stably expressed 
for a particular experimental set-up. Certain experiments may need more than one reference gene 
to validate the expression of genes of interest (Bustin et al 2009, Vandesompele et al 2002).  
FAM labelled mouse geNorm™ reference gene selection kit with 6 reference genes: 18s ribosomal 
RNA, Beta-actin (ACTB), β2 microglobulin (B2M), eukaryotic initiation factor-4A (eIF4A), 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 60S ribosomal protein L13a (RLP13A) 
were used to determine stable reference gene expression (Primerdesign®,UK). Reference genes 
stably expressed in both genotypes across all time points were identified by analysing geNorme 
CT values in qbase+ software by Biogazelle®. The qbase+ software evaluates two values: 
geNorm“M” and geNorm“V”. 
The “M” value indicates the average expression stability value of a particular reference gene at 
each step of a stepwise exclusion of the least stable reference genes. geNorm“V” is known as the 
“pairwise variation”. The value “V” determines the optimal number of reference genes required in a 
particular experiment. If an optimal number of reference genes is not determined, then the three 
most stably expressing reference genes are chosen and run along with the gene of interest each 
time.   
Each qPCR assays was setup in sterile MicroAmp® Optical 384-Well Reaction Plate (Life 
technologies™), in Scie-Plas UV sterilisation PCR cabinet (Topac, USA) on ice. All qPCR assays 
were run and analysed in Applied Biosystems™ 7900 Real Time PCR machine. Since all the 
primers were FAM labelled (absorbance maximum of 492 nm, emission maximum of 517 nm), 
FAM detectors were used to quantify amplification.  
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5.2.3.iii qPCR reaction mix (for all reference genes and genes of interest): 
Resuspended primer mix:   1.0µl 
Precision™ 2x qPCR Mastermix:  10.0µl 
RNAse/DNAse free water:   4.0µl 
cDNA:      5.0µl (generated from 5ng RNA per reaction) 
 
5.2.3.iv Thermocycler conditions used in Applied Biosystems™ 7900 Real Time PCR machine: 
1) Enzyme activation :  95oC – 10min 
2) Denaturation:   95oC – 15sec 
3) Data collection:  60oC – 60sec 
Repeat step 2 and 3, 40 times. 
 
5.2.3.v “CT value”  
qPCR quantification is in terms of threshold cycle value - “CT value”. An amplification threshold 
for a certain gene is set for every experiment. Briefly, the number of PCR cycles required to reach 
the amplification threshold is the CT value. The CT value is inversely proportional to the 
expression of the gene. Hence higher the CT value, lower the expression of the gene. An 
example of an amplification plot generated by the qPCR machine is represented and annotated 
overleaf (Figure 5.1). 
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5.2.3.vi Calculating relative expression of a gene of Interest: 
CT values are obtained for all the reference genes and the gens of interest.  If multiple reference 
genes are used the mean CT value of all the reference genes is calculated.  
1) The relative expression / normalised expression of a gene of interest is calculated as “Delta 
CT” (Δ CT): 
Δ CT = CT value (gene of interest) – mean CT value of all the reference genes. 
2) Fold change  in expression and calculation of “Delta delta CT” (Δ Δ CT) 
Δ Δ CT = Δ CT value (one genotype/ timepoint) – Δ CT value (other genotype/ timepoint) 
Fold change=  2- Δ Δ CT 
Amplification curve 
Amplification threshold  
CT value ~18.7  Gene of Interest & 
florescent probe used 
Fig 5.1: Amplification plot generated by the qPCR machine showing the amplification threshold, the gene of 
interest (RAMP3) and the florescent probe (FAM) detector used. The CT value can be calculated as the X value 
(~18.7 ) corresponding to the point at which the amplification curve intersects the threshold.  
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5.2.3.vii Graphical representation and statistical analysis: 
All graphical representations and statistical analysis were carried out in GraphPad Prism® 6. Two 
way ANOVA test and Bonferroni’s post multiple comparison test were performed to determine the 
statistical significance of RAMP expression between genotypes and different differentiation time-
points. P value ≤ 0.05 was considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
186 
 
5.3 Results 
5.3.1 End point PCR to detect RAMP cDNA expression in primary osteoblasts: 
5.3.1.i RAMP1 
RAMP1 was expressed in all WT and RAMP3 KO primary osteoblast cDNA at all differentiation 
time points. Non reverse transcription (RT-) control of each sample was used as a genomic DNA 
control. None of the WT or RAMP3 KO RT- controls amplified a PCR product. RAMP1 cDNA was 
amplified in +ve control - mouse brain cDNA, but not in its RT- control (Fig. 5.2). All amplicons 
were confirmed to be RAMP1 cDNA sequences by sequencing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.0kbs 
1.5kbs 
1.0kbs 
500bps 
100bps 
WT RAMP3 KO 
Fig 5.2 : Agarose gel electrophoresis (1.5%) for end point PCR to detect RAMP1 cDNA expression in WT and 
RAMP3 KO primary osteoblast cultures differentiated for 0, 5, 1,15 and 20 days. 186bps cDNA amplicon was 
amplified in +ve control (mouse brain cDNA) and in both WT and RAMP3 KO primary osteoblast cDNA  
differentiated for 0,5,10,15 and 20 days. None of the RT- samples or controls amplified a product. Three 
experimental repeats of the entire sample set were carried out. 
 
 
200bps 
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5.3.1.ii RAMP2:  
Expression of RAMP2 was observed in all WT and RAMP3 KO primary osteoblast cDNA at all 
differentiation time points. Non reverse transcription (RT-) control of each sample was used as a 
genomic DNA control. RAMP2 cDNA was amplified in +ve control (mouse brain cDNA) but no 
product was amplified in the RT- control. Genomic RAMP2 amplification was observed in mouse 
brain RT- control. Genomic RAMP2 amplification was also observed in WT day 15, day15 RT-, 
day 20 RT- and brain RT- cDNA preparations (Fig. 5.3). All amplicons were confirmed to be 
RAMP2 cDNA sequences by sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.0kbs 
1.5kbs 
1.0kbs 
500bps 
300bps 
WT RAMP3 
KO 
Fig 5.3: Agarose gel electrophoresis (1.5%) for end point PCR to detect RAMP2 cDNA expression in WT and 
RAMP3 KO primary osteoblast cultures differentiated for 0, 5, 1,15 and 20 days. 302bps cDNA amplicon was 
amplified in +ve control (mouse prostate cancer cell line BMA 178-2) and in both WT and RAMP3 KO primary 
osteoblast cDNA  differentiated for 0,5,10,15 and 20 days. None of the RT- samples or controls amplified a 
product. Genomic RAMP2 amplification was observed in WT day 15, day15 RT-, day 20 RT- and +ve control RT- 
preparations. Three experimental repeats of the entire sample set were carried out. 
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5.3.1.iii RAMP3:  
Expression of RAMP3 cDNA was only observed in all WT primary osteoblast cDNA at all 
differentiation time points but not in the RAMP3 KO samples as expected. Non reverse 
transcription (RT-) control of each sample was used as a genomic DNA control. None of the WT 
or RAMP3 KO RT- controls amplified products. RAMP3 cDNA was amplified in +ve control 
(mouse brain cDNA) but not in its RT- control (Fig. 5.4). All amplicons were confirmed to be 
RAMP3 cDNA sequences by sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.4: Agarose gel electrophoresis (1.5%) for end point PCR to detect RAMP3 cDNA expression in WT and 
RAMP3 KO primary osteoblast cultures differentiated for 0, 5, 1,15 and 20 days. 100bps cDNA amplicon was 
amplified in +ve control (mouse brain cDNA ) and in WT primary osteoblast cDNA  differentiated for 0,5,10,15 
and 20 days. None of the RAMP3 KO primary osteoblast time-points expressed RAMP3 cDNA. Similarly none of 
the RT- samples or controls amplified products. Three experimental repeats of the entire sample set were carried 
out. 
 
 
5.0kbs 
1.5kbs 
1.0kbs 
500bps 
100bps 
WT RAMP3 KO 
200bps 
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5.3.2 Quantitative PCR: 
5.3.2.i Reference gene identification using geNorm™ kit: 
The geNorm™ kit by Primerdesign® was used to determine the most  stably expressing 
housekeeping genes in WT and RAMP3 KO primary osteoblasts and the number of reference 
genes required to validate the quantification of expression of genes of interest in these samples.  
 
As mentioned earlier, the mouse geNorm™ reference gene selection kit consisted of 6 known 
reference genes 18s, ACTB, B2M, ElF4A2, GAPDH and RPL13A. The relative expression of 
these genes was determined in both WT and RAMP3 KO primary osteoblast cDNA at 5 time 
points during differentiation: day0, 5, 10, 15 and 20.  
 
The CT values obtained for each of the reference genes was used to calculate the most stably 
expressing gene across (geNorm M) and the minimal number of reference genes needed for the 
experimental set up (geNorm V). 
 
Figures 5.5 and 5.6 overleaf are graphical representations generated by the qBase+ software, 
showing relative expression of each reference gene at each time point in WT (Fig. 5.5) and in 
RAMP3 KO (Fig. 5.6). 
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18s B2M ElF14A2 GAPDH RPL13A ACTB 
18s B2M ElF14A2 GAPDH RPL13A ACTB 
18s B2M ElF14A2 GAPDH RPL13A ACTB 
18s B2M ElF14A2 GAPDH RPL13A ACTB 
18s B2M ElF14A2 GAPDH RPL13A ACTB 
WT primary osteoblast differentiation day 0 
WT primary osteoblast differentiation day 5 
WT primary osteoblast differentiation day 10 
WT primary osteoblast differentiation day 15 
WT primary osteoblast differentiation day 20 
A 
B 
C 
D 
E 
Fig 5.5: A graphical representation of relative cDNA expression of the reference genes (from left to right in each 
histogram): 18s, B2M, Elf14A2, GAPDH, RPL13A and ACTB, at each differentiation time point (top to bottom) 
day0 (A), day5 (B), day10 (C), day15 (D) and day20 (E) of WT primary osteoblast. Each sample was run in 
triplicate, per gene, and three independent experimental repeats were carried out (n =3).  
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RAMP3KO primary osteoblast differentiation day 0 
RAMP3KO primary osteoblast differentiation day 5 
RAMP3KO primary osteoblast differentiation day 10 
RAMP3KO primary osteoblast differentiation day 15 
RAMP3KO primary osteoblast differentiation day 20 
18s B2M ElF14A2 GAPDH RPL13A ACTB 
18s B2M ElF14A2 GAPDH RPL13A ACTB 
18s B2M ElF14A2 GAPDH RPL13A ACTB 
18s B2M ElF14A2 GAPDH RPL13A ACTB 
18s B2M ElF14A2 GAPDH RPL13A ACTB 
A 
B 
C 
D 
E 
Fig 5.6: A graphical representation of relative cDNA expression of the reference genes (from left to right in each 
histogram): 18s, B2M, Elf14A2, GAPDH, RPL13A and ACTB, at each differentiation time point (top to bottom) 
day0 (A), day5 (B), day10 (C), day15 (D) and day20 (E) of RAMP3 KO primary osteoblast. Each sample was 
run in triplicate, per gene, and three independent experimental repeats were carried out (n =3). 
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5.3.2.i.a geNorm M value: 
The relative expressions were used to determine the average expression stability of each 
reference gene i.e. the geNorm “M” value.  
The following graphs are generated by the qBase+ software representing the geNorm M value of 
WT (Fig. 5.7) and RAMP3 KO (Fig. 5.8) cultures. In each graph the genes are ranked according 
to their increasing stability. The values on the graph start with the least stable reference gene to 
the left and ends with the most stable reference gene to the right.  
The determined “geNorm M” value suggests that the least stable reference gene in both WT and 
RAMP3KO primary osteoblasts, across all time points to be RPL13A. The genes ranked in the 
increasing order of stability in WT (Fig. 6.7) osteoblasts are: RPL13A, GAPDH, B2M, 18s, ACTB 
(βactin), and ElF14A2 (most stable). Likewise in RAMP3 KO, (Fig. 5.8) the order of genes in the 
increasing order of stability are: RPL13A (least stable), GAPDH, ElF14A2, B2M, ACTB (βactin), 
and 18s (most stable). This result is co-relates to the relative expression of individual reference 
gene represented in previous (Fig. 5.5 and 5.6). 
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Fig 5.7: Graphical representation of average expression stability – “geNorm M” value” of reference genes in 
WT primary osteoblast cultures across all time points. . The values on the graph start with the least stable 
reference gene to the left and ends with the most stable reference gene to the right. Least stable gene 
expressed in WT across all time points is RPL13A.Whereas most stably expressing gene is ElF14A2. 
Fig 5.8: Graphical representation of average expression stability – “geNorm M value” of reference genes in 
RAMP3KO primary osteoblast cultures across all time points. The values on the graph start with the least 
stable reference gene to the left and ends with the most stable reference gene to the right. Least stably 
expressing reference gene in RAMP3 KO primary osteoblasts is RPL13A, and the most stably expressing 
gene is 18s. 
RAMP3 KO 
WT 
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5.3.2.i.b geNorm V value: 
The final geNorm analysis is calculating the geNorm V value for different pairwise variations to 
determine the optimal number of reference genes for the particular experiment. Pairwise variation 
is “V (n/n+1)” where “n” is the number of reference genes considered. An optimal “n” i.e. the 
number of reference genes, is the one that results in a geNorm V value <0.15 (red line marking 
the threshold). The graphical output generated by qBase+ for WT and RAMP3 KO osteoblast with 
5 time points each with respect to the geNorm M values determined for each gene is as follows 
(Fig. 5.9).  
 
 
 
 
 
 
Since none of the “V (n/n+1)” result in a geNorm V value below 0.15 (red threshold line), the 
optimal number of reference target genes for the experiment remained undetermined. In instances 
when the optimal number of reference genes remains undetermined, qBase+ recommends 
minimal of three common (to both genotypes) and most stably expressing reference genes for 
that particular experiment. However the geNorm M graphs (Figs 5.7 and 5.8) suggested that only 
two common reference gens: 18s and ACTB were the most stably expressing in both WT and 
RAMP3 KO across all time points. Hence only two genes: 18s and ACTB were selected as 
reference genes to normalise the expression of all the genes of interest.  
 
Fig 5.9: Graphical representation of “geNorm V value” to determine the optimal number of reference genes 
from the experiment. On Y-axis is the geNorm V value and on X-axis are the pairwise variations “V (n/n+1)” 
where n is equivalent to the number of reference genes considered. None of the “n” values (from left to right 
on X-axis: 2, 3, 4, 5) resulted in a geNorm V value below 0.15. 
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5.3.2.ii Genes of interest:  
5.3.2.ii.a RAMP1 
RAMP1 expression of a sample at a differentiation time-point was normalised to the mean 
expression of 18s and ACTB at the corresponding time point. As mentioned previously this value 
is ΔCT RAMP1. Following this ΔΔCT values were calculated for the change in expression between 
day0 and each of the higher time-points. The fold change was calculated by the formula 2- ΔΔCT. 
Each sample was run in triplicate and 4 independent experimental repeats were performed. Two-
way ANOVA test and Bonferroni’s post multiple comparison test were used to determine statistical 
differences in fold changes between day0 and each time-point of each genotypes. Statistical 
differences were also determined between WT and RAMP3 KOs at each time-point. It was 
observed that there was a significant difference in the fold change between ΔΔCT values of day10 
and 15 of RAMP3 KO and WTs. Statistical differences in fold change within each genotype in 
detailed below in table 5.3 and represented in Fig 5.10 overleaf. CT and ΔCT of individual 
experiments are summarised in the Appendix (section 9.1.4.i).  
 
 
Bonferroni's multiple 
comparisons test 
Mean Diff. 95% CI of diff. Significant? Summary P Value 
WT   
 
  
Day0 Vs. Day5 -4.200 -9.604 to 1.204 No ns 0.2357 
Day0 Vs. Day10 -9.893 -14.66 to -5.128 Yes **** < 0.0001 
Day0 Vs. Day15 -28.64 -33.40 to -23.87 Yes **** < 0.0001 
Day0 Vs. Day20 -7.325 -12.73 to -1.921 Yes ** 0.0037 
Day5 Vs. Day10 -5.693 -11.39 to 0.002839 No ns 0.0502 
Day5 Vs. Day15 -24.44 -30.13 to -18.74 Yes **** < 0.0001 
Day5 Vs. Day20 -3.125 -9.365 to 3.115 No ns > 0.9999 
Day10 Vs. Day15 -18.74 -23.84 to -13.65 Yes **** < 0.0001 
Day10 Vs. Day20 2.568 -3.128 to 8.265 No ns > 0.9999 
Day15 Vs. Day20 21.31 15.62 to 27.01 Yes **** < 0.0001 
RAMP3 KO      
Day0 Vs. Day5 -2.670 -8.074 to 2.734 No ns > 0.9999 
Day0 Vs. Day10 -2.590 -7.356 to 2.176 No ns > 0.9999 
Day0 Vs. Day15 -13.20 -17.97 to -8.434 Yes **** < 0.0001 
Day0 Vs. Day20 -3.850 -8.262 to 0.5622 No ns 0.1230 
Day5 Vs. Day10 0.08000 -5.616 to 5.776 No ns > 0.9999 
Day5 Vs. Day15 -10.53 -16.23 to -4.834 Yes *** 0.0001 
Day5 Vs. Day20 -1.180 -6.584 to 4.224 No ns > 0.9999 
Day10 Vs. Day15 -10.61 -15.70 to -5.515 Yes **** < 0.0001 
Day10 Vs. Day20 -1.260 -6.026 to 3.506 No ns > 0.9999 
Day15 Vs. Day20 9.350 4.584 to 14.12 Yes **** < 0.0001 
WT vs RAMP3       
Day10 7.303 2.706 to 11.90 Yes ** 0.0010 
Day 20 15.44 10.84 to 20.03 Yes **** < 0.0001 
Table 5.3: Statistical analysis of RAMP1 mRNA expression in primary osteoblasts. 
CI: Confidence interval; Ns: Non significant 
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Fig 5.10: Bar graph representing normalised expression as fold change of RAMP1 mRNA in WT (grey) and 
RAMP3 KO (blue) primary osteoblasts differentiated for 0, 5, 10, 15 and 20 days. n=4 each time-point each 
genotype. Two-way ANOVA test followed by Bonferroni’s post multiple comparison correction test, was used 
for statistical analysis. P value ≤0.05 was considered significant. No significant difference in RAMP1 
expression between WT and RAMP3KO primary osteoblasts. In WT osteoblasts, significant difference was 
observed between day 0 and day 10 (****), day 0 and day 15 (****) and day 0 and day 20 (**) of 
differentiation. In RAMP3 KO osteoblasts statistical difference was observed only between day0 and day15 
(****). There was a significant difference between RAMP3KO and WT at day 10 and day 15. 
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5.3.2.ii.b RAMP2 
As with RAMP1, ΔΔCT RAMP2 values were determined for calculating the fold change between 
day0 and each time-point per genotype. Each sample was run in triplicate and 3 independent 
experimental repeats were carried out. Two-way ANOVA test and Bonferroni’s post-test, showed 
no significant difference between WT and RAMP3 KO. Similar to RAMP1, a significant difference 
in RAMP2 expression between the differentiation time-points within each genotype was observed. 
RAMP2 expression was significantly increased in both the WT and RAMP3 osteoblasts from fifth 
day of differentiation. The CT and ΔCT values of individual experiments are summarised in the 
Appendix (section 9.1.4.i). The statistical analysis is summarised below in table 5.4 and 
represented in Fig 5.11 overleaf.  
 
 
Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
WT      
Day 0 Vs. Day5 -99.18 -192.2 to -6.194 Yes * 0.0319 
Day 0 Vs. Day10 -177.4 -270.4 to -84.38 Yes *** 0.0002 
Day 0 Vs. Day15 -212.1 -305.1 to -119.1 Yes **** < 0.0001 
Day 0 Vs. Day20 -80.41 -163.6 to 2.762 No ns 0.0625 
Day5 Vs. Day10 -78.19 -180.1 to 23.67 No ns 0.2344 
Day5 Vs. Day15 -112.9 -214.8 to -11.06 Yes * 0.0240 
Day5 Vs. Day20 18.77 -74.21 to 111.8 No ns > 0.9999 
Day10 Vs. Day15 -34.74 -136.6 to 67.13 No ns > 0.9999 
Day10 Vs. Day20 96.96 3.978 to 189.9 Yes * 0.0375 
Day15 Vs. Day20 131.7 38.71 to 224.7 Yes ** 0.0031 
RAMP3 KO      
Day 0 Vs. Day5 -59.26 -142.4 to 23.91 No ns 0.3342 
Day 0 Vs. Day10 -206.6 -289.7 to -123.4 Yes **** < 0.0001 
Day 0 Vs. Day15 -212.7 -305.7 to -119.7 Yes **** < 0.0001 
Day 0 Vs. Day20 -117.1 -210.1 to -24.12 Yes ** 0.0088 
Day5 Vs. Day10 -147.3 -230.5 to -64.14 Yes *** 0.0003 
Day5 Vs. Day15 -153.5 -246.4 to -60.47 Yes *** 0.0007 
Day5 Vs. Day20 -57.85 -150.8 to 35.14 No ns 0.5890 
Day10 Vs. Day15 -6.150 -99.14 to 86.84 No ns > 0.9999 
Day10 Vs. Day20 89.46 -3.526 to 182.4 No ns 0.0645 
Day15 Vs. Day20 95.61 -6.251 to 197.5 No ns 0.0755 
 
CI: Confidence interval; Ns: Non significant 
Table 5.4: Statistical analysis of RAMP2 mRNA expression in primary osteoblasts. 
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Fig 5.11: Bar graph representing normalised expression of RAMP2 cDNA in WT (grey) and RAMP3 KO 
(blue) primary osteoblasts differentiated for 0, 5, 10, 15 and 20 days. n=3 each time-point each genotype. 
Two-way ANOVA test followed by Bonferroni’s post multiple comparison correction test, was used for 
statistical analysis. P value ≤0.05 was considered significant. No significant difference in RAMP2 expression 
between WT and RAMP3KO primary osteoblasts. In WT osteoblasts, significant difference was observed 
between day 0 and day 5 (*), day 0 and day 10 (***), day 0 and day 15 (****), day 0 and day 20 (****), 
day5 and day 10 (*), day5 and day 15 (*) and between day15 and day 20 of differentiation. Similarly in 
RAMP3 KO osteoblasts statistical difference was observed between day 0 and day 10 (****), day 0 and day 
15 (****), day 0 and day 20 (***), day 5 and day 15 and day 5 and day 20 (***) of differentiation (**** 
< 0.0001) 
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5.3.2.ii.c RAMP3 : 
The ΔΔCT RAMP3 values were only determined for WT osteoblasts as PCR products were not 
amplified in RAMP3 KO osteoblasts. Each sample was run in triplicate and 3 independent 
experimental repeats were carried out. Two-way ANOVA and Bonferroni’s post-test showed a 
significant difference between the differentiation time-points within WTs osteoblasts. RAMP3 
expression was significantly reduced in both the WT and RAMP3 osteoblasts from fifth day of 
differentiation. The CT and ΔCT of individual experiments are summarised in the Appendix 
(section 9.1.4.i). The statistical analysis is summarised below in table 5.5 and represented in Fig 
5.12 overleaf.  
 
 
Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
WT      
Day0 Vs. Day5 0.5828 0.2123 to 0.9533 Yes *** 0.0009 
Day0 Vs. Day10 0.5701 0.1996 to 0.9406 Yes ** 0.0011 
Day0 Vs. Day15 0.6418 0.2713 to 1.012 Yes *** 0.0003 
Day0 Vs. Day20 0.8000 0.2761 to 1.324 Yes ** 0.0012 
Day5 Vs. Day10 -0.01266 -0.3831 to 0.3578 No ns > 0.9999 
Day5 Vs. Day15 0.05897 -0.3115 to 0.4295 No ns > 0.9999 
Day5 Vs. Day20 0.2173 -0.3067 to 0.7412 No ns > 0.9999 
Day10 Vs. Day15 0.07163 -0.2989 to 0.4421 No ns > 0.9999 
Day10 Vs. Day20 0.2299 -0.2940 to 0.7539 No ns > 0.9999 
Day15 Vs. Day20 0.1583 -0.3657 to 0.6822 No ns > 0.9999 
RAMP3 KO      
Day0 Vs. Day5 0.0 -4.808 To 4.808 No Ns > 0.9999 
Day0 Vs. Day10 0.0 -4.808 To 4.808 No Ns > 0.9999 
Day0 Vs. Day15 0.0 -4.808 To 4.808 No Ns > 0.9999 
Day0 Vs. Day20 0.0 -4.808 To 4.808 No Ns > 0.9999 
Day5 Vs. Day10 0.0 -4.808 To 4.808 No Ns > 0.9999 
Day5 Vs. Day15 0.0 -4.808 To 4.808 No Ns > 0.9999 
Day5 Vs. Day20 0.0 -4.808 To 4.808 No Ns > 0.9999 
Day10 Vs. Day15 0.0 -4.808 To 4.808 No Ns > 0.9999 
Day10 Vs. Day20 0.0 -4.808 To 4.808 No Ns > 0.9999 
Day15 Vs. Day20 0.0 -4.808 To 4.808 No Ns > 0.9999 
 
CI: Confidence interval; Ns: Non significant 
Table 5.5: Statistical analysis of RAMP3 mRNA expression in primary osteoblasts. 
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Fig 5.12: Bar graph representing normalised expression of RAMP3 cDNA in WT (grey) and RAMP3 KO 
(blue) primary osteoblasts differentiated for 0, 5, 10, 15 and 20 days. n=3 each time-point each genotype. 
Two-way ANOVA followed by Bonferroni’s post multiple comparison correction test was used for statistical 
analysis. P value ≤0.05 was considered significant. No PCR product was detected in RAMP3KO osteoblast. . 
In WT osteoblasts, significant difference was observed between day 0 and day 5 (***) day 0 and day 10 
(**), day 0 and day 15 (***) and day0 and day 20 (**) of differentiation.  
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5.4 Discussion 
This study demonstrates an osteoblast-differentiation dependent expression of individual RAMPs. 
The end-point PCR showed that all the three RAMPs; 1, 2 and 3 are expressed by WT 129/SvEv 
primary osteoblasts and RAMP1 and 2 are expressed in the RAMP3 KO primary osteoblast as 
expected (See Figs. 5.2, 5.3 and 5.4). We observed that in WT primary osteoblast cultures, the 
expression of RAMP2 was the highest, followed by that of RAMP3 and that RAMP1 expression 
was the lowest  however this could only be verified by qPCR (See Figs. 5.2, 5.3 and 5.4). The 
RAMP3 KO primary cultures did not amplify a product for RAMP3 cDNA as expected. However, 
similar to the WT primary osteoblast cDNA, RAMP3 KOs demonstrated a higher expression of 
RAMP2 than RAMP 1 during differentiation. Interestingly we also observed that in the WTs the 
expression of RAMP3 cDNA reduced with the progression of osteoblast differentiation which could 
again only be verified by qPCR (see Fig 5.4).  
qPCR was performed using custom designed validated RAMP primers for the double–dye 
hydrolysis qPCR technique, more commonly known as the Taqman qPCR technique. Since the 
Taqman technique specifically quantifies the amplification of target sequence, we could be certain 
that the CT values generated reflected the target sequence amplification and not-specific random 
cDNA amplification. With increasing evidence that housekeeping gene expression varies with 
experimental conditions, transgenic manipulation amongst others, in same cell types, we intended 
to determine a stably expressed housekeeping/reference gene/s for our experiments. In 
accordance to the literature evidence, we observed in 6 reference genes that we selected to 
investigate, that their expression not only varied between genotypes, but also differs between the 
osteoblast differentiation time-points (see Fig. 5.5 and 5.6). Despite the variation in genotype and 
change in expression of reference genes during osteoblasts differentiation, we identified two stably 
expressing reference genes: 18s and β-actin (see Fig. 5.9), which were used in our subsequent 
experiments.  
Despite strong RAMP amplicons observed in endpoint PCR, the CT values acquired by qPCR for 
all the RAMPs were above 25. CT value for RAMP1 throughout differentiation in both WT and 
RAMP3 ranged between 34 – 38, RAMP2 ranged between 25 – 38, RAMP3 CT values in WTs 
ranged between 26 – 38 and RAMP3 was not amplified in RAMP3KO primary osteoblast cDNA 
as expected (see Appendix 9.1.4.i). CT values higher than 37 were. The strong RAMP amplicons 
observed in endpoint PCR could have resulted from the higher concentrations of cDNA template 
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(2µg) compared to the low concentration of cDNA template used in qPCR reactions (5ng). The 
acceptance of expression level of a gene by qPCR technique with a CT value beyond 32 is 
debated. However in our qPCR reactions, if there was no amplification, (for example in case of 
non-template control reactions and the reactions of RAMP3 primer in RAMP3 KO primary 
osteoblast cDNA preparations) the qPCR machine did not generate an amplification plot and 
could not determine a CT value. Even with high CT values, an amplification plot was generated 
for the WT and RAMP3 primary osteoblasts. Therefore the higher CT values for RAMPs were not 
artifactual values resulting from nonspecific non-amplified reactions, but were robust 
quantifications that reflected the low concentrations of the RAMPs in primary osteoblasts. CT 
values higher than 37 were excluded. More over each reaction had a copy number control which 
validated the efficiency of the primers. The CT values for copy number positive control are 
detailed in the appendix 9.1.4.i. 
In WT primary osteoblast cDNA, RAMP2 expression was more than that of RAMP3 which was in-
turn higher than RAMP1. In RAMP3 KO primary osteoblast cDNA, RAMP2 expression was higher 
than that of RAMP1. Since RAMP1 expression is the least amongst RAMPs and given the 
evidence that RAMP1 KO mice do not have a skeletal phenotype, it appears that RAMP1 does not 
play an important role in regulating the skeleton (as observed in data from our pilot study, Section 
1.5) (Tsujikawa et al 2007).  
There were no significant differences in 2 expressions between WT and RAMP3 KO primary 
osteoblast cDNA throughout differentiation; hence the expression of RAMP2 in osteoblasts is 
independent of RAMP3 expression. Interestingly, WT osteoblasts had significantly higher fold 
change in RAMP1 expression at day 10 and day15 compared to the RAMP3 KOs (see Fig 5.10). 
Furthermore, in both WTs and RAMP3 KOs, the expression of RAMP1 and 2 increased from day 
5 of differentiation (see Fig. 5.10 and 5.11) and the expression of RAMP3 decreased from day 5 
of differentiation (see Fig. 5.12). This can indicate that osteoblast maturation requires an increase 
in RAMP1 and 2 expressions and a decrease in RAMP3 expression. We can therefore propose 
that the effects of reduction in RAMP3 during osteoblast maturation are enhanced in the RAMP3 
KO primary osteoblasts, due to the absence of RAMP3. We have also shown the RAMP3 KO 
primary osteoblasts have a different osteoblast differentiation profile in chapter 5. Since RAMP1 
and RAMP2 expressions do not change in RAMP3 KOs, the differences in the osteoblast 
maturation are due to the absence of RAMP3. Coincidently, maturation of osteoclasts into 
multinucleated cells also requires reduction in RAMP3 expression (Granholm et al 2008). Hence 
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in RAMP3 KO mice, both the osteoblasts and osteoclasts have enhanced development which 
could influence the bone remodelling process. 
Bone remodelling process peaks at young age when the bones grow to form an adult skeleton to 
achieve a peak bone mass density by the age of 20. Since we see maximum advancement of the 
skeletal phenotype in the RAMP3 KO mice when they are neonates, we can suggest that the 
enhanced bone remodelling resulting from the improved osteoblast and osteoclast maturation 
could be responsible for the RAMP3 KO mice skeletal phenotype.  
In conclusion, with osteoblast differentiation,  
 RAMP1 and 2 mRNA expression increases, however RAMP1 expression levels are 
extremely low to begin with, and 
 RAMP3 mRNA decreases.  
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Chapter 6: Effect of anabolic stimulations in WT and RAMP3 KO 129/SvEv 
primary osteoblasts. 
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6.1 Introduction 
In this chapter we investigate the effects of various anabolic stimulations in WT and RAMP3 KO 
129/SvEv primary osteoblasts. 
6.1.1 Effect of Parathyroid hormone (PTH), Adrenomedullin (AM) and Amylin (AMY) 
stimulation: 
The first half of this chapter focuses on the effect of PTH, AM and AMY stimulation on the 
expression of RAMPs. As discussed earlier, all the three peptides PTH, AM and AMY have an 
effect on osteoblasts differentiation and proliferation. Although the downstream cell signalling 
pathways following PTH, AM and AMY stimulation have been studied in depth by independent 
groups (Christopoulos et al 1999, Cornish et al 2001, Cornish et al 1995, Cornish et al 1997, 
Ishizuya et al 1997), currently there is no literature evidence that reflects the change in the 
endogenous expression of the receptors for these peptides.  
All the four GPCRs- PTHR1/PTHR2, CLR and CTR form heterodimers with RAMPs 2 and 3 to 
form functional receptors for PTH, AM and AMY respectively. These accessory proteins 
ingeniously modulate the GPCR ligand specificity (Christopoulos et al 1999, Hay et al 2006, 
McLatchie et al 1998). RAMPs not only form functional receptors for these receptors, but also 
induce trafficking of partner GPCRs and chaperon them to the cell surface (McLatchie et al 1998, 
Parameswaran & Spielman 2006, Sexton et al 2001). Given the evidence that RAMPs form 
stable intracellular homodimers (Sexton et al 2001), it may be possible that on ligand activation, 
the homodimers in the cytoplasm dissociate to form heterodimers with partner GPCRs to enhance 
receptor presentation in response to the particular stimuli. Since alterations in RAMP2 and 
RAMP3 have shown to result is a skeletal phenotype, in transgenic mice, we were interested in 
investigating the change in the expression of these two receptors in WT and RAMP3 KO primary 
osteoblasts when stimulated with the aforementioned peptides. Furthermore we wanted to 
determine whether under stimulated conditions, RAMP2 protein compensated for the loss of 
RAMP3 in the RAMP3 KOs osteoblasts. 
 
 
 
6 Chapter 6: Effect of anabolic stimulations in WT and RAMP3 KO 129/SvEv primary osteoblasts. 
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6.1.2 The Wnt/β-catenin and RAMP3 association:  
The latter half of this chapter is focussed on the Wnt/β-catenin pathway and RAMP3 association. 
One of the important regulatory pathways in the skeleton is the canonical Wnt pathway. Detailed 
review of the Wnt pathways is beyond the scope of this project. Briefly, in the canonical Wnt 
pathway, Wnt activates a heteromeric receptor complex that is made up Fizzled protein and LRP5 
or 6 receptor (Bhanot et al 1996, Clevers & Nusse 2012, Wehrli et al 2000). Fizzled proteins are 
a family of seven transmembrane GPCRs and LRP5/6 are members of single transmembrane, 
low density lipoproteins. Activation of the Wnt receptor complex results in an increase in the 
phosphorylate β-catenin level in the cytoplasm which then translocates into the nucleus and 
activates targets genes (Rubinfeld et al 1993). DKK1 is a secreted protein that antagonises Wnt 
by binding to LRP5/6 (Bafico et al 2001, Semenov et al 2001, Semenov et al 2008). In bone, 
Wnt activation determines the fate of mesenchymal stem cells (MSCs) as it induces the MSCs to 
differentiate into osteoblasts.  
There is recent evidence in the involvement of Wnt in regulation of RAMP3 expression. Many 
research groups have identified that RAMP3 is one of target genes of the Wnt pathway. In 2005 
two independent groups Kenny et al and Ziegler et al reported down regulation of RAMP3 on 
phosphorylated β-catenin induction using northern blotting (Kenny et al 2005, Ziegler et al 
2005). Following this, in 2009 Ro¨hrs et al showed that RAMP3 expression is down regulated in 
the first 24 hours post Wnt3A stimulation (Rohrs et al 2009). Hence RAMP3 is one of the early 
response genes targeted by Wnt. Results from chapter 4 suggest that primary osteoblasts have 
an advanced differentiation pattern in the RAMP3 KO mice when compared to the WTs. Since the 
canonical Wnt pathway is one of the important regulatory pathways in osteoblast differentiation 
and since Wnt is proposed to reduce RAMP3 expression, we hypothesised, that the RAMP3 KO 
mice had enhanced Wnt / β-catenin pathway that could result in an advanced osteoblast 
differentiation. We aimed to investigate both, the endogenous Wnt regulated phosphorylated β-
catenin levels in RAMP3 KO and the effect of external Wnt stimulation on the phosphorylated β-
catenin levels in RAMP3 KOs in comparison to the WT primary osteoblasts. 
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6.2 Methods 
6.2.1 Stimulation of primary osteoblast cultures: 
Detailed calvarial primary culture protocol is described in Section 5.2.1. Independent WT and 
RAMP3 KO primary cultures were established for stimulation experiments. PTH, AM and AMY 
stimulated WT and RAMP3 KO osteoblasts were studied for expression of RAMP 2 and RAMP 3. 
Un-stimulated WT and RAMP3 KO primary osteoblasts were studied for expression of total β-
catenin. And DKK1 and DKK1 + Wnt3A stimulated WT and RAMP KO primary osteoblasts were 
studied for the expression of phosphorylated β-catenin.  
6.2.1.i Experimental set-up for RAMP2 and RAMP3 expression:  
Three of each WT and RAMP3 KO primary osteoblasts were differentiated for 20 days in T25 
culture flasks (Nunc™). Since concentration of 10-12M and greater of PTH, AM, AMY have be 
reported to stimulate osteoblasts in vitro, we used 10-9M concentration in our experiments 
(Matsumoto et al 1986, Cornish et al 1995, Cornish et al 1997). On the 20th day of 
differentiation, the osteogenic media was decanted and replaced with stimulation media containing 
10nM/ml working concentration of one of full length peptides: PTH (Sigma®), AM(Sigma®), AMY 
(Sigma®) for 20 minutes. After stimulation, the stimulation media was decanted and cells were 
lysed. The whole cell lysates were used as protein sample. Protocol detailed in section 6.2.2. 
6.2.1.ii Experimental set-up for total β-catenin expression:  
Four of each WT and RAMP3 KO primary osteoblast cultures were differentiated for 10, 15 and 
20 days in T25 culture flasks. On each of these time points, cells were harvested by the protocol 
detailed in section 7.2.2. 
6.2.1.iii Experimental set-up for phosphorylated β-catenin expression:  
Three of each WT and RAMP3 KO primary osteoblast cultures differentiated for 20 days in T25 
culture flasks. Wnt3A at a concentration of 100ng/ml has been reported to give a potent β-
catenin response in vitro (Hannoush 2008). One of the flasks, each culture was stimulated with 
media containing working concentration 100ng/ml of recombinant Wnt3A (R&D Systems™, 
Catalogue no: 1324-WN) for 20 mins. Cells were harvested from non-stimulated and Wnt3A 
stimulated flasks for each culture, each genotype by the protocol detailed in section 7.2.2. 
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6.2.1.iv Experimental set-up for endogenous phosphorylated β-catenin expression:  
Three of each WT and RAMP3 KO primary osteoblast cultures were differentiated for 20 days in 
6 well culture plates (Nunc™). A dose dependent decrease in phosphorylated-β-catenin has been 
reported with a dose range of: 0, 5ng, 50ng, 100ng, 200ng, 250ng/ml DKK1, hence these 
concentrations were used in our experimental setup (Qiang Ya-Wei et al 2007). The osteogenic 
media of each well was decanted and replaced with stimulation media containing one of the 
working concentrations (0, 5ng, 50ng, 100ng, 200ng, 250ng) of recombinant human DKK1 
(R&D Systems™, Catalogue no: 5439-DK) . The stimulation media was decanted and cells were 
lysed and the whole cell lysate on each well was used as a protein sample. (Section 6.2.2)  
6.2.1.v Experimental set-up for phosphorylated β-catenin expression on Wnt3A stimulation:  
The WT and RAMP3 KO primary osteoblasts were differentiated for 20 days in 6 well culture 
plates (Nunc™). The osteogenic media of each well was decanted and replaced with stimulation 
media containing one of the working concentrations of recombinant human DKK1 (0, 5, 50, 100, 
200, 250ng/ml). The stimulation media was decanted and replaced with stimulation media-2 
containing 100ng/ml recombinant mouse Wnt3A (R&D Systems™, Catalogue no: 1324-WN) for 
20 minutes. This stimulation media-2 was removed and cells were lysed, the details of which are 
in the following section 6.2.2. 
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6.2.2 Protein expression analysis:  
6.2.2.i Total cell lysate protein from differentiating primary osteoblasts: 
Cells were harvested from one T25 flask each culture (PTH, AM and AMY stimulation) or one 
well of the 6 well plate (DKK and Wnt stimulation) for each peptide stimulation concentration for 
each culture. First, the medium was removed and the cells were washed in PBS. 500µl (T25) or 
200μl (one well of a 6 well plate) ice-cold NP40 lysis buffer (recipe in appendix) having fresh 
protease inhibitor cocktail 1X (PIC) was added to the cells and the cells were scraped and 
collected in 1.5ml tubes. This homogenate was then sonicated on ice at 10μm for 10 short pulses 
using a probe sonicator (Soniprep 150, Sanyo, Japan). The final supernatant was stored as 
aliquots at -20˚C.  
 
6.2.2.ii Total brain lysate protein-positive control: 
Whole brain homogenates from previously snap frozen WT (SVEV/129) mice was prepared for 
Western blotting. The mouse brain (snap frozen tissue stored at -80oC) was weighed and allowed 
to soften at -20oC for an hour prior being chopped into small pieces. The chopped tissue was 
placed in a 7ml tissue grinder tube and 15 volumes of ice-cold 0.25 M Sucrose/Buffer A 
containing freshly prepared protease inhibitor cocktail 1X (PIC), was added. The tissue was first 
homogenized by 15 passes of the loose pestle and then by 15 passes of the tight pestle. This 
homogenate was centrifuged at 600 g for 5mins at 4˚C and the supernatant was retained. The 
supernatant was then sonicated using a probe sonicator (Soniprep 150, Sanyo, Japan) by 10 
brief pulses at 10μm before aliquoting and snap freezing it in liquid nitrogen. The samples were 
stored as aliquots at -20oC. 
 
 
6.2.2.iii Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
Western blotting was carried out in 7% (CTR and CLR) and 15% (RAMP1/2/3) polyacrylamide 
gels. Biorad Mini-PROTEAN™ system was routinely used to carry out electrophoresis of proteins. 
The resolving and stacking (5%) gels were cast in 1.5 mm thickness plates. Once the samples 
were loaded in the gel, they were allowed to stack at 50 V for 50 mins after which the samples 
were resolved at 125 V for 2 hours. 
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6.2.2.iv Protein sample preparation for SDS - PAGE  
For cell lines approx. 40-100μg and for mouse brain homogenate approximately 40 μg of proteins 
were loaded on to the gels. All protein samples were denatured in 2X and 4X Laemmli sample 
buffer, containing β-mercaptoethanol (Sigma®, Poole, UK), by boiling at 100˚C for 5 minutes 
prior to electrophoresis (please refer appendix for working solution concentrations). Following 
denaturation, the samples were gently vortexed before being loaded into the wells. Additionally, 5 
μl of biotinylated molecular weight standards (Cell signalling®, Massachusetts, USA) and 5 μl of 
prestained All Blue™ (Biorad®, California, USA) molecular weight standards were also loaded.  
 
6.2.2.v Western Blotting:  
Resolved proteins were electro-blotted on to Hybond™ nitrocellulose membrane (Amersham®, 
Massachusetts, USA). The Hybond™ membrane was pre-soaked in 100% methanol for 5 min 
then equilibrated in transfer buffer prior to use. The stacking gel of the polyacrylamide gel was 
excised and the orientation was noted. The sandwich for the electroblotting was prepared using 
two Teflon pads and 4 filter papers (3MM grade, Whatman® chromatography paper, Brenford, 
UK) per gel. The Teflon pads and the filter papers were also soaked in transfer buffer prior to 
blotting. The blotting arrangement comprised 2 3M Whatman filter papers and 1 Teflon pad on 
either side of the gel and membrane sandwich. Care was taken to avoid air bubbles between the 
different layers of the sandwich. The above arrangement was placed in a transfer cassette with 
the Hybond™ membrane positioned towards the cathode (white surface). The cassette was placed 
in the transfer tank containing ice-cold transfer buffer. The transfer tank itself was placed in an ice 
box and the transfer was allowed to occur at 50 V for 9 hours. Please refer appendix for working 
solution concentrations mentioned in this section.  
 
6.2.2.vi Immuno-blotting  
For each experiment, immune-blotting was carried out for the protein of interest and for a 
housekeeping protein, β-actin, used as a loading control. The membranes containing the 
transferred proteins were removed from the electro-blotting cassette and the lane containing the 
biotinlylated marker was excised out with the aid of the prestained markers. Washing solutions 
used for immune-blotting were: PSB-tween (PBS with 0.25% Tween 20) for non- phosphorylated 
proteins and TBS-tween (TBS with 0.25% Tween 20) for phosphorylated proteins.  
 
Membranes were first incubated for 1 hr at room temperature in the blocking solution i.e., either 
PBST containing 5% (w/v) dried skimmed milk or TBST containing 5% BSA on a roller mixer. 
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After giving the membranes two – 5 min washes in PBST/TBST, the membrane was incubated 
with primary antibodies dilution made up in blocking solution at 40C overnight (See Table 7.1 for 
the dilutions used for each antibody), with gentle rotation on a roller . The membrane part 
containing the biotinylated marker was stored in PBST/TBST during this incubation. The primary 
antibody was washed out with three 5-min washes in PBST/TBST and the membrane was 
incubated with corresponding HRP-tagged secondary antibody made-up in blocking solution for 1 
hour at room temperature. The biotinylated markers were incubated in PBST/TBST containing 
HRP-anti biotin for 1 hour at room temperature. Both pieces of the membranes were given two 5-
min washes in PBST/TBST and were incubated in ECL Plus (Pierce®, Rockford Illinois, USA) 
chemiluminescence detection substrate that contained equal volumes of solution A and solution B 
premixed for 5 mins on a roller. The membranes were recovered from the chemiluminescence 
detection solution and were aligned together and placed in X-ray/photo film development 
cassette after removing excess chemiluminescence solution. The chemiluminescence was 
detected on Amersham Hyperfilm™ (Amersham®, Chalfont St Giles, UK) and multiple exposures 
were taken for each blot. The exposed photo films were developed manually in 1:10 diluted 
developer (AGFA- Gevaert N.V:G153-REF HT536 developer, Belgium) until bands of appropriate 
intensities appeared. The films were then briefly washed in water to remove excess developer and 
were fixed in fixer (AGFA-Gevaert N.V: G354 Rapid Fixer- REF 2828Q, Belgium) before being 
washed in water and left to dry. Please refer appendix for working solution concentrations 
mentioned in this section. Table 6.1 below summarises the details of all the antibodies and the 
dilutions at which they were used.  
 
Primary 
antibody 
 
Product details Raised 
in 
Dilution 
used 
Secondary 
antibody 
Dilution 
used 
Dilutions 
made in 
RAMP2 Abcam®,ab96546 Rabbit 1:200 
Anti-rabbit-HRP 
DAKO®# P04498 1:1000 
5% milk in 
PBST 
RAMP3 Abcam®, ab123598 Rabbit 1:100 
Anti-rabbit-HRP 
DAKO®# P04498 1:1000 
5% milk in 
PBST 
β-catenin Abcam®, ab27798 Rabbit 1:300 
Anti-rabbit-HRP 
DAKO®# P04498 1:5000 
5% milk in 
PBST 
Phosphorylated β-
catenin 
(Ser33/37/Thr41) 
Cell signaling®#9561 Rabbit 1:200 
Anti-rabbit-HRP 
DAKO®# P04498 1:5000 5% BSA in TBST 
β-actin Abcam®, ab16039-500 Rabbit 1:5000 
Anti-rabbit-HRP 
DAKO®# P04498 1:5000 
5% milk in 
PBST 
 
Table 6.1: Details of Antibodies  used in Western blotting. 
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6.2.2.vii Quantification of protein expression: 
Quantification of the expression of protein of interest on the immunoblots was performed by 
densitometry. GS-900™ Calibrated Densitometer (Bio-Rad™) was used to identify the peak band 
density. The peak band densities of the protein of interest were normalised to the peak band 
intensities of the house keeping protein used as a loading control. These normalised expression 
values were subjected to statistical analysis. 
 
6.2.3 Statistical analysis: 
All the datasets were analysed using two way-ANOVA test in GraphPad Prism® 6 followed by 
Bonferroni’s post multiple analysis correction test. P value ≤ 0.05 was considered significant. The 
statistical analysis was presented as bar graphs generated by the GraphPad Prism® 6. 
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6.3 Results 
6.3.1 Parathyroid hormone (PTH), Adrenomedullin (AM) and Amylin (AMY) stimulation: 
6.3.1.i  RAMP3 expression on PTH, AM and AMY stimulation: 
Expression levels of RAMP3 in differentiated WT primary calvarial osteoblasts were determined 
under basal and stimulated conditions. Twenty days differentiated WT 129/SvEv primary 
osteoblasts were stimulated with 10nM working concentration of full length PTH, AM and AMY 
peptides. 100µg protein was loaded in each well. Western blotting showed a significant increase in 
the expression of 17kDa RAMP3 monomer in PTH, AM and AMY stimulated WT primary 
osteoblasts, compared to basal/non-stimulate WT primary osteoblasts. Figure 6.1A overleaf is a 
representative Western blot showing the expression of RAMP3 and the loading control β-actin. 
Statistical analysis of the RAMP3 expression is presented in figure 6.1B. 
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Fig 6.1: A) Representative Western blot showing expression of RAMP3 ~17kD (top) and β-actin (bottom) in 
differentiated WT primary calvarial osteoblasts cultures stimulated with PTH, AD and AMY. Stimulation with 
the CT family of peptides resulted in significant increase in RAMP3 expression in comparison to non-
stimulated control cells. On day 20 of differentiation, osteoblasts were stimulated with 10nM concentration of 
full-length PTH, AM and AMY peptides for 20 mins prior being harvested for Western Blotting. Whole cell 
lysates were collected from three independent stimulated cultures (each genotype). Each independent 
culture was Western blotted twice. β-actin was the loading control. 100µg protein loaded in each well. 
Exposures were between 2-3 mins. 
B) Quantification of levels of RAMP3 in peptide-stimulated differentiated WT osteoblasts, after normalizing to 
respective β-Actin levels. Levels of RAMP 3 were significantly higher osteoblasts stimulated with either PTH, 
AM or AMY in comparison to non-stimulated control cells. n=3 each genotype. Data was analysed using 
Two-way ANOVA test followed by post multiple comparison correction using Bonferroni’s test.  
Significance of p value: **** ≤0.0001, *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.005 
 
A 
B 
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6.3.1.ii  RAMP2 expression in RAMP3 KO and WT 129/SvEv primary osteoblasts: 
Levels of RAMP2 in response to the stimulation by 10nM working concentrations of full length 
PTH, AM and AMY peptides were investigated in WT and RAMP3 KO mice primary calvarial 
differentiated osteoblasts.100µg protein was loaded in each well.  
Western blotting for RAMP2 showed two distinct bands – one corresponding to the monomeric 
form of RAMP 2 (~13 kDa) and another higher molecular weight band (~55 kDa).  
Similar to a response observed in the levels of RAMP3, both WT and RAMP3 KO osteoblasts 
showed significantly increased levels of RAMP2 upon stimulation with each PTH, AM and AMY 
full length peptides. However, the expression of RAMP2 did not vary between peptides. 
Furthermore, it was observed that stimulated WT primary osteoblasts had significantly higher 
levels of RAMP2 monomer than stimulated RAMP3 KO osteoblasts. It was even more interesting 
to observe that this was opposite with respect to the higher molecular weight band of RAMP 2 
that is; there were significantly higher levels of this form of the 55kDa RAMP 2 in the stimulated 
RAMP3 KO osteoblasts compared to that of the WT cells. Hence in response to stimulation both 
WTs and RAMP3 KOs have increased RAMP2 on stimulation, but the RAMP3 KOs have less 
13kDa RAMP2 and more 55kDa RAMP2 expression. 
The expression levels of both these bands was normalised to the expression of housekeeping 
protein β-actin and statistically analysed using two-way ANOVA test followed by Bonferroni’s post 
multiple comparison test. Figure 6.2 overleaf is a representative Western blot showing the 
expression of both monomer and higher molecular weight RAMP2 along with the loading control 
β-actin. Statistical analysis of both monomer and higher molecular weight RAMP2 expression is 
presented in Figure 6.3. 
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Fig 6.2: Representative Western Blot showing expression of RAMP2 in differentiated WT and RAMP3 KO primary 
calvarial osteoblasts cultures stimulated with PTH, AD and AMY. Stimulation with the CT family of peptides resulted in 
significant increase in RAMP2 expression in both WT and RAMP3 KO osteoblasts in comparison to non-stimulated 
control cells. Primary calvarial osteoblasts from WT animals were cultured in-vitro and were allowed to differentiate upto 
20 days. On day 20 of differentiation, osteoblasts were stimulated with PTH, AM and AMY (0, 5, 50, 100, 200, 
250ng/ml) for 20 mins prior being harvested for Western Blotting. Whole cell lysates were collected from three 
independent stimulated cultures (each genotype). Each independent culture was Western blotted twice. Western blotting 
for RAMP2 showed two significant bands (monomer at ~13 kDa and a higher molecular weight band at ~55 kDa), both 
of which were quantified. Mouse brain protein lysate was used as a positive control and β-actin was used as the loading 
control. 100µg protein loaded in each well. Exposures were between 2-3 mins. 
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Fig 6.3: Quantification of levels of RAMP 2 in peptide-stimulated differentiated WT and RAMP 3 KO primary 
calvarial osteoblasts, after normalizing to respective β-Actin levels. Levels of RAMP 2 were significantly 
higher osteoblasts stimulated with either PTH, AM or AMY in comparison to non-stimulated control cells from 
both WT and RAMP3 KO mice. Additionally upon stimulation with each peptide, levels of high molecular 
band RAMP 2 were significantly higher in the RAMP 3 KO cells compared to the respective WT cells 
(control). However, levels of monomeric form of RAMP2 were observed significantly lower in the RAMP3 KO 
cells compared to the respective WT cells (control). n=3 each genotype. Data was analysed using Two-way 
ANOVA test followed by post multiple comparison correction using Bonferroni’s test.  
Significance of p value: **** ≤0.0001, *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.005 
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6.3.2 Wnt/ β-catenin pathway in RAMP3 KO primary osteoblasts 
6.3.2.i Total β-catenin expression in WT and RAMP3 KO 129/SvEv primary osteoblasts: 
Expression levels of total β-catenin were determined in WT and RAMP3 KO primary osteoblasts 
at day 10, 15 and 20 of differentiation. It was observed that total β-catenin expression gradually 
decrease in both WT and RAMP3 KO primary osteoblast samples along with progression of the 
osteoblast differentiation. Both WT and RAMP3 KO osteoblasts had high levels of total β-catenin 
at day 10 of differentiations that were significantly reduced by day 20. 
Despite a gradual decrease in the total β-catenin levels, it was interesting to observe that RAMP3 
KO osteoblasts had consistently and significantly higher levels of total β-catenin throughout the 
differentiation process when compared to the WTs (day 10, 15 and 20). Fig 6.4A is a 
representative Western blot image showing the expression of total β-catenin and the loading 
control- β-actin, in both WT and RAMP3 KO primary osteoblasts. Figure 6.4B is a bar graph 
representing the statistical differences in the expression of total β-catenin normalised to β-actin. 
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Fig 6.4: A) Representative Western Blot showing increased expression of total β-catenin in RAMP3 KO 
differentiating osteoblasts in comparison to WTs (*). Four independent primary calvarial osteoblasts from WT and 
RAMP 3 KO animals were cultured in-vitro and were allowed to differentiate in osteogenic medium for upto 20 days. 
Whole cell lysates were harvested from these four independent differentiation cultures (each genotype), at day 10, 
15 and 20. Each independent culture was immuno-blotted twice for β-catenin expression. Wnt stimulated primary 
osteoblast and mouse brain tissue lysate were used as positive controls. Samples were immuno-blotted for β-actin 
as a loading control. 40µg protein loaded in each well. Exposures were between 2-3 mins. 
B) Quantification of levels of total β-catenin in WT and RAMP3 KO differentiating osteoblasts, after normalizing to 
respective β-actin levels. Levels of β-catenin were significantly increased in RAMP3 KO differentiating osteoblasts 
compared to WT at each time point. There was also differentiation dependent significant decrease in levels of β-
catenin in both WT and RAMP3 KO osteoblasts. n=8 each genotype. Data was analysed using Two-way ANOVA 
test followed by post multiple comparison correction using Bonferroni’s test.  
Significance of p value: **** ≤0.0001, *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05 
A 
B 
* * * 
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6.3.2.ii Phosphorylated β-catenin expression in WT and RAMP3 KO 129/SvEv primary 
osteoblasts on Wnt3A stimulation: 
To determine if the Wnt pathway is influences by the increased total β-catenin levels in RAMP3 
KO primary osteoblasts, we stimulated both WT and RAMP3 KO primary osteoblasts that were 
differentiated for 20 days with Wnt3A and determined the levels of phosphorylate β-catenin.  
Western blots showed significantly increased levels of phosphorylated β-catenin in RAMP3 KO 
cultures, in both basal and in stimulated conditions in comparison to WT cultures. Expression 
levels of phosphorylated β-catenin were normalised to expression of β-actin. Figure 6.5A is a 
representative Western blot for of phosphorylated β-catenin and β-actin in day 20 differentiated, 
non- stimulated and Wnt3A stimulated WT and RAMP3 KO primary osteoblasts. Figure 6.5B is a 
bar graph depicting the significant differences.  
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Fig 6.5: A) Representative Western Blot increased phosphorylated β-catenin levels in 20 days differentiated 
RAMP3KO primary calvarial osteoblast cultures compared to WT primary osteoblasts, under basal and Wnt 
stimulated conditions (top panel) .Primary calvarial osteoblasts from WT and RAMP 3 KO animals were cultured in-
vitro and were allowed to differentiate upto 20 days. On day 20 of differentiation, osteoblasts were stimulated with 
100ng/ml working concentration of Wnt3A for 20 mins prior being harvested for Western Blotting. Whole cell 
lysates were collected from three independent stimulated cultures (each genotype). Each independent culture was 
Western blotted twice for phosphorylated β-catenin. β-actin was the loading control (bottom panel). 40µg protein 
loaded in each well. Exposures were between 2-3 mins. 
B) Quantification of levels of phosphorylated β-catenin in WT and RAMP3 KO basal and Wnt stimulated,20 days 
differentiated osteoblasts, after normalizing to respective β-Actin levels using two way-ANOVA test. RAMP3 KOs 
have significantly higher phospho-β-catenin at both non-stimulated (p≤0.0001) and Wnt stimulated (p= 0.0002) 
conditions. There is a significant increase in both Wnt stimulated WT and RAMP3 KO primary osteoblast cultures 
(p=≤0.0001) compared to non-stimulated WT and RAMP3 KO primary osteoblast p=≤0.0001) respectively.  
Significance of p value: **** ≤0.0001, *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05 
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6.3.2.iii Effect of DKK1 stimulation on endogenous phosphorylated β-catenin expression in WT 
and RAMP3 KO 129/SvEv primary osteoblasts: 
We next investigated whether the levels of phosphorylated β-catenin (active form) in RAMP3 KO 
osteoblasts responded to DKK1 stimulation as WT osteoblasts do. Given that activation of β-
catenin is dependent upon Wnt activation, 20 days differentiated WT and RAMP3 KO osteoblasts 
were subjected to a range of working concentrations: 1,5ng/ml, 50ng/ml, 100ng/ml, 200ng/ml, 
250ng/ml of recombinant human DKK1, a known Wnt antagonist. We were interested in 
determining a dose dependent alteration in levels of phospho-β-catenin in both RAMP3 and WT 
primary osteoblasts.  
Western blotting for phosphorylated β-catenin in both WT and RAMP3 KO differentiated 
osteoblasts showed a highly significant dose-dependent decrease in levels of β-catenin with 
increase in DKK1 concentration. RAMP3 KO osteoblasts had significantly higher expression of 
phospho-β-catenin levels throughout compared to the WTs. The highest significance in the 
difference in the phospho-β-catenin levels of RAMP3 KO and WTs was observed at the DKK1 
concentration of 100ng/ml when the expression of phospho-β-catenin starts dropping in both the 
cultures. This difference was obvious in the western blots. Figure 6.6 overleaf is a representative 
Western blot showing the expression of phospho-β-catenin and β-actin (loading control) in WT 
and RAMP3 KO primary osteoblasts stimulated with a range of DKK1 concentrations. Figure 6.7 
is a graphical representation of the significant differences determined using two-way ANOVA test. 
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Fig 6.6: Representative Western Blot showing a dose dependent decrease in phosphorylated β-catenin 
(~90kD) levels in 20 day differentiation WT and RAMP3 KO primary calvarial osteoblasts cultures stimulated 
with different concentrations of DKK1. RAMP3 KO cultures had significantly higher expression of phosphorylated 
β–catenin compared to WT at each DKK stimulation concentration. Primary calvarial osteoblasts from WT and 
RAMP 3 KO animals were cultured in-vitro and were allowed to differentiate upto 20 days. On day 20 of 
differentiation, osteoblasts were stimulated with different concentrations of recombinant human DKK1 (0, 5, 50, 
100, 200, 250ng/ml) for 20 mins prior being harvested for Western Blotting. Whole cell lysates were collected 
from three independent stimulated cultures (each genotype). Each independent culture was Western blotted 
once for phosphorylated β-catenin. β-actin (~42kD) was the loading control. 40µg protein loaded in each well.  
Exposures were between 5-7 mins. 
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Fig 6.7: Quantification of levels of phosphorylated β-catenin on DKK1 stimulations, in WT and RAMP3 KO DKK 
stimulated differentiated osteoblasts, after normalizing to respective β-Actin levels Both WT and R3 KO 
differentiated osteoblasts showed a significant dose-dependent decrease in phosphorylated β-catenin levels with 
increase in DKK1 concentration. Levels of phosphorylated β-catenin were higher in RAMP3 KO osteoblasts than 
WT irrespective of DKK concentration. n=3 each genotype. Data was analysed using Two-way ANOVA test 
followed by post multiple comparison correction using Bonferroni’s test.  
Significance of p value: **** ≤0.0001, *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05 
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6.3.2.iv  Effect of DKK1 and Wnt3A stimulation on Phosphorylated β-catenin expression in WT 
and RAMP3 KO 129/SvEv primary osteoblast: 
On determining the dose dependent response of phospho-β-catenin to DKK1 in both WT and 
RAMP3 KO mice we further wanted to determine the effect of exogenous Wnt3A stimulation post 
DKK1 stimulation. WT and RAMP3 KO primary osteoblast cultures were differentiated for 20 days 
and on the 20th day of differentiation they were first stimulated with a range of DKK1 
concentrations (0, 5, 50, 100, 200, 250ng/ml) followed by a stimulation of Wnt3A (100ng/ml). 
Cells were harvested for protein after the Wnt3A stimulation. It should be noted that since the 
cultures were first stimulated with DKK1 and then by Wnt3A, what we are observing in this 
experiment is an increase in phospho-β-catenin concentrations after the DKK1 insult has reduced 
the endogenous phospho-β-catenin in the cells.  
The increase in phospho-β-catenin in both WT and RAMP3KO following Wnt3A stimulation 
insignificant. However, interestingly the exogenous Wnt3A stimulation increase significantly more 
amount of phospho-β-catenin in RAMP3 KO primary osteoblasts in comparison to the WT primary 
osteoblasts. The increase in phospho-β-catenin in RAMP3 KOs begins with concentrations of the 
prior DKK1 stimulation as high as 200ng/ml. On contrary, the phospho-β-catenin of WT 
osteoblasts only increased when the previous DKK1 stimulation concentration is of 50ng/ml. 
Finally in accordance to what we have previously determined (Fig 6.5), when there is no prior 
DKK1 (0ng/ml) stimulation, RAMP3 KOs have the maximum and significantly higher levels of 
phospho-β-catenin expression when compared to the WTs. Figure 6.8 overleaf is a 
representative Western blot showing the expression of phospho-β-catenin in WT and RAMP3 KO 
primary osteoblasts stimulated with both DKK1 and Wnt3A. Figure 6.9 is a graphical 
representation of the significant differences determined using two-way ANOVA test. 
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Fig 6.8: Representative Western Blot showing increase in phospho-β-catenin (~90kD) levels in both WT and 
RAMP3KO osteoblasts on Wnt stimulation following DKK1 stimulation. It was observed that the expression of 
phospho-β-catenin levels is significantly higher in RAMP3KO s when compared to the WTs. Maximum stimulation 
of phospho-β-catenin in both WT and RAMP3KOs is when the cells are not stimulated with DKK1. Primary 
calvarial osteoblasts from WT and RAMP 3 KO animals were cultured in-vitro and were allowed to differentiate 
upto 20 days. On day 20 of differentiation, osteoblasts were first stimulated with different concentrations of DKK 
(0, 5, 50, 100, 200, 250ng/ml) and were then subjected to Wnt stimulation for 20 mins prior being harvested 
for Western Blotting. Whole cell lysates were collected from three independent stimulated cultures (each 
genotype). Each independent culture was Western blotted once. β-actin was the loading control. 40µg protein 
loaded in each well. Exposures were between 2-3 mins. 
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Fig 6.9: Quantification of levels of phosphorylated β-catenin in WT and RAMP3 KO DKK1 and Wnt3A stimulated 
differentiated osteoblasts, after normalizing to respective β-Actin levels.  Wnt3A stimulation significantly increases 
the expression of phospo-β-catenin in both WTs and RAMP3 KOs. Levels of phosphorylated β-catenin were 
significantly higher in RAMP3 KO osteoblasts than WT osteoblasts when the prior DKK1 stimulation is of the 
concentration 200ng.ml (**), 100ng/ml (****) and 0ng/ml (*).Data was analysed using Two-way ANOVA test 
followed by post multiple comparison correction using Bonferroni’s test.  
Significance of p value: **** ≤0.0001, *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05 
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6.4 Discussion  
The principal objectives addressed in this body of work are investigating the effects of PTH, AM 
and AMY stimulation on RAMP2 and RAMP3 expression in WT 129/SvEv primary osteoblasts. 
Additionally we further determined the expression of total and phosphorylated β-catenin on Wnt3A 
and DKK1 stimulation in both WT and RAMP3 KO 129/SvEv primary osteoblasts using Western 
blotting. 
Our work gives novel evidence to support of a functional association of RAMP3 and RAMP2 with 
PTH, AM and AMY peptides in primary osteoblasts. We have successfully demonstrated that 
stimulation of primary osteoblasts with these peptides results in an increase in the expression of 
RAMP3 monomer in WT 129/SvEv primary osteoblasts (see Fig 6.1). PTH receptor 1 (PTHR1) is 
known to be expressed by osteoblasts and plays an important role in regulating osteoblast 
differentiation by inducing ERK1/2 phosphorylation (Datta et al 2010, Fermor & Skerry 1995). In 
contrast, expression of PTHR2 is bone is not yet clearly demonstrated to date, although it is 
known to be highly expressed in brain (Takasu et al 1999). There is evidence supporting that 
RAMP2 forms a heterodimer with PTHR1 whereas RAMP3 forms a heterodimer with PTHR2 
(Christopoulos et al 1999, Hay et al 2006). Since we have observed that RAMP3 expression is 
increased on PTH stimulation, it can be hypothesized that RAMP3 is also associated with PTHR1 
that is yet to be identified or that RAMP2 mediated PTHR1 downsignalling results in an increase 
in RAMP3 expression. Furthermore, it is also plausible that the PTHR1/RAMP3 association could 
be responsible for the catabolic skeletal regulation given that RAMP3 KO mice with enhanced 
skeletal phenotype would lack this receptor mediatied bone resorption. These mechanisms have 
yet to be clearly understood.  
Stimulation with both AM and AMY also resulted in an increase in the expression of RAMP3 
(Fig.6.1) suggesting that the primary WT 129/SvEv osteoblasts not only express a functional AM 
receptor 2: CLR/RAMP3 heterodimer but also express a functional AMY receptor 3: 
CTR/RAMP3 heterodimer in contradiction to previous reports that suggest CTR not being 
expressed in osteoblasts (Naot et al 2001, Naot & Cornish 2008).  
In our experiments, we observed that RAMP2 was expressed in two forms. A monomeric form 
which was ~13kDa and a higher molecular weigth form of ~55kDa (see Fig. 6.2 and 6.3). 
Interestingly on stimulation with PTH, AM and AMY, the WT primary osteoblasts expressed 
demonstrated a higher expression of both the 13kDa monomer and the 55kDa form in both WT 
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and RAMP3 KO osteoblasts compared to their non-stimulated controls. Additionally it was 
observed that levels of ~13kDa monomer were significantly lower in stimulated the RAMP3 KO 
osteoblasts compared to stimulated WT osteoblasts. It was more interesting to observe that this 
was opposite in the case of the ~55kDa form- that is., stimulated RAMP3 KO cells demonstrated 
significantly higher levels of ~55kDa form in comparison to stimulated WT primary osteoblasts. In 
2006, Nikitenko et al showed that only when co-transfected with RAMP3 or RAMP2, human CLR 
is expressed as a fully glycosylated 55kDa protein however CLR can have different glycosylation 
states that result in lower molecular weight of the protein (suplimentary figure 2 (Nikitenko et al 
2006)). Since it is known that RAMPs are capable of changing the glycosylation state of their 
partner GPCR (Nag et al 2012, Parameswaran & Spielman 2006), the 55kDa protein can 
therefore possibly be a heteromer of non-glycosylated GPCR and RAMP2. If this is true, what we 
observe in the RAMP3 KO primary osteoblasts is that RAMP2 compensates for the absence of 
RAMP3 to form a heterodimer with GPCR, hence the expression of RAMP2 monomers is reduced 
as the more monomers are used for forming heterdimers with GPCR in the RAMP3 KOs when 
compared to the WTs. This hypothesis is schematically represented in figure 6.10 below. 
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Fig 6.10: Schematic representation of the hypothesised compensatory mechanism between RAMP2 
and RAMP3 in the RAMP3 KO primary osteoblasts. 
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It can also be proposed that RAMP2 forms stable multimeric complex that dissociates to form 
monomers which inturn form heterodimers with several GPCRs on stimulation by respective 
peptides. There is evidence that in pufferfish, RAMPs except for RAMP1 and RAMP3 can form 
stable multimers that are expressed on the plasma membrane (Nag et al 2012). We also know 
that RAMP1 and RAMP3 form stable homodimers in the cytoplasm but presecnce of cytoplasmic 
RAMP2 homodimers are not yet reported (Sexton et al 2001). In concordace to these reports, we 
did not observe RAMP2 dimers in 129/SvEv primary osteoblasts. It is plausible that the RAMP1 
and 3 form homodimers where as RAMP2 forms tetramers. From our data we can propose that in 
RAMP3 KOs, there is an increased expression of RAMP2 tetramer to compensate for the 
absence of RAMP3 dimers in the cytoplasm so that RAMP2 monomers can further compensate 
for RAMP3 to form heterodimers with GPCRs. 
It should be noted that with only  20min stimulation period of the peptides, the quantified 
expressions of RAMPs in this study only reflects the change in state of dimerization of RAMPs i.e 
the change in hetero-dimer to monodimer state or vice versa but not the translational event. 
Increased duration of the stimulation or repeated stimulations for a longer period of time would not 
only enhance the effect of peptide stimulation on RAMP expression but also give a true reflection 
of the translation events post stimulation.  
With an aim to investigate the association between Wnt and RAMP3, we have determined novel 
characteristics of the Wnt/β-catenin pathway in the RAMP3 KO primary osteoblasts. We 
observed that the RAMP3 KO primary osteoblasts had a significantly higher expression of total β-
catenin which was accounted for by increased levels of active/phosphorylated β-catenin (see Fig. 
6.4 and 6.5). These findings are in concordance with previous reports of reduction of RAMP3 
expression on Wnt3A stimulation (Rohrs et al 2009). Further, with increasing concentrations of 
DKK1, we observed that in comparison to the WT osteoblasts, RAMP3 KOs require higher DKK1 
concentrations to reduce the amounts of endogenous phosphorylated β-catenin (Fig. 6.6 and 
6.7). Additionaly post DKK1 stimulation, an exogenous stimulation of 100ng/ml Wnt3A, resulted 
in significantly higher expression of phosphorylated β-catenin in the RAMP3 KO primary 
osteoblast compared to the WTs (Fig. 6.8 and 6.9). Given the evidence that Wnt signalling plays 
an important role in osteoblast differentiation (Glass et al 2005), we can suggest, that the 
RAMP3 KO mice have enhanced osteoblast differentiation which results from increased active 
phospho-β-catenin level acting throught the Wnt3A pathway/s. This hypothesis is supported by 
our findings reported in chapters 2 and 4. 
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In conclusion, we have successfully shown that RAMP2 and RAMP3 both respond to PTH, AM 
and AMY stimulation and that RAMP2 possibly compensates for RAMP3 in the RAMP3 KO 
osteoblasts to form heterodimers with GPCRs. We have also provided novel evidence of 
increased Wnt signalling in the RAMP3 KO osteoblasts that could potentially be responsible for 
the enhanced osteoblast differentiation observed in RAMP3 KOs. 
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Chapter 7: Expression of calcitonin receptor (CTR) in primary osteoblasts. 
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7.1 Introduction 
The Calcitonin family of peptides are known therapeutic targets for treating osteopenic skeletal 
disorders. The effects of CT family of peptides on osteoclasts and osteoblast have been studied 
for several decades. However, the research on expression of the receptors for CT family of 
peptides is limited. An in-depth review of the expression of receptors for CT peptides to date is 
discussed in Chapter 1. This chapter aims to address the conflicting literature evidence of 
expression of Amylin (AMY) receptor that comprises the Calcitonin receptor (CTR) and receptor 
activity modifying proteins (RAMPs), in osteoblasts.  
Effects of administration of AMY on the skeleton are studied in a number of local and systemic 
mice and rat models. Systemic administration of AMY reduction on PTH mediates resorption in 
neonatal mice (Alam et al 1993, Pietschmann et al 1993). A daily subcutaneous local 
administration of AMY(1-8) over the hemicalveria of mice resulted in a reduction of local bone 
resorption, where as a systemic administration of both full length and AMY (1-8), reduced the 
bone resorption indices and increased histomorphometric indices, suggesting that AMY affects 
both osteoclasts and osteoblasts (Cornish et al 1995, Cornish et al 1998a). 
In vitro effects of AMY on rat osteoclast cultures are reported to be due to the down regulation of 
osteoclast mobility (Alam et al. 1993). The expression of AMY receptors in osteoclasts is also 
well understood. The CTR is well established osteoclast marker (Hattersley & Chambers 1989). 
There is evidence of variable expression of CTR during osteoclastogenesis (Lerner 2006). In rat 
osteoblasts, Cornish et. al. reported that AMY induced proliferation at 10-11 M concentration is 
accompanied by increase in intracellular cAMP levels (Cornish et al 1995, Cornish et al 1999). 
Human osteoblast like cell proliferation is reported at concentrations between 10-9M and 10-6M 
along with increased osteocalcin expression on exposure to 1,25(OH)2D3 10-8M (Villa et al 
1997). This indicated the presence of an AMY receptor in osteoblasts. It is known that a 
traditional AMY receptor comprises CTR and one of the RAMP isoforms. 
The “CT receptor” was first identified in pig, in human and then rat (Albrandt et al 1993, Gorn et 
al 1992, Lin et al 1991, Martin et al 1995). The CTR transcription variants are classified as 
avian/teleost, artiodactyl and rat/human based on the biological and structural differences 
(Martin et al 1995). Human CTR transcript variants were cloned from BIN67 and T47D cells 
(Gorn et al 1992, Kuestner et al 1994). The shorter transcript variant expressed in T47D is 
predominantly expressed compared to the 16 amino acid longer variant is expressed in BIN67 
7 Chapter 7: Expression of calcitonin receptor – CTR, in primary osteoblasts. 
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cells (Gorn et al 1992, Kuestner et al 1994). The 16 amino acid insert resulted in ablation of 
intracellular calcium mobilization however there is no difference in affinity toward calcitonin 
between the two variants (Pondel 2000). When co-transfected with RAMP 1 and 3, CTR1 variant 
(16 aa insert minus) exhibited induced 125I rat AMY binding, although RAMP1-AMY receptor had a 
higher affinity toward salmon AMY and less to human  125I CT and rat  125I AMY, RAMP3-AMY 
receptor did not show this difference in affinity (Christopoulos et al 1999). A similar binding data 
was reported my Chen et al, CTR1 variant had higher affinity towards salmon 125I CT and less 
affinity towards human 125I CT and rat 125I AMY (Chen et al 1997b). 
When identifying the CT receptor in rat, Sexton et al identified two CTR transcripts, the known 
CTR1a (478 amino acids) and a longer transcript CTR1b (515 amino acids), from rat 
hypothalamic cDNA library. Subsequently these variants were also reported to be expressed in 
LLC-PK1, a porcine kidney epithelial cell line (Zolnierowicz et al 1994). The additional 37 amino 
acids in CTR1b variant results in a change in the second extracellular domain of CTR which is 
expected to affect the ligand-receptor interaction (Sexton et al 1993). Salmon CTR (125I-sCTR) 
shows a much higher affinity toward CTR1a compared to CTR1b and interestingly both rat and 
human CTR did not compete to bind to CTR1b even at as higher concentration as 10-6M 
(Houssami et al 1994, Martin et al 1995, Sexton et al 1993). It has been reported earlier that the 
CTR transcription variants expressed in rat are also expressed in mouse (Martin et al 1995). The 
tissue specific difference in expression in the variants may be targets for endogenous tissue 
specific isoforms of ligands (Martin et al 1995). 
The CTR1b transcript is expressed predominantly in the brain (hypothalamus, nucleus 
accumbens, cerebral cortex and brain stem) while CTR1a is expressed by several peripheral 
tissues CTR (Sexton et al 1993). In kidney CTR1a and 1b are both expressed however it is 
observed that CTR1b expression is very low compared to that of CTR1a. In 1986, Nicholson et al 
demonstrated that osteoclasts abundantly expressed CTR, while no CTR expression could be 
detected in osteoblasts (Nicholson et al 1986). In rat osteoclast, both CTR1a and CTR1b variants 
are expressed, however CTR1a expression predominates CTR1b expression (Ikegame et al 
1995). The rat osteosarcoma osteoblast like cell line UMR106-06 is reported to develop the 
ability to bind to salmon calcitonin only on prolonged maintenance, suggesting that this particular 
sub-clone of UMR106 cell line expresses CTR (Forrest et al 1985). It was reported that UMR106 
-06 expressed CTR1a transcript at mRNA level (Forrest et al 1985, Martin et al 1995). mRNA 
expression of CTR was also confirmed in the UMR106-06 cell line in a different study using RT-
235 
 
PCR and Northern Blot, although CTR was not expressed at mRNA level in primary rat osteoblast 
cultures (Naot et al 2001). In 2003, using RT-PCR, expression of CTR mRNA in primary human 
osteoblast culture was reported for the first time by Villa et. al. however this study had a small 
sample group (n=2) (Villa et al 2003). In a much more extensive study on primary human 
osteoblast cultures (n=16) CTR mRNA was not detected by real time PCR (Naot & Cornish 
2008).  
RAMP2 but neither RAMP1 nor RAMP3, is expressed in pure osteoclast like cultures derived from 
mouse bone marrow co-culture and spleen (Nakamura et al 2005). This implies that the AMY 
activity in osteoclasts, is predominantly due to the receptor that comprises the CTR-RAMP2 
heterodimer. High RAMP1, less RAMP2 and no RAMP3 mRNA expression in primary human 
osteoblast culture have been reported earlier (Villa et al 2003). RAMP2 mRNA was highly 
expressed in human bone marrow cultures which could account for the RAMP2 expression on 
osteoclast (Naot & Cornish 2008). Osteoblastic cell line MC3T3-E1 expresses all the three 
RAMPs however, the expression of RAMP1 and RAMP2 but not RAMP3 mRNA increases on 
dexamethasone treatment (Uzan et al 2004). RAMP1 is also expressed in human osteosarcoma 
cell line MG63 (Kawase et al 2003). A summary of CT peptide receptor expression in osteoclast 
and osteoblast is illustrated in Fig. 7.1 below. 
 
 
 Fig 7.1: A schematic representation summarising the expression of CT family of peptide receptors in osteoclasts 
and osteoblast. Osteoclasts express CTR, CLR and RAMPs hence all the four CT peptides affect osteoclasts. 
However Osteoblasts express RAMPs and CLR hence should only be affected by CGRP and ADM only. AMY 
induces proliferation of osteoblast, but the mechanisms remain unknown. 
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Determining and characterising AMY receptors in osteoblasts is essential as the mechanism/s by 
which AMY induces proliferation of osteoblasts remain unknown. Moreover, CTR is a well-
established osteoclast marker and is used in many studies. If CTR is expressed in osteoblasts, 
our fundamental understanding of the role of calcitonin and its receptor in the skeleton will be 
altered. The expression of RAMP isoforms in osteoblasts, during differentiation, is detailed in 
chapter 5. In this chapter we focus on the expression of the GPCR CTR in differentiating primary 
osteoblasts. 
Since expression of CTR in osteoblast remains debated to date, we hypothesised that 
osteoblasts either express a novel AMY receptor that does not comprise CTR, or that the CTR 
in osteoblastic AMY receptor is a transcript variant of the known full length CTR. 
The objectives were: 
1) To determine whether primary calvarial osteoblasts from WT 129/SvEv mice expressed 
CTR or CTR variants that formed an AMY receptor. 
2) To compare the sequence of the CTR cDNA sequence to known CTR variants (if 
expressed). 
3) To determine if both the WT and RAMP3 KO primary osteoblasts expresses known or 
novel CTR variant protein during differentiation  
4) To determine if the CTR protein expression profile is different in WT and RAMP3 KO 
primary osteoblasts during differentiation. 
5) To determine if a CTR variant expressed in WT and RAMP3 KO primary osteoblasts, 
does it respond to Amylin stimulation. 
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7.2 Methods and materials 
7.2.1: Protein sample preparation 
7.2.1.i Total cell lysate protein from differentiating primary osteoblasts: 
Detailed calvarial primary culture protocol is described in Section 5.2. Total protein was collected 
from differentiating primary osteoblasts of WT (SVEV/129) and RAMP3 KO genotype on day 0, 
5, 10, 15 and 20 of differentiation. One T25 flask each culture was harvested at every time point. 
The medium was removed and the cells were washed in PBS. 200μl ice-cold NP40 lysis buffer 
(recipe in appendix) having fresh protease inhibitor cocktail 1X (PIC) was added to the cells and 
the cells were scraped and collected in 1.5ml tubes. This homogenate was then sonicated on ice 
at 10μm for 10 short pulses using a probe sonicator (Soniprep 150, Sanyo, Japan). The final 
supernatant was stored as aliquots at -20˚C.  
 
7.2.1.ii Total cell lysate protein from basal and AMY stimulated primary osteoblasts: 
Detailed protocol of harvesting protein from stimulated osteoblasts is described in section 6.2.1 
and 6.2.2. Briefly, WT and RAMP3 KO primary osteoblasts were differentiated for 20 days and 
stimulated with 10nM working concentration of full length AMY peptide for 20 min prior to 
harvesting cells. Cell harvesting protocol is discussed in the above section 7.2.1.i. 
 
7.2.1.iii Total brain lysate protein a positive control: 
Whole brain homogenates from previously snap frozen WT (SVEV/129) mice was prepared for 
Western blotting. The mouse brain (snap frozen tissue stored at -80oC) was weighed and allowed 
to soften at -20oC for an hour prior being chopped into small pieces. The chopped tissue was 
placed in a 7ml tissue grinder tube and 15 volumes of ice-cold 0.25 M Sucrose/Buffer A 
containing freshly prepared protease inhibitor cocktail 1X (PIC), was added. The tissue was first 
homogenized by 15 passes of the loose pestle and then by 15 passes of the tight pestle. This 
homogenate was centrifuged at 600 g for 5mins at 4˚C and the supernatant was retained. The 
supernatant was then sonicated using a probe sonicator (Soniprep 150, Sanyo, Japan) by 10 
brief pulses at 10μm before aliquoting and snap freezing it in liquid nitrogen. The samples were 
stored as aliquots at -20oC. 
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7.2.2 Western Blotting for CTR: 
Detailed protocol for SDS PAGE and immuno-blotting is described in Section 7.2.2. To determine 
CTR protein in WT (SVEV) and RAMP3 KO differentiating primary osteoblast cell lysate, SDS 
PAGE was carried out in 7% resolving gel with 50µg of protein was loaded in each well. Primary 
antibody - rabbit CTR antibody (Abcam®, Cambridge, UK) against 476-496 aa residues of rat 
CTR was used at 1:200 dilution and made up in PBST. This primary antibody recognised both 
CTR1a and CTR1b isoforms of CTR. Secondary antibody - goat antirabbit-HRP (Dako®, Aligent 
Technologies Company, Cambridge, UK) was used as a 1:3000 dilution made up in 5% blocking 
solution (skimmed milk in PBST w/v). 
 
7.2.3 RNA sample preparation: 
7.2.3.i Total RNA from differentiating primary osteoblasts: 
Detailed calvarial primary culture protocol is described in Section 5.2. Total RNA was collected 
from differentiating calvarial primary osteoblasts of WT (SVEV/129) and RAMP3 KO genotype on 
day 20 of differentiation. One T25 flask each culture was harvested at every time point. The 
medium was removed and 500μl of TRIZOL® reagent was added to the cells. The cells were 
collected in 1.5 ml tubes by scraping. Total RNA was then extracted using the protocol provided 
by the manufacturer (Invitrogen™). RNA in each sample was quantified in NanoDrop® (Thermo 
Scientific, Wilmington, USA), a micro-volume UV-vis spectrophotometer, at A260 purity of 
preparation checked by determining the 260/280 ratio. Samples were then stored at -200C. 
 
7.2.3.ii Total RNA from mouse brain – positive control: 
Total RNA was extracted from previously snap frozen WT (SVEV/129) mouse. The mouse brain 
(snap frozen tissue stored at -80˚C) was weighed and allowed to soften at -20oC for an hour 
prior being chopped into small pieces. The 100mg chopped tissue was placed in a 7 ml tissue 
grinder tube and 1ml of ice-cold TRIZOL® reagent was added. The tissue was first homogenized 
by 15 passes of the loose pestle and then by 15 passes of the tight pestle. This homogenate was 
used to extract total RNA according to manufacturer’s guidelines (Invitrogen™). RNA was 
quantified and stored similar to total RNA from cell cultures. 
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7.2.4 Reverse transcription to generate cDNA: 
cDNA was generated from total RNA samples using ABI high capacity RNA – cDNA kit (Applied 
Biosciences, Life Technologies™, California, USA). For every 1μg of RNA a 20μl reaction mix was 
prepared by adding 10μl of 2X RT buffer mix, 1μl of 20X RT enzyme mix and Nuclease free water 
(up to 20μl) to the RNA sample. This mix was then set up in the following PCR reaction:  
1) 37 0C – 1hr  
2) 95 0C – 5 min  
3) 4 0C – hold  
cDNA (end product) was then stored at -200C. 
 
7.2.5 End point PCR:  
GoTaq® DNA Polymerase kit (Promega Cooperation, Madison, USA) was used to detect CTR 
expression in osteoblast cDNA. Each 25μl reaction mix contained 5μl of 5X Green GoTaq® 
reaction buffer, dNTP at a final concentration of 0.2mM (10mM each dNTP stock), MgCl2 at a  
final concentration of 1.5mM (25mM each stock) and GoTaq® DNA Polymerase 2.5units. 
Proportions for PCR mix mentioned below along with the PCR conditions. PCR amplicons were 
visualized by electrophoresis in 1.5% Agarose gel (Sigma®) prepared in Tris-base-EDTA buffer 
and containing 0.5ug/ml ethidium bromide. 
 
PCR reaction mix: 
5X Green GoTaq® reaction buffer: 5μl 
MgCl2: 0.75μl 
dNTP mix : 0.5μl 
Forward Primer: 1.25μl 
Reverse primer: 1.25μl 
GoTaq® DNA Polymerase: 0.5μl 
cDNA: 1-2μg 
          Nuclease free water: upto 25μl 
 
 
 
PCR conditions: 
1) 950C - 3min 
2) 950C - 30 sec 
3) 550C - 30 sec (for all CTR primer pairs) 
4) 720C - 30 sec (repeated 2-4, 35 cycles) 
5) 720C - 5min 
6) Hold at 40C 
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7.2.6 Determining expression and sequence of CTR cDNA in calvarial, primary osteoblasts: 
The CTR gene comprises 16 exons. The protein coding region spans from the latter half of exon 3 
to the first half of exon 16 (Fig. 7.2). Expression and sequence of full length CTR cDNA in WT 
osteoblast was determined using pairs of overlapping primers each of which resulted in an 
approximately 350bp amplicon. 17 primer pairs were designed such that each primer pair would 
re-amplify about 150bp of previous primer pair amplicon followed by a new leading 150bp stretch. 
Overlapping amplification helped confirm the cDNA sequences. A schematic representation of the 
use of overlapping primers is illustrated in figure below (Fig.7.2). Since all the primers amplified 
approximately 350bps of the cDNA, absence of amplicon or change in the sized of the expected 
amplicon indicated the change in the cDNA sequence of osteoblast. Primer sequence and 
amplification regions are detailed in Table 7.1 overleaf. 
 
 
 
 
 
 
Fig 7.2: A schematic representation of the experimental design. Overlapping primers amplified overlapping regions 
which helped confirmed the cDNA sequence whilst amplification. In the above schematic example, Primer pair 1 f 
(forward) and r (reverse) amplifies the region 1 to 300, primer pair 2 f and r amplifies region 150 to 450 so on 
and so forth. In total 17 primer pairs where designed to facilitate sequencing of the full length CTR cDNA.  
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Primer ID Primer Sequence Tm Position - mCalcr1b mRNA Amplicon 
mCTR1f 5’ GTCAGGAAAAGAAGTGCCCG 3’ 59.12 0C 83 - 108 
337bps mCTR1r 3’ CGCAGACTTCACTGGGCATC 5’ 61.36 0C 360 - 341 
mCTR2f 5’ GGCTTTCAGTGGAGAAGGGG 3’ 60.32 0C 240 - 259 
360bps mCTR2r 3’ TTTGCGGAGATTCCGCCTTT 5’ 60.61 0C 599 - 580 
mCTR3f 5’ CTGAGCTGTGCCCAGACAT 3’ 59.70 0C 433 - 451 
341bps mCTR3r 3’ CATAGCATTTGTACTGAGCATCCA 5’ 59.18 0C 774 - 751 
mCTR4f 5’ GGTTCCTTCTCGTGAACAGGT 3’ 59.93 0C 610 - 630 
350bps mCTR4r 3’ CCACTCTCCATTTTCATCACAGT 5’ 58.67 0C 939 - 957 
mCTR5f 5’ TTCCTGTACTTGGTTGGCCG 3’ 60.25 0C 720 - 739 
357bps mCTR5r 3’ GGAGTGACCCACAAGAGCC 5’ 60.00 0C 1076 - 1058 
mCTR6f 5’ GATGTGCTGGGACGACACTC 3’ 60.74 0C 842 - 861 
328bps mCTR6r 3’ GAACATGTGCTTGTGCAAGGT 5’ 59.93 0C 1169 - 1149 
mCTR7f 5’ TAGACACCCTGACAGCAACC 3’ 59.31 0C 962 - 981 
339bps mCTR7r 3’ TCCCACTGCATTGTCCACAT 5’ 59.59 0C 1300 - 1281 
mCTR8f 5’ TGGTTGCTTCCATGCTGATCT 3’ 59.99 0C 1093 - 1113 
343bps mCTR8r 3’ TCGCAGAGCATCCAGAAGTAG 5’ 59.59 0C 1435 - 1415 
mCTR9f 5’ TGAGGTTGTGCCCAATGGAG 3’ 60.25 0C 1214 - 1233 
346bps mCTR9r 3’ ACGAGTGATGGCGTGGATAA 5’ 59.18 0C 1559 - 1540 
mCTR10f 5’ GAGTGCACACGAGGGAAAGA 3’ 59.97 0C 1322 - 1341 
358bps mCTR10r 3’ GCGGACAATGTTGAGAAGAAAGA 5’ 59.50 0C 1679 - 1657 
mCTR11f 5’ CATGGCTGTGTTTACCGACG 3’ 59.56 0C 1463 - 1482 
329bps mCTR11r 3’ ACACAACAAACTGGATCCCCA 5’ 59.78 0C 1791 - 1771 
mCTR12f 5’ AGTGCAGAAACCCACTTGCT 3’ 60.11 0C 1590 - 1609 
323bps mCTR12r 3’ TGCACCTCATGGTTGCAGAA 5’ 60.18 0C 1912 - 1893 
mCTR13f 5’ AGATGAGGCAAACCCACGAG 3’ 60.04 0C 1693 – 1712 
344bps mCTR13r 3’ ATCTGGCTCAGCGAAGGCTA 5’ 61.05 0C 2036 - 2017 
mCTR14f 5’ TCCAACAAGGTGCTTGGGAA 3’ 59.74 0C 1806 - 1825 
345bps mCTR14r 3’ GGATGCGTCTTGCTGGATGA 5’ 60.46 0C 2150 - 2133 
mCTR15f 5’ CCAGTGGACGCAGTTCAAGA 3’ 60.25 0C 1928 - 1947 
322bps mCTR15r 3’ CCTGGGAGGATGGGAATCAC 5’ 59.52 0C 2249 - 2230 
mCTR16f 5’ CAGGAACCACGGAATCCTCC 3’ 60.11 0C 2061 - 2080 
336bps mCTR16r 3’ TCCAGGATGAATGATGGAGTTCA 5’ 59.22 0C 2396 - 2374 
mCTR17f 5’ AAGCCACCCCAAGCATTGT 3’ 60.51 0C 2162 - 2180 
350bps mCTR17r 3’ CTCAACGGTACAAATGGCTCAA 5’ 59.19 0C 2511 - 2490 
Table 7.1:  Primer sequences for determining full-length mouse osteoblast CTR sequence. 
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7.2.7 Sequencing and in-silico analysis of osteoblast CTR cDNA:  
PCR products from each primer pair was sequenced in Applied Biosystems' 3730 DNA Analyser 
using BIgDye v3.1 by the Core Genomic Facility (University of Sheffield). Sequences were 
checked and corrected for misreads using the FinchTV TM (Geospiza Inc. Seattle, WA). Using the 
nucleotide query available at NCBI’s basic local alignment search tool (BLAST), all the sequences 
were then checked for sequence similarity against mouse genomic and transcript database. 
Dissimilarities in the osteoblast CTR sequence, when compared to known full length CTR 
(Ensembl name Calcr-001) were identified using BLAST2n. Whole osteoblast CTR cDNA 
sequence was predicted by “stitching” together all the overlapping sequences in silico , using the 
overlapping regions as references. This whole osteoblast CTR cDNA sequence was aligned 
against two known protein coding CTR isoforms CTR1a (Ensembl name Calcr-001; Transcript ID 
ENSMUST00000075644) and CTR1b (Ensembl name Calcr-003; Transcript ID 
ENSMUST00000171613), using multiple sequence alignment tool CLUSTALW (EBM-EBI). 
Protein molecular weight of the known CTR isoforms and the osteoblast CTR isoform where 
predicted and compared online using ‘Protein Molecular Weight’ at www.bioinformatics.org. 
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7.3 Results 
7.3.1 PCR using overlapping primer pairs: 
Amplification for 17 overlapping regions across the full-length CTR cDNA was carried out in three 
independent WT primary osteoblast cultures. Primer pairs 1, 2, 3, 4, 5, 6, 8, 9, 11, 12, 13, 14, 15, 
16 and 17 amplified expected CTR regions in all three WT cultures. Amplicons for primer pair 8 
and 9 were smaller than expected amplicon size. Primer pairs 7 and 10 did not amplify cDNA in 
any of the cultures (Fig. 7.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7.3: PCR amplicons for each primer pair (1-17) amplified in brain cDNA (top panel) and WT primary 
osteoblast cDNA (bottom panel). Lane 1 was loaded with 5µL of O’RangeRuler 200 bp DNA Ladder (Thermo 
Scientific™). Lanes 2 to lane 18 are loaded with PCR products of primer 1 to primer 17 respectively. Lane 19 is 
loaded with non-template control. Primer pairs 7 and 10 amplify cDNA in brain cDNA but not in primary osteoblast 
cDNA (red asterisks). Primer pairs 8 and 9 amplify ~200bps cDNA and ~340bps cDNA amplicons in brain 
however in primary osteoblast cDNA only the smaller ~200bps amplicons were amplified (marked on the image). 
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200 bps 
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* * Small  
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7.3.2 Sequencing:  
Each of the amplicons was sequenced and the sequences were checked in software Finch TV™. 
Sequencing results, of a representative WT primary osteoblast cDNA for each amplicon are 
summarized in the appendix section 10.1.4.i. 
7.3.3 Generating full length osteoblast CTR cDNA sequence in-silico from short overlapping 
PCR fragments and predicting protein sequence:  
Example: Representative example of joining amplicon sequences: primer pairs 3,4 and 5: 
 
Step 1: Identifying common sequences/regions to overlap (blue highlights): 
Amplicon 3 sequence:  
NNGGCATAAACTGAAAGGTGAGTGCTTATATAAGCATCGCTTATGGAAGGAGAAGAAACCGAGGGAGCAGGGCTA
CCACTTAGAGGATTTGAAAATGACTCCAAGGAGGTCCAGAGTGAAAAGGCGGAATCTCCGCAAACCGAAGATGAG
GTTCCTTCTCGTGAACAGGTTCACCCTGCTGCTCCTGCTCCTAGTGAGCCCAACTCCAGTTCTTCAGGCTCCTAC
CAATCTCACTGACTCCGGCCTTGATCAGGAGCCATTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCA
GTACAAATGCTATGA  
 
Amplicon 4 sequence: 
GGGGGCCCGGCTCTAGTGAGCCACTCCAGTTCTTCAGGCTCCTACCAATCTCACTGACTCCGGCCTTGATCAGGA
GCCATTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCAGTACAAATGCTATGACCGGATTCATCAGTT
GCCCTCTTATGAAGGAGAAGGTCTGTACTGCAACCGCACCTGGGATGGCTGGATGTGCTGGGACGACACTCCCGC
TGGAGCCACAGCCTATCAGCACTGCCCTGACTACTTCCCGGACTTTGACACAGCAGAAAAGGTTTCAAAATACTG
TGATGAAAAGGGAGAGTGG 
 
Amplicon 5 sequence: 
NNNNNGGTGGAAGGAAATGAAAATGACCGGATTCATCAGTTGCCCTCTTATGAAGGAGAAGGTCTGTACTGCCCT
TTTACCTGGGATGGCTGGATGTGCTGGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGCCCTGACTAC
TTCCCGGACTTTGACACAGCAGAAAAGGTTTCAAAATACTGTGATGAAAATGGAGAGTGGTTTAGACACCCTGAC
AGCAACCGAACCTGGTCCAACTATACTCTGTGCAACGCTTTCACTTCTGAGAAACTGCAAAATGCGTACGTTCTT
TATTACCTGGCTCTTGTGGGTCACTCC 
 
Step 2: Aligning the common overlapping regions: 
NNGGCATAAACTGAAAGGTGAGTGCTTATATAAGCATCGCTTATGGAAGGAGAAGAAACCGAGGGAGCAGGGCTA
CCACTTAGAGGATTTGAAAATGACTCCAAGGAGGTCCAGAGTGAAAAGGCGGAATCTCCGCAAACCGAAGATGAG
GTTCCTTCTCGTGAACAGGTTCACCCTGCTGCTCCTGCTCCTAGTGAGCCCAACTCCAGTTCTTCAGGCTCCTAC
CAATCTCACTGACTCCGGCCTTGATCAGGAGCCATTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCA
GTAC........ 
.........................................................GGATGCTCAGTACAAATG
CTATGACCGGATTCATCAGTTGCCCTCTTATGAAGGAGAAGGTCTGTACTGCAACCGCACCTGGGATGGCTGGAT
GTGCTGGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGCCCTGACTACTTCCCGGACTTTGACACAGC
AGAAAAGGTTTCAAAATACTGTGATGAAAAGGGAGAGTGG...................................
.............................AAAATGGAGAGTGGTTTAGACACCCTGACAGCAACCGAACCTGGTC
CAACTATACTCTGTGCAACGCTTTCACTTCTGAGAAACTGCAAAATGCGTACGTTCTTTATTACCTGGCTCTTGT
GGGTCACTCC 
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Step 3: Joining the sequences to obtain a larger cDNA fragment sequence  
NNGGCATAAACTGAAAGG.TGAGTGCTTATATAAGCATCGCTTATGGAAGGAGAAGAAACCGAGGGAGCAGGGCT
ACC 
ACTTAGAGGATTTGAAAATGACTCCAAGGAGGTCCAGAGTGAAAAGGCGGAATCTCCGCAAACCGAAGATGAGGT
TCCTTCTCGTGAACAGGTTCACCCTGCTGCTCCTGCTCCTAGTGAGCCCAACTCCAGTTCTTCAGGCTCCTACCA
ATCTCACTGACTCCGGCCTTGATCAGGAGCCATTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCAGT
ACAAATGCTATGACCGGATTCATCAGTTGCCCTCTTATGAAGGAGAAGGTCTGTACTGCAACCGCACCTGGGATG
GCTGGATGTGCTGGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGCCCTGACTACTTCCCGGACTTTG
ACACAGCAGAAAAGGTTTCAAAATACTGTGATGAAAAGGGAGAGTGGTTTAGACACCCTGACAGCAACCGAACCT
GGTCCAACTATACTCTGTGCAACGCTTTCACTTCTGAGAAACTGCAAAATGCGTACGTTCTTTATTACCTGGCTC
TTGTGGGTCACTCC 
All the short overlapping PCR fragments were stitched together and the whole osteoblast CTR 
variant sequence was predicted in-silico. This osteoblast CTR variant cDNA sequences had a 
1491bp translating cDNA region, without exon 10 sequence. Start codon and stop codon were 
identified to determine the reading frame. The cDNA sequence in GenBank format is as follows:  
 
 
     1 ACAGAGGATT TGAAAATGAC TCCAAGGAGG TCCAGAGTGA AAAGGCGGAA TCTCCGCAAA                                                                   
    61 CCGAAGATGA GGTTCCTTCT CGTGAACAGG TTCACCCTGC TGCTCCTGCT CCTAGTGAGC                                                                    
   121 CCAACTCCAG TTCTTCAGGC TCCTACCAAT CTCACTGACT CCGGCCTTGA TCAGGAGCCA                                                                    
   181 TTCCTGTACT TGGTTGGCCG CAAGAAGCTG CTGGATGCTC AGTACAAATG CTATGACCGG                                                                    
   241 ATTCATCAGT TGCCCTCTTA TGAAGGAGAA GGTCTGTACT GCAACCGCAC CTGGGATGGC                                                                    
   301 TGGATGTGCT GGGACGACAC TCCCGCTGGA GCCACAGCCT ATCAGCACTG CCCTGACTAC            
   361 TTCCCGGACT TTGACACAGC AGAAAAGGTT TCAAAATACT GTGATGAAAA TGGAGAGTGG                                                                   
   421 TTTAGACACC CTGACAGCAA CCGAACCTGG TCCAACTATA CTCTGTGCAA CGCTTTCACT                                                                    
   481 TCTGAGAAAC TGCAAAATGC GTACGTTCTT TATTACCTGG CTCTTGTGGG TCACTCCTTG                                                                    
   541 TCGATTGCTG CTTTGGTTGC TTCCATGCTG ATCTTCTGGA TTTTCAAGAA CCTTAGCTGC                                                                    
   601 CAGAGGGTGA CCTTGCACAA GCACATGTTC CTTACTTATA TTCTGAATTC TATCATTATC                                                                    
   661 ATCATCCACC TGGTTGAGGT TGTGCCCAAT GGAGATCTGG TGCGGCGGGA TCCT.ATAAGT 
   721 TGCAAGGTTC TACACTTTTT ACATCAGTAC ATGATGTCTT GCAACTACTT CTGGATGCTC                                                                    
   781 TGCGAGGGGA TCTATCTTCA TACTCTGATT GTCATGGCTG TGTTTACCGA CGAGCAACGC                                                            
   841 CTACGCTGGT ACTATCTTCT TGGCTGGGGG TTCCCGATAG TGCCAACCAT TATCCACGCC                                                                    
   901 ATCACTCGTG CCCTCTACTA CAACGACAAC TGCTGGCTGA GTGCAGAAAC CCACTTGCTT 
   961 TACATCATCC ATGGACCCGG TCATGGTGGC TCTGGTGGTC ACTTCTTCTT TCTTCTCAAC 
  1021 ATTGTCCGCG TGCTTGTGAC CAAGATGAGG CAAACCCACG AGGCCGAGTC CTACATGTAC     
  1081 CTGAAGGCTG TGAAGGCCAC CATGGTCCTT GTGCCCCTGC TGGGGATCCA GTTTGTTGTG                                                              
  1141 TTTCCCTGGA GGCCCTCCAA CAAGGTGCTT GGGAAGATCT ATGATTATCT CATGCACTCT 
  1201 CTGATTCATT TCCAGGGATT CTTTGTGGCG ACTATCTACT GCTTCTGCAA CCATGAGGTG                                                              
  1261 CAAGTCACCC TGAAGCGCCA GTGGACGCAG TTCAAGATCC AGTGGAGCCA ACGCTGGGGA                                                             
  1321 AGGCGCCGCC GCCCCACCAA CCGCGTAGTT AGTGCTCCTC GGGCTGTAGC CTTCGCTGAG                                                                                                                               
  1381 CCAGATGGCC TCCCCATTTA CATCTGCCAT CAGGAACCAC GGAATCCTCC AATCAGCAAC                                                                  
  1441 AACGAAGGCG AGGAGAGTAC TGAAATGATC CCCATGAACG TCATCCAGCA AGACGCATCC 
  1501 GCTTGAATGT GAAGCCACCC CAAGCATTGT GATCCACTGA GCCTTCATTT CCTGGGGAAA 
 
Start codon 
Stop codon 
Antibody 
binding 
region in 
the 
translated 
protein 
No exon 10  
* 
UTR 
UTR 
Full length osteoblast CTR cDNA sequence:  
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This sequence was then aligned on NCBI using Basic logic alignment tool – BLAST and 
BLAST2n. First the osteoblast CTR cDNA sequence was aligned against the full length CTR 
variant, Calcr 001 sequence using BLAST2n (Zhang et al 2000). The alignment results showed 
a break in the alignment of the two sequences at the exon 10 sequence region. This was 
represented in the dot matrix plot. The graphical summary and the dot matrix plot for the 
alignment of the two sequences is presented in Figure 7.4. Apart from exon 10 region the two 
sequences showed 99% identities in their alignment (Table 7.2). For the detailed BLAST 
sequence alignment please ref appendix page 9.1.4.ii. 
 
   
 
 
 
 
BLAST2n of 
osteoblast CTR 
against : 
Sequence ID Length Match Score Expect Identities Gaps 
Full length Calcr 
001 mose 
variant. 
lcl|46219 
Range 1: 1306 to 
2151 
Range 2: 481 to 
1196 
2460 2 1552 
bits(840) 
0.0 845/847(99
%) 
2/847(0
%) 
1323 
bits(716) 
0.0 716/716(10
0%) 
0/716(0
%) 
B 
A 
Fig 7.4: NCBI BLAST2n result. The predicted osteoblast CTR cDNA sequence is aligned against Calcr001 – full 
length CTR sequence. Image A, is screen shot of the graphical summary of the BLAST2n hits. Image B, is a 
screen shot of the dot matrix plot for the alignment between the two sequences. 
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Table 7.2: BLAST2n alignment result for osteoblast CTR and full length CTR variant Calcr001 
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The osteoblast CTR sequence was further aligned against the whole mouse genomic and 
transcript database. Four BLAST hits were obtained (Fig. 7.5). Two of which were against mouse 
transcript database; Mus musculus CTR variant 1a and 1b.The alignment results are briefly 
represented summarised in table 7.3. The detailed BLAST results are attached in the appendix 
section 9.1.6.ii (Morgulis et al 2008, Zhang et al 2000). 
 
 
 
 
 
BLAST hit Mouse 
transcripts 
Sequence ID Length Match Score Expect Identities Gaps 
Mus musculus 
calcitonin 
receptor (Calcr), 
transcript variant 
1a, mRNA 
ref|NM_001042725.
1 
Range 1: 291 to 1850 
3471 1 
2870 
bits(1554) 
0.0 
1559/1561 
(99%) 
2/1561 
(0%) 
Mus musculus 
calcitonin 
receptor (Calcr), 
transcript variant 
1b, mRNA 
ref|NM_007588.2| 
Range 1: 1365 to 
2210 
Range 2: 540 to 1255 
3831 2 
1552 
bits(840) 
0.0 
845/847 
(99%) 
2/847 
(0%) 
1323 
bits(716) 
0.0 
716/716 
(100%) 
0/716 
(0%) 
 
 
 
Fig 7.5: Screen shot of the graphical summary of NCBI BLAST alignment of osteoblast CTR cDNA sequence 
against mouse genomic and transcript database 
Table 7.3 Osteoblast CTR cDNA sequence query, BLAST hits for mouse transcript database 
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7.3.4 PCR for full length CTR: 
Full length CTR expression was confirmed by a PCR with forward Primer 4 and reverse primer 7. 
Three independent WT osteoblast cDNA preparations, RAW 264 cell (generously provided by Dr. 
Grabowski, University of Sheffield) cDNA preparation and mouse brain cDNA preparation were 
tested for full length cDNA expression. It was observed that all the three WT osteoblast cDNA 
preparations expressed a product ~1700bps. Raw 264 cell and mouse brain cDNA preparations 
both amplified 2 products, one ~1700bps and other ~2200bps (Fig. 7.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.0 kbps 
1.5 kbps 
1.0 kbps 
2.5 kbps 
3.0 kbps 
5.0 kbps 
4.0 kbps 
900 bps 
800 bps 
700 bps 
600 bps 
Fig 7.6: PCR amplicons for full length CTR amplicon amplified by forward primer 4 and reverse primer 17. Lane 1 
was loaded with 1kbp DNA ladder Lanes 2, 3 and 4 are three independent WT osteoblast culture cDNA preps. 
Lane 6 is RAW264 cDNA and lane 8 is mouse brain cDNA. All the WT osteoblast expressed a ~1.7kbp amplicon 
and both the RAW264 and mouse brain cDNA expressed two amplicons ~1.7kbp and ~2.2 bps. In RAW264, the 
higher 2.2kbp band intensity is noticeably higher compared to the lower amplicon. 
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7.3.5 Predicting osteoblast CTR variant protein sequence: 
The protein coding sequence determined using of the reading frame was used to predict the 
protein sequence of CTR expressed in osteoblast (see section 7.3.3). This osteoblast CTR 
variant was 496 amino acids long and 37 amino acids shorter than the full length CTR protein. 
The molecular weight was predicted to be 57.95 kDa using : The Sequence Manipulation Suite: 
Protein Molecular Weight (Stothard 2000).The osteoblast protein sequence in FASTA format is : 
 
>MouseCTRosteoblast 
  
MTPRRSRVKRRNLRKPKMRFLLVNRFTLLLLLLVSPTPVLQAPTNLTDSGLDQEPFLYLV 
GRKKLLDAQYKCYDRIHQLPSYEGEGLYCNRTWDGWMCWDDTPAGATAYQHCPDYFPDFD 
TAEKVSKYCDENGEWFRHPDSNRTWSNYTLCNAFTSEKLQNAYVLYYLALVGHSLSIAAL 
VASMLIFWIFKNLSCQRVTLHKHMFLTYILNSIIIIIHLVEVVPNGDLVRRDPISCKVLH 
FLHQYMMSCNYFWMLCEGIYLHTLIVMAVFTDEQRLRWYYLLGWGFPIVPTIIHAITRAL 
YYNDNCWLSAETHLLYIIHGPVMVALVVNFFFLLNIVRVLVTKMRQTHEAESYMYLKAVK 
ATMVLVPLLGIQFVVFPWRPSNKVLGKIYDYLMHSLIHFQGFFVATIYCFCNHEVQVTLK 
RQWTQFKIQWSQRWGRRRRPTNRVVSAPRAVAFAEPDGLPIYICHQEPRNPPISNNEGEE 
STEMIPMNVIQQDASA 
 
 
The osteoblast CTR protein sequence was aligned against the whole mouse CTR protein 
sequence, mouse CTR 1b protein sequence and mouse CTR1a protein sequence to determine the 
differences and similarities between all the registered CTR sequences on the mouse protein 
database. Multiple sequence alignment tool CLUSTALW 2.1 was used to perform stack alignment 
for all the 4 sequences (Higgins & Sharp 1988, Thompson et al 1994).  
CLUSTALW output showed that the osteoblast CTR protein is identical to the traditional calcitonin 
receptor CTR1a, which is also 496 amino acids long and does not have exon 10 sequence in its 
cDNA, hence missing 37amino acids. This missing 37 amino acids’ region is clearly observed in 
the CLUSTAW output (Fig. 7.7). On the other hand CTR variant 1b is exactly similar to the full 
length CTR protein sequence and is 533 amino acids long.  
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CTRwholeMouse_AAI19273.1       MTPRRSRVKRRNLRKPKMRFLLVNRFTLLLLLLVSPTPVLQAPTNLTDSG 50 
CTR1aMouse_NP_001036190.1      MTPRRSRVKRRNLRKPKMRFLLVNRFTLLLLLLVSPTPVLQAPTNLTDSG 50 
CTRmouseosteoblast             MTPRRSRVKRRNLRKPKMRFLLVNRFTLLLLLLVSPTPVLQAPTNLTDSG 50 
CTR1bMouse_NP_031614.2         MTPRRSRVKRRNLRKPKMRFLLVNRFTLLLLLLVSPTPVLQAPTNLTDSG 50 
                               ************************************************** 
 
CTRwholeMouse_AAI19273.1       LDQEPFLYLVGRKKLLDAQYKCYDRIHQLPSYEGEGLYCNRTWDGWMCWD 100 
CTR1aMouse_NP_001036190.1      LDQEPFLYLVGRKKLLDAQYKCYDRIHQLPSYEGEGLYCNRTWDGWMCWD 100 
CTRmouseosteoblast             LDQEPFLYLVGRKKLLDAQYKCYDRIHQLPSYEGEGLYCNRTWDGWMCWD 100 
CTR1bMouse_NP_031614.2         LDQEPFLYLVGRKKLLDAQYKCYDRIHQLPSYEGEGLYCNRTWDGWMCWD 100 
                               ************************************************** 
 
CTRwholeMouse_AAI19273.1       DTPAGATAYQHCPDYFPDFDTAEKVSKYCDENGEWFRHPDSNRTWSNYTL 150 
CTR1aMouse_NP_001036190.1      DTPAGATAYQHCPDYFPDFDTAEKVSKYCDENGEWFRHPDSNRTWSNYTL 150 
CTRmouseosteoblast             DTPAGATAYQHCPDYFPDFDTAEKVSKYCDENGEWFRHPDSNRTWSNYTL 150 
CTR1bMouse_NP_031614.2         DTPAGATAYQHCPDYFPDFDTAEKVSKYCDENGEWFRHPDSNRTWSNYTL 150 
                               ************************************************** 
 
CTRwholeMouse_AAI19273.1       CNAFTSEKLQNAYVLYYLALVGHSLSIAALVASMLIFWIFKNLSCQRVTL 200 
CTR1aMouse_NP_001036190.1      CNAFTSEKLQNAYVLYYLALVGHSLSIAALVASMLIFWIFKNLSCQRVTL 200 
CTRmouseosteoblast             CNAFTSEKLQNAYVLYYLALVGHSLSIAALVASMLIFWIFKNLSCQRVTL 200 
CTR1bMouse_NP_031614.2         CNAFTSEKLQNAYVLYYLALVGHSLSIAALVASMLIFWIFKNLSCQRVTL 200 
                               ************************************************** 
 
CTRwholeMouse_AAI19273.1       HKHMFLTYILNSIIIIIHLVEVVPNGDLVRRDPMHIFHHNTHMWTMQWEL 250 
CTR1aMouse_NP_001036190.1      HKHMFLTYILNSIIIIIHLVEVVPNGDLVRRDP----------------- 233 
CTRmouseosteoblast             HKHMFLTYILNSIIIIIHLVEVVPNGDLVRRDP----------------- 233 
CTR1bMouse_NP_031614.2         HKHMFLTYILNSIIIIIHLVEVVPNGDLVRRDPMHIFHHNTHMWTMQWEL 250 
                               *********************************                  
 
CTRwholeMouse_AAI19273.1       SPPLPLSAHEGKMDPHASEVISCKVLHFLHQYMMSCNYFWMLCEGIYLHT 300 
CTR1aMouse_NP_001036190.1      --------------------ISCKVLHFLHQYMMSCNYFWMLCEGIYLHT 263 
CTRmouseosteoblast             --------------------ISCKVLHFLHQYMMSCNYFWMLCEGIYLHT 263 
CTR1bMouse_NP_031614.2         SPPLPLSAHEGKMDPHASEVISCKVLHFLHQYMMSCNYFWMLCEGIYLHT 300 
                                                   ****************************** 
 
CTRwholeMouse_AAI19273.1       LIVMAVFTDEQRLRWYYLLGWGFPIVPTIIHAITRALYYNDNCWLSAETH 350 
CTR1aMouse_NP_001036190.1      LIVMAVFTDEQRLRWYYLLGWGFPIVPTIIHAITRALYYNDNCWLSAETH 313 
CTRmouseosteoblast             LIVMAVFTDEQRLRWYYLLGWGFPIVPTIIHAITRALYYNDNCWLSAETH 313 
CTR1bMouse_NP_031614.2         LIVMAVFTDEQRLRWYYLLGWGFPIVPTIIHAITRALYYNDNCWLSAETH 350 
                               ************************************************** 
 
CTRwholeMouse_AAI19273.1       LLYIIHGPVMVALVVNFFFLLNIVRVLVTKMRQTHEAESYMYLKAVKATM 400 
CTR1aMouse_NP_001036190.1      LLYIIHGPVMVALVVNFFFLLNIVRVLVTKMRQTHEAESYMYLKAVKATM 363 
CTRmouseosteoblast             LLYIIHGPVMVALVVNFFFLLNIVRVLVTKMRQTHEAESYMYLKAVKATM 363 
CTR1bMouse_NP_031614.2         LLYIIHGPVMVALVVNFFFLLNIVRVLVTKMRQTHEAESYMYLKAVKATM 400 
                               ************************************************** 
 
CTRwholeMouse_AAI19273.1       VLVPLLGIQFVVFPWRPSNKVLGKIYDYLMHSLIHFQGFFVATIYCFCNH 450 
CTR1aMouse_NP_001036190.1      VLVPLLGIQFVVFPWRPSNKVLGKIYDYLMHSLIHFQGFFVATIYCFCNH 413 
CTRmouseosteoblast             VLVPLLGIQFVVFPWRPSNKVLGKIYDYLMHSLIHFQGFFVATIYCFCNH 413 
CTR1bMouse_NP_031614.2         VLVPLLGIQFVVFPWRPSNKVLGKIYDYLMHSLIHFQGFFVATIYCFCNH 450 
                               ************************************************** 
 
CTRwholeMouse_AAI19273.1       EVQVTLKRQWTQFKIQWSQRWGRRRRPTNRVVSAPRAVAFAEPDGLPIYI 500 
CTR1aMouse_NP_001036190.1      EVQVTLKRQWTQFKIQWSQRWGRRRRPTNRVVSAPRAVAFAEPDGLPIYI 463 
CTRmouseosteoblast             EVQVTLKRQWTQFKIQWSQRWGRRRRPTNRVVSAPRAVAFAEPDGLPIYI 463 
CTR1bMouse_NP_031614.2         EVQVTLKRQWTQFKIQWSQRWGRRRRPTNRVVSAPRAVAFAEPDGLPIYI 500 
                               ************************************************** 
 
CTRwholeMouse_AAI19273.1       CHQEPRNPPISNNEGEESTEMIPMNVIQQDASA 533 
CTR1aMouse_NP_001036190.1      CHQEPRNPPISNNEGEESTEMIPMNVIQQDASA 496 
CTRmouseosteoblast             CHQEPRNPPISNNEGEESTEMIPMNVIQQDASA 496 
CTR1bMouse_NP_031614.2         CHQEPRNPPISNNEGEESTEMIPMNVIQQDASA 533 
                               ********************************* 
         
 
 
 
 
 
 
Multiple sequence alignment, CLUSTALW output for mouse CTR protein sequences 
Fig 7.7: Multiple sequence alignment tool - CLUSTALW output. Colourful alphabets represent amino acids.”*” 
represents highly conserved sequences. The black box highlights the region that determines the differences in the 
sequences. 
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7.3.6 CTR protein expression in differentiating primary osteoblast lysates: 
CTR protein expression was determined in both WT (129/SvEv) and RAMP3 KO differentiating 
primary osteoblast cell lysates. Total cell lysate of primary osteoblasts containing 50µg of protein 
was loaded in each well. Mouse brain lysate was used as a positive control. Beta-actin was used 
as loading control and brain tissue lysate was used as a positive control for CTR expression. In 
both the WT and RAMP3 KO osteoblast culture lysates, ~58kDa band was observed. In the 
positive control there were two bands a higher band ~62kD and a lower band ~58kDa. 
 
In WT cultures, it was observed that CTR expression increases with osteoblast differentiation. 
Significantly highest expression of CTR was at day 20 of differentiation. With similar amounts of 
total protein lysates, RAMP3 KO osteoblasts exhibited a different pattern of CTR expression. CTR 
expression was observed to be minimal at day 5 and 15, moderate at day 10 and maximum and 
equivalent to WT expression at day 20 of differentiation. The difference between the CTR 
expression on day 20 compared to all the other time points was significant in RAMP3 KOs. The 
expression of CTR was quantified by densitometry and normalised to β-Actin expression. Figure 
7.8 overleaf shows a representative blot and the graphical representation of densitometry 
quantification. 
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Fig 7.8: Representative Western blot from four independent cultures, immuno-blotted in duplicate, to determine 
CTR expression in WT and RAMP3 KO (R3 -/-) osteoblast cultures (A) and densitometry quantification of CTR 
expression normalised to β-Actin (B). The top panel in a Western blot is for CTR (2 min exposure) and bottom 
panel is for loading control - β-Actin (2 min exposure) of the same. 50µg of each protein lysate sample was 
loaded. Lanes 2, 4, 6 and 8 are WT cell lysates whereas, lanes 3, 5, 7 and 9 are RAMP3 KO lysates. Brain 
tissue lysate (lane 1) was used as a positive control for CTR expression which showed 2 bands corresponding to 
approximately 62kD and 58kD size. Differentiation time points day 5, 10, 15 and 20 for each WT and RAMP3 KO 
preparations are indicated on top. ~58kD CTR protein was observed in both WT and RAMP3 KO cultures 
however, the expression pattern was different to each genotype. β-Actin was expressed at 42kD. Fig B is a bar 
graph showing the quantification (mean ± SEM) of CTR expression normalised to β-Actin in four independent 
experiments. The increase in CTR expression at day 20 of differentiation was significant in both WT and RAMP 
KO primary cultures, in comparison to other time point in the respective cultures. 
Significance of p value: **** ≤0.0001, *** ≤ 0.001, ** ≤ 0.01, * ≤ 0.05 
 
58kD 
62kD 
1 2 3 4 5 6 7 8 
CTR 
β-Actin 
Day 5 Day 20 Day 15 Day10 
58kD 
42kD 
9 
A 
B 
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7.3.7: Expression of CTR in WT and RAMP3 KO primary osteoblasts in response to PTH, AM 
and AMY stimulation: 
We further intended to verify if the CTR variant expressed in the WT and RAMP3 KO primary 
osteoblasts is functional. To test this we investigated the change in CTR expression in both WT 
and RAMP3 KO primary osteoblasts upon Amylin stimulation .Differentiated (20 day) WT and 
RAMP3 KO primary osteoblasts were stimulated with 10nM working concentration of full length 
Amylin (AMY). Protocol is detained earlier section 6.2.1 and 6.2.2. Since Western blotting was 
performed on two AMY stimulated and non-stimulated WT and RAMP3 KO primary osteoblast 
cultures, statistical analysis was not performed.  
The immune-blot for CTR showed increased expression of CTR of ~58kDa in the AMY stimulated 
WT and RAMP3 KOs compared to respective non-stimulated preparations. Whole brain lysate 
was used as a positive control showed only a higher molecular weight CTR ~65kDa. Figure 7.9 
below is a representative blot showing CTR expression in AMY stimulated WT and RAMP3 KO 
primary cultures. 
 
 
 
 
 
 
Fig 7.9: Representative Western Blot showing expression of CTR in 20 days differentiated WT and RAMP 3 
KO primary calvarial osteoblasts cultures stimulated with 10nM full length AMY. Stimulation with the CT family 
of peptides resulted in increased expression of CTR ~58kDa in comparison to non-stimulated control cells.  
The CTR protein in whole brain lysate had a higher molecular weight ~65kDa. β-actin was used as the 
loading control. Exposures were between 2-3 mins. 
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7.4 Discussion 
The mechanisms by which AMY induces osteoblast proliferation are not yet clearly understood, 
we therefore aimed to determine the expression of AMY receptor in differentiating WT primary 
calvarial osteoblast cultures derived from 129/SvEv mice. We hypothesised that osteoblasts 
either express a novel AMY receptor that does not comprise CTR, or that the CTR in an 
osteoblast AMY receptor is a transcript variant of the known full length CTR. The chief objective 
was to determine whether both CTR mRNA and protein were expressed in primary differentiating 
osteoblasts and if so to determine the complete sequence of this CTR variant. 
Using overlapping primers and Western blotting, we successfully demonstrated that 129/SvEv 
mouse derived primary calvarial osteoblasts express a CTR transcriptional variant throughout 
differentiation. Overlapping primer sequences proved to be an efficient technique to determine and 
map a complete cDNA sequence of a formerly unknown CTR variant. Not only did we determine 
the complete sequence of the CTR transcript, but also determined the exact difference in 
transcript compared to the full length CTR. In-silico analysis then confirmed that the CTR 
transcript we determined in the WT 129/SvEv cDNA was similar to the known CTR1a transcript, 
which is a 37 amino acids shorter variant than the full length CTR1b transcript. As discussed 
earlier, the additional 37 amino acids in CTR1b variant result in a change in the second 
extracellular domain of CTR which is expected to affect the ligand-receptor interaction (Sexton et 
al 1993). Figure 7.10 below highlights this domain. 
 
 
 
 
 
 
 
  
    
 
  
CTR1a CTR1b 
Fig 7.10: Representative 3D ribbon protein models of CTR transcripts 1a (left) and 1b (right). The additional 37 
amino acids in CTR1b result in the change in the extracellular domain marked by black dashed-circle. Figure 
generated from (CLR- GPCR) ribbon model created by Prof. P. Artymiuk, University of Sheffield. 
255 
 
The positive controls used in the study: differentiated RAW264 cDNA (mRNA) and mouse brain 
cDNA (mRNA and protein) show expression of both the CTR variants at mRNA as seen in figure 
7.6 and protein level 7.8 consistent with earlier findings by Sexton et al and Ikegame et al 
(Ikegame et al 1995, Sexton et al 1993). In WT primary osteoblasts only CTR1a was expressed 
at both mRNA and protein level. To date only ‘06’ sub clone of the UMR106-cells have shown 
robust expression of CTR1a, but not CTR1b on prolonged maintenance. This indicates that CTR1a 
may be the only CTR variant expressed in osteoblasts. Since CTR1a is has a higher affinity 
toward both CT and AMY compared to CTR1b, it is certain that even with just CTR1a expression, 
the 129/SvEv osteoblasts could have potent CT and AMY receptors. Although osteoclasts, 
express both CTR1a and CTR1b, unlike in brain, expression of CTR1a is higher than CTR1b. This 
indicates that the expression of CTR1a could be a tissue (bone) specific expression. The 
expression of different CTR variants in brain osteoclasts and osteoblasts is summarised in table 
7.4 below. 
 
 Brain  Osteoclasts Osteoblasts 
CTR1a     
CTR1b    Not expressed 
 
CTR protein expression was observed to be different at each time point during differentiation in 
the WT primary osteoblasts; it is therefore clear that the expression of CTR in osteoblasts is 
dependent on osteoblast differentiation and osteogenic environment (Fig 7.8). WT primary 
osteoblasts have maximum expression of CTR when they are completely differentiated. However, 
CTR expression in osteoclasts increases during early osteoclast differentiation stage when the 
hematopoietic stem cells (HSCs) proliferate and start differentiating into early osteoclast 
precursors. (N. Surangika Soysa et al. 2012). This reflects the cell specific regulatory function of 
CTR. In RAMP3 KOs, it was observed that RAMP3 KO osteoblast cultures had lower CTR 
expression compared to WTs until day 20 of differentiation. On the day 20 of differentiation the 
CTR expression in RAMP3 KOs increases and is similar to that of WTs. Since the cytoplasmic tail 
of RAMP3 interacts with the N-ethylmaleimide-sensitive factor (NSF) via the PDZ motif that 
recycles GPCR-RAMP3 complexes (Parameswaran et al., 2006), the reduction in CTR 
expression in the RAMP3 KO primary osteoblasts in early osteoblast differentiation stages could 
Table 7.4: CTR expression in brain, osteoclasts and osteoblasts 
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due to reduced CTR in the cell cytoplasm which results from the loss of this recycling within the 
RAMP3 KO primary osteoblasts. Nevertheless the increase in the CTR expression in both WT 
and RAMP3 KOs at day 20 of differentiation could be due to a dynamic increase in mRNA and 
protein translation events induced at the late osteoblast differentiation stage in the absence of 
RAMP3. This up-regulation of CTR could result in an increase in CTR expression (saturated 
protein levels) at magnitudes that render the difference in circulating CTR levels in WT and 
RAMP3 KOs insignificant. Figure 7.11 below summarises this hypothesis. 
 
 
Fig 7.11: Schematic representation of the regulation of osteoclasts and osteoblast differentiation by Calcitonin 
receptor (CTR). 
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The current study gives novel evidence of expression of a CTR variant similar to the known 
CTR1a and all the three RAMPs in WT primary osteoblasts during differentiation (chapter 6). We 
have successfully shown that the CTR variant responses to Amylin stimulation in both WTs and 
RAMP3 KO primary osteoblasts (Fig 7.8). Hence it is plausible that these primary osteoblasts 
have the traditional AMY receptor components that form receptors which can certainly be targeted 
by tissue specific ligand isoforms (Sexton et al 1993). Furthermore, since the osteoblast CTR 
resembles the dominant CT receptor isoform CTR1a in structure, it is expected that on activation, 
the osteoblast CTR is as potent as the CTR1a.  
This work can be taken further by investigating the functional aspects of the receptor in 
osteoblasts. For example, ligand binding assays can be used to determine if CT peptides compete 
to bind to the ‘CTR1a+RAMP1/2/3’ receptor in primary osteoblasts. Downstream signalling can 
be elucidated by determining the effect of different antagonists on cAMP activation. The receptor-
ligand interactions and downstream G-protein activation can be investigated using FRET analysis 
in differentiating primary osteoblast cell membrane preparations. To visualise the receptor-ligand 
interaction and to determine whether the ‘CTR1a+ RAMP 1/2/3’ receptor in osteoblasts is 
expressed at the osteoblast cell membrane, primary osteoblasts can be stimulated with different 
tagged ligands (Biotinylated-AMY/CT) and studied using confocal microscopy.  
This novel data shall certainly enhance our understanding of skeletal regulation mediated by the 
CT family of peptides.  
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8.1 Summary and discussion 
The current study provides us novel insights into the role of RAMP3 as a regulator of bone mass. 
We have successfully filled in few gaps in literature with respect to the current understanding of 
RAMPs as accessory proteins. In this section we shall focus on the significant findings and the 
implications of our work. 
8.1.1 RAMP3 KO mice have an age dependent anabolic skeletal phenotype:  
This work provides novel evidence to RAMP3 mediated skeletal regulation. RAMP3 KO mice have 
accelerated skeletal development at birth which results in protection against age related bone 
loss. It was observed that at neonatal age, RAMP3 KOs mice have a gross skeletal enhancement 
however with age; the enhancement is confined to trabecular bone of long bones and the 
significance of difference is higher in females. It can be debated that the technical limitations of 
microCT could be responsible for the inefficiency in detecting the gross differences in adult mice.  
Histological evidence suggests that the enhanced skeletal development in the adult RAMP3 KO 
mice is an anabolic effect. It was observed that the number of osteoblasts in the trabecular bone 
was significantly higher than the number of osteoblasts in WTs, and that the RAMP3 KO 
osteoblasts covered a larger surface of the trabecular bone compared to WT osteoblasts. We 
determined no differences in osteoclast numbers. Interestingly the adult RAMP3 KO mice also 
showed a difference in the growth plate in comparison to the WTs. The length of the chondrocyte 
columns in RAMP3 KO mice was significantly more in comparison to the chondrocyte columns in 
WTs and was suggestive of enhanced differentiation of the proliferative cells into hypertrophic 
cells and that RAMP3 KOs had enhanced endochondral ossification. This is a novel evidence of 
the involvement of RAMP3 in endochondral ossification. The increased osteoblasts numbers in 
the trabecular bone and the enhanced differentiation of the proliferative cells to form hypertrophic 
cells that get mineralised at the growth plate again supported the hypothesis that the skeletal 
phenotype of the RAMP3 KOs was an anabolic phenomenon. 
Further investigation of the differentiation pattern of the primary osteoblasts of both WT and 
RAMP3 KO mice revealed that RAMP3 KO primary osteoblasts had an altered differentiation 
pattern. We observed a prolonged ALP activity in the RAMP3 KO osteoblasts that could be 
responsible for enhanced differentiation of the pre-osteoblasts into mature osteoblasts in the 
RAMP3 KO mice. RAMP3 KO mice also had fewer but larger colony forming units (CFUs). The 
Chapter 8: Discussion. 
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CFUs mineralised equal amount of matrix in both RAMP3 KO and WT cultures despite there 
being significantly fewer CFUs in RAMP3 KOs. However collagen formation in RAMP3 KOs was 
significantly reduced. This could suggest that more MSCs differentiated into osteoblasts compared 
to the number of MSCs that differentiation into chondrocytes. The differences in primary 
osteoblast differentiation pattern provoked the investigation of Wnt/β-catenin pathway in RAMP3 
KO mice, as the canonical Wnt pathway defines osteoblast differentiation and given the evidence 
the RAMP3 is an early response gene of the Wnt/β-catenin pathway and that RAMP3 expression 
decreases with increased expression of Wnt (Kenny et al 2005, Rohrs et al 2009, Ziegler et al 
2005). We successfully demonstrated that the RAMP3 KO primary osteoblasts had significantly 
more total and phosphorylated β-catenin and that the RAMP3 KOs required more DKK1 to reduce 
the endogenous phosphorylated-β-catenin levels when compared to the WT primary osteoblast. 
We also showed that an exogenous Wnt3A stimulation induced significantly more amount of 
phosphorylated β-catenin in RAMP3 KO osteoblasts compared to the WTs. These findings along 
with the differences observed in the growth plates of RAMP3 KOs and the difference in the 
differentiation patterns of primary osteoblasts suggest the RAMP3 KO mice have enhanced 
differentiation of osteoblasts that result in increased skeletal development.  
Additionally Wnt plays an important role in mouse embryogenesis (C. R. Kemp 2007). We can 
propose that in WTs, the increase in Wnt during embryogenesis results in reduction of RAMP3. 
This could imply that reduction in RAMP3 but not RAMP2 expression is characteristic during 
embryogenesis, hence the RAMP3 KO mice are viable as RAMP3 expression is dispensable, but 
RAMP2 KO mice are embryonically lethal as RAMP2 expression is indispensable during 
embryogenesis (C. R. Kemp 2007, Dackor et al 2007, Kenny et al 2005, Ziegler et al 2005). 
We can also propose that the acceleration in the development of the gross skeleton in RAMP3 
KOs at early age is regulated by the Wnt signalling that regulates embryogenesis. Whereas in 
adults, Wnt signalling pathway that regulates the ware and tare of the bone, could be responsible 
for the enhanced trabecular bone in adult RAMP3 KOs. 
8.1.2 RAMP2 protein compensates for RAMP3 protein in an event of stimulation: 
Investigating RAMP expressions during primary osteoblast differentiation gave novel insight into 
the regulation of RAMPs in osteoblast differentiation. We observed that in WTs with the 
advancement of osteoblast differentiation, there is an increase in RAMP1 and RAMP2 expression 
and a decrease in RAMP3 expression. The decrease in RAMP3 expression in mature osteoblasts 
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escalated the notion that RAMP3 KO mice have enhancement in osteoblast differentiation. 
Interestingly there was no significant difference in the mRNA expression of RAMP1 and RAMP3 in 
RAMP3 KO and WT at any time-point during osteoblasts differentiation. Therefore, there is no 
compensation between RAMPs at mRNA level. This is in concordance with the reports by Dackor 
et al and Kadmiel et al (Dackor et al 2007, Kadmiel et al 2012).   
Although there is no compensation between RAMP2 and RAMP3 at mRNA level, it is possible 
that RAMPs compensate each other at a protein level. We can hypothesis that RAMPs form 
stable multimers that are maintained in compartments in the cytoplasm and these multimers 
dissociate to form monomers which can form complexes with GPCRs on appropriate stimulation 
(Sexton et al 2001). The current study gives novel evidence of up-regulation of RAMP3 monomer 
in WT and RAMP2 monomers in both WT and RAMP3 KO osteoblasts on PTH, AM and AMY 
stimulation when compared to their non-stimulated controls. Interestingly we observed that two 
forms of RAMP2: monomer ~13kDa and a multimer ~55kDa were expressed in the mouse brain 
lysate that was used as a positive control, WT primary osteoblasts and RAMP3 KO primary 
osteoblasts. On stimulation with the peptides PTH, AM and AMY, RAMP3 KO primary osteoblasts 
express significantly more amounts of the higher molecular weight RAMP2 compared to WT 
primary osteoblasts, suggesting that multimeric form of RAMP2 can compensate for the absence 
of RAMP3 in the RAMP3 KO osteoblasts. This compensatory mechanism if existent is 
independent of the mRNA expressions as the compensation would be between circulating levels 
of RAMP proteins in the cytoplasm. Moreover, we know that dimerization is a prerequisite for CLR 
(McLatchie et al 1998). If we hypothesize that RAMP2 and RAMP3 compete to form heterodimer 
with CLR to form a functional receptor for AM, an alteration in the expression of either RAMP2 or 
RAMP3 may cause a shift in the interaction (Figure 8.1). 
 
 
 
 
 
 
 RAMP2 RAMP3 CLR 
RAMP2 KO:  AM1 = RAMP2           CLR          RAMP3 
RAMP2          CLR          RAMP3 = AM2:  RAMP3 
KO Fig 8.1: Schematic representation of the competitive heterodimerisation between RAMP2 and RAMP3 with CLR. 
X 
 
X 
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If there is a compensatory mechanism or competitive heterodimerisation between RAMP2 and 
RAMP3, we can also postulate that the skeletal phenotype of the RAMP3 KO could be a result of 
overexpression of RAMP2. Apart from RAMP2/ CLR, this phenomenon could result in enhanced 
activation of other the receptor complexes like RAMP2/PTHR1 and RAMP2/CTR in the RAMP3 
KOs (Hay et al 2003, McLatchie et al 1998, Parameswaran & Spielman 2006). This would in-
turn result in an increase in bone formation through the activity of the peptides PTH, AM and AMY 
respectively.  
8.1.3 RAMP2 and RAMP3, differences and preferences: 
Both RAMP2 and RAMP3 are involved in forming functional receptors for Adrenomedullin and 
Amylin. However, interestingly knockout animals of RAMP2 and RAMP3 have completely different 
phenotypes. As mentioned earlier, RAMP2 gene silencing results in embryonic lethality, which is 
also seen in AM KO mice (Dackor et al 2007). On the other hand RAMP3 KO mice are viable 
and do not put on weight with age (Dackor et al 2007). This suggests that RAMP2 has a more 
profound physiological function during the developmental stages and that it brings about the basal 
effect of GPCR signalling. Whereas, RAMP3 plays a role in maintaining normal physiology during 
adulthood and that it may be induced only in times of physiological stress (Dackor et al 2007). 
Another evidence to support this concept is that the cytoplasmic tail of RAMP3 interacts with the 
N-ethylmaleimide-sensitive factor (NSF) via the PDZ motif, and enhances recycling and rapid re-
sensitizing of CLR/RAMP3 complex to plasma membrane (Parameswaran & Spielman 2006) 
i.e., RAMP3 has the ability to traffic and recycle partner GPCRs, which would be useful in 
challenged physiological conditions. 
However, reasons for such different phenotypes are not yet clearly understood. One of the 
possible explanations other than the Wnt theory proposed earlier would be a difference in affinity 
between RAMP2 and RAMP3 towards CLR and CTR, to form heterodimer complexes. i.e., given 
a choice, RAMP2 could prefer heterodimerisation with CLR (to form AM receptor), over CTR (to 
form receptor for AMY), whereas RAMP3 could prefer CTR over CLR. RAMP2 and AM 
association is evident from KO studies. It is known that the N-terminal of AM is involved in 
vasodilation whereas a short peptide region 27-52 is implicated to induce mitogenic effect in 
osteoblasts via MAPK activation (Cornish et al 2003). Since embryonically lethal RAMP2 KO 
mice show pericardial effusion signifying the importance of RAMP2 in vascular development, it 
can be suggested that RAMP2 interaction with AM is related to the vasodilation activity of AM 
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(Dackor et al 2007, Dackor et al 2006). On the other hand, the association of RAMP3 and AMY 
is evident for the fact that RAMP3 KO mice strikingly share the skeletal phenotype with the AMY 
KO mice. Both RAMP3 KO and AMY KO adult mice have increased growth plate thickness and 
increase in the trabecular thickness with no change in net trabecular bone volume (Davey et al 
2006). 
8.1.4 Calcitonin receptor in osteoblasts:  
Apart from investigating the role of RAMP3 in regulating skeletal development, this work also 
investigated the expression of CTR in osteoblasts. Our work provides novel evidence of 
expression of the traditional CTR receptor by both WT and RAMP3 KO 129/SvEv primary 
osteoblasts. The CTR expressed by the primary osteoblasts resembles the known CTR1a in 
sequence and structure. We have successfully shown that this receptor responds to AMY 
stimulation, hence suggesting the CTR in the osteoblasts resembles CTR1a in function too. 
Further, we have given evidence that CTR expression increases significantly when the osteoblasts 
are fully matured and form mineralised matrix suggesting that CTR plays an important role late 
osteoblast differentiation in contrast to its role in regulating early osteoclast differentiation (Soysa 
et al 2012). It could be possible that the previous reports of CTR not being expressed in the 
osteoblasts were not carried out in mature mineralising osteoblasts. However, our findings could 
be specific to the 129/SvEv background mouse strain.  
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8.2. Technical limitations 
One of the major technical limitations of this study was the resolution available for bone microCT 
analysis. It was observed that the resolution of 17.5µm was insufficient to detect the differences 
between the WT and RAMP3 KO whole bones despite there being differences at microscopic 
levels. Another major difficulty was mimicking the effects of ovariectomy in the 129/SvEv mice. 
WT 129/SvEv mice did not develop classical ovariectomy induced bone loss phenotype; hence 
this intervention could not produce reliable comparisons between the two genotypes. As discussed 
earlier this could be due to the breeding of the WT 129/SvEv animals. Hence pure WT 
129/SvEv animals should be used as controls for any future skeletal analysis.  
Histological analysis was limited by the quality of the sections. Due to the inconsistency of the 
sections, analyses of results from experiments from such as dual calcein labels in the trabecular 
bone were not comparable. The use of slide scanner however helped overcome the inconsistency 
in H&E and TRAP stained sections as measurements could be confined to a consistent area 
electronically on the Aperio® software. Nevertheless, since the slide scanner available in the 
University of Sheffield was not equipped for fluorescent microscopy, calcein labelled sections 
could not be analysed electronically. 
It was difficult to yield satisfactory amounts of protein from differentiated primary osteoblast 
cultures. It was evident that RAMPs were expressed in very low concentrations, and hence 
analyses of comparable RAMP protein levels could not be performed on basal (non - stimulated) 
primary osteoblasts. Detectable RAMP protein bands were observed only after loading upto 
~100µg of protein in our stimulation experiments. Given that the expression of RAMPs were very 
low, a considerable time was used for optimizing the Western Blotting protocols. Furthermore, we 
had to test several commercial RAMP 1/2 and 3 antibodies before selecting the RAMP2 and 
RAMP3 antibody for this study as commercially available antibodies are not efficient. It was 
disappointing that the production of the mouse anti-RAMP1 antibody that was very efficient was 
discontinued by Abcam®. RAMP1 Western blotting protocol was previously optimised on 
osteoblast like cell lines. However due to the unavailability of the antibody at a later stage, the 
expression of RAMP1 protein was not determined. 
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8.3 Future work 
In the time available for this project it was not possible to investigate all the skeletal aspects of the 
RAMP3 KO 129/SvEv mice. Future investigations would aim to first address the limitations that 
were incurred during this project. WT 129/SvEv pure breeding line should be established and 
protocols for ovariectomy should be optimised in the WTs before comparing the skeletal 
phenotypes of RAMP3 KO and the WTs in the event of this intervention. Given the evidence that 
RAMP2 plays an important role in embryogenesis, it would be worth monitoring the gestation 
period of the RAMP3 KO mice to determine if the skeletal development in the RAMP3 KO mice is 
due to increased gestation. Furthermore, samples sections for histology should be consistent and 
comparable if similar investigations are conducted again in future.  
This work can be taken ahead by investigating the skeletal phenotype of double tissue specific 
KOs of RAMPs and the partner GPCRs. Since both RAMP3 KOs and AMY KO have similar 
skeletal phenotypes, it will certainly be useful to study the skeletal phenotype of a tissue specific 
RAMP3/CTR KOs. Additionally the effect of RAMP3 antibody on skeleton of WT, fracture models 
and osteoporotic models could be elucidated. The effect of RAMP3 antibody can further be 
investigated with other therapies like PTH (1-34) treatment or anti-DKK1 therapy to determine if 
blocking RAMP3 enhances effect of these treatments.  
To investigate the compensatory mechanisms between RAMP2 and RAMP3, the protein 
concentrations of individual RAMPs could be determined in the cytoplasm and the cell membranes 
of WT and RAMP3 KO primary osteoblasts under basal and stimulated conditions. Compensation 
of RAMPs on the cell membrane could also be studied by immunocytochemistry with different 
probes for different RAMPs.  
With the limited time of this project we could only identify the CTR variant in the primary 
osteoblasts of the 129/SvEv mice, future investigations would aim in determining the functional 
aspects of the CTR in the primary osteoblasts in a differentiation dependent experimental set-up. 
The functional aspects of the osteoblast CTR variant in native WT and RAMP3 KO cell membrane 
preparations can be studied using Fluorescence Resonance Energy Transfer (FRET) technique. 
This technique would help us determine the pattern of G-protein activation for the osteoblast CTR 
variant.   
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8.4 Conclusion 
In conclusion we have successfully demonstrated that RAMP3 is a potential anabolic therapeutic 
target for age dependent skeletal disorders. 
The association of Wnt/β-catenin pathway and RAMP3 signalling could make this target even 
more promising. Ideally, the proposed therapy would involve RAMP3 antibody treatment coupled 
with other anabolic therapies like anti-DKK1 treatment or PTH (1-34).  Moreover, we have 
successfully provided novel evidence to the expression of Calcitonin receptor (CTR) identical to 
CTR1a variant in primary osteoblasts.   
The outcomes of this study shall help us further understand the subtle modulations of GPCR 
activations through RAMPs in both healthy and disease state physiology. 
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Chapter 9: Appendix 
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9.1 Appendix 
9.1.1 Chapter 2: Advanced skeletal phenotype of RAMP3 KO mice 
Skeletal Stains 
Alcian Blue solution (always freshly prepared): 
20 mg Alcian Blue (8GX grade) 
22ml D/W 
160 ml 100% Ethanol 
40 ml Glacial Acetic Acid (increase or reduce proportionately as required) 
 
Alizarin Red S Solution (always freshly prepared): 
100 ml 1% KOH solution (freshly prepared - 1% (w/v) KOH in water). 
1 mg Alizarin Red 
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9.1.2 Chapter 3: Skeletal response of RAMP3KO mice to ovariectomy: 
9.1.2.i Statistical analysis of microCT analysis of baseline, sham and OVX WT and RAMP3 KO 
mice 
 
Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
Whole Femur BV 
WT      
Baseline Vs. Sham  0.5107 -1.814 to 2.835 No NS > 0.9999 
Baseline Vs. OVX 0.03765 -2.287 to 2.362 No NS > 0.9999 
Sham Vs OVX -0.4730 -2.797 to 1.851 No NS > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.0425 -2.367 to 2.282 No NS > 0.9999 
Baseline Vs. OVX 0.02402 -2.300 to 2.348 No NS > 0.9999 
Sham Vs OVX 0.06651 -2.258 to 2.391 No NS > 0.9999 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.0001 -2.324 to 2.324 No NS > 0.9999 
Sham Vs Sham -0.5533 -2.878 to 1.771 No NS > 0.9999 
OVX Vs OVX -0.0137 -2.338 to 2.311 No NS > 0.9999 
WHOLE TIBIA BV 
WT      
Baseline Vs. Sham  0.3697 -1.639 to 2.378 No NS > 0.9999 
Baseline Vs. OVX -0.6057 -2.614 to 1.403 No NS > 0.9999 
Sham Vs OVX -0.9754 -2.984 to 1.033 No NS > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.5564 -2.565 to 1.452 No NS > 0.9999 
Baseline Vs. OVX -0.3499 -2.358 to 1.658 No NS > 0.9999 
Sham Vs OVX 0.2065 -1.802 to 2.215 No NS > 0.9999 
WT Vs. RAMP3KO      
Baseline Vs Baseline 0.2705 -1.738 to 2.279 No NS > 0.9999 
Sham Vs Sham -0.6556 -2.664 to 1.353 No NS > 0.9999 
OVX Vs OVX 0.5262 -1.482 to 2.535 No NS > 0.9999 
FEMUR CORTICAL BV 
WT      
Baseline Vs. Sham  0.07057 -0.1082 to 0.2493 No NS > 0.9999 
Baseline Vs. OVX -0.0981 -0.2878 to 0.09149 No NS > 0.9999 
Sham Vs OVX -0.1687 -0.3583 to 0.02092 No NS 0.1176 
RAMP3 KO      
Baseline Vs. Sham  0.001026 -0.1778 to 0.1798 No NS > 0.9999 
Baseline Vs. OVX 0.1203 -0.05847 to 0.2991 No NS 0.5681 
Sham Vs OVX 0.1193 -0.05950 to 0.2981 No NS 0.5908 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.04631 -0.2251 to 0.1325 No NS > 0.9999 
Sham Vs Sham -0.1158 -0.2946 to 0.06293 No NS 0.6732 
OVX Vs OVX 0.1721 -0.01748 to 0.3618 No NS 0.1024 
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Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
FEMUR CORTICAL THICKNESS 
WT      
Baseline Vs. Sham  -0.00806 -0.03343 to 0.01731 No NS > 0.9999 
Baseline Vs. OVX -0.00896 -0.03587 to 0.01795 No NS > 0.9999 
Sham Vs OVX -0.00090 -0.02781 to 0.02601 No NS > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  0.00100 -0.02437 to 0.02637 No NS > 0.9999 
Baseline Vs. OVX 0.01176 -0.01361 to 0.03713 No NS > 0.9999 
Sham Vs OVX 0.01076 -0.01461 to 0.03613 No NS > 0.9999 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.01073 -0.03610 to 0.01464 No NS > 0.9999 
Sham Vs Sham -0.00167 -0.02704 to 0.02370 No NS > 0.9999 
OVX Vs OVX 0.00999 -0.01693 to 0.03690 No NS > 0.9999 
FEMUR TRABECULAR BONE VOLUME 
WT      
Baseline Vs. Sham  0.01131 -0.08108 to 0.1037 No NS > 0.9999 
Baseline Vs. OVX 0.03514 -0.06285 to 0.1331 No NS > 0.9999 
Sham Vs OVX 0.02383 -0.07416 to 0.1218 No NS > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.02136 -0.1137 to 0.07103 No NS > 0.9999 
Baseline Vs. OVX 0.04185 -0.05614 to 0.1398 No NS > 0.9999 
Sham Vs OVX 0.06321 -0.03478 to 0.1612 No NS 0.6790 
WT Vs. RAMP3KO      
Baseline Vs Baseline 0.02588 -0.06651 to 0.1183 No NS > 0.9999 
Sham Vs Sham -0.00679 -0.09917 to 0.08560 No NS > 0.9999 
OVX Vs OVX 0.03259 -0.07070 to 0.1359 No NS > 0.9999 
FEMUR TRABECULAR BONE VOLUME/ TISSUE VOLUME BV/TV 
WT      
Baseline Vs. Sham  0.3381 -1.897 to 2.573 No NS > 0.9999 
Baseline Vs. OVX 1.534 -0.8364 to 3.905 No NS 0.6611 
Sham Vs OVX 1.196 -1.175 to 3.567 No NS > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.1111 -2.482 to 2.260 No NS > 0.9999 
Baseline Vs. OVX 1.366 -1.004 to 3.737 No NS > 0.9999 
Sham Vs OVX 1.478 -1.021 to 3.976 No NS 0.9567 
WT Vs. RAMP3KO      
Baseline Vs Baseline 0.4712 -1.764 to 2.706 No NS > 0.9999 
Sham Vs Sham 0.02200 -2.349 to 2.393 No NS > 0.9999 
OVX Vs OVX 0.3034 -2.196 to 2.802 No NS > 0.9999 
FEMUR TRABECULAR THICKNESS 
WT      
Baseline Vs. Sham  0.001238 -0.00426 to 0.0067 No NS > 0.9999 
Baseline Vs. OVX 0.002925 -0.00290 to 0.0088 No NS > 0.9999 
Sham Vs OVX 0.001687 -0.0041 to 0.0075 No NS > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.00123 -0.0067 to 0.00426 No NS > 0.9999 
Baseline Vs. OVX 0.00180 -0.0040 to 0.00763 No NS > 0.9999 
Sham Vs OVX 0.00303 -0.0028 to 0.00886 No NS > 0.9999 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.00070 -0.0062 to 0.0048 No NS > 0.9999 
Sham Vs Sham -0.00317 -0.0087 to 0.0023 No NS > 0.9999 
OVX Vs OVX -0.00182 -0.0079 to 0.0043 No NS > 0.9999 
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Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
 
FEMUR TRABECULAR SEPARATION 
WT      
Baseline Vs. Sham  -0.00234 -0.03985 to 0.03514 No NS > 0.9999 
Baseline Vs. OVX -0.01241 -0.05218 to 0.02736 No NS > 0.9999 
Sham Vs OVX -0.01006 -0.04983 to 0.02971 No NS > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.00075 -0.03825 to 0.03675 No NS > 0.9999 
Baseline Vs. OVX -0.02431 -0.06408 to 0.01546 No NS 0.8494 
Sham Vs OVX -0.02356 -0.06333 to 0.01621 No NS 0.9607 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.00201 -0.03951 to 0.03548 No NS > 0.9999 
Sham Vs Sham -0.00040 -0.03790 to 0.03709 No NS > 0.9999 
OVX Vs OVX -0.01391 -0.05583 to 0.02801 No NS > 0.9999 
FEMUR TRABECULAR NUMBER 
WT      
Baseline Vs. Sham  0.03158 -0.3657 to 0.4288 No NS > 0.9999 
Baseline Vs. OVX 0.2575 -0.1639 to 0.6788 No NS 0.8406 
Sham Vs OVX 0.2259 -0.1955 to 0.6473 No NS > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.00918 -0.4305 to 0.4122 No NS > 0.9999 
Baseline Vs. OVX 0.2522 -0.1691 to 0.6736 No NS 0.9122 
Sham Vs OVX 0.2614 -0.1827 to 0.7055 No NS 0.9736 
WT Vs. RAMP3KO      
Baseline Vs Baseline 0.1294 -0.2678 to 0.5267 No NS > 0.9999 
Sham Vs Sham 0.08866 -0.3327 to 0.5100 No NS > 0.9999 
OVX Vs.OVX 0.1242 -0.3200 to 0.5683 No NS > 0.9999 
FEMUR TRABECULAR PATTERN FACTOR 
WT      
Baseline Vs. Sham 2.794 -5.932 to 11.52 No NS > 0.9999 
Baseline Vs. OVX -4.188 -13.44 to 5.068 No NS > 0.9999 
Sham Vs OVX -6.983 -16.24 to 2.273 No NS 0.3173 
RAMP3 KO      
Baseline Vs. Sham -0.5119 -9.238 to 8.214 No NS > 0.9999 
Baseline Vs. OVX -1.935 -11.19 to 7.320 No NS > 0.9999 
Sham Vs OVX -1.423 -10.68 to 7.832 No NS > 0.9999 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.8172 -9.544 to 7.909 No NS > 0.9999 
Sham Vs Sham -4.124 -12.85 to 4.603 No NS > 0.9999 
OVX Vs.OVX 1.436 -8.321 to 11.19 No NS > 0.9999 
TIBIA CORTICAL BONE VOLUME 
WT      
Baseline Vs. Sham  -0.04029 -0.1766 to 0.09604 No NS > 0.9999 
Baseline Vs. OVX -0.1901 -0.3264 to -0.05374 Yes ** 0.0020 
Sham Vs OVX -0.1498 -0.2861 to -0.01345 Yes * 0.0227 
RAMP3 KO      
Baseline Vs. Sham  -0.08672 -0.2230 to 0.04961 No NS 0.7367 
Baseline Vs. OVX -0.02630 -0.1626 to 0.1100 No NS > 0.9999 
Sham Vs OVX -0.02978 -0.1661 to 0.1066 No NS > 0.9999 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.07358 -0.2099 to 0.06275 No NS > 0.9999 
Sham Vs Sham -0.1200 -0.2563 to 0.01633 No NS 0.1271 
OVX Vs.OVX 0.09019 -0.04614 to 0.2265 No NS 0.6203 
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Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
 
TIBIA CORTICAL THICKNESS 
WT      
Baseline Vs. Sham 0.01433 -0.00158 to 0.0302 No NS 0.1089 
Baseline Vs. OVX 0.00913 -0.00678 to 0.0250 No NS > 0.9999 
Sham Vs OVX -0.00519 -0.0211 to 0.0107 No NS > 0.9999 
RAMP3 KO      
Baseline Vs. Sham 0.02734 0.01143 to 0.04326 Yes *** 0.0001 
Baseline Vs. OVX 0.00401 -0.01190 to 0.01993 No NS > 0.9999 
Sham Vs OVX -0.00961 -0.0255 to 0.00630 No NS 0.9106 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.00859 -0.02451 to 0.0073 No NS > 0.9999 
Sham Vs Sham 0.00442 -0.0115 to 0.02034 No NS > 0.9999 
OVX Vs.OVX -0.01372 -0.0296 to 0.00219 No NS 0.1458 
TIBIA TRABECULAR BONE VOLUME 
WT      
Baseline Vs. Sham  0.01446 -0.02864 to 0.05757 No ns > 0.9999 
Baseline Vs. OVX 0.02640 -0.01424 to 0.06703 No ns 0.6588 
Sham Vs OVX 0.01193 -0.03117 to 0.05504 No ns > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.02187 -0.06498 to 0.02123 No ns > 0.9999 
Baseline Vs. OVX 0.03910 -0.00154 to 0.07974 No ns 0.0671 
Sham Vs OVX 0.06098 0.01787 to 0.1041 Yes ** 0.0018 
WT Vs. RAMP3KO      
Baseline Vs Baseline 0.009008 -0.03163 to 0.04965 No ns > 0.9999 
Sham Vs Sham -0.02733 -0.07277 to 0.01811 No ns 0.9061 
OVX Vs OVX 0.02171 -0.01892 to 0.06235 No ns > 0.9999 
TIBIA TREABECULAR BV/TV 
WT      
Baseline Vs. Sham  0.6249 -0.7808 to 2.031 No ns > 0.9999 
Baseline Vs. OVX 1.318 -0.08815 to 2.723 No ns 0.0816 
Sham Vs OVX 0.6927 -0.7131 to 2.098 No ns > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.1951 -1.686 to 1.296 No ns > 0.9999 
Baseline Vs. OVX 1.853 0.4473 to 3.259 Yes ** 0.0038 
Sham Vs OVX 2.048 0.5571 to 3.539 Yes ** 0.0024 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.4701 -1.876 to 0.9357 No ns > 0.9999 
Sham Vs Sham -1.290 -2.781 to 0.2009 No ns 0.1415 
OVX Vs OVX 0.0653 -1.340 to 1.471 No ns > 0.9999 
TIBIA TRABECULAR THICKNESS 
WT      
Baseline Vs. Sham  0.00413 -0.00036 to 0.00862 No ns 0.0933 
Baseline Vs. OVX 0.00535 0.00086 to 0.00985 Yes * 0.0108 
Sham Vs OVX 0.00122 -0.00327 to 0.00571 No ns > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.00122 -0.00598 to 0.00355 No ns > 0.9999 
Baseline Vs. OVX 0.00292 -0.00157 to 0.00742 No ns 0.6614 
Sham Vs OVX 0.00414 -0.00061 to 0.00891 No ns 0.1383 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.00089 -0.00539 to 0.00360 No ns > 0.9999 
Sham Vs Sham -0.00624 -0.01101 to -0.0014 Yes ** 0.0041 
OVX Vs OVX -0.00332 -0.0078 to 0.00117 No ns 0.3575 
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Bonferroni's Multiple 
Comparisons Test 
Mean Diff. 95% CI Of Diff. Significant? Summary P Value 
TIBIA TRABECULAR SEPARATION 
WT      
Baseline Vs. Sham  0.03403 -0.1108 to 0.1788 No ns > 0.9999 
Baseline Vs. OVX 0.00898 -0.1358 to 0.1538 No ns > 0.9999 
Sham Vs OVX -0.02505 -0.1699 to 0.1198 No ns > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  0.02326 -0.1303 to 0.1769 No ns > 0.9999 
Baseline Vs. OVX -0.04003 -0.1848 to 0.1048 No ns > 0.9999 
Sham Vs OVX -0.06330 -0.2169 to 0.09030 No ns > 0.9999 
WT Vs. RAMP3KO      
Baseline Vs Baseline 0.06574 -0.07907 to 0.2106 No ns > 0.9999 
Sham Vs Sham 0.05497 -0.09863 to 0.2086 No ns > 0.9999 
OVX Vs OVX 0.01673 -0.1281 to 0.1615 No ns > 0.9999 
TIBIA TRABECULAR NUMBER 
WT      
Baseline Vs. Sham  0.06817 -0.2010 to 0.3373 No ns > 0.9999 
Baseline Vs. OVX 0.2055 -0.06363 to 0.4747 No ns 0.3000 
Sham Vs OVX 0.1374 -0.1318 to 0.4065 No ns > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -0.09717 -0.3827 to 0.1883 No ns > 0.9999 
Baseline Vs. OVX 0.3457 0.07656 to 0.6149 Yes ** 0.0051 
Sham Vs OVX 0.3587 0.07324 to 0.6442 Yes ** 0.0064 
WT Vs. RAMP3KO      
Baseline Vs Baseline -0.08417 -0.3533 to 0.1850 No ns > 0.9999 
Sham Vs Sham -0.1653 -0.4508 to 0.1201 No ns > 0.9999 
OVX Vs OVX 0.05602 -0.2131 to 0.3252 No ns > 0.9999 
TIBIA TRABECULAR PATTERN FACTOR 
WT      
Baseline Vs. Sham  -42.90 -62.10 to -23.71 Yes **** < 0.0001 
Baseline Vs. OVX -45.56 -64.75 to -26.36 Yes **** < 0.0001 
Sham Vs OVX -2.653 -21.85 to 16.54 No ns > 0.9999 
RAMP3 KO      
Baseline Vs. Sham  -60.72 -81.08 to -40.36 Yes **** < 0.0001 
Baseline Vs. OVX -63.23 -82.42 to -44.04 Yes **** < 0.0001 
Sham Vs OVX -2.512 -22.87 to 17.85 No ns > 0.9999 
WT Vs. RAMP3KO      
Baseline Vs Baseline -1.461 -20.65 to 17.73 No ns > 0.9999 
Sham Vs Sham -19.27 -39.63 to 1.084 No ns 0.0758 
OVX Vs OVX -19.13 -38.33 to 0.06053 No ns 0.0513 
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9.1.3 Chapter 4: Characterising RAMP3 KO osteoblasts 
9.1.3.i Primary Osteoblast culture buffers and solutions: 
1) Hanks with calcium and magnesium (without phenol red) (Lonza®) 
2) Phosphate buffered saline (Sigma®) 
3) Penicillin-Streptomycin solution (Sigma®) 
4) Collagenase 1A (Sigma®) (stock solution:10mg/ml in Hank’s stored as 1ml aliquots at -
200C) 
5) 4mM tertasodium EDTA in PBS 
6) Trypsin-EDTA solution (Gibco®) 
7) Non - differentiation media : Alpha minimum essential media (MEM) (Gibco®) with 10% 
heat inactivated fetal calf serum (FCS) (Sigma®), 0.5% penicillin-streptomycin solution 
8) Osteoblast differentiation media: Alpha MEM, 10%FCS, 0.5% penicillin-streptomycin 
solution 5mM/l β-Glycerophosphate (Sigma®) (stock solution: 0.5M in alpha MEM), 
10nM dexamethasone (stock: 1mM in 100% methanol) and 100µg/ml Ascorbic acid 
(Sigma®) 
 
9.1.4 Chapter 5: Expression of RAMPs in differentiating primary osteoblasts 
9.1.4.i CT and Delta CT values of RAMP1, 2 and 3 in WT and RAMP3 osteoblasts: 
RAMP1 
  
n=1 n=2 n=3 n=4 
 
Time-point avg.CT Delta CT avg.CT Delta CT avg.CT Delta CT avg.CT 
Delta 
CT 
W
T 
DAY 0 38.23 21.43 39.55 20.96 39.05 22.29 38.16 21.00 
DAY 5 36.92 19.14 38.41 19.15 - - 34.97 16.89 
DAY 10 35.88 18.25 36.52 17.33 37.25 19.25 37.55 19.68 
DAY 15 34.88 16.86 34.53 16.11 34.82 17.23 35.12 17.79 
DAY 20 35.97 18.68 36.24 17.97 37.63 16.24 37.01 15.29 
 
R
A
M
P
3
 K
O
 DAY 0 38.91 20.30 37.20 19.32 38.92 21.76 38.38 21.36 
DAY 5 39.06 18.76 36.47 18.04 36.55 18.82 36.19 18.66 
DAY 10 37.79 16.92 36.80 18.10 37.76 19.93 38.43 20.45 
DAY 15 37.76 16.82 35.94 15.67 36.76 19.20 35.15 17.37 
DAY 20 38.69 18.13 36.78 17.23 38.69 21.10 36.92 19.02 
 
 
NTC Undetermined 
 
Undetermined 
 
Undetermined 
 
Undetermined 
 
 
CNC 17.49 
 
20.27 
     
 
NTC: Non Template Control; CNC: Copy Number Control; avg CT = average of three CT values. 
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RAMP2 
  
n=1 n=2 n=3 n=4 
 
Time-point avg.CT Delta CT avg.CT Delta CT avg.CT Delta CT avg.CT 
Delta 
CT 
W
T 
DAY 0 35.35 18.16 33.53 14.94 38.68 21.40 32.77 15.61 
DAY 5 28.62 11.09 28.41 9.15 36.60 18.99 25.96 7.88 
DAY 10 26.95 9.32 26.58 7.39 27.98 10.33 27.49 9.61 
DAY 15 26.23 8.25 25.39 6.97 26.54 7.33 25.50 8.17 
DAY 20 29.13 11.83 28.65 10.39 29.03 7.84 27.05 5.34 
 
R
A
M
P
3
 K
O
 DAY 0 35.95 17.34 34.12 16.24 34.81 17.38 37.01 19.99 
DAY 5 29.33 9.03 29.48 11.05 29.40 11.77 29.31 11.78 
DAY 10 27.24 6.36 26.32 7.62 27.23 9.57 27.88 9.90 
DAY 15 26.44 5.50 28.72 8.45 26.94 9.56 27.52 9.74 
DAY 20 27.50 6.95 26.93 7.39 27.99 10.44 28.48 10.58 
 
 
NTC Undetermined 
 
Undetermined 
 
Undetermined 
 
Undetermined 
 
 
CNC 20.44 
 
20.87 
     
 
RAMP3 
  
n=1 n=2 n=3 
 
Time-point avg.CT Delta CT avg.CT Delta CT avg.CT Delta CT 
W
T 
DAY 0 35.35 18.16 33.53 14.94 38.68 21.40 
DAY 5 28.62 11.09 28.41 9.15 36.60 18.99 
DAY 10 26.95 9.32 26.58 7.39 27.98 10.33 
DAY 15 26.23 8.25 25.39 6.97 26.54 7.33 
DAY 20 29.13 11.83 28.65 10.39 29.03 7.84 
 
R
A
M
P
3
 K
O
 
DAY 0 
No PCR product 
amplified 
(undetermined) 
No PCR product 
amplified 
(undetermined) 
No PCR product 
amplified 
(undetermined) 
No PCR product 
amplified 
(undetermined) 
No PCR product 
amplified 
(undetermined) 
No PCR product 
amplified 
(undetermined) 
DAY 5 
DAY 10 
DAY 15 
DAY 20 
 
NTC Undetermined 
 
Undetermined 
 
Undetermined 
 
 
CNC 18.27 
 
18.30 
 
18.02 
 
 
NTC: Non Template Control; CNC: Copy Number Control; avg CT = average of three CT values. 
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9.1.5. Chapter 6: Expression of RAMPs in response to stimulation.  
9.1.5.i Western Blotting Reagents 
1)Sample buffer 
1X Laemmli Sample Buffer (LSB): 
62.5 mM Tris-HCl (pH 6.8), 
2% (w/v) SDS, 10% Glycerol, 
5% (v/v) Beta mercaptoethanol (2-ME) 
0.001% (w/v) Bromophenol blue (Laemmli, 1970). 
2)5X Running Buffer 
72g glycine 1M 
15.5g Tris base 130mM 
25ml 20%SDS 
975ml D/W 
4)  Resolving gel 12% 15% 17% 
ddH2O 7.9ml 3.7ml 3.2ml 
30% Acrylamide 3.73ml 8ml 11.3ml 
1.5M Tris 8.8 4.0ml 4ml 5ml 
10% SDS 160µl 160µl 200µl 
10% APS 160µl 160µl 200µl 
TEMED 16 µl 16 µl 20 µl 
Total volume  for 2 
gels 
16ml 16ml 20ml 
5) Stacking gel 6% 
 ddH2O 5.3ml 
30% Acrylamide 2ml 
0.5M Tris 6.8 2.5ml 
10% SDS 100µl 
10% APS 100µl 
TEMED 10 µl 
Total volume  for 2 gels 10ml 
 
6) Blocking 
solution 
5% 5% 
Milk 2.5gms 0.5gms 
PBST 50 ml 10ml 
Total vol 50 10ml 
 
7) Washing solutions 
PBST 0.25% 0.25% 
Tween 20 2.5gms 1.25gms 
PBS 1L 500ml 
TBST 0.25% 0.25% 
Tween 20 2.5gms 1.25gms 
TBS 1L 500ml 
 
3) Transfer Buffer 
3g Tris base 25mM 
14.4g glycine 200mM 
200ml Methanol 20% (v/v) 
800ml D/w 
TBS 10X 
80g NaCl 
2g KCl 
30g Tris base 
800ml Water 
pH to 7.4 and make up to 1L 
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8) Cell Harvesting 
Buffer A: 
20 mM HEPES (pH 7.4), 
10 mM KCl, 1.5 mM MgCl2, 
1 mM dithiothrietol (DTT), 
250 mM sucrose. 
Protease inhibitor cocktail -1X  
0.25M Sucrose/Buffer A: 
50 mM triethanolamine (TEA) (pH 7.5), 
25 mM KCl, 5 mM MgCl2, 
0.5 mM DTT, 0.5 mM phenylmethanesulfonyl flouoride (PMSF), 
250 mM sucrose 
Protease inhibitor cocktail -1X 
PMSF stock solution 
100 mM PMSF solution was prepared in 100% ethanol solution and stored at 4˚C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NP40 lysis buffer 
50mM Tris-HCl pH 8.0 
150mM NaCl 
1% NP-40 
Protease inhibitor cocktail 1X 
*100mM PMSF for phosphorylated proteins 
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9.1.6 Chapter 7: Expression of CTR  in differentiating primary osteoblasts: 
9.1.6.i Sequencing results: Sequences of the amplicons of all individual overlapping primer 
pairs: Sequences of PCR products amplified by each primer pair. cDNA prepared from three 
independent WT (SVEV) primary osteoblast cultures differentiated for 20 days, was amplified 
against each primer (n=3 for each primer pair). 
 
 
Primer pairs Produce size Product sequencing result 
mCTR3 f /r 315 
 
NNGGCATAAACTGAAAGGTGAGTGCTTATATAAGCATCGCTTATGGAAGG 
AGAAGAAACCGAGGGAGCAGGGCTACCACTTAGAGGATTTGAAAATGACT 
CCAAGGAGGTCCAGAGTGAAAAGGCGGAATCTCCGCAAACCGAAGATGAG 
GTTCCTTCTCGTGAACAGGTTCACCCTGCTGCTCCTGCTCCTAGTGAGCC 
CAACTCCAGTTCTTCAGGCTCCTACCAATCTCACTGACTCCGGCCTTGAT 
CAGGAGCCATTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCA 
GTACAAATGCTATGA 
 
mCTR4 f /r 319 
 
GGGGGCCCGGCTCTAGTGAGCCACTCCAGTTCTTCAGGCTCCTACCAATC 
TCACTGACTCCGGCCTTGATCAGGAGCCATTCCTGTACTTGGTTGGCCGC 
AAGAAGCTGCTGGATGCTCAGTACAAATGCTATGACCGGATTCATCAGTT 
GCCCTCTTATGAAGGAGAAGGTCTGTACTGCAACCGCACCTGGGATGGCT 
GGATGTGCTGGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGC 
CCTGACTACTTCCCGGACTTTGACACAGCAGAAAAGGTTTCAAAATACTG 
TGATGAAAAGGGAGAGTGG 
 
mCTR5 f /r 327 
 
NNNNNGGTGGAAGGAAATGAAAATGACCGGATTCATCAGTTGCCCTCTTA 
TGAAGGAGAAGGTCTGTACTGCCCTTTTACCTGGGATGGCTGGATGTGCT 
GGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGCCCTGACTAC 
TTCCCGGACTTTGACACAGCAGAAAAGGTTTCAAAATACTGTGATGAAAA 
TGGAGAGTGGTTTAGACACCCTGACAGCAACCGAACCTGGTCCAACTATA 
CTCTGTGCAACGCTTTCACTTCTGAGAAACTGCAAAATGCGTACGTTCTT 
TATTACCTGGCTCTTGTGGGTCACTCC 
 
mCTR6 f /r 303 
 
NNNNNCGGCCAAATCAGCACTGACCTGACTACTTCCCGGACTTTGACACA 
GCAGAAAAGGTTTCAAAATACTGTGATGAAAATGGAGAGTGGTTTAGACA 
CCCTGACAGCAACCGAACCTGGTCCAACTATACTCTGTGCAACGCTTTCA 
CTTCTGAGAAACTGCAAAATGCGTACGTTCTTTATTACCTGGCTCTTGTG 
GGTCACTCCTTGTCGATTGCTGCTTTGGTTGCTTCCATGCTGATCTTCTG 
GATTTTCAAGAACCTTAGCTGCCAGAGGGTGACCTTGCACAAGCACATGT 
TCA 
 
mCTR8 f /r 209 
 
NNNNNNNNNNAACCTGCTTCAGGGTGACCTTGCACAAGCACATGTTCCTT 
ACTTATATTCTGAATTCTATCATTATCATCATCCACCTGGTTGAGGTTGT 
GCCCAATGGAGATCTGGTGCGGCGGGATCCTATAAGTTGCAAGGTTCTAC 
ACTTTTTACATCAGTACATGATGTCTTGCAACTACTTCTGGATGCTCTGC 
GAA 
 
Table 9.2: Sequences of amplicons of each overlapping primer pairs: 
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mCTR9 f /r 212 
 
NNNNNNNNNGGACTATATTTGCAAGGTTCTACACTTTTTACATCACGTAC 
ATGATGTCTTGCAACTACTTCTGGATCCTTTGCGAGGGGATCTATCTTCA 
TACTCTGATTGTCATGGCTGTGTTTACCGACGAGCAACGCCTACGCTGGT 
ACTATCTTCTTGGCTGGGGGTTCCCGATAGTGCCAACCATTATCCACGCC 
ATCACTCGTAAA 
mCTR11 f /r 295 
 
NNNNNNNNNNTTCNTGGCTGGGGGTTCCCGATAGTGCCAACCATTATCCA 
CGCCATCACTCGTGCCCTCTACTACAACGACAACTGCTGGCTGAGTGCAG 
AAACCCACTTGCTTTACATCATCCATGGACCCGTCATGGTGGCTCTGGTG 
GTCAACTTCTTCTTTCTTCTCAACATTGTCCGCGTGCTTGTGACCAAGAT 
GAGGCAAACCCACGAGGCCGAGTCCTACATGTACCTGAAGGCTGTGAAGG 
CCACCATGGTCCTTGTGCCCCTGCTGGGGATCCGTTTTGTTGTGT 
mCTR12 f /r 293 
 
NGGGACCCGGTCATGGTGGCTCTGGTGGTCACTTCTTCTTTCTTCTCAAC 
ATTGTCCGCGTGCTTGTGACCAAGATGAGGCAAACCCACGAGGCCGAGTC 
CTACATGTACCTGAAGGCTGTGAAGGCCACCATGGTCCTTGTGCCCCTGC 
TGGGGATCCAGTTTGTTGTGTTTCCCTGGAGGCCCTCCAACAAGGTGCTT 
GGGAAGATCTATGATTATCTCATGCACTCTCTGATTCATTTCCAGGGATT 
CTTTGTGGCGACTATCTACTGCTTCTGCAACCATGAGGTGCAA 
 
mCTR13 f /r 316 
 
NNNNNATGTACTGAGGCTGTGAGGCCACCATGGTCCTTGTGCCCCTGCTG 
GGGATCCAGTTTGTTGTGTTTCCCTGGAGGCCCTCCAACAAGGTGCTTGG 
GAAGATCTATGATTATCTCATGCACTCTCTGATTCATTTCCAGGGATTCT 
TTGTGGCGACTATCTACTGCTTCTGCAACCATGAGGTGCAAGTCACCCTG 
AAGCGCCAGTGGACGCAGTTCAAGATCCAGTGGAGCCAACGCTGGGGAAG 
GCGCCGCCGCCCCACCAACCGCGTAGTTAGTGCTCCTCGGGCTGTAGCCT 
TCGCGTAGCCAGATAA 
 
mCTR14 f /r 310 
 
NNNNNNNNNTCTCTGATTCTTTCCAGGGATTCTTTGTGGCGACTATCTAC 
TGCTTCTGCAACCATGAGGTGCAAGTCACCCTGAAGCGCCAGTGGACGCA 
GTTCAAGATCCAGTGGAGCCAACGCTGGGGAAGGCGCCGCCGCCCCACCA 
ACCGCGTAGTTAGTGCTCCTCGGGCTGTAGCCTTCGCTGAGCCAGATGGC 
CTCCCCATTTACATCTGCCATCAGGAACCACGGAATCCTCCAATCAGCAA 
CAACGAAGGCGAGGAGAGTACTGAAATGATCCCCATGAACGTCATCCAGC 
AGAACGCATC 
 
mCTR15 f /r 297 
 
NNNNNAGGCGGGGGAAGGGCGCCGCCGCCCCACCAACCGCGTAGTTAGTG 
CTCCTCGGGCTGTAGCCTTCGCTGAGCCAGATGGCCTCCCCATTTACATC 
TGCCATCAGGAACCACGGAATCCTCCAATCAGCAACAACGAAGGCGAGGA 
GAGTACTGAAATGATCCCCATGAACGTCATCCAGCAAGACGCATCCGCTT 
GAATGTGAAGCCACCCCAAGCATTGTGATCCACTGAGCCTTCATTTCCTG 
GGGAAAGACAGACCATGTGTTTCAAGTGATTCCATCCCTCCCAGTAA 
 
mCTR16 f /r 302 
 
NGGCCGAGAGAGTACTGAATGATCCCCATGAACGTCATCCAGCAAGACGC 
ATCCGCTTGAATGTGAAGCCACCCCAAGCATTGTGATCCACTGAGCCTTC 
ATTTCCTGGGGAAAGACAGACCATGTGTTTCAAGTGATTCCCATCCTCCC 
AGGAGCTGACCATATCATTTGTGAAGAAGTGTTAAGTGAATTTGTCCATA 
GTGAATTTGAAGAAAGTGATTCTTGGTACTATTGCTTTGGGAGTCAGTCT 
AGGAATAGAGTCTCCCATTGCAACTTGTGAACTCCATCTTCATCCTGGAA 
AA 
 
mCTR17 f /r 205 
NNNNNTTCTGGGGAAGAAGACCATGTGTTTCAAGTGATTCCCATCCTCCC 
AGGAGCTGACCATATCATTTGTGAAGAAGTGTTAAGTGAATTTGTCCATA 
GTGAATTTGAAGAAAGTGATTCTTGGTACTATTGCTTTGGGAGTCAGTCT 
AGGAATAGAGTCTCCCATTGCAACTTGTGAACTCCATCATTCATCCTGGA 
CTGAGATGACTGTGTTCGTAGGAAAGCAGGCAAGGTGTTCAAAAGATGTC 
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9.1.6.ii NCBI BLAST results:  
 
9.1.6.ii.a NCBI BLAST2n result for osteoblast CTR cDNA and full length CTR variant 
Calcr001:  
Sequence alignments: Sequence ID: lcl|46219  Length: 2460,   Number of Matches: 2 
 
1) Range 1: 1306 to 2151 
Score Expect Identities Gaps Strand 
1552 bits(840) 0.0 845/847(99%) 2/847(0%) Plus/Plus 
 
Query  715   ATAAGTTGCAAGGTTCTACACTTTTTACATCAGTACATGATGTCTTGCAACTACTTCTGG  774 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1306  ATAAGTTGCAAGGTTCTACACTTTTTACATCAGTACATGATGTCTTGCAACTACTTCTGG  1365 
 
Query  775   ATGCTCTGCGAGGGGATCTATCTTCATACTCTGATTGTCATGGCTGTGTTTACCGACGAG  834 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1366  ATGCTCTGCGAGGGGATCTATCTTCATACTCTGATTGTCATGGCTGTGTTTACCGACGAG  1425 
 
Query  835   CAACGCCTACGCTGGTACTATCTTCTTGGCTGGGGGTTCCCGATAGTGCCAACCATTATC  894 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1426  CAACGCCTACGCTGGTACTATCTTCTTGGCTGGGGGTTCCCGATAGTGCCAACCATTATC  1485 
 
Query  895   CACGCCATCACTCGTGCCCTCTACTACAACGACAACTGCTGGCTGAGTGCAGAAACCCAC  954 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1486  CACGCCATCACTCGTGCCCTCTACTACAACGACAACTGCTGGCTGAGTGCAGAAACCCAC  1545 
 
Query  955   TTGCTTTACATCATCCATGGACCCGGTCATGGTGGCTCTGGTGGTC-ACTTCTTCTTTCT  1013 
             |||||||||||||||||||||||| ||||||||||||||||||||| ||||||||||||| 
Sbjct  1546  TTGCTTTACATCATCCATGGACCC-GTCATGGTGGCTCTGGTGGTCAACTTCTTCTTTCT  1604 
 
Query  1014  TCTCAACATTGTCCGCGTGCTTGTGACCAAGATGAGGCAAACCCACGAGGCCGAGTCCTA  1073 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1605  TCTCAACATTGTCCGCGTGCTTGTGACCAAGATGAGGCAAACCCACGAGGCCGAGTCCTA  1664 
 
Query  1074  CATGTACCTGAAGGCTGTGAAGGCCACCATGGTCCTTGTGCCCCTGCTGGGGATCCAGTT  1133 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1665  CATGTACCTGAAGGCTGTGAAGGCCACCATGGTCCTTGTGCCCCTGCTGGGGATCCAGTT  1724 
 
Query  1134  TGTTGTGTTTCCCTGGAGGCCCTCCAACAAGGTGCTTGGGAAGATCTATGATTATCTCAT  1193 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1725  TGTTGTGTTTCCCTGGAGGCCCTCCAACAAGGTGCTTGGGAAGATCTATGATTATCTCAT  1784 
 
Query  1194  GCACTCTCTGATTCATTTCCAGGGATTCTTTGTGGCGACTATCTACTGCTTCTGCAACCA  1253 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1785  GCACTCTCTGATTCATTTCCAGGGATTCTTTGTGGCGACTATCTACTGCTTCTGCAACCA  1844 
 
Query  1254  TGAGGTGCAAGTCACCCTGAAGCGCCAGTGGACGCAGTTCAAGATCCAGTGGAGCCAACG  1313 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1845  TGAGGTGCAAGTCACCCTGAAGCGCCAGTGGACGCAGTTCAAGATCCAGTGGAGCCAACG  1904 
 
Query  1314  CTGGGGAAGGCGCCGCCGCCCCACCAACCGCGTAGTTAGTGCTCCTCGGGCTGTAGCCTT  1373 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1905  CTGGGGAAGGCGCCGCCGCCCCACCAACCGCGTAGTTAGTGCTCCTCGGGCTGTAGCCTT  1964 
 
Query  1374  CGCTGAGCCAGATGGCCTCCCCATTTACATCTGCCATCAGGAACCACGGAATCCTCCAAT  1433 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1965  CGCTGAGCCAGATGGCCTCCCCATTTACATCTGCCATCAGGAACCACGGAATCCTCCAAT  2024 
 
Query  1434  CAGCAACAACGAAGGCGAGGAGAGTACTGAAATGATCCCCATGAACGTCATCCAGCAAGA  1493 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2025  CAGCAACAACGAAGGCGAGGAGAGTACTGAAATGATCCCCATGAACGTCATCCAGCAAGA  2084 
 
Query  1494  CGCATCCGCTTGAATGTGAAGCCACCCCAAGCATTGTGATCCACTGAGCCTTCATTTCCT  1553 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2085  CGCATCCGCTTGAATGTGAAGCCACCCCAAGCATTGTGATCCACTGAGCCTTCATTTCCT  2144 
 
Query  1554  GGGGAAA  1560 
             ||||||| 
Sbjct  2145  GGGGAAA  2151 
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2) Range 2: 481 to 1196  
Score Expect Identities Gaps Strand 
1323 bits(716) 0.0 716/716(100%) 0/716(0%) Plus/Plus 
 
 
Query  1     ACAGAGGATTTGAAAATGACTCCAAGGAGGTCCAGAGTGAAAAGGCGGAATCTCCGCAAA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481   ACAGAGGATTTGAAAATGACTCCAAGGAGGTCCAGAGTGAAAAGGCGGAATCTCCGCAAA  540 
 
Query  61    CCGAAGATGAGGTTCCTTCTCGTGAACAGGTTCACCCTGCTGCTCCTGCTCCTAGTGAGC  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541   CCGAAGATGAGGTTCCTTCTCGTGAACAGGTTCACCCTGCTGCTCCTGCTCCTAGTGAGC  600 
 
Query  121   CCAACTCCAGTTCTTCAGGCTCCTACCAATCTCACTGACTCCGGCCTTGATCAGGAGCCA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601   CCAACTCCAGTTCTTCAGGCTCCTACCAATCTCACTGACTCCGGCCTTGATCAGGAGCCA  660 
 
Query  181   TTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCAGTACAAATGCTATGACCGG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  661   TTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCAGTACAAATGCTATGACCGG  720 
 
Query  241   ATTCATCAGTTGCCCTCTTATGAAGGAGAAGGTCTGTACTGCAACCGCACCTGGGATGGC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  721   ATTCATCAGTTGCCCTCTTATGAAGGAGAAGGTCTGTACTGCAACCGCACCTGGGATGGC  780 
 
Query  301   TGGATGTGCTGGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGCCCTGACTAC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  781   TGGATGTGCTGGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGCCCTGACTAC  840 
 
Query  361   TTCCCGGACTTTGACACAGCAGAAAAGGTTTCAAAATACTGTGATGAAAATGGAGAGTGG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  841   TTCCCGGACTTTGACACAGCAGAAAAGGTTTCAAAATACTGTGATGAAAATGGAGAGTGG  900 
 
Query  421   TTTAGACACCCTGACAGCAACCGAACCTGGTCCAACTATACTCTGTGCAACGCTTTCACT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  901   TTTAGACACCCTGACAGCAACCGAACCTGGTCCAACTATACTCTGTGCAACGCTTTCACT  960 
 
Query  481   TCTGAGAAACTGCAAAATGCGTACGTTCTTTATTACCTGGCTCTTGTGGGTCACTCCTTG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  961   TCTGAGAAACTGCAAAATGCGTACGTTCTTTATTACCTGGCTCTTGTGGGTCACTCCTTG  1020 
 
Query  541   TCGATTGCTGCTTTGGTTGCTTCCATGCTGATCTTCTGGATTTTCAAGAACCTTAGCTGC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1021  TCGATTGCTGCTTTGGTTGCTTCCATGCTGATCTTCTGGATTTTCAAGAACCTTAGCTGC  1080 
 
Query  601   CAGAGGGTGACCTTGCACAAGCACATGTTCCTTACTTATATTCTGAATTCTATCATTATC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1081  CAGAGGGTGACCTTGCACAAGCACATGTTCCTTACTTATATTCTGAATTCTATCATTATC  1140 
 
Query  661   ATCATCCACCTGGTTGAGGTTGTGCCCAATGGAGATCTGGTGCGGCGGGATCCTAT  716 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1141  ATCATCCACCTGGTTGAGGTTGTGCCCAATGGAGATCTGGTGCGGCGGGATCCTAT  1196 
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9.1.4.ii.b  NCBI BLAST result for osteoblast CTR cDNA sequence:  
Sequence alignments:  
1) Mus musculus calcitonin receptor (Calcr), transcript variant 1a, mRNA 
Sequence ID: ref|NM_001042725.1|  Length: 3471   Number of Matches: 1  
 
Range 1: 291 to 1850 
Score Expect Identities Gaps Strand 
2870 bits(1554) 0.0 1559/1561(99%) 2/1561(0%) Plus/Plus 
 
 
Query  1     ACAGAGGATTTGAAAATGACTCCAAGGAGGTCCAGAGTGAAAAGGCGGAATCTCCGCAAA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  291   ACAGAGGATTTGAAAATGACTCCAAGGAGGTCCAGAGTGAAAAGGCGGAATCTCCGCAAA  350 
 
Query  61    CCGAAGATGAGGTTCCTTCTCGTGAACAGGTTCACCCTGCTGCTCCTGCTCCTAGTGAGC  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  351   CCGAAGATGAGGTTCCTTCTCGTGAACAGGTTCACCCTGCTGCTCCTGCTCCTAGTGAGC  410 
 
Query  121   CCAACTCCAGTTCTTCAGGCTCCTACCAATCTCACTGACTCCGGCCTTGATCAGGAGCCA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  411   CCAACTCCAGTTCTTCAGGCTCCTACCAATCTCACTGACTCCGGCCTTGATCAGGAGCCA  470 
 
Query  181   TTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCAGTACAAATGCTATGACCGG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  471   TTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCAGTACAAATGCTATGACCGG  530 
 
Query  241   ATTCATCAGTTGCCCTCTTATGAAGGAGAAGGTCTGTACTGCAACCGCACCTGGGATGGC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  531   ATTCATCAGTTGCCCTCTTATGAAGGAGAAGGTCTGTACTGCAACCGCACCTGGGATGGC  590 
 
Query  301   TGGATGTGCTGGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGCCCTGACTAC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  591   TGGATGTGCTGGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGCCCTGACTAC  650 
 
Query  361   TTCCCGGACTTTGACACAGCAGAAAAGGTTTCAAAATACTGTGATGAAAATGGAGAGTGG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  651   TTCCCGGACTTTGACACAGCAGAAAAGGTTTCAAAATACTGTGATGAAAATGGAGAGTGG  710 
 
Query  421   TTTAGACACCCTGACAGCAACCGAACCTGGTCCAACTATACTCTGTGCAACGCTTTCACT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  711   TTTAGACACCCTGACAGCAACCGAACCTGGTCCAACTATACTCTGTGCAACGCTTTCACT  770 
 
Query  481   TCTGAGAAACTGCAAAATGCGTACGTTCTTTATTACCTGGCTCTTGTGGGTCACTCCTTG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  771   TCTGAGAAACTGCAAAATGCGTACGTTCTTTATTACCTGGCTCTTGTGGGTCACTCCTTG  830 
 
Query  541   TCGATTGCTGCTTTGGTTGCTTCCATGCTGATCTTCTGGATTTTCAAGAACCTTAGCTGC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  831   TCGATTGCTGCTTTGGTTGCTTCCATGCTGATCTTCTGGATTTTCAAGAACCTTAGCTGC  890 
 
Query  601   CAGAGGGTGACCTTGCACAAGCACATGTTCCTTACTTATATTCTGAATTCTATCATTATC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  891   CAGAGGGTGACCTTGCACAAGCACATGTTCCTTACTTATATTCTGAATTCTATCATTATC  950 
 
Query  661   ATCATCCACCTGGTTGAGGTTGTGCCCAATGGAGATCTGGTGCGGCGGGATCCTATAAGT  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  951   ATCATCCACCTGGTTGAGGTTGTGCCCAATGGAGATCTGGTGCGGCGGGATCCTATAAGT  1010 
 
Query  721   TGCAAGGTTCTACACTTTTTACATCAGTACATGATGTCTTGCAACTACTTCTGGATGCTC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1011  TGCAAGGTTCTACACTTTTTACATCAGTACATGATGTCTTGCAACTACTTCTGGATGCTC  1070 
 
Query  781   TGCGAGGGGATCTATCTTCATACTCTGATTGTCATGGCTGTGTTTACCGACGAGCAACGC  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1071  TGCGAGGGGATCTATCTTCATACTCTGATTGTCATGGCTGTGTTTACCGACGAGCAACGC  1130 
 
Query  841   CTACGCTGGTACTATCTTCTTGGCTGGGGGTTCCCGATAGTGCCAACCATTATCCACGCC  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1131  CTACGCTGGTACTATCTTCTTGGCTGGGGGTTCCCGATAGTGCCAACCATTATCCACGCC  1190 
 
Query  901   ATCACTCGTGCCCTCTACTACAACGACAACTGCTGGCTGAGTGCAGAAACCCACTTGCTT  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1191  ATCACTCGTGCCCTCTACTACAACGACAACTGCTGGCTGAGTGCAGAAACCCACTTGCTT  1250 
 
283 
 
Query  961   TACATCATCCATGGACCCGGTCATGGTGGCTCTGGTGGTC-ACTTCTTCTTTCTTCTCAA  1019 
             |||||||||||||||||| ||||||||||||||||||||| ||||||||||||||||||| 
Sbjct  1251  TACATCATCCATGGACCC-GTCATGGTGGCTCTGGTGGTCAACTTCTTCTTTCTTCTCAA  1309 
 
Query  1020  CATTGTCCGCGTGCTTGTGACCAAGATGAGGCAAACCCACGAGGCCGAGTCCTACATGTA  1079 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1310  CATTGTCCGCGTGCTTGTGACCAAGATGAGGCAAACCCACGAGGCCGAGTCCTACATGTA  1369 
 
Query  1080  CCTGAAGGCTGTGAAGGCCACCATGGTCCTTGTGCCCCTGCTGGGGATCCAGTTTGTTGT  1139 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1370  CCTGAAGGCTGTGAAGGCCACCATGGTCCTTGTGCCCCTGCTGGGGATCCAGTTTGTTGT  1429 
 
Query  1140  GTTTCCCTGGAGGCCCTCCAACAAGGTGCTTGGGAAGATCTATGATTATCTCATGCACTC  1199 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1430  GTTTCCCTGGAGGCCCTCCAACAAGGTGCTTGGGAAGATCTATGATTATCTCATGCACTC  1489 
 
Query  1200  TCTGATTCATTTCCAGGGATTCTTTGTGGCGACTATCTACTGCTTCTGCAACCATGAGGT  1259 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1490  TCTGATTCATTTCCAGGGATTCTTTGTGGCGACTATCTACTGCTTCTGCAACCATGAGGT  1549 
 
Query  1260  GCAAGTCACCCTGAAGCGCCAGTGGACGCAGTTCAAGATCCAGTGGAGCCAACGCTGGGG  1319 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1550  GCAAGTCACCCTGAAGCGCCAGTGGACGCAGTTCAAGATCCAGTGGAGCCAACGCTGGGG  1609 
 
Query  1320  AAGGCGCCGCCGCCCCACCAACCGCGTAGTTAGTGCTCCTCGGGCTGTAGCCTTCGCTGA  1379 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1610  AAGGCGCCGCCGCCCCACCAACCGCGTAGTTAGTGCTCCTCGGGCTGTAGCCTTCGCTGA  1669 
 
Query  1380  GCCAGATGGCCTCCCCATTTACATCTGCCATCAGGAACCACGGAATCCTCCAATCAGCAA  1439 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1670  GCCAGATGGCCTCCCCATTTACATCTGCCATCAGGAACCACGGAATCCTCCAATCAGCAA  1729 
 
Query  1440  CAACGAAGGCGAGGAGAGTACTGAAATGATCCCCATGAACGTCATCCAGCAAGACGCATC  1499 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1730  CAACGAAGGCGAGGAGAGTACTGAAATGATCCCCATGAACGTCATCCAGCAAGACGCATC  1789 
 
Query  1500  CGCTTGAATGTGAAGCCACCCCAAGCATTGTGATCCACTGAGCCTTCATTTCCTGGGGAA  1559 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1790  CGCTTGAATGTGAAGCCACCCCAAGCATTGTGATCCACTGAGCCTTCATTTCCTGGGGAA  1849 
 
Query  1560  A  1560 
             | 
Sbjct  1850  A  1850 
 
 
2) Mus musculus calcitonin receptor (Calcr), transcript variant 1b, mRNA 
Sequence ID: ref|NM_007588.2|     Length: 3831      Number of Matches: 2   
1) Range 1: 1365 to 2210 
Score Expect Identities Gaps Strand 
1552 bits(840) 0.0 845/847(99%) 2/847(0%) Plus/Plus 
 
Query  715   ATAAGTTGCAAGGTTCTACACTTTTTACATCAGTACATGATGTCTTGCAACTACTTCTGG  774 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1365  ATAAGTTGCAAGGTTCTACACTTTTTACATCAGTACATGATGTCTTGCAACTACTTCTGG  1424 
 
Query  775   ATGCTCTGCGAGGGGATCTATCTTCATACTCTGATTGTCATGGCTGTGTTTACCGACGAG  834 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1425  ATGCTCTGCGAGGGGATCTATCTTCATACTCTGATTGTCATGGCTGTGTTTACCGACGAG  1484 
 
Query  835   CAACGCCTACGCTGGTACTATCTTCTTGGCTGGGGGTTCCCGATAGTGCCAACCATTATC  894 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1485  CAACGCCTACGCTGGTACTATCTTCTTGGCTGGGGGTTCCCGATAGTGCCAACCATTATC  1544 
 
Query  895   CACGCCATCACTCGTGCCCTCTACTACAACGACAACTGCTGGCTGAGTGCAGAAACCCAC  954 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1545  CACGCCATCACTCGTGCCCTCTACTACAACGACAACTGCTGGCTGAGTGCAGAAACCCAC  1604 
 
Query  955   TTGCTTTACATCATCCATGGACCCGGTCATGGTGGCTCTGGTGGTC-ACTTCTTCTTTCT  1013 
             |||||||||||||||||||||||| ||||||||||||||||||||| ||||||||||||| 
Sbjct  1605  TTGCTTTACATCATCCATGGACCC-GTCATGGTGGCTCTGGTGGTCAACTTCTTCTTTCT  1663 
 
Query  1014  TCTCAACATTGTCCGCGTGCTTGTGACCAAGATGAGGCAAACCCACGAGGCCGAGTCCTA  1073 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1664  TCTCAACATTGTCCGCGTGCTTGTGACCAAGATGAGGCAAACCCACGAGGCCGAGTCCTA  1723 
 
284 
 
Query  1074  CATGTACCTGAAGGCTGTGAAGGCCACCATGGTCCTTGTGCCCCTGCTGGGGATCCAGTT  1133 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1724  CATGTACCTGAAGGCTGTGAAGGCCACCATGGTCCTTGTGCCCCTGCTGGGGATCCAGTT  1783 
 
Query  1134  TGTTGTGTTTCCCTGGAGGCCCTCCAACAAGGTGCTTGGGAAGATCTATGATTATCTCAT  1193 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1784  TGTTGTGTTTCCCTGGAGGCCCTCCAACAAGGTGCTTGGGAAGATCTATGATTATCTCAT  1843 
 
Query  1194  GCACTCTCTGATTCATTTCCAGGGATTCTTTGTGGCGACTATCTACTGCTTCTGCAACCA  1253 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1844  GCACTCTCTGATTCATTTCCAGGGATTCTTTGTGGCGACTATCTACTGCTTCTGCAACCA  1903 
 
Query  1254  TGAGGTGCAAGTCACCCTGAAGCGCCAGTGGACGCAGTTCAAGATCCAGTGGAGCCAACG  1313 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1904  TGAGGTGCAAGTCACCCTGAAGCGCCAGTGGACGCAGTTCAAGATCCAGTGGAGCCAACG  1963 
 
Query  1314  CTGGGGAAGGCGCCGCCGCCCCACCAACCGCGTAGTTAGTGCTCCTCGGGCTGTAGCCTT  1373 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1964  CTGGGGAAGGCGCCGCCGCCCCACCAACCGCGTAGTTAGTGCTCCTCGGGCTGTAGCCTT  2023 
 
Query  1374  CGCTGAGCCAGATGGCCTCCCCATTTACATCTGCCATCAGGAACCACGGAATCCTCCAAT  1433 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2024  CGCTGAGCCAGATGGCCTCCCCATTTACATCTGCCATCAGGAACCACGGAATCCTCCAAT  2083 
 
Query  1434  CAGCAACAACGAAGGCGAGGAGAGTACTGAAATGATCCCCATGAACGTCATCCAGCAAGA  1493 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2084  CAGCAACAACGAAGGCGAGGAGAGTACTGAAATGATCCCCATGAACGTCATCCAGCAAGA  2143 
 
Query  1494  CGCATCCGCTTGAATGTGAAGCCACCCCAAGCATTGTGATCCACTGAGCCTTCATTTCCT  1553 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2144  CGCATCCGCTTGAATGTGAAGCCACCCCAAGCATTGTGATCCACTGAGCCTTCATTTCCT  2203 
 
Query  1554  GGGGAAA  1560 
             ||||||| 
Sbjct  2204  GGGGAAA  2210 
 
2) Range 2: 540 to 1255  
Score Expect Identities Gaps Strand 
1323 bits(716) 0.0 716/716(100%) 0/716(0%) Plus/Plus 
 
 
 
Query  1     ACAGAGGATTTGAAAATGACTCCAAGGAGGTCCAGAGTGAAAAGGCGGAATCTCCGCAAA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  540   ACAGAGGATTTGAAAATGACTCCAAGGAGGTCCAGAGTGAAAAGGCGGAATCTCCGCAAA  599 
 
Query  61    CCGAAGATGAGGTTCCTTCTCGTGAACAGGTTCACCCTGCTGCTCCTGCTCCTAGTGAGC  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  600   CCGAAGATGAGGTTCCTTCTCGTGAACAGGTTCACCCTGCTGCTCCTGCTCCTAGTGAGC  659 
 
Query  121   CCAACTCCAGTTCTTCAGGCTCCTACCAATCTCACTGACTCCGGCCTTGATCAGGAGCCA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  660   CCAACTCCAGTTCTTCAGGCTCCTACCAATCTCACTGACTCCGGCCTTGATCAGGAGCCA  719 
 
Query  181   TTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCAGTACAAATGCTATGACCGG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  720   TTCCTGTACTTGGTTGGCCGCAAGAAGCTGCTGGATGCTCAGTACAAATGCTATGACCGG  779 
 
Query  241   ATTCATCAGTTGCCCTCTTATGAAGGAGAAGGTCTGTACTGCAACCGCACCTGGGATGGC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  780   ATTCATCAGTTGCCCTCTTATGAAGGAGAAGGTCTGTACTGCAACCGCACCTGGGATGGC  839 
 
Query  301   TGGATGTGCTGGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGCCCTGACTAC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  840   TGGATGTGCTGGGACGACACTCCCGCTGGAGCCACAGCCTATCAGCACTGCCCTGACTAC  899 
 
Query  361   TTCCCGGACTTTGACACAGCAGAAAAGGTTTCAAAATACTGTGATGAAAATGGAGAGTGG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  900   TTCCCGGACTTTGACACAGCAGAAAAGGTTTCAAAATACTGTGATGAAAATGGAGAGTGG  959 
 
Query  421   TTTAGACACCCTGACAGCAACCGAACCTGGTCCAACTATACTCTGTGCAACGCTTTCACT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  960   TTTAGACACCCTGACAGCAACCGAACCTGGTCCAACTATACTCTGTGCAACGCTTTCACT  1019 
 
Query  481   TCTGAGAAACTGCAAAATGCGTACGTTCTTTATTACCTGGCTCTTGTGGGTCACTCCTTG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1020  TCTGAGAAACTGCAAAATGCGTACGTTCTTTATTACCTGGCTCTTGTGGGTCACTCCTTG  1079 
 
285 
 
Query  541   TCGATTGCTGCTTTGGTTGCTTCCATGCTGATCTTCTGGATTTTCAAGAACCTTAGCTGC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1080  TCGATTGCTGCTTTGGTTGCTTCCATGCTGATCTTCTGGATTTTCAAGAACCTTAGCTGC  1139 
 
Query  601   CAGAGGGTGACCTTGCACAAGCACATGTTCCTTACTTATATTCTGAATTCTATCATTATC  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1140  CAGAGGGTGACCTTGCACAAGCACATGTTCCTTACTTATATTCTGAATTCTATCATTATC  1199 
 
Query  661   ATCATCCACCTGGTTGAGGTTGTGCCCAATGGAGATCTGGTGCGGCGGGATCCTAT  716 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1200  ATCATCCACCTGGTTGAGGTTGTGCCCAATGGAGATCTGGTGCGGCGGGATCCTAT  1255 
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